---
document_datetime: 2024-05-13 15:53:51
document_pages: 130
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/ryzneuta-epar-public-assessment-report_en.pdf
document_name: ryzneuta-epar-public-assessment-report_en.pdf
version: success
processing_time: 220.5457842
conversion_datetime: 2025-12-19 21:56:38.097526
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

25 January 2024 EMA/62813/2024 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Ryzneuta

International non-proprietary name: efbemalenograstim alfa

Procedure No. EMEA/H/C/005828/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                    | 9                                                                                                                   |
|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier ...................................................................................          | 9                                                                                                                   |
| 1.2. Legal basis, dossier content.................................................................................          | 9                                                                                                                   |
| 1.3. Information on Paediatric requirements.................................................................                | 9                                                                                                                   |
| 1.4. Information relating to orphan market exclusivity...................................................                   | 9                                                                                                                   |
| 1.4.1. Similarity                                                                                                           | ....................................................................................................... 9           |
| 1.5. Applicant's request(s) for consideration................................................................10             |                                                                                                                     |
| 1.5.1. New active substance status                                                                                          | ............................................................................10                                      |
| 1.6. Scientific advice................................................................................................10    |                                                                                                                     |
| 1.7. Steps taken for the assessment of the product......................................................10                  |                                                                                                                     |
| 2. Scientific discussion..............................................................................                      | 11                                                                                                                  |
| 2.1. Problem statement............................................................................................11        |                                                                                                                     |
| 2.1.1. Disease or condition                                                                                                 | .......................................................................................11                           |
| 2.1.2. Epidemiology and risk factors...........................................................................11           |                                                                                                                     |
| 2.1.3. Aetiology and pathogenesis                                                                                           | .............................................................................12                                     |
| 2.1.4. Clinical presentation, diagnosis and stage/prognosis............................................12                   |                                                                                                                     |
| 2.1.5. Management                                                                                                           | .................................................................................................12                 |
| 2.2. About the product.............................................................................................13       |                                                                                                                     |
| 2.3. Type of application and aspects on development                                                                         | ...................................................13                                                               |
| 2.4. Quality aspects.................................................................................................14     |                                                                                                                     |
| 2.4.1. Introduction                                                                                                         | ..................................................................................................14                |
| 2.4.2. Active substance............................................................................................14       |                                                                                                                     |
| General information.................................................................................................14      |                                                                                                                     |
| Manufacture, process controls and characterisation                                                                          | ......................................................15                                                            |
| Specification...........................................................................................................18  |                                                                                                                     |
| Stability                                                                                                                   | .................................................................................................................19 |
| 2.4.3. Finished medicinal product                                                                                           | ..............................................................................19                                    |
| Description of the product and Pharmaceutical development..........................................19                       |                                                                                                                     |
| Manufacture of the product and process controls..........................................................20                 |                                                                                                                     |
| Product specification................................................................................................20     |                                                                                                                     |
| Stability of the product.............................................................................................21     |                                                                                                                     |
| Adventitious agents                                                                                                         | .................................................................................................22                 |
| GMO......................................................................................................................22 |                                                                                                                     |
| 2.4.4. Discussion on chemical, and pharmaceutical aspects                                                                   | ...........................................23                                                                       |
| 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                   | ......................23                                                                                            |
| 2.4.6. Recommendation(s) for future quality development                                                                     | ............................................23                                                                      |
| 2.5. Non-clinical aspects...........................................................................................24      |                                                                                                                     |
| 2.5.1. Introduction                                                                                                         | ..................................................................................................24                |
| 2.5.2. Pharmacology................................................................................................24       |                                                                                                                     |
| 2.5.3. Pharmacokinetics                                                                                                     | ...........................................................................................26                       |

<div style=\"page-break-after: always\"></div>

| 2.5.4. Toxicology.....................................................................................................27   |                                                                                                       |
|----------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| 2.5.5. Ecotoxicity/environmental risk assessment                                                                           | ........................................................29                                            |
| 2.5.6. Discussion on non-clinical aspects                                                                                  | ....................................................................30                                |
| 2.5.7. Conclusion on the non-clinical aspects...............................................................31             |                                                                                                       |
| 2.6. Clinical aspects.................................................................................................31   |                                                                                                       |
| 2.6.1. Introduction                                                                                                        | ..................................................................................................31  |
| 2.6.2. Clinical pharmacology                                                                                               | .....................................................................................34               |
| 2.6.3. Discussion on clinical pharmacology..................................................................45             |                                                                                                       |
| 2.6.4. Conclusions on clinical pharmacology................................................................47              |                                                                                                       |
| 2.6.5. Clinical efficacy                                                                                                   | ..............................................................................................47      |
| 2.6.6. Discussion on clinical efficacy.........................................................................106         |                                                                                                       |
| 2.6.7. Conclusions on the clinical efficacy..................................................................108           |                                                                                                       |
| 2.6.8. Clinical safety                                                                                                     | ..............................................................................................108     |
| 2.6.9. Discussion on clinical safety...........................................................................120         |                                                                                                       |
| 2.6.10. Conclusions on the clinical safety..................................................................124            |                                                                                                       |
| 2.7. Risk Management Plan.....................................................................................124          |                                                                                                       |
| 2.7.1. Safety concerns                                                                                                     | ...........................................................................................124        |
| 2.7.2. Pharmacovigilance plan.................................................................................124          |                                                                                                       |
| 2.7.3. Risk minimisation measures...........................................................................124            |                                                                                                       |
| 2.7.4. Conclusion                                                                                                          | ..................................................................................................125 |
| 2.8. Pharmacovigilance                                                                                                     | ..........................................................................................125         |
| 2.8.1. Pharmacovigilance system.............................................................................125            |                                                                                                       |
| 2.8.2. Periodic Safety Update Reports submission requirements...................................125                        |                                                                                                       |
| 2.9. Product information.........................................................................................125       |                                                                                                       |
| 2.9.1. User consultation                                                                                                   | .........................................................................................125          |
| 2.9.2. Additional monitoring....................................................................................125        |                                                                                                       |
| 3. Benefit-Risk Balance ...........................................................................                        | 126                                                                                                   |
| 3.1. Therapeutic Context........................................................................................126        |                                                                                                       |
| 3.1.1. Disease or condition                                                                                                | .....................................................................................126              |
| 3.1.2. Available therapies and unmet medical need....................................................126                   |                                                                                                       |
| 3.1.3. Main clinical studies......................................................................................126      |                                                                                                       |
| 3.2. Favourable effects...........................................................................................126      |                                                                                                       |
| 3.3. Uncertainties and limitations about favourable effects                                                                | ..........................................127                                                         |
| 3.4. Unfavourable effects                                                                                                  | .......................................................................................127            |
| 3.5. Uncertainties and limitations about unfavourable effects.......................................128                    |                                                                                                       |
| 3.6. Effects Table                                                                                                         | ..................................................................................................128 |
| 3.7. Benefit-risk assessment and discussion..............................................................129               |                                                                                                       |
| 3.7.1. Importance of favourable and unfavourable effects                                                                   | ...........................................129                                                        |
| 3.7.2. Balance of benefits and risks..........................................................................129          |                                                                                                       |
| 3.8. Conclusions....................................................................................................129    |                                                                                                       |

<div style=\"page-break-after: always\"></div>

## 4. Recommendations  ............................................................................... 129

<div style=\"page-break-after: always\"></div>

## List of abbreviations

2-FBP

2-Fluorobiphenyl

5-FU

5-Fluorouracil

ADA

Anti-drug antibody

AE

Adverse event

AESI

Adverse event of special interest

AET

Analytical evaluation threshold

ALP

Alkaline Phosphatase

ALP

Alkaline Phosphatase

ALT

Alanine aminotransferase

ANC

Absolute neutrophil count

AQL

Acceptable quality limit

ARDS

Acute respiratory distress syndrome

AST

Aspartate aminotransferase

ASTM

American society for testing materials

AUC

Area under the curve

BHT

Butylhydroxytoluene or 2,6-di-tert-butyl-4-methylphenol

BM

Bone Marrow

CCI

Container closure integrity

CCS

Container closure system

CHO

Chinese hamster ovary

ChT

Chemotherapy

CI

Confidence interval

CL (CL/F)

Clearance (apparent CL)

Cmax

Maximum Plasma Concentration

CSR

Clinical Study Report

CY

Cyclophosphamide

DP

Drug Product

DS

Drug Substance

EC

Epirubicin 100 mg/m2 + cyclophosphamide 600 mg/m2

EC50

Half Maximal Effective Concentration

ECG

Electrocardiogram

ECOG

Eastern Cooperative Oncology Group

EDTA

Ethylene diamine tetraacetic acid

EFA

Effective filter area

ELISA

Enzyme-Linked Immunosorbent Assay

EMA

European Medicines Agency

EOP2

End-of-Phase 2

EU

European Union

F-627

efbemalenograstim alfa (Ryzneuta)

FAS

Full analysis set

FDA

Food and Drug Administration

FN

Febrile neutropenia

γ GT

Gamma glutamyl transferase

G-CSF

Granulocyte colony-stimulating factor

GC

Glucocorticoid

GCP

Good Clinical Practice

GC-MS

Gas chromatography-mass spectrometry

GLU

Glucose

HCT

Hematocrit

HGB

Hemoglobin

HPLC

High performance liquid chromatography

ICH

International Conference on Harmonization

icIEF

Imaged capillary isoelectric focusing

ICR

Imprinting Control Region

Ig

Immunoglobulin

IIV

Inter-individual variability

IPC

In-process control

iPSP

Initial Pediatric Study Plan

ISE

Integrated Summary of Efficacy

ISS

Integrated Summary of Safety

ITT

Intent-to-Treat

IV

Intravenous

IVTA

In Vivo Target Activation

Ka

Absorption rate constant

kDa

Kilodalton

LSMean

Least squares mean

LOR

Limit of report

MAA

Medicines Authorisation Application

mAb

Monoclonal Antibody

MCHC

Mean Corpuscular Hemoglobin Concentration

M-NFS-60

Mouse Leukemia G-CSF Cell Dependent

MEB

Medicines Evaluation Board

MHRA

Medicines and Healthcare products Regulatory Agency

MONO

Monocyte

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

| MI                    | Multiple imputation                                                    |
|-----------------------|------------------------------------------------------------------------|
| NEU                   | Neutrophil                                                             |
| NOAEL                 | No Observed Adverse Effect Level                                       |
| nrCE-SDS              | Non-reduced capillary electrophoresis-SDS                              |
| OD                    | Optical Density                                                        |
| PD                    | Pharmacodynamic                                                        |
| PEG                   | Polyethylene glycol                                                    |
| Peg                   | Pegfilgrastim                                                          |
| PES                   | Polyethersulfone                                                       |
| PFS                   | Pre-filled syringe                                                     |
| PK                    | Pharmacokinetic                                                        |
| PP                    | Per protocol                                                           |
| PS20                  | Polysorbate 20                                                         |
| RBC                   | Red Blood Cell                                                         |
| rCE-SDS               | Reduced capillary electrophoresis-SDS                                  |
| rhG-CSF               | Recombinant human granulocyte colony-stimulating factor                |
| RNS                   | Rigid needle shield                                                    |
| RP-HPLC               | Reverse phase high performance liquid chromatography                   |
| RPM                   | Revolutions per minute                                                 |
| SAE                   | Serious adverse event                                                  |
| SAP                   | Statistical Analysis Plan                                              |
| SC                    | Subcutaneous(ly)                                                       |
| SD                    | Standard deviation                                                     |
| SD rat                | Sprague-Dawley Rat                                                     |
| SDS-PAGE              | Sodium dodecyl sulfate- polyacrylamide gel electrophoresis             |
| SE-HPLC               | Size exclusion high performance liquid chromatography                  |
| SmPC                  | Summary of product characteristics                                     |
| SPA                   | Special Protocol Assessment                                            |
| STAT3                 | Signal Transducer and Activator of Transcription 3                     |
| Study 04 (05) (11631) | Study GC-627-04 (GC-627-05) (SP11631)                                  |
| t1/2                  | Apparent terminal elimination half life                                |
| TA                    | Docetaxel 75 mg/m2 + doxorubicin 60 mg/m2                              |
| TAC[500]              | Docetaxel 75 mg/m2 + doxorubicin 50 mg/m2 + cyclophosphamide 500 mg/m2 |
| TAC[600]              | Docetaxel 75 mg/m2 + doxorubicin 50 mg/m2 + cyclophosphamide 600 mg/m2 |
| TC                    | Docetaxel 75 mg/m2 + cyclophosphamide 600 mg/m2                        |
| TEAEs                 | Treatment-emergent adverse events                                      |
| TK                    | Toxicokinetics                                                         |

<div style=\"page-break-after: always\"></div>

| Tmax    | Time to Maximum Observed Concentration   |
|---------|------------------------------------------|
| US      | United States of America                 |
| V (V/F) | Volume of distribution (apparent V)      |
| WBC     | White Blood Cell                         |
| WFI     | Water for injection                      |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Evive Biotechnology Ireland Limited submitted on 9 September 2021 an application for marketing authorisation to the European Medicines Agency (EMA) for Ryzneuta, through the centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 10 December 2020.

The applicant applied for the following indication:

Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

## 1.2. Legal basis, dossier content

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application.

The application submitted is composed of administrative information, complete quality data, non-clinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies).

## 1.3. Information on Paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decisions PIP P/0414/2020 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0414/2020 was not yet completed as some measures were deferred.

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

<div style=\"page-break-after: always\"></div>

## 1.5. Applicant's request(s) for consideration

## 1.5.1. New active substance status

The applicant requested the active substance efbemalenograstim alfa contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union.

## 1.6. Scientific advice

The applicant did not seek scientific advice from the CHMP.

## 1.7. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Vilma Petrikaite Co-Rapporteur:  Tomas Radimersky

| The application was received by the EMA on                                                                                                                                                                                                                   | 9 September 2021   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| The procedure started on                                                                                                                                                                                                                                     | 30 September 2021  |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                                                                                                                 | 27 December 2021   |
| The CHMP Co-Rapporteur's first Assessment was circulated to all CHMP and PRAC members on                                                                                                                                                                     | 7 January 2022     |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on                                                                                                                                                                 | 3 January 2022     |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                                                                                                                      | 27 January 2022    |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                                                                                                                          | 19 May 2022        |
| The following GMP and GCP inspections were requested by the CHMP and their outcome taken into consideration as part of the Quality/Safety/Efficacy assessment of the product:                                                                                |                    |
| - A GCP inspection at 2 sites: Contract Research Organization in Canada between 21 March 2022 - 25 March 2022 and a remote inspection of the sponsor in China between 28 March 2022 - 8 April 2022. The outcome of the inspections carried out was issued on | 27 May 2022        |

<div style=\"page-break-after: always\"></div>

| - A GMP inspection at one manufacturing site in China between 28 August - 01 September 2023. The outcome of the inspection carried out was issued on                                     | 30 November 2023   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Questions to all CHMP and PRAC members on                          | 30 June 2022       |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                 | 7 July 2022        |
| The CHMP agreed on a list of outstanding issues in writing and/or in an oral explanation to be sent to the applicant on                                                                  | 21 July 2022       |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                          | 18 December 2023   |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on                 | 9 January 2024     |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Ryzneuta on | 25 January 2024    |
| Furthermore, the CHMP adopted a report on New Active Substance (NAS) status of the active substance contained in the medicinal product (see Appendix on NAS)                             | 25 January 2024    |

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

Ryzneuta is intended to be indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

This indication is the same as for the product Neulasta (pegfilgrastim), which was granted a marketing authorisation in EU on 22 August 2002.

## 2.1.2. Epidemiology and risk factors

Neutropenia, including the febrile neutropenia (FN) is frequent in patients using chemotherapy (ChT) regimens. According to the European Organisation for Research and Treatment of Cancer (EORTC) guideline,

<div style=\"page-break-after: always\"></div>

primary prophylactic granulocyte colony-stimulating factor (G-CSF) treatment is recommended in case the overall risk of FN for a patient is ≥ 20%. When using chemotherapy regimens associated with a FN risk of 1020%, particular attention should be given to the assessment of patient characteristics that may increase the overall risk of FN. Most standard-dose ChT regimens are associated with 6-8 days of neutropenia, and FN is observed in ∼ 8 cases per 1000 patients receiving ChT. FN is responsible for considerable morbidity as 20%30% of patients present complications that require in-hospital management, with an overall in-hospital mortality of ∼ 10% (Klastersky et al, 2016).

Evidence from multiple randomised trials supports the benefit of primary prophylaxis in reducing the frequency of hospitalisation for antibiotic therapy, documented infection, and rates of FN in adults. The impact on survival is less clear.

## 2.1.3. Aetiology and pathogenesis

Neutropenia, including the febrile neutropenia is characterised by decreased absolute neutrophil counts (ANC). There are many causes of a neutropenia, including the febrile neutropenia, and one of them is the treatment with cytotoxic ChT for malignancy.

## 2.1.4. Clinical presentation, diagnosis and stage/prognosis

There is a clear relationship between the severity of neutropenia (which directly influences the incidence of FN) and the intensity of ChT. Some chemotherapy regimens are more myelosuppressive than others. Currently, the different ChT regimens are classified as producing a high risk (&gt;20%), an intermediate risk (10%-20%) or a low risk (&lt;10%) of FN. Depending on the type of cytotoxic chemotherapy, the incidence rate and the magnitude of neutropenia might differ. High cyclophosphamide dose, etoposide and high anthracycline doses have been identified as significant predictors for severe neutropenia.

It has been shown that several factors, other than ChT itself, are responsible for increasing the risk of FN and its complications. Among them, age plays a major role with older patients having a higher risk of FN following ChT, with worse morbidity and mortality rates. Other factors are advanced disease, history of prior FN, no antibiotic prophylaxis or G-CSF use, mucositis, poor performance status and/or cardiovascular disease. The risk of FN and its complications increases when one or several co-morbidities are present in the patient. These considerations will be instrumental in deciding whether a ChT-treated patient should receive primary prophylaxis to decrease the potential risk of FN.

In the case of FN, prognosis is worst in patients with proven bacteraemia, with mortality rates of 18% in Gram-negative and 5% in Gram-positive bacteraemia (for bacteraemias due to coagulase-negative Staphylococcus only, no attributable mortality has been reported). The presence of a focal site of presumed infection (e.g., pneumonia, abscess, cellulitis) also makes the outcome worse. Mortality varies according to the Multinational Association of Supportive Care in Cancer (MASCC) prognostic index: lower than 5% if the MASCC score is ≥ 21, but possibly as high as 40% if the MASCC score is &lt;15.

## 2.1.5. Management

Prophylactic antibacterial, antifungal, and antiviral agents have been administered to prevent the development of infection as a complication of neutropenia. Granulocyte colony-stimulating factor (G-CSF) and

<div style=\"page-break-after: always\"></div>

granulocyte-macrophage colony-stimulating factor (GM-CSF) are used to reduce the duration and degree of neutropenia. G-CSF increases the proliferation and differentiation of neutrophils from progenitor cells, induces maturation and enhances the survival and function of mature neutrophils.

Recombinant hG-CSF (filgrastim) has been introduced in clinical use since 1991 under the trade name Neupogen. Recombinant hG-CSF is produced in E. coli . Its amino acid sequence is identical to that of natural human G-CSF, except for the addition of an N-terminal methionine necessary for the expression in E. coli and it is not glycosylated. The PEGylated formulation of G-CSF (trade name Neulasta), a recombinant Nmethionyl form of human G-CSF, covalently bound to a single 20 kDa polyethylene glycol (PEG) molecule, is produced in E. coli cells and is also modified with the addition of the N-terminal methionine. Lipegfilgrastim (trade name Lonquex) is a conjugate of recombinant N-methionyl human granulocyte-colony stimulating factor (r met-Hu-G-CSF, Filgrastim) and a single PEG molecule. To generate Lipegfilgrastim, a PEG molecule is covalently attached, via a carbohydrate linker, to filgrastim at Threonine134. This site-specific glycoPEGylation is achieved through sequential action of two recombinant glycosyltransferase enzymes, with activated sugar nucleotide donor substrates. The long-acting G-CSFs have prolonged half-life, permitting the administration of a single dose after each (generally weekly) chemotherapy cycle rather than daily administration.

## 2.2. About the product

Ryzneuta (also known as F-627 or efbemalenograstim alfa) is a biologic drug, intended to reduce the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). It is a recombinant fusion protein consisting of human G-CSF and human IgG2 Fc fragments. Ryzneuta is glycosylated with a molecular weight of approximately 94 kDa and is produced in CHO cells with a serum-free medium. Ryzneuta has an immunoglobulin-like structure with a G-CSF dimer at the N-terminal. Based on the design of the molecule, Ryzneuta is expected to have identical mode of action as filgrastim, lenograstim, and pegfilgrastim, with different pharmacokinetic (PK) and pharmacodynamic (PD) profiles.

The unique engineered Fc-fragment design of F-627 is expected to exhibit a long serum half-life and therefore reduce duration of neutrophil recovery in patients treated with chemotherapy and/or radiation with one administration per treatment cycle.

Ryzneuta is provided as a 20 mg/mL solution for injection in a 1 mL prefilled syringe (PFS) designed to administer the entire contents of the syringe. The targeted clinical dosing regimen is one 20 mg dose (a single pre-filled syringe) of Ryzneuta for each chemotherapy cycle, given at least 24 hours after cytotoxic chemotherapy.

## 2.3. Type of application and aspects on development

The development programme comprised a total of 10 clinical studies completed in over 1200 subjects.

Completed clinical studies include 2 Phase I studies in healthy males and 8 studies in women with breast cancer receiving chemotherapy, comprised of 3 Phase I studies, 2 Phase II studies, and 3 Phase III studies.

- A total of 54 healthy volunteers (all male) were subcutaneously (SC) administered efbemalenograstim alfa at doses ranging from 30 to 360 μ g/kg/dose or as a single 20 mg fixed dose. A total of 734 breast cancer patients were administered efbemalenograstim alfa at doses of 80, 240, or 320 μ g/kg/dose for up to 6 repeat doses, or as a 10 or 20 mg fixed dose for up to 4 doses. Following completion of two Phase II

<div style=\"page-break-after: always\"></div>

dose-ranging studies in breast cancer patients (SP-CDR-1-1302 [N = 138] and GC-627-02 [N = 232]), a fixed dose of 20 mg was selected for Phase III.

- The primary evidence for the establishment of a positive benefit-risk for efbemalenograstim alfa originates from 3 Phase III studies, particularly Phase III Study GC-627-04, that has established the efficacy of once-per-cycle efbemalenograstim alfa at a fixed dose of 20 mg over placebo in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in patients with cancer receiving myelosuppressive chemotherapy. Furthermore, the Phase III Studies GC-627-05 and SP11631 demonstrated that such efficacy was non-inferior to pegfilgrastim and filgrastim, respectively.

## 2.4. Quality aspects

## 2.4.1. Introduction

The finished product, Ryzneuta, is presented as a solution for injection containing 20 mg of efbemalenograstim alfa, as active substance, in 1 mL solution for injection.

Efbemalenograstim alfa is recombinant human granulocyte colony-stimulating factor Fc fusion protein derived from mammalian cell culture.

Other ingredients are: Sodium acetate trihydrate, glacial acetic acid, sorbitol (E420), polysorbate 20, edetic acid and water for injections.

The product is available in a pre-filled syringe (Type I glass), with a rubber stopper, stainless steel needle and needle cap. The needle cap on the prefilled syringe contains dry natural rubber.

## 2.4.2. Active substance

## General information

The recommended international non-proprietary (INN) name of the active substance is efbemalenograstim alfa. The company code of the active substance (AS), and consequently the finished product (FP), is F-627, which is used throughout the report, as F-627 AS and F-627 FP, respectively. The AS is also referred to as drug substance (DS). The FP is also referred to as drug product (DP).

F-627 AS is a recombinant fusion protein that is composed of human granulocyte colony-stimulating factor (G-CSF) moiety linked to a human IgG2-Fc though a 16-amino acid linker. F-627AS is expressed in a Chinese hamster ovary (CHO) cell line in serum-free culture and exists as a homodimer of 2 G-CSF-Fc molecules. F627 AS dimer contains 413 amino acids, 22 total cysteine residues involved 8 intrachain and 2 interchain disulfide bonds. Each F-627 molecule contains an N linked glycan at the consensus glycosylation site on Asn263. F-627 AS has an immunoglobulin-like structure.

<div style=\"page-break-after: always\"></div>

The G-CSF moiety of F-627 AS is a glycoprotein that functions with the same mechanism of action as its endogenous counterpart G-CSF and stimulates the survival, proliferation, differentiation and function of neutrophil precursors and mature neutrophils. It is used in the treatment of chemotherapy-induced neutropenia by enhancing the production of neutrophils. F-627 AS also binds to the Neonatal Fc Receptor (FcRn) which extends the serum half-life of F-627 AS. These interactions with G-CSF receptor and FcRn represent F-627 AS mechanism of action for its clinical potency.

## Manufacture, process controls and characterisation

## Description of manufacturing process and process controls

The active substance is manufactured at Evive Biopharmaceutical Beijing, Ltd, located at No. 99 Kechuang 14th street, BDA Beijing, China. Appropriate GMP documentation is available for all sites involved in manufacture and control of the active substance.

A valid GMP certificate for the AS manufacturer Evive Biopharmaceutical (Beijing) Ltd., located at Building 3 Floor 1 2 3, No 99 Kechuang 14th Street, Tongzhou, Beijing, 101111 China has been provided during the procedure, to address a major objection raised by the CHMP. F-627 AS is expressed by CHO cells in serumfree suspension culture. Each manufactured batch of F-627 AS is derived from a single vial of the Working Cell Bank (WCB). The AS is stored under long term conditions. Reprocessing steps have been adequately justified for two operations: viral filtration and formulated drug filtration.

Batch definition and nomenclature for the DS and the DP have been appropriately explained.

The description of the manufacturing process is sufficiently detailed, and its control strategy is considered adequate.

F-627 AS is packaged in a bag which complies with the requirements of the Ph. Eur and with EU Directive 10/2011. Specification of container closure system is aligned with the certificate of release provided by the supplier.

The extraction studies and compatibility of container system have been conducted.

Overall, the DS container closure system is found adequate.

## Control of materials

Materials used in the manufacturing process of F-627 AS, their application and corresponding quality standards were listed. Sufficient information on raw materials used in the AS manufacturing process has been submitted during the procedure. Compendial raw materials are tested in accordance with the corresponding monograph, while specifications (including test methods) for non-compendial raw materials are presented.

Manufacturer qualification and material testing policy was also provided and is acceptable.

During limiting subcloning of F-627 AS research cell bank (RCB) to produce F-627 AS MCB, a material of animal origin was used. An evaluation of potential TSE/BSE risk of F-627 FP is provided. The TSE/BSE risk from the MCB and from F-627 is negligible.

All used raw materials are from non-animal origin, except one material. component of the feed medium. Several virus control actions are performed prior to the peptone being used in the F-627 AS manufacturing.

<div style=\"page-break-after: always\"></div>

Acceptable documents have been provided for raw materials of biological origin used in the establishment of cell substrate.

Monoclonality of MCB was investigated and demonstrated. Different methods were used in case to ensure characterisation of monoclonality.

A two-tiered cell banking system is used, and sufficient information is provided regarding testing of MCB, WCB, end of production cells (EPC) and release of future WCBs. Genetic stability has been demonstrated for cells at and beyond the limit of cell age. Details of MCB, WCB and EPC preparation were provided. MCB, WCB and EPC are stored in polypropylene cryopreservation vials in vapor phase of liquid nitrogen. Routine characterisation of MCB and WCB was presented and is aligned with ICH Q5A and ICH Q5D guidelines, in combination with viral safety qualification. Stability testing plan for MCB and WCB was provided, and it is considered sufficient. A protocol for manufacture and qualification of future WCBs is provided.

## Control of critical steps and intermediates

A comprehensive overview of critical in-process controls (IPCs) and critical in-process tests performed throughout the manufacturing process of F-627 AS is given. Acceptable information has been provided on the control system in place to monitor and control the AS manufacturing process with regard to critical, as well as non-critical operational parameters and in-process tests. Actions taken if limits are exceeded are specified. Individual control parameters (process parameters and in-process tests) have been determined using quality by design (QbD) principles, such as evaluation of quality attributes, FMEA scoring, and categorization of individual process controls (critical, key, and non-key process parameters; critical and non-critical IPC). Process parameters were established through four sequential steps: FMEA, screening DOE, confirmatory DOE and final Critical Process Parameters assessment and proven acceptable ranges determination. Experimental data and statistical analysis results were submitted. All optimised operating parameters of the upstream and downstream processes were submitted and are considered acceptable. The acceptance criteria/expected ranges show reasonable agreement with the acquired data. Overall, F-627 AS manufacturing process is considered adequately controlled.

## Process validation

The F-627 AS manufacturing process has been validated adequately.

A series of chromatography resin are used for purification of multiple batches, and multiple cycles may be performed per batch, as supported by small scale resin recycle studies, which demonstrated that the cleaning and regeneration procedures used in commercial manufacturing had no adverse impact on viral clearance capability and minimal impact on product quality attributes.

Consistency in production has been shown on  consecutive full scale commercial batches manufactured according to a validation protocol and predefined product performance qualification (PPQ) acceptance criteria. The IPC, the unit operating ranges during the five PPQ runs, and the PPQ batch release data confirm that the control strategy performs as intended to consistently manufacture an AS, meeting predetermined quality attributes. It is confirmed that the process consistently produces F-627 AS of reproducible quality that complies with the predetermined specification and in-process acceptance criteria.

For the proposed reprocessing steps the applicant has provided qualification protocols which are considered acceptable.

F-627 AS shipping validation runs were presented for both air transportation and truck transportation, supporting the proposed conditions.

<div style=\"page-break-after: always\"></div>

## Manufacturing process development

The commercial AS manufacturing process was developed in parallel with the clinical development program. Several important changes have been introduced during the development of the manufacturing process, including optimizing the feeding strategy by switching continuous feeding to batch feeding, replacing the bioreactor for better microbial control, optimising and replacing with better performance chromatography resins, and optimising and implementing multiple robust virus removal or inactivation steps in the purification process of AS production.

Analytical comparability studies for batches manufactured at different production scales were conducted to support their introduction into clinical studies:

During process development, consecutive commercial-scale PPQ runs were performed. The information gathered during the PPQ campaign was used to review the PPQ control strategy which, in turn, it was optimised to become the commercial control strategy to ensure consistency of F-627 product quality and manufacturing process performance. The process parameters were updated with regards to input and output parameter category, operating ranges, and acceptance criteria for IPCs. The updated control strategy, resulting in the commercial control strategy, has been justified.

Changes introduced to the analytical methods during the process development are described in the dossier, of relevance is the change of the potency test as data from two methods is presented in the dossier.

## Characterisation

The F-627 AS has been sufficiently characterised by physicochemical and biological state-of-the-art methods revealing that the AS has the expected structure of recombinant fusion protein. Different AS batches have been included in the different characterisation studies. Most studies have been performed on the reference standard and on PPQ batches. An overview of the batches included in the different characterisation studies has been provided. The characterisation studies include release testing using the proposed commercial release analytical methods and extended characterisation methods to assess the primary, secondary and higher order structure, as well as post-translational modifications. The analytical results are consistent with the proposed structure. In addition, the biological and immunological characteristics have been sufficiently addressed. Furthermore, heterogeneity of the AS was adequately characterised through forced degradation studies. Post-translational modifications such as N- and O- glycosylation, and C-thermal Lysine truncations were determined. Biological characterisation of F-627 AS indicates that it has the ability to bind with high affinity to G-CSF and FcRn.

Product related impurities are controlled at product release and stability to ensure product quality and patient safety.

For the process reagents, the raw material safety risk assessment is performed. Clearance of process related impurities was assessed and there is no accumulation of these impurities. The evaluation of potential extractables and leachables at the level of F-627 AS, considering all materials that are in contact with AS during the process, including also the container closure system, were provided. The provided leachables study for the AS storage bag does not cover the whole proposed shelf-life of F-627 AS. The applicant is recommended to extend the duration of the leachables study to cover the whole proposed shelf-life of DS and the data should be submitted for review (REC). Furthermore, the extractable research report confirms no additional control is needed. In summary, the characterisation is considered appropriate for this type of molecule.

<div style=\"page-break-after: always\"></div>

## Specification

The proposed F-627 AS release and stability specifications have been provided. The release specification includes general tests (all Ph. Eur.), tests for identity, purity, impurities, potency, test for polysorbate 20, tests for safety (endotoxin, bioburden, both Ph. Eur.) and adventitious agents testing for unprocessed bulk.

The acceptance criteria were in some cases updated according to calculation (mean ± 3 SD); however, criteria are still outside of ranges that were found in clinical batches. The Applicant is recommended to revise and restrict the DS release and stability specifications, if possible, when data from an additional 30 batches are available (REC).

During the procedure the AS specification acceptance criterion for HCP have been tightened

The proposed release specification is in line with guidance and acceptable.

## Analytical methods

The analytical methods used have been adequately described and non-compendial methods appropriately validated in accordance with ICH guidelines.

The potency assay is used to determine the biological activity of F-627 AS.

## Batch analysis

Batch data from batches manufactured according to the proposed commercial manufacturing process has been provided, of which some at full scale. These batches include the PPQ batches and GMP batches used for method validation, stability studies and clinical and non-clinical studies. All batches meet the specification in place at time of testing. The provided batch data demonstrates adequate batch-to-batch consistency.

## Reference materials

reference standards have been qualified throughout the F-627 AS development history. The manufacturer qualified and used the Interim-1 reference standard as the potency assay standard throughout the entire F627 FP clinical development. This standard contained different excipients and container (glass vials) compared to the currently prepared AS.

During F-627 AS product development lifecycle, multiple interim reference standards were prepared and used for physical and chemical tests where the test values are not calculated based on the values of the reference standard. They were qualified against the previous standards (biochemical and physical tests). After initiation of phase III studies, primary reference standard (PRS) was prepared from a representative AS lot and fully qualified for all biochemical and physical test. An internal assay control was prepared from an independent representative AS lot and is used as assay control for potency assay. Until a working reference standard (WRS) is implemented, the PRS and Bioassay Control standard will be used as standards for commercial batch release and stability testing.

Future F-627 AS primary and WRS will be characterised against PRS.

The use of future Primary and Working RS will be subject to regulatory scrutiny.

<div style=\"page-break-after: always\"></div>

## Stability

Real time, real condition stability data on full scale batches of AS from the commercial manufacturing process stored in the intended container for up to 36 months according to the ICH guidelines were provided.

All samples stored at the recommended storage temperature met the stability specification acceptance criteria and demonstrate no significant trends through the latest time point tested.

The stability results indicate that the AS is sufficiently stable and justify the proposed shelf life in the proposed container.

Photostability testing following the ICH guideline Q1B was performed and demonstrate that F-627 AS is photostable.

Freeze-thaw stability studies were performed. The freeze and thaw process mimic the commercial freezethaw process during the FP production process. The data demonstrated that the F-627 AS can withstand three freeze-thaw cycles without compromise critical product qualities.

## 2.4.3. Finished medicinal product

## Description of the product and Pharmaceutical development

F-627 FP 20 mg/1mL solution for injection (Ryzneuta) is supplied as a sterile, preservative free, clear and colorless solution containing 20 mg of F-627 AS (efbemalenograstim alfa) as AS in a single use prefilled syringe for subcutaneous administration. F-627 FP is formulated with sodium acetate, sorbitol, polysorbate 20, EDTA, pH 5.2.

The FP has the identical formulation as the AS. No overages are used.

All excipients are well known pharmaceutical ingredients and their quality is compliant with pharmacopoeial standards. There are no novel excipients used in the finished product formulation.

The objective of the F-627 FP formulation development program was to develop a formulation that is stable and robust for manufacturing, storage, transportation, and administration of F-627 FP by subcutaneous injection. The F-627 FP was initially developed as a lyophilised powder for reconstitution for subcutaneous injection and it was used for nonclinical and early clinical trials to facilitate weight-based dose finding. A bridging study in human healthy volunteers demonstrated comparable PK from the two dosage forms. The development of the F-627 FP in PFS took into consideration the need of suitability of the excipients and the primary container closure system for subcutaneous injection and to maintain F-627 FP stability over the proposed shelf life.

The manufacturing process was developed to consistently produce a uniform FP of expected quality with minimal generation of additional impurities.  The F-627 FP manufacturing process includes thawing of the frozen AS solution, pooling and mixing, sterilisation via filtration, aseptic fill and finish and 100% visual inspection. A standard fill/finish process is used to fill and stopper the pre-filled syringes for F-627 FP. The specific critical product quality attributes were identified. QbD elements have been applied in the development of the finished product and their manufacturing process. However, no design spaces were claimed for the manufacturing process of the finished product. The quality target product profile has been provided during the procedure and it includes the following quality attributes: intended use in clinical setting

<div style=\"page-break-after: always\"></div>

(patient population), route of administration and regimen, safety and tolerability, pharmaceutical form(s) and strength(s), delivery systems, dose frequency and duration of treatment, shelf-life, transportation, in-use stability, sterility, tonicity, pH, excipients, and no preservatives.

The primary packaging is constituted by a syringe (Type I glass) with staked needle, a rigid needle shield covers the needle, and a bromobutyl rubber stoppers, flurotec coated. The materials comply with Ph. Eur. and EC requirements. A valid Notified Body Opinion for the syringe has been provided during the procedure to address a major objection raised by the CHMP. Toxicology assessment of the extractable compounds and elements from the container closure system concluded that even under worst-case daily exposure conditions, the compounds and elements identified from the Extractables study of F-627 FP in PFS pose no safety concern to patients except the unknown compound detected by LC-MS analysis. The compound was not detected in performed leachables study. The choice of the container closure system has been further validated by stability data and is adequate for the intended use of the product.

## Manufacture of the product and process controls

The manufacturer responsible for batch release of the FP is Catalent Germany Schorndorf GmbH, located at Steinbeisstrasse 1-2, D-73614 Schorndorf, Germany.

The applicant is recommended to replace the testing site and to transfer the testing methods, as per agreed plan (REC).

The F-627 FP manufacturing process includes thawing of the frozen AS solution, pooling and mixing, sterilisation via filtration, aseptic fill and finish and 100% visual inspection.

The manufacturing process has been validated. It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner. The in-process controls are adequate.

The control strategy for the F-627 FP sterile fill process includes microbial controls and fill uniformity controls through a combination of controls of process parameters and testing of in-process samples.

In-process controls (IPCs) are implemented to evaluate process performance. IPCs allow direct assessment of product  quality  or  process  consistency.  IPC  limits  are  predefined  based  on  results  obtained  from  process development, process characterisation and process validation runs.

The validation of F-627 FP 20 mg/1.0 mL solution for injection FP at commercial scale was performed at the proposed manufacturing site, which also manufactured all batches of F-627 FP 20 mg/1.0 mL solution for injection for US phase III clinical studies. The PPQ lots demonstrate that the Fill &amp; Finish process is reproducible and will consistently deliver DP syringes meeting pre-determined quality attributes for identity, strength, purity, safety, and quality of F-627 FP.

## Product specification

The proposed F-627 FP release specification, , includes general tests (all Ph. Eur), test for identity, purity and impurity tests, test for protein concentration, potency, test for polysorbate 20, tests for safety (endotoxin and sterility), container closure integrity and test for container closure functionality. Parameters included into

<div style=\"page-break-after: always\"></div>

the specification are adequate to control the quality of the F-627 at release.

The specifications have been set in line with experience gained during development and specifically with the data from clinical and PPQ batches.

The acceptance criteria were in some cases updated according to calculation (mean ± 3 SD); however, criteria are still outside of ranges that were found in clinical batches. The Applicant is recommended to revise and restrict the FP release and stability specifications, if possible, when data from an additional 30 batches are available (REC).

The majority of methods are used to control both the AS and finished product, except those related to the container closure system of the finished product.

Upon request of the CHMP, the potential presence of elemental impurities in the finished product has been assessed on a risk-based approach in line with the ICH Q3D Guideline for Elemental Impurities. Based on the risk assessment, it can be concluded that it is not necessary to include any elemental impurity controls. The information on the control of elemental impurities is satisfactory.

To address a major objection raised by the CHMP, a risk evaluation concerning the presence of nitrosamine impurities in the finished product has been performed considering all suspected and actual root causes in line with the 'Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products' (EMA/409815/2020) and the 'Assessment report- Procedure under Article 5(3) of Regulation EC (No) 726/2004- Nitrosamine impurities in human medicinal products' (EMA/369136/2020). Based on the information provided it is accepted that no risk was identified on the possible presence of nitrosamine impurities in the AS or the related finished product. Therefore, no additional control measures are deemed necessary.

## Analytical methods

The analytical methods used have been adequately described and (non-compendial methods) appropriately validated in accordance with ICH guidelines.

## Batch analysis

Batch analysis data on PPQ commercial scale batches and clinical batches of the finished product were provided. The results are within the specifications and confirm consistency of the manufacturing process.

## Reference materials

See discussion under AS.

## Stability of the product

A shelf-life of 36 months at 5°C ± 3°C and for up to 48 hours before use at room temperature (not above 30°C) is proposed.

Real time/real condition stability data of 3 commercial scale batches of finished product for up to 36 months (5°C ± 3°C) and for up to 6 months under accelerated conditions (25°C ± 2°C, / 60% ± 5% RH), according to the ICH guidelines were provided. The batches of finished product are identical to those proposed for marketing and were packed in the primary packaging proposed for marketing.

<div style=\"page-break-after: always\"></div>

The following parameters are tested during shelf-life: general tests, purity and impurity tests, protein concentration, potency, polysorbate 20, safety (sub-visible particulates and sterility). During stability studies of PPQ batches sterility test was replaced by CCIT test and it was declared that this test will be used during stability testing. The proposed stability tests and parameters are acceptable.

Based on available stability data, the shelf-life of 36 months at 5°C ± 3°C as stated in the SmPC are acceptable.

Photostability testing was performed on the AS only. Since the formulation of F-627 AS and FP is the same, stability profile obtained from AS is representative of that of FP. A short-term Time Out of Refrigerator photostability stability study was performed with a F-627 FP batch at controlled room temperature and ambient light condition. The results demonstrated that unprotected F-627 FP is stable for up to 7 days with no meaningful change under the studied condition.

## Adventitious agents

The range of viral testing for MCB, WCB and EPC is considered sufficient. All the characterization and testing results demonstrate that MCB and WCB are free of adventitious viruses and suitable for manufacturing F-627 Drug Substance for the commercial production. The EPC testing results demonstrate that F-627 cells are free of any tested virus at the end of bioreactor production.

Viral testing matrix for F-627 UPB is considered adequate. The retrovirus like particles (RLPs) testing is performed on the UPB for at least three GMP manufacturing lots. Each batch of UPB is routinely tested according to the release specification.

The F-627 downstream process was designed to have multiple effective, robust and orthogonal viral clearance (VC) steps including VI (viral inactivation) and viral removal, to ensure viral safety of the active substance. Multiple VC-steps were evaluated during Phase II and Phase III clinical stages.

Commercial VC (viral clearance) studies were performed on four model viruses. The virus selection is considered acceptable as it is based on potential viruses that may come from raw materials as contaminants and viruses with different physicochemical characteristics to represent a wide viral spectrum, per ICH Q5A. Prior to initiating the formal VC validation study, the preliminary VC experiments were performed.

Prior to the F-627 VC validation studies, multiple scale-down qualification runs were performed for chromatography columns, to demonstrate the representativeness of the column performance and product quality between the scale-down model and the commercial scale manufacturing process.

The Applicant provided summary of the results of VC studies for commercial production process, as well as the study reports.

The summary of overall Log10 reduction values for all four viruses was also provided.

The TSE/BSE risk is considered negligeable taking into consideration the virus removal steps and virus validation studies.

## GMO

Not applicable.

<div style=\"page-break-after: always\"></div>

## 2.4.4. Discussion on chemical, and pharmaceutical aspects

The applicant has applied QbD principles in the development of the AS and/or finished product and their manufacturing process. However, no design spaces were claimed for the manufacturing process of the AS, nor for the finished product. Information on development, manufacture and control of the AS and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use. During the procedure three major objections concerning 1. the GMP status of the AS manufacturer, 2. the provision of a Notified Body Opinion for the integral device and 3. the lack of a nitrosamine risk-assessment have been adequately addressed.

At the time of the CHMP opinion, there were a number of minor unresolved quality issues having no impact on the Benefit/Risk ratio of the product, which pertain revising the active substance and finished product specification once more batch data are available, replacing the testing sites and to transfer the testing methods, as per agreed plan, and the provision of additional stability data for a leachable study for the AS. These points are put forward and agreed as recommendations for future quality development.

## 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data has been presented to give reassurance on viral/TSE safety.

## 2.4.6. Recommendation(s) for future quality development

In the context of the obligation of the MAHs to take due account of technical and scientific progress, the CHMP recommends the following points for investigation:

1. The provided leachables study for active substance storage bag does not cover the whole proposed shelflife of the active substance (27 months from 36 months are covered by the leachables study). The applicant is recommended to extend the duration of the leachables study to cover the whole proposed shelf-life of the active substance and the data should be submitted for review by end of April 2024.
2. The applicant is recommended to revise the active substance release and stability specifications, when data from additional 30 batches are available.
3. The applicant is recommended to replace the testing sites and to transfer the testing methods, as per agreed plan.
4. The applicant is recommended to revise the finished product release and stability specifications for purity parameters (non-reduced and reduced CE-SDS LMWS fragments, and for SE-HPLC dimers and HMWS), when data from an additional 30 batches are available.

<div style=\"page-break-after: always\"></div>

## 2.5. Non-clinical aspects

## 2.5.1. Introduction

For the preparation of non-clinical studies, the applicant relied on the scientific knowledge for G-CSF and the published literature for the biological properties, including known non-clinical safety of the different constructs of rhG-CSFs.

The bioactivity of F-627 was evaluated in comparison with rhG-CSF (filgrastim) and pegfilgrastim. Experimental neutropenic animal models were used to evaluate the efficacy of F-627 in the treatment of neutropenia, including a 5-FU-induced neutropenia mouse model, a radiation induced neutropenia mouse model, and a cyclophosphamide (CY)-induced neutropenic monkey model.

## 2.5.2. Pharmacology

## 2.5.2.1. Primary pharmacodynamic studies

The Applicant submitted two in vitro investigations and six studies with mice, rats, and monkeys. The animal species and pathology models used is considered as relevant for the intended purposes.

In an in vitro study (F-627-BA-09-11-19), the activity of F-627 to stimulate M-NFS-60 cell line were evaluated and results were compared to rhG-CSF and pegfilgrastim activity. rhG-CSF, F-627 and pegfilgrastim were able to stimulate the proliferation of the cells in a dose-dependent manner. Thought, the F-627 EC50 was higher (695.5 pg/mL (7.77 pM)) compared to rhG-CSF and pegfilgrastim (129 pg/mL and 547 pg/mL, respectively).

Another in vitro study (F-627-BA-10-1-2.1) confirmed that addition of anti-human G-CSF mAb neutralized the proliferation of M-NFS-60 cells stimulated by F-627.

The results from studies in healthy rats (studies F-627-EF-Rat-081130 / F-627-EF-Rat-090203) showed that F-627 increased white blood cell (WBC) and neutrophil counts in a dose-dependent manner after a single SC injection. The minimal effective dose of F-627 in normal SD rats was 3 μ g/kg, which resulted in the same levels of WBC and neutrophils elevations as the daily injection of rhG-CSF.

A study in healthy female mice (F627-IVTA-100125) assessed the impact of F-627, pegfilgrastim, and rhGCSF to increase neutrophils and activation of STAT3 (Signal Transducer and Activator of Transcription 3) in the bone marrow. Results showed that F-627 increased ANC 2-5 times for up to 48 h and this increase persisted until 72 h. Mice treated with rhG-CSF showed an approximately 2-fold increase of ANC at 12 and 24 hours and returned to baseline at 48 hours. Mice treated with pegfilgrastim had an approximately 2-, 3-, and 2-fold increase of ANC at 12, 24, and 48 hours, respectively. Inequal increase in ANC can be related to inequal dosage of active substances as F-627 dose was 2.5 times higher (100 μ g/kg) than pegfilgrastim, and rhG-CSF (40 μ g/kg) in weight units (but equal in G-CSF molar). All test substances (rhG-CSF, pegfilgrastim, and F-627) increased approximately 17-20 times pSTAT3 at 1 hour compared to baseline. Pegfilgrastim and F-627 maintained high levels of pSTAT3 at 24 hours that returned to normal at 48 hours. Demonstrated increased neutrophil levels can be attributed to G-CSF receptor-mediated STAT3 activation in the bone marrow.

<div style=\"page-break-after: always\"></div>

In healthy male cynomolgus monkeys (study A200911-T007), F-627 (300 and 3000 μ g/kg dose)significantly increased leukocytes (WBC), including neutrophiles, values compared to the control group, reaching Cmax on day 3 and 6, whereas lymphocytes and monocytes were maximally increased at day 6. No other nonhaematologically important effects were observed in the study.

Neutropenic mice (study F-627-EF-Mic-090206/091023), treated with F-627 (at 30, 100, and 300 μ g/kg) or pegfilgrastim (100 μ g/kg) showed increased WBC including ANC levels on day 8. Furthermore, F-627 (100, 500 and 1500 μ g/kg) increased ANC in a dose-related manner at all checked points after neutropenia induction whereas pegfilgrastim (100 and 300 μ g/kg) showed a dose-response only on Day 10 and Day 12. The onset of neutrophils recovery was quicker in F-627 groups.

In sublethal irradiated and neutropenic mice (study F-627-EF-Mice-100104 &amp; 091118) F-627 significantly increased WBC and ANC count on Day 3 compared to carrier group. There was no ANC increase on day 6 but it recovered on day 14.

A study in monkeys with CY-induced neutropenia (A200911-P002) showed that treatment with F-627 at 60 μg/kg dose increased ANC values after Day 9 with similar trends as the pegfilgrastim group. F-627 and pegfilgrastim maintained increased ANC levels for 3 days in comparable manner in chemotherapy-induced neutropenic monkey.

Pharmacodynamic dose response data on statistical and biological significance level for  tested doses  were observed in  different  animal  species  (healthy  vs.  models)  including  time  and  dose  dependency  comparing pegfilgrastim and F-627. Approximately 3-4 times higher doses of F-627 are needed compared to pegfilgrastim to reach a similar effect on ANC reflecting the molecular weight differences of the two (1500 μ g/mL F-627 vs 300 μ g/mL for pegfilgrastim).

## 2.5.2.2. Secondary pharmacodynamic studies

No dedicated non-clinical studies were submitted by the applicant. This omission was justified with the evaluation of the clinical safety database regarding secondary effects of G-CSF, performed in 2012.

## 2.5.2.3. Safety pharmacology programme

The Applicant assessed in two studies in mice the possible impact of F-627 to central nervous system (CNS) and one in vitro study evaluating hERG Inhibition and risk to cardiovascular system.

Study results in Kun Ming (KM) mice (A200911-T081) showed no difference in the numbers of spontaneous activity and standing up of mice among the F-627 treated and control groups.

Additionally, possible synergistic effects of F-627 to KM mice on the general anaesthesia with pentobarbital sodium (study A200911-T084) did not reveal significant difference in sleeping time in test mice compared to the control group.

The assessment of activity to supress hERG with F-627 (100 ng/mL, 300 ng/mL, and 1000 ng/mL), showed little activity of test article to prolong heart QT interval because less than 15% potassium channel current of hERG was inhibited.

<div style=\"page-break-after: always\"></div>

## 2.5.2.4. Pharmacodynamic drug interactions

No dedicated studies were submitted since no relevant pharmacodynamics interactions unrelated to the mode of action of F-627 were identified in primary pharmacodynamics studies. This is considered acceptable.

## 2.5.3. Pharmacokinetics

F-627 PK data were obtained from studies performed in rat and monkey. Related toxicokinetic studies are presented in repeat-dose toxicity section.

Concentrations of F-627 and F-627 antibodies were quantified in rat and monkey blood or serum using ELISA and radiolabeled F-627 with Iodine methods. For GLP studies, validated methods were used for the quantification of F-627 in serum following standards at the time.

The study in rats (F-627-2011-PK-01) with F-627 DS dosed at 10, 30, and 100 μ g/kg SC indicate that Cmax and AUC increased with dose. Obtained clearance data were higher in 10 μ g/kg dose group (CL - 64±14 ml/h/kg) compared to 100 μ g/kg (24±3 ml/h/kg). Tmax and t1/2 values seem to be too dispersed (Tmax 12 h at 10, 30 μ g/kg dose and 22 h in 100 μ g/kg group, t1/2 - 25, 10 and 8 h). The Applicant considers the concentrations of F-627 increased non-proportionally with dose due to saturation of the receptors. Study results could be considered as orientational.

In study R16-026-QT, PK parameters of F-627 Drug Product in prefilled syringe (PFS) and F-627 Drug Product in Lyophilized (Lyo) form in SD rats after SC application at 285 μ g/kg dose were compared. The Cmax in PFS arm were 1766±279 ng/ml compared to 1290±144 ng/ml Lyo group or 36.9% higher. This resulted in 29.1% increase in AUC. Tmax was 24 h and t1/2 5.7 h in Lyo group and 5.4 h in PFS rats. The bioavailability of F-627 PFS and Lyo after SC administration were 46.3 % and 48.7 %, respectively.

The PK parameters were assessed from bridging toxicity study in healthy Cynomolgus monkeys (study A200911-T014(PK)) with F-627 injected SC at doses of 75, 225 and 675 μ g/kg and serum collected up to 168 h. For 225 μ g/kg, the mean AUC0-last for female and male monkeys was 47,750 and 35,588 ng/mL*hr with CL of 5 and 7 mL/hr/kg, respectively. In general, PK parameters were gender comparable.

F-627 Pharmacokinetics were explored in neutropenia (induced with CY) monkeys (study A200911-P002) with pegfilgrastim as comparator. The first dose was administered on Day 5 when the animals were in a severe neutropenic state. The second dosing was on Day 10 after CY-treatment when the animals were no longer neutropenic. After the first dose the tendency of higher exposure (Cmax, AUC and MRT) were observed compared to values after the second dose (e.g., in monkeys receiving the first dose 150 μ g/kg, the AUC0-last was 86434 and 82496 ng/mL*hr for female and male monkeys, respectively. In the same animals given the second dose, the AUC0-last was 14 301 and 12 796 ng/mL*hr for female and male monkeys, respectively). Comparable results were obtained in pegfilgrastim group (of note the MRT time appeared longer in pegfilgrastim group, especially after first dose). Opposite results were obtained for clearance - after first dose it was not intense (2-7 ml/h/kg) and increased after the second dose (12-24 ml/h/kg), similarly as in pegfilgrastim arm. The PK properties of monkeys receiving a second dose were similar to that of normal monkeys. The results demonstrated that the recovery of ANC after Day 9 for the 60 μ g/kg and 150 μ g/kg F627 groups showed similar trends as the pegfilgrastim group. This information is in line with study A200911P002 regarding the efficacy of F-627 in WBC and ANC recovery evaluated in neutropenic cynomolgus monkey model.

<div style=\"page-break-after: always\"></div>

Tissue distribution and excretion of F-627 after single dose administration (30 μ g/kg, SC) in SD rats was assessed in study F-627-Rat-Dis-R1. F-627 was radio-iodinated by chloramine T method. The rank order of 125I- F-627 exposure (0-36 h) was as follows:

Female rats: serum &gt; ovary &gt; oviduct &gt; spleen &gt; uterus &gt; liver &gt; pancreas &gt;adrenals &gt; heart &gt; intestine &gt; spinal cord &gt; adrenals &gt; bone marrow &gt; eyeball &gt;adipose &gt; muscle &gt; brain.

Male rats: serum &gt; lung &gt; spleen &gt; liver &gt; spermaduct &gt; pancreas &gt; heart &gt;intestine &gt; adrenals &gt; bone marrow &gt; testicles &gt; eyeball &gt; thymus &gt; spinal cord &gt;muscle &gt; adipose &gt; brain.

This confirm that F-627 is distributed through the whole organism with different extent and that F-627 degraded products and metabolites main excretion routes in rats is urine (57.9 %) and faeces (23.5%).

Omission of biotransformation studies in this application is in line with ICH guideline requirements and is acceptable.

Omission of pharmacokinetic drug interactions data is acceptable.

## 2.5.4. Toxicology

## 2.5.4.1. Single dose toxicity

The single dose toxicity was assessed in rat and monkeys in non-GLP studies. The observed non-lethal dose was the maximum dose used in both species (7500 µg/kg in rats and 3000 µg/kg in monkeys). Single dose rat and monkey studies identified dose related increases in WBC and neutrophils as expected from the pharmacology of a G-CSF analogue. Furthermore, main toxicities findings in the rat and monkey toxicity studies included spleen enlargement, and infiltration of neutrophils in specific organs, all of which were believed to be due to the exaggerated pharmacology effects of G-CSF. In the single-dose toxicity study in monkeys, a few animals presented lower serum GLU (which resulted in a 41.44% lower mean value) and mildly elevated ALP.

## 2.5.4.2. Repeat dose toxicity

One GLP repeat dose toxicity study in rats and three non-GLP repeat dose toxicity studies with weekly subcutaneous injection and recovery periods were conducted- 1-month, 3-month and 6-month duration in rat and 3-month duration in monkey. The duration of repeat-dose studies was based on the intended duration of clinical exposure and disease indication. This duration of animal dosing has generally been 1-3 months for most biotechnology-derived pharmaceuticals according to the ICH guideline S6 (R1). As F-627 is intended for short term use, 6-month repeat dose toxicity study were not required.

In the one-month dose-ranging study in SD rats, (A200911-T011-1) increase total numbers of leukocytes, granulocytes, monocytes and/or lymphocytes in peripheral blood were observed in all F627 treated groups. RBC, HGB, and HCT% decreased slightly at ≥ 100 μ g/kg while evidence of increased extramedullary hematopoiesis was observed in spleens of animals at ≥ 100 μ g/kg. Ductal enlargement in breast tissues was observed with necrotic tissues mixed with NEU in the lumen. These changes were reported frequently in all three F-627 dose groups and not observed in the control group. Minimal to slight changes to the mammary gland in rats are considered species-specific effects of F-627 and G-CSF compounds in general, which may

<div style=\"page-break-after: always\"></div>

interfere with the hormonal development of the mammary gland by the release of cytokines. These toxicological findings in rats are not considered clinically relevant.

In a 6-month repeated-dose toxicology study in rats (8357255), a drug-related serious chronic inflammation and osteogenic disorders of the tarsal bones, joints, and surrounding soft tissues leading to moribund conditions and unscheduled euthanasia was observed. Nearly all approved G-CSF therapies have shown chronic inflammation and bone effects in preclinical toxicology studies (rodents and NHPs without similar effects in neutropenic cancer patients treated with chemotherapeutics).

In a 3-month toxicity study in monkeys the glucose levels at 24 hrs after 5th dosing for F-627 75, 225, and 675 μ g/kg groups were significantly decreased by 73.5, 68.3, and 89.4% respectively (P ≤ 0.05). GLU values decreased at 24 hr after the last dosing by 28.8% and 36% for 75 μ g/kg and 225 μ g/kg groups (P ≤ 0.05), respectively. GLU values of F-627 dose groups were comparable to that of the control group by the end of recovery period. Additionally, several ECG changes were detected in monkeys. At 24 hrs after the 6th dosing for 75 and 675 µg/kg groups, the heart rates were increased (P ≤ 0.05), while the RR duration and Q-T intervals were shortened (P ≤ 0.05). Also, at 24 hrs after the 6th dosing, the QRS time shortened for 675µg/kg group (P ≤ 0.05). The P wave time decreased at 24 hrs after the last dosing for 225 g/kg group (P ≤ 0.05), but not dose dependent. Based on the nonclinical data, and other G-CSF therapies, the minor changes of the ECG parameters in nonclinical studies are considered toxicological non-adverse findings. Also, in monkeys (A200911-T014), myocardium necrosis with chronic inflammatory cell infiltration in control and dose groups were considered as spontaneous incidents.

As noted in single-dose toxicity studies, liver findings indicating potential hepatic injury have been observed in both species (as well as in clinical studies). In monkeys dosed weekly (A200911-T014), before the 3rd dosing, levels of C3 and C4 for 75, 225, and 675 μ g/kg increased significantly (P ≤ 0.05). These parameters at the rest of the time points were not different from those of control group. At the end of 3-month dosing and recovery period, levels of IgG, IgM and CIC for serum and urine were not different from those of control animals.

There was no gender difference in AUC and Cmax in rats after 1st dosing. The Cmax and AUC in male rats appeared to be lower than in female rats after last dosing. After 14 dosing, the AUC (0-168 h) and Cmax values were all decreased significantly in male and female animals compared to the 1st dosing.

## 2.5.4.3. Genotoxicity

No dedicated genotoxicity studies were submitted, which is acceptable in accordance with the ICH Safety Guideline S6(R1) Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals.

## 2.5.4.4. Carcinogenicity

No dedicated carcinogenicity studies were submitted, which is acceptable in accordance with the ICH Safety Guideline S6(R1) Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals.

## 2.5.4.5. Reproductive and developmental toxicity

There were no effects on any fertility endpoints detected during the fertility and early embryofetal development GLP study in rats at the dose 2-fold of the proposed clinical dose in humans.

<div style=\"page-break-after: always\"></div>

The Applicant submitted embryofetal development GLP studies in rats and rabbits The NOAEL was 750 μ g/kg/dose in rats and 100 μ g/kg/dose in rabbits, which is about 2-fold and 0,3-fold of human clinical dose accordingly.

PPND study was performed in rats. The route of administration of F-627 was subcutaneous injection since this is the route of clinical administration for humans. The increases in WBC parameters, including neutrophil counts, ant other hematological changes in F0 rats, were expected results based on the pharmacology of F627. No F-627-related effects were noted on the F1 generation at any dosage level. Therefore, NOAEL is the highest dose used, which is about 2-fold of the proposed clinical dose (20 mg/dose).

## 2.5.4.6. Local tolerance

F-627 is no local irritant and based on the 20-fold toxicological safety factor applied to the i.v. bolus dose in rabbits Single-dose and repeat-dose studies suggest no significant local side reactions are expected in humans who will receive much lower clinical doses. The complete recovery of the slight local reactions also suggests that the findings are likely related to repeated needle injection trauma and do not represent any specific toxic effects or local immunological reaction caused by the F-627.

## 2.5.4.7. Other toxicity studies

Tendency of ADA formation was assessed in repeat-dose toxicity studies in rats and monkeys. ADA developed for some animals in a dose independent manner. A dose and study duration dependent immunogenicity with the production of neutralizing anti-drug antibodies was observed in both tested species.

In rats, except for clearly pharmacologically driven effects such as bone marrow granulocyte proliferation and spleen extramedullary erythropoiesis (mainly granulocyte) a histopathological examinations also revealed islet granulocyte proliferation in hepatic sinusoids, increased thyroid granulocyte islet proliferation, increased granulocytes in pulmonary vasculature and alveoli, bone resorption and osteogenic disorders with synovial and adjacent tissue inflammation in ankle joints, ductal breast enlargement with necrotic tissues and granulocytes in the lumen.

In monkeys, dose dependent increase of granulocytes in the splenic red pulp inside capillaries of the liver and lungs was observed. The granulocytes (seen primarily as lobulated nuclear cells) in the bone marrow of animals in the 225 and 675 μ g/kg groups were also increased. Additionally, neutrophil infiltrations were found in the tongue mucosa of these two groups.

F-627 was administered at maximum dose 100 μ g/kg, 675 μ g/kg, and 1000 μ g/kg in toxicity studies with rabbits, monkeys, and rats respectively. This provides a safety margin of 0,19 (embryofoetal study), 2,5 (repeat-dose toxicity) and 4,7 (repat -dose toxicity) in terms of AUC0-t.

## 2.5.5. Ecotoxicity/environmental risk assessment

Based on the CHMP Guideline on the environmental risk assessment of medicinal products for human use (CHMP/SWP/4447/00 corr. 2) which states that proteins are exempted from the need to submit studies because they are unlikely to result in a significant risk to the environment due to their nature, the applicant submitted a justification for not submitting an environmental risk assessment, which is considered acceptable.

<div style=\"page-break-after: always\"></div>

## 2.5.6. Discussion on non-clinical aspects

The Applicant submitted data from two in vitro investigations and six studies with mice, rats, and monkeys. The animal species and pathology models used were considered relevant for the intended purposes.

An in vitro study confirmed the stimulatory effects of F-627 for M-NFS-60 cell line in a dose-dependent manner, with a higher EC50 compared to rhG-CSF and pegfilgrastim. In mice, F-627 increased neutrophils count and activated STAT 3 in the bone marrow at a level comparable to rhG-CSF and pegfilgrastim.

In a neutropenic mice study, the onset of neutrophils recovery was quicker in F-627 groups compared to pegfilgrastim. In a neutropenia model in monkey, F-627 and pegfilgrastim maintained increased ANC levels for 3 days in comparable manner without showing clear superiority.

The applicant justified the omission of NC Secondary Pharmacodynamics studies with the evaluation of the clinical safety database regarding secondary effects of G-CSF, including potential increased risk for malignancy, in 2012. The warning that granulocyte colony-stimulating factor (G-CSF) can promote growth of myeloid cells in vitro and similar effects may be seen on some non-myeloid cells in vitro is included in the SmPC section 4.4.

The PK parameters were assessed from bridging toxicity study in healthy Cynomolgus monkeys. Results demonstrates that PK profiles of F-627 were nonlinear. Clearance decreased with dose increase. Mean AUC0last and Cmax increased in more than a dose-proportional manner. Parameters were gender comparable. PK parameters determined in neutropenia (induced with CY) monkeys revealed the tendency of higher exposure (Cmax, AUC and MRT) after first dose compared to values after the second dose. Comparable results were obtained in pegfilgrastim group (of note the MRT time appeared longer in pegfilgrastim group, especially after first dose). Opposite results were obtained for clearance - after first dose it was not intense (2-7 ml/h/kg) and increased after second (12-24 ml/h/kg), similarly as in pegfilgrastim arm. The tissue distribution study in rats depicted radio-iodinated F-627 in majority of organs and tissue that presumably contained G-CSF receptors.

Overall weight of evidence did not suggest risks for drug induced liver injury (DILI). However, transient elevation of liver enzymes and TBIL can be expected as noted from clinical data with F-627 and with other GCSF class of products.

Many of the F-627-related effects in toxicity studies such as leg swelling, lameness, hematological changes, increased spleen weights, myeloid hyperplasia in bone marrow, extramedullary hematopoiesis, and microscopic findings in the footpad of animals (chronic inflammation of the tarsal bones, joints, and surrounding soft tissues) noted are consistent with responses in rats administered with G-CSF analogues lenograstrim or TS-DP2 (Lee et. al., 2015). However, several events, like decreased glucose level, ECG changes in monkeys, local reaction in the site of injection in local tolerance studies in rabbits were considered by the applicant as not F-627 related. The applicant´s rationale was based on the fact that in healthy settings (unlike neutropenic conditions) the exaggerated pharmacology of G-CSF therapies can lead to chronic inflammation and osteogenic disorders of bones, joints and soft tissues.

The range and type of genotoxicity studies routinely conducted for pharmaceuticals are not applicable to biotechnology-derived pharmaceuticals and therefore were considered by the applicant as not necessary. Moreover, the administration of large quantities of peptides/proteins may yield uninterpretable results. It is not expected for F-627 to interact directly with DNA or other chromosomal material, therefore carcinogenicity of F-627 was not assessed by Applicant. Furthermore, F-627 is unlikely to be carcinogenic in view of clinical experience with other G-CSF products, data from transgenic models of overexpression of G-CSF and short-

<div style=\"page-break-after: always\"></div>

term therapy. However, F-627 is a product which has the potential to support or induce proliferation of transformed cells and clonal expansion possibly leading to neoplasia. This is reflected in section 4.8 of the SmPC.

F-627 is a natural substance the use of which will not alter the concentration or distribution of the substance in the environment. Therefore, F-627 is not expected to pose a risk to the environment.

## 2.5.7. Conclusion on the non-clinical aspects

Overall, the primary pharmacodynamic studies provided adequate evidence that efbemalenograstim alfa possess G-CS properties and where applicable, safety relevant information has been included in the SmPC. From a non-clinical point of view, efbemalenograstim alfa has been adequately characterised and is recommended for marketing authorisation.

## 2.6. Clinical aspects

## 2.6.1. Introduction

## GCP aspects

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

A triggered GCP inspection of the pivotal studies at the sponsor, Evive Biotech (formerly Generon (Shanghai) Corporation Ltd.), China, and the CRO, Everest Clinical Research Corporation, Canada, was requested by CHMP. While the inspection revealed GCP deviations at both sites, the inspectors concluded that these deviations have no impact on the efficacy and safety results presented and therefore the data are considered reliable for regulatory decision-making.

<div style=\"page-break-after: always\"></div>

## · Tabular overview of clinical studies

Table 1. Summary of clinical studies evaluating the efficacy of Ryzneuta (F-627)

| StudyNumber      | Study Design                                                                                                                                                                                                                                                                           | TreatmentArms                                                                                                                                                                                  | Nunber of Treated Subjects by Treatment   | StudyPopulation/ Eligibility Criteria                                                                                                                                                            | Primary Efficacy Objective                                                                                                                                                                                                                                                       | Primary Efficacy Endpoint                |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|
| PhaseIII Studies |                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                |                                           |                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                  |                                          |
| GC-627-04        | Phase III, multicenter, randomized (2:1), multi- dose,double-blind,placebo- controlled,superiority study of4 21-day cycles of treatment in females with Stage II-IV breast cancer receiving concurrent TA chemotherapy Locations: Hungary, Russia, Ukraine, US                         | F-627 20 mg [PFS]/dosed on cycle Day 2) for 4 cycles Placebo/dosed on cycle Day 2 for 1 cycle + F-627 20 mg [PFS]/dosed on cycle Day 2 for3 cycles                                             | N=83 N=39 Total= 122                      | Females ≥18 and <75 years of age; diagnosis of Stage II- IV breast cancer in the adjuvant or metastatic setting: ECOG performance status ≤2; scheduled for chemotherapy                          | To evaluate the efficacy and safety ofF-627 given as a single 20 mg fixed-dose PFS in the subject's first chemotherapy cycle in comparison toPlacebo                                                                                                                             | Duration of Grade 4 NP in Cycle 1        |
| GC-627-05        | Phase IlI, multicenter, randomized,multi-dose, open-label, active controlled,non-inferiority study of4 21-day cycles of treatment plus6-month follow-up in females with Stage I-III breast cancer receiving concurrent TC chemotherapy Locations: Bulgaria, Hungary,Russia,Ukraine, US | F-62720 mg[PFS]/dosed on cycle Day 2 for 4 cycles Pegfilgrastim (Neulasta°) 6 mg/dosed on cycle Day 2 for 4 cycles                                                                             | N=197 N =196 Total=393                    | Females ≥18 years of age; diagnosis of Stage I-III invasive breast cancer that required neoadjuvant or adjuvant chemotherapy: ECOGperformance status ≤2; scheduled for TC chemotherapy treatment | To evaluate the efficacy ofF-627 given as a single fixed-dose (20 mg; PFS) as compared to Neulasta? standard dosing (6 mg) in the first chemotherapy cycle                                                                                                                       | Duration of Grade 4 NP in Cycle 1        |
| Study Nunber     | Study Design                                                                                                                                                                                                                                                                           | TreatmentArms                                                                                                                                                                                  | Number of Treated Subjects by Treatment   | StudyPopulation/ Eligibility Criteria                                                                                                                                                            | Primary Efficacy Objective                                                                                                                                                                                                                                                       | Primary Efficacy Endpoint                |
| SP11631          | Phase IlI, multicenter, randomized, open-label, multi-dose, active controlled,non-inferiority study of4 21-day cycles of treatmentinfemaleswith breast cancer receiving concurrent EC chemotherapy Location: China                                                                     | F-627 20 mg [PFS]/dosed on cycle Day 3 for 4 cycles Filgrastim (GRAN?) 5 μg/kg/day/dosed on cycle Day 3+ daily up to 2 weeks for 4 cycles                                                      | N=122 N= 120 Total = 242                  | Females, 18-75 years old; require adjuvant chemotherapy after radical mastectomy for breast cancer; planned to receive 4 cycles ofEC chemotherapy; ECOG performance status of≤2                  | To compare the efficacy of recombinant human granulocyte colony stimulating factor-Fc fusion protein (F-627) versusrecombinant human granulocyte colony stimulating factor (GRAN?) in Cycle 1 of prophylactic treatment in subjects with breast cancer receiving EC chemotherapy | Duration of Grade 3 or 4 NP in Cycle 1 1 |
| Phase II Studies |                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                |                                           |                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                  |                                          |
| SP-CDR-1-1302    | Phase II, multicenter, randomized, open-label, multi-dose, active- controlled,non-inferiority study of4 21-day cycles of treatment in postoperative breast cancerfemales receiving concurrent EC chemotherapy Location: China                                                          | F-627 20 mg [Lyo]/dosed on cycle Day 3 for 4 cycles F-627 10 mg [Lyo]/dosed on cycle Day 3)for 4 cycles Filgrastim (GRAN?) 5 μg/kg/day/dosed on cycle Day 3 + daily up to 2 weeks for 4 cycles | N=51 N = 42 N = 45 Total=138              | Females, 18-70 years old; postoperative patients with breast cancer who require adjuvant chemotherapy, and are planned to receive 4 cycles of EC chemotherapy: ECOG performance status ≤2        | To compare the efficacy ofrecombinant human granulocyte colony stimulating factor-Fc fusion protein (F-627) with recombinant human granulocyte colony stimulating factor (filgrastim) for prophylactic treatment in breast cancer patients receiving chemotherapy in Cycle 1     | Duration of Grade 3 or4 NP in Cycle 1    |

<div style=\"page-break-after: always\"></div>

| Study Number   | Study Design                                                                                                                                                                                                                                          | TreatmentArms                                                                                                                                                                                                                                  | Number of Treated Subjects by Treatment                                                          | Study Population/ Eligibility Criteria                                                                                                                                                                 | Primary Efficacy Objective                                                                                                                                                                                                                                                                     | Primary Efficacy Endpoint                                                                                                                                                                |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| GC-627-02      | Phase II, multicenter, randomized,multi-dose, open-label, active- controlled,non-inferiority study of4 21-day cycles of treatment in females with Stage I-IV breast cancer feceivingconcurrentTCor TAC[600] chemotherapy Locations:Russia,Ukraine, US | F-627 80 μg/kg [Lyo]/dosed on cycle Day2for 4 cycles (TC only) F-627 240 μg/kg [Lyo]/dosed on cycle Day 2 for 4 cycles F-627 320 μg/kg [Lyo]/dosed on cycle Day 2 for 4 cycles Pegfilgrastim (Neulasta) 6 mg/dosed on cycle Day 2 for 4 cycles | N =35 (TC = 35) N=67 (TC =37; TAC = 30) N=65 (TC=34; TAC = 31) N=65 (TC=35; TAC = 30) Total: 232 | Females,≥18and ≤75 years of age; diagnosis of Stage I- IV invasive breast cancer;ECOG performance status ≤2; scheduled for TC or TAC chemotherapy                                                      | To evaluate the efficacy ofthe F-627 given as a single dose (either 80. 240, or 320 μg/kg/dose) in each chemotherapy cycle in comparison to the standard dosing of Neulasta? (Neulastim? pegfilgrastim; 6 mg) in breast cancer subjects experiencing myelotoxic chemotherapy, either TC or TAC | Duration of Grade 3 or 4 NP in Cycle 1                                                                                                                                                   |
| PhaseIStudies  |                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                |                                                                                                  |                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                          |
| SP-CDR-1-1301  | Phase I, multicenter, open- label, multi-dose, dose- escalation study of621-day cycles of treatment in female postoperative breast cancer subjects receiving adjuvant TAC[500] chemotherapy Location: China                                           | F-627 240 μg/kg [Lyo]/dosed on cycle Day 2 for 6 cycles F-627 320 μg/kg [Lyo]/dosed on cycle Day 2 for 6 cycles                                                                                                                                | N=7 N=8 Total= 15                                                                                | Females, 18-75 years old; patients with breast cancer whorequireadjuvant chemotherapy after radical mastectomy, and are planned to receive 6 cycles of TAC chemotherapy; ECOG performance status of0-1 | Exploratory objective: To observe the number of days in which ANC is <0.5 x 109/L after the completion of chemotherapy in Cycle 1, the average time of ANC recovery, and the number of days in which ANC is <1 x 109/L                                                                         | Exploratory (PD) endpoints: The number of days in which ANC is <0.5 x 10%/L, the time of ANC recovery from nadir to 1.0 x 10%/L, and the number of days in which ANC is <1 x10%/L        |
| StudyNumber    | Study Design                                                                                                                                                                                                                                          | Treatment Arms                                                                                                                                                                                                                                 | Number of Treated Subjects by Treatment                                                          | Study Population/ Eligibility Criteria                                                                                                                                                                 | Primary Efficacy Objective                                                                                                                                                                                                                                                                     | Primary Efficacy Endpoint                                                                                                                                                                |
| 2012-F-627-CH1 | Phase I, single center,open- label, multi-dose, dose- escalation studyof4 21-day cycles of treatment in cancer subjects receiving female postoperative breast EC chemotherapy followed by paclitaxel or docetaxel and supportive care Location: China | F-627 80 μg/kg [Lyo]/dosed on cycle Day 3 for 4 cycles F-627 240 μg/kg [Lyo]/dosed on cycle Day 3 for 4cycles F-627 320 μg/kg [Lyo]/dosed on cycle Day 3 for 4 cycles                                                                          | N=6 N=6 N=6 Total = 18                                                                           | Females,18-75years old; postoperative breast cancer patients whorequire adjuvant are planned to chemotherapy and receive 4 cycles of EC chemotherapy; ECOG performance status of0-1                    | Exploratory objective: To observe the number of days in which ANC is <0.5×10%/L in Cycle 1 of chemotherapy, the mean time of ANC recoveryto1×109/L and the number of days in which ANC is <1 x 10°/L                                                                                           | Exploratory (PD) endpoints: The duration (days) and percentage of 10°/L, the ANC <0.5 x duration (days) and percentage of ANC <1.0 x 10°/L, and the time for ANC recovery to 1.0 x 109/L |
| SP11502        | Phase I, single center, open- label, multi-dose study of6 21-day cycles of treatment in female postoperative breast cancer subjects receiving adjuvant TAC[500] chemotherapy Location: China                                                          | F-627 320 μg/kg [Lyo]/dosed on cycle Day 1 for 6 cycles                                                                                                                                                                                        | N=7                                                                                              | Females, 18-75 years old; patients with breast cancer whorequire adjuvant chemotherapy after radical mastectomy; planned to receive 6 cycles of TAC chemotherapy; ECOG performance status of 0-1       | Exploratory objective: To observe the number of days in which ANC is <0.5 × 109/L, the average time of ANC recovery, and the number of days in which neutrophil count is <1.0 x 109/L after the completion of the Cycle 1 of chemotherapy.                                                     | Exploratory (PD) endpoints: The number of days when ANC is <0.5 × 10°/L,the number of days when ANC is <1.0 x 109/L, and the time of ANC recovery to 1.0 x 109L fromnadir                |

Abbreviations: ANC = absolute neutrophil count; EC = epirubicin 100 mg/m2 + cyclophosphamide 600 mg/m2; Eastem Cooperative Oncology Group (ECOG); Lyo = lyophilized formulation;NP=neutropenia;PD=pharmacodynamics;PFS=liquidform pre-filled syringe;PK=pharmacokinetic;TA=docetaxel 75mg/m²+doxorubicin 60 mg/m2; TAC[500] = docetaxel 75 mg/m2 + doxorubicin 50 mg/m2 + cyclophosphamide 500 mg/m2 chemotherapy; TAC[600] = docetaxel 75 mg/m2 + doxorubicin 50 mg/m2 + cyclophosphamide 600 mg/m²chemotherapy;TC=docetaxel 75 mg/m²+cyclophosphamide 600 mg/m²;US=United Statesof America.

A re-analysis of SP11631 was conducted in the ISE for the same primary endpoint as in GC-627-04 and GC627-05, that is the duration of Grade 4 (severe) neutropenia in Cycle 1.

<div style=\"page-break-after: always\"></div>

## 2.6.2. Clinical pharmacology

## 2.6.2.1. Pharmacokinetics

The clinical pharmacology program included 6 studies conducted in Australia, China, Europe, and the United States (Table 2). Two studies were conducted in healthy subjects and provided information on a single dose administration of F-627. Four studies were conducted in patients with breast cancer receiving myelosuppressive chemotherapy and provided multiple-dose information. All studies utilized absolute neutrophil counts (ANC) as the primary PD measure. The population PK and the PK/PD correlation were also evaluated. There were no clinical (or nonclinical) studies of F-627 specifically designed to assess drug-drug interactions.

Table 7. Overview of clinical pharmacology studies of Ryzneuta (F-627)

| Study Type                                                                                                                                                                                                                                                              | Protocol#/PKReport#                                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|
| Single DoseStudies in Healthy Subjects                                                                                                                                                                                                                                  |                                                                      |
| PhaseI single ascending dose study in healthy males A Phase I, open-label, comparative PK, PD and safety study of F-627 at a single dose of 20 mg either in liquid form in a pre-filled syringe or in lyophilizedform bysubcutaneous injection in healthy male subjects | GC-F-627-01/ GC-F-627-01-PK report GC-F-627-03/GC-F-627-03-PK-report |
| Multiple Dose Studies in Patients                                                                                                                                                                                                                                       |                                                                      |
| PhaseI ascending dose study in patients withbreast cancer receiving EC                                                                                                                                                                                                  | 2012-F-627-CH1/2012-F-627-CH1-PK-report                              |
| A Phase Ib clinical trial to evaluate the safety,PK and PD of F-627 in patients with breast cancer receiving TAC[500] (two F-627 doses: 240 μg/kg and 320 μg/kg)                                                                                                        | SP-CDR-1-1301/SP-CDR-1-1301-PK-rep0rt                                |
| A Phase Ib clinical trial to evaluate the safety,PK and PD of F-627 in  patients with breast cancer receiving TAC[500] (one F-627 dose: 320 μg/kg)                                                                                                                      | SP11502/SP11502-PK-report                                            |
| A Phase II, randomized, multi-center, open-label, fixed dose, Neulasta? active-controlled clinical trial ofF-627 in women with breast cancer receiving myelotoxic chemotherapy (sparse PK samples collected for population PK analysis)                                 | GC-627-05                                                            |

75 mg/m2 + doxorubicin 50 mg/m2 + cyclophosphamide 500 mg/m² chemotherapy

All PK parameters were calculated using conventional non-compartmental methods using actual times of sampling, unless otherwise stated in the clinical study report.

## Population PK model

The population PK analysis was conducted to characterize the PK profile of F-627 in healthy volunteers or patients with breast cancer after treatment with F-627. Data from six clinical studies, including four studies (2012-F-627-CH1, SP-CDR-1-1301, SP11502, and GC-627-05) in female patients with breast cancer receiving myelosuppressive chemotherapy and two Phase I PK studies (GC-F-627-01 and GC-F-627-03) in healthy male volunteers. The nonlinear mixed-effect model (NONMEM) dataset contained 3820 records from 289 patients, in which there were 2495 concentration records. All data were used for population PK analysis. Demographic and baseline characteristics of the patient populations, as well as formulation (liquid vs. lyophilized), weight-adjusted dose of F-627, and baseline ANC, were also included in this population PK analysis as potential covariates. To assess the impact of immunogenicity on the PK of F-627, both base

<div style=\"page-break-after: always\"></div>

model and final model were fit to the data, excluding 30 subjects whose immunogenicity test results were positive.

## Covariates

The following covariates were evaluated for their potential significant impact on the PK of F-627, if applicable: population: female with breast cancer, or male healthy volunteers, race, sex, body weight, body mass index (BMI), age, lean body mass (LBM), baseline ANC, weight-adjusted dosage level, and formulation.

## Methodology

Base structural model development was performed using a nonlinear mixed effect model (NONMEM). Covariate model development consisted of a stepwise forward selection and a backward elimination procedure. The likelihood ratio test was used to evaluate the significance of incorporating or removing covariates. Final model refinement included the exploration of model improvement through reparameterization, interpretation of magnitude of variability, interpretation of standard errors of the fixed and random effects parameters, and simplification of covariate model. Model evaluation was performed through visual predictive check. One thousand replicates of the original dataset were simulated, based on the final model, and a 90% prediction interval was computed based on the simulated datasets.

The one-compartment model with first order absorption and linear elimination kinetics adequately describes serum F-627 PK based on the data. Age and formulation have influence on the absorption rate constant (KA) of F-627. Dosing method, lean body mass, and age have effect on the apparent body clearance (Cl/F) of F627. The formulation was found to influence the apparent volume of distribution (Vz/F) of F-627. The exclusion of subjects with ADA positive results did not significantly change the final estimates and precision of PK parameters of base model or final model, suggesting that the immunogenicity has no effect on the PK of F-627.

Model validation was examined through an internal approach, visual predictive check (VPC).

## Statistical methods

All measured variables and derived parameters were listed individually and, if appropriate, tabulated by descriptive statistics. Descriptive statistics and summary tables include sample size, absolute and relative frequency of categorical variables and sample size, arithmetic mean, standard deviation, median, minimum, and maximum for means of continuous variables. Conventional statistical methods were used to test statistical hypotheses, unless otherwise stated in the clinical study report.

## Absorption

## Study GC-F-627-01

Study GC-F-627-01 was a Phase I, first-in-human, open-label, single-dose, dose-escalation study conducted in healthy male subjects. The primary objective was to assess the safety and tolerability of a single subcutaneous (SC) injection of F-627 in 30 healthy male subjects. The secondary objectives were to determine the PK/PD profiles of a single dose of F-627 at 30, 60, 120, 240, and 360 μ g/kg.

Mean Tmax values increased as dose increased, ranging from 9.33 ± 3.27 hr (for 30 μ g/kg doses) to 36.00 ± 0.00 hr (240 μ g/kg doses) and 32.67 ± 11.15 hr (360 μ g/kg). Between 30 μ g/kg and 360 μ g/kg (12-fold increase), the relationship was nonlinear with the mean value of Cmax increasing approximately 32-fold (30 μ g/kg: 21.33 ± 10.25 ng/mL; 360 μ g/kg: 692.67 ± 243.39 ng/ml). The relationship between dose level and AUC(0-inf) was nonlinear.

<div style=\"page-break-after: always\"></div>

Figure 6. PK Parameters by F-627 vs mean dose Level (mean ± SD) - Study GC-F-627-01

<!-- image -->

Table 3. Summary PK Parameters by F-627 Assigned Dose Level (mean ± SD) - Study GC-F-627-01

| DoseLevel   | Cmax (ng/mL)   | Tmax (hr)   | tμ(hr)      | AUC (0-inf) (hr*ng/mL)   |
|-------------|----------------|-------------|-------------|--------------------------|
| 30 μg/kg    | 21.3 ± 10.3    | 9.3±3.3     | 43.9 ± 9.3  | 777±213                  |
| 60 μg/kg    | 44.6± 17.7     | 10.7 ± 4.1  | 56.1±23.3   | 1847±686                 |
| 120 μg/kg   | 219.9± 76.6    | 19.3±8.2    | 59.3±23.5   | 8439±2769                |
| 240 μg/kg   | 758.8±160.1    | 36.0±0      | 62.8± 10.8  | 46664±17258              |
| 360 μg/kg   | 692.7± 243.4   | 32.7±11.2   | 71.4 ± 27.4 | 44087±18275              |

Figure 7 . Median F-627 Serum Concentrations versus Time Profiles Following Subcutaneous Administration of Single Doses of F-627 in Healthy Male Subjects (Log-Linear Scale) - Study GC-F-627-01

<!-- image -->

Note: From Appendix 2 in GC-F-627-01-PK report.

<div style=\"page-break-after: always\"></div>

## Study GC-F-627-03

This was a randomized, single center, open-label, PK, PD, and safety study of F-627 at a single SC dose of 20 mg, either in a liquid form in a pre-filled syringe (PFS) or in lyophilized form, in healthy male subjects. Early clinical studies had used the lyophilized formulation of F-627, and the subsequent Phase III studies were planned to use the liquid formulation in a PFS when the liquid formulation was developed. Twenty-four (24) male healthy subjects (12/group) were enrolled and randomly assigned to one of the two single dose groups of F-627 (20 mg liquid form or 20 mg lyophilized form). Blood samples for serum F-627 concentration measurements (PK samples) were collected on Day 1 before F-627 administration, at 0.5, 2, 4, 16, 24, 36, 48, 72, and 96 h after F-627 administration, and on Days 6 (120 h post-dose), 7, 9, 11, and 15.

After subcutaneous injection of F-627 at 20 mg doses, F-627 serum concentrations increased, the T1/2 values ranged from 40.52 to 81.12 hours in formulation liquid form prefilled syringe and from 27.64 to 103.85 hours in formulation lyophilized form. The MRT0-t values ranged from 37.09 to 55.53 hours in formulation liquid form prefilled syringe and from 38.01 to 56.07 hours in formulation lyophilized form. The Mean Vz\\_F\\_obs and Mean Cl\\_F\\_obs values were 42091.83 mL and 6.12 mL/hr/kg in formulation liquid form prefilled syringe and 71856.60 mL and 7.59 mL/hr/kg in formulation lyophilized form, respectively. The exposure of Mean Cmax and Mean AUC0-t values of F-627 were 1201.71 ng/mL and 76284.50 hr*ng/mL in formulation liquid form prefilled syringe and 908.76 ng/mL and 55590.05 hr*ng/mL in formulation lyophilized form respectively.

Table 4. Summary of Pharmacokinetics Parameters for F-627 in Human serum - Study GC-F-627-03

| Treatment                         | T12 (hr)       | Tmax (hr)       |   C max (ng/mL) |   AUCo-t (hr*ng/mL) |   VzF_obs (mL) |   ClF_obs (mL/hr/kg) |   MRTo-t (hr) |   AUCO-inf (hr*ng/mL) |   MRTO-inf (hr) |   Difference % |
|-----------------------------------|----------------|-----------------|-----------------|---------------------|----------------|----------------------|---------------|-----------------------|-----------------|----------------|
| F-627LiquidForm Prefilled Syringe | 58.72          | 36.00           |         1201.71 |             76284.5 |        42091.8 |                 6.12 |         44.38 |               76357   |           45.12 |           31.4 |
|                                   | (40.52-81.12)  | (24.00 - 48.00) |          669.8  |             49527.8 |        47469.7 |                 5.96 |          4.82 |               49512.6 |            4.54 |           31.4 |
| F-627Lyophilized Form             | 63.86          | 36.00           |          908.76 |             55590.1 |        71856.6 |                 7.59 |         45.93 |               55674.2 |           47.45 |           31.4 |
| F-627Lyophilized Form             | (27.64-103.85) | (16.00-48.00)   |          474.41 |             29727.8 |       125447   |                 9.44 |          5.2  |               29700.6 |            7.47 |           31.4 |

Difference%ofAUCo-t=(AUCo.fromformulation1-AUCo.fromformation2)/MeanofAUCo.from twoformation)*100%

X1=Ti2(h) and Tmax(h)is median value(range),otherparameters are meanvalue(standard deviation).

<div style=\"page-break-after: always\"></div>

Figure 8. Mean Concentrations (ng/mL) of F-627 in Human Serum: Dose Level 20 mg (n=12) - Study GC-F627-03

<!-- image -->

Note:From GC-F-627-03-PK-report (Figure B.1)

## Study 2012-F-627-CH1

Study 2012-F-627-CH1 was a single-center, open-label, single-dose, and repeated-dose Phase I clinical trial in female patients with postoperative breast cancer who require adjuvant chemotherapy. This study included 3 dose cohorts, 80, 240, and 320 μ g/kg of F-627, each of which enrolled 6 subjects sequentially, for 18 subjects total. Subjects in each cohort received a single dose of F-627 by SC injection 48 h (2 days) after the completion of chemotherapy.

Cmax (Cycle 1- Cycle3) was 25.77 (7.22) - 29.06 (27.53) in 80 (μ g/kg) dose group, 226.80(101.70) - 73.09 (26.16) in 240 ( μ g/kg), 192.87 (76.06 ） - 85.17 (46.71 ） in 320 ( μ g/kg), AUC0-t (h*ng/mL) 2477.75 1586.35 in 80 (μ g/kg), 15230.79 - 4347.35 in 240 ( μ g/kg), and 19858.38 - 6556.98 in 320 ( μ g/kg). Dose increase led to higher exposure. The PK results showed that Cmax and AUC0-t of the 80 and 240 μ g/kg cohorts increased with the increasing dose in Cycles 1 and 3, with significant dose relevance.

Table 5. Mean PK parameters of each dose cohort - PK analysis set - Study 2012-F-627-CH1

| Dose (μg/kg)   | Cycle                        | T2*(h)               | Cmax(ng/mL)         | Imax X(h)               | AUCo- (h*ng/mL)            | IA (mL/ kg)               | CI/F (mL/h/kg)      | MRIo (h)      |
|----------------|------------------------------|----------------------|---------------------|-------------------------|----------------------------|---------------------------|---------------------|---------------|
| 80             | 49.88 1 (38.71-76.67)        | 25.77 (7.22)         | 24.00 (12.00-36.00) | 2477.75 (661.64)        | 2457.22 (975.35)           | 31.34 (7.14)              |                     | 86.85 (11.70) |
|                | 73.44 3x (55.28-210.58)      | 29.06 (27.53)        |                     | 12.00 (5.80-12.00)      | 1586.35 (632.57)           | 6196.75 (3477.13)         | 45.41 (16.47)       | 87.08 (18.97) |
| 240            | 34.71 1 (19.39-86.05)        | 226.80 (101.70)      | 36.00               | (12.00-48.00)           | 15230.79 (4851.43)         | 1238.80 (1336.92)         | 17.11 (6.94)        | 61.98 (18.90) |
|                | 61.95 3 (45.79-131.79) 56.37 | 73.09 (26.16) 192.87 |                     | 9.10 (6.00-24.20) 48.15 | 4347.35 (2135.28) 19858.38 | 6132.23 (2997.45) 1597.02 | 62.45 (35.67) 18.89 | 75.61 (7.44)  |
| 320            | (31.14-112.95) 44.58         | (76.06)              |                     | (24.30-120.20)          | (7503.75)                  | (646.10)                  | (9.78)              | 88.69 (18.73) |
|                | 3 (31.05-109.27)             |                      | 85.17 (46.71)       | 12.00 (11.50-12.00)     | 6556.98 (2683.30)          | 4079.81 (2189.98)         | 56.38 (26.24)       | 96.29 (25.61) |

X1 = median Ti2 (hr) and Tmax (hr)

X2=Since 2 blood sampling time points were missing for one subject in this cohort ( in the 240μg/kg cohort developed febrile neutropenia on day 9 of cycle 1 and was treated with GRAN? for 2 days. Therefore, PK blood sampling inaccurate. Except for Tmsx and Cmax all other parameters were calculated for reference only and were not included in the calculation of mean and median.

Datasource:PKStudyReportForm1

<div style=\"page-break-after: always\"></div>

## Study SP11502

Study SP11502 was a single-center, open-label Phase Ib clinical study in female patients with breast cancer who received the TAC chemotherapy. Study SP11502 enrolled 7 subjects with breast cancer who received up to 6 cycles of TAC chemotherapy at 21-day intervals. In each cycle, F-627 (320 μ g/kg) was administered by SC injection within 4 h after the completion of myelotoxic chemotherapy.

The mean Pharmacokinetic Parameters for F-627 in Human serum are presented in the table below.

Table 6. Summary of Mean Pharmacokinetic Parameters for F-627 in Human serum - Study SP11502

|   Cycle |   Dose (μg/kg) | t1/2 (h)   | Tmax (h)   | Cmax (ng/mL)   | AUCo-t (h*ng/mL)   | AUCo-inf (h*ng/mL)   | Vz/F (mL/kg)   | CI/F (mL/h/kg)   |
|---------|----------------|------------|------------|----------------|--------------------|----------------------|----------------|------------------|
|       1 |            320 | 41.81      | 36.00      | 294.59         | 25142.48           | 33352.07             | 1295.41        | 17.88            |
|       1 |            320 | (53.11)    | (13.15)    | (191.50)       | (19402.86)         | (24102.32)           | (958.63)       | (16.23)          |
|       3 |            320 | 41.29      | 24.00      | 222.61         | 14359.26           | 14462.68             | 2945.99        | 26.23            |
|       3 |            320 | (39.80)    | (10.73)    | (164.68)       | (6383.90)          | (6360.73)            | (2554.60)      | (12.43)          |

Note:DerivedfromSP11502-PK-reportTable 2.

## Study SP-CDR-1-1301

Study SP-CDR-1-1301 was a Phase Ib clinical trial to evaluate F-627 as a supportive therapy in postoperative patients with breast cancer receiving myelotoxic chemotherapy. Eligible subjects were chemotherapy-naïve. The adjuvant chemotherapy regimen for this trial was TAC, that is docetaxel 75 mg/m2, IV + doxorubicin 50 mg/m2, IV + cyclophosphamide 500 mg/m2, IV on Day 1; repeat cycle every 21 days for 6 cycles.

The mean concentrations of F-627 in human serum are presented in the table below.

Table 7. Summary of Mean Pharmacokinetic Parameters for F-627 in Human Serum (in Clinical pharmacology overview) - Study SP-CDR-1-1301

|   Cycle |   DoseLevel (μg/kg) |   t1/2 (l) |   Tmax (h) |   Cmax (ng/mL) |   AUCo-t (h*ng/mL) |   Vz/F (mL/kg) |   CI/F (mL/h/kg) |
|---------|---------------------|------------|------------|----------------|--------------------|----------------|------------------|
|       1 |                 240 |      48.3  |         36 |         216.4  |            21629.3 |        1594.98 |            19.58 |
|       3 |                 240 |      37.12 |         24 |         174.37 |            12358.8 |        2131.57 |            40.89 |
|       1 |                 320 |      47.7  |         36 |         315.13 |            30741.7 |         755.45 |            13.52 |
|       3 |                 320 |      43.16 |         30 |         278.75 |            18264.2 |        2059.22 |            27.97 |

1t12 and Tmax are median values.

Note:DerivedfromSP-CDR-1-1301-PK-report:Table1.

Table 8. Summary of Mean Pharmacokinetic Parameters for F-627 in Human Serum - SPC-CDR-1-1301.

| Cyc le   |   Dose Level (bx/a1) |   T12 (hr) |   (hr) |   (ng/mL) |   AUCo-t (hr*ng/mL) |   Vz obs (mL/kg) |   CI/F obs (mL/hr/kg) |   MRTnt (hr) |   DNC mx (kg*ng) mL/ug) |   DNAU Co-t (kg*hr* ng/ mL/ug) |
|----------|----------------------|------------|--------|-----------|---------------------|------------------|-----------------------|--------------|-------------------------|--------------------------------|
| 1        |                  240 |      47.42 |  47.25 |    200.7  |             19941.8 |          1476.08 |                 20.82 |        81.46 |                    0.84 |                          83.09 |
|          |                  240 |      41.4  |  42.75 |    157.07 |             11261   |          2555.6  |                 43.94 |        84.26 |                    0.65 |                          46.92 |
| 1        |                  320 |      49.76 |  41.14 |    347.18 |             33972.1 |           754.41 |                 11.42 |        70.49 |                    1.08 |                         106.16 |
| 3        |                  320 |      43.06 |  30.86 |    313.42 |             20362.5 |          1564.27 |                 22.63 |        64.45 |                    0.98 |                          63.63 |

<div style=\"page-break-after: always\"></div>

## Study GC-627-05

This was a Phase III, multicenter, randomized, open-label, two arm, active-controlled study which randomized female subjects with Stage I to III invasive breast cancer who were receiving neoadjuvant or adjuvant myelotoxic Taxotere® + cyclophosphamide (TC; 75 mg/m2 docetaxel + 600 mg/m2 cyclophosphamide) chemotherapy treatment. Subjects may have been scheduled for more than 4 cycles of chemotherapy; however, study participation was limited to a subject's first 4 cycles. Qualified subjects were randomized to 1 of 2 arms in a 1:1 ratio (20 mg F 627:6 mg Neulasta) using a central web-based randomization system on Day 1 of the first chemotherapy cycle. Actual enrolment was 393 subjects, 197 in the F-627 arm and 198 in the pegfilgrastim arm. Subjects were administered the study drug according to their randomization arm one day after chemotherapy in each cycle (Day 2 of each cycle). Blood samples for F-627 serum concentration measurement were taken for all subjects randomized to the F-627 treatment arm only. Three serum samples were taken at pre-dose and on Study Days 4 and 8 of chemotherapy in Cycles 1 and 3. This corresponded to Days 2, 4, and 8 for Cycle 1 and Days 44, 46, and 50 for Cycle 3. The serum concentrations were used to assess the population PK and PD of F-627.

In this study it was shown that mean concentrations are lower in Cycle 3 and in later days of administration (e.g. Day 1 vs. Day 8).

Table 9. F-627 Serum Concentrations (ng/mL) by Cycle and Study Day - Study GC-627-05

|                 | Day   | #ofBLQ   | N   | Mean (SD)     | Median   | Min, Max    |
|-----------------|-------|----------|-----|---------------|----------|-------------|
| All Subjects    |       |          |     |               |          |             |
| Cycle 1         | Day2  | 192      | 0   | N/A           | N/A      | N/A         |
|                 | Day4  | 2        | 190 | 918.7 (660.5) | 840.7    | 7.39, 4621  |
|                 | Day 8 | 1        | 192 | 192.8 (268.9) | 61.8     | 2.16, 1357  |
| Cycle 3         | Day 2 | 184      | 5   | 5.22 (7.10)   | 1.88     | 1.67, 17.9  |
|                 | Day4  | 3        | 181 | 543.4 (496.5) | 429.0    | 3.77, 2489  |
|                 | Day 8 | 2        | 183 | 90.3 (193.4)  | 23.9     | 3.88,1399   |
| Age≥65Years Old |       |          |     |               |          |             |
| Cycle 1         | Day2  | 25       | 0   | N/A           | N/A      | N/A         |
|                 | Day4  | 0        | 26  | 787.9 (714.1) | 505.2    | 20.9, 2422  |
|                 | Day 8 | 0        | 26  | 231.6 (313.8) | 83.9     | 7.02, 1357  |
| Cycle 3         | Day2  | 22       | 2   | 2.23 (0.784)  | 2.23     | 1.67, 2.78  |
|                 | Day4  | 0        | 24  | 440.1 (404.5) | 320.9    | 22.5,1215   |
|                 | Day 8 | 1        | 22  | 72.6 (104.7)  | 32.2     | 4.48, 425.6 |
| Age<65YearsOld  |       |          |     |               |          |             |
| Cycle 1         | Day2  | 167      | 0   | N/A           | N/A      | N/A         |
|                 | Day 4 | 2        | 164 | 939.5 (651.5) | 865.8    | 7.39, 4621  |
|                 | Day 8 | 1        | 166 | 186.7 (261.7) | 55.1     | 2.16,1266   |
| Cycle 3         | Day2  | 162      | 3   | 7.21 (9.25)   | 1.88     | 1.86, 17.9  |
|                 | Day4  | 3        | 157 | 559.2 (508.4) | 434.2    | 3.77, 2489  |
|                 | Day 8 | 1        | 161 | 92.7 (202.6)  | 23.7     | 3.88, 1399  |

Note: BLQ = below the lower quantifable limit; Max = maximum; Min = minimum; N/A = not available; SD = standard deviation. Note:FromPopulationPKReport:Table 2.

<div style=\"page-break-after: always\"></div>

Table 10. Serum Concentrations (ng/mL) by Cycle and Study Day after Excluding ADA Positive Subjects Study GC-627-05

|         | Day   |   #ofBLQ |   N | Mean (SD)     | Median   | Min,Max    |
|---------|-------|----------|-----|---------------|----------|------------|
| Cycle 1 | Day 2 |      162 |   0 | N/A           | N/A      | N/A        |
|         | Day 4 |        1 | 161 | 900.3(656.9)  | 835.4    | 7.39,4621  |
|         | Day8  |        1 | 162 | 183.2(259.2)  | 60.7     | 2.16, 1357 |
| Cycle3  | Day2  |      156 |   3 | 7.45 (9.06)   | 2.78     | 1.67, 17.9 |
|         | Day 4 |        3 | 152 | 526.1 (489.2) | 411.3    | 6.20,2489  |
|         | Day 8 |        2 | 154 | 86.1 (177.0)  | 23.9     | 3.88,1325  |

Note:ADA=anti-drugantibody,BLQ=belowthelowerquantifiablelimit;Max=maximum;Min=minimum;N/A=notavailable; SD=standarddeviation.

Note:FromPopulationPKReport:Table3

## Distribution

## F-627 Population PK Analysis

In the final POP PK model apparent volume of distribution (V/F) was 20.3 (95% Bound: 16.6, 24.0).

The final population V/F was expressed as: (1) for liquid formulation, TVV = 7, (2) for lyophilized formulation, TVV = 20.3. Population apparent volume of distribution (V/F) was 20.3 L as assessed with POP PK.

## Elimination

## Excretion

## Study GC-F-627-01

There was no clear trend for change in t 1/2 across the dose levels. Apparent clearance, decreased markedly with an increase in dose which tended to reach a plateau at 240 and 360 μ g/kg dose.

The half-life and clearance did not change in a dose dependent manner. Elimination of efbemalenograstim alfa is non-linear with respect to dose.

The lyophilized form seemed to have a greater clearance than the PFS formulation.

## Metabolism

Metabolism studies were not conducted. This is considered acceptable.

## Dose proportionality and time dependencies

Single-dose PK and PD of F-627 administered subcutaneously (SC) to healthy males were characterized over a sequential range of doses (30, 60, 120, 240, and 360 μ g/kg;), with 6 subjects per dose level (GC-F-62701). Nonlinearity was observed in both the rate and extent of F-627 exposure, measured by mean maximum concentrations (Cmax) and area under the curve (AUC), respectively, with increased dose. Over the 12-fold range of doses (from 30 μ g/kg to 360 μ g/kg), mean Cmax increased by approximately 32-fold (from 21 ng/mL for the 30 μ g/kg dose to 693 ng/ml for the 360 μ g/kg dose) and mean Tmax was delayed from 9 hours (30 μ g/kg dose) to 33 hours (360 μ g/kg dose). Similarly, a 60-fold increase in AUC from 30 μ g/kg to 360 μ g/kg was observed, although AUC values plateaued at the two highest doses (240 μ g/kg and 360 μ g/kg). Of note, apparent clearance (CL) decreased with increased dose, with a similar plateauing observed at the two highest doses, indicating a saturable clearance mechanism at the higher serum F-627

<div style=\"page-break-after: always\"></div>

concentrations.

Nonlinearity of F-627 PK was also observed in female breast cancer patients receiving adjuvant chemotherapy regimens of EC (2012-F-627-CH1) and TAC (SP-CDR-1-1301 and SP11502). In the first 2 studies, F-627 was administered at least 24 hours after chemotherapy, whereas the latter study tested F-627 administration on the same day as chemotherapy. The PK of F-627 was evaluated in Cycles 1 and 3 and in all three studies the Cmax and AUC0-t increased, and CL decreased, in a dose-dependent manner; however, Cmax, and AUC0-t were generally much lower in Cycle 3 than in Cycle 1. Greater than dose proportional increases in F-627 Cmax and AUC0-t were observed overall, with a larger magnitude of PK nonlinearity observed in Cycle 1 compared to Cycle 3. Similar to healthy subjects for the 2 higher doses, serum F-627 concentration in each dose peaked at 24 to 48 hours after dosing, and gradually declined over time with a mean elimination half-life (t1/2) in Cycle 1 of about 48 hours (range: 19 to 84 hours; SP-CDR-1-1301). Overall, the PK of F-627 was highly variable.

## Study GC-F-627-01

Cmax  was  examined  in  relation  to  dose  level.  Between  30 μ g/kg  and  360 μ g/kg  (12-fold  increase),  the relationship was nonlinear with the mean value of Cmax increasing approximately 32-fold (30 μ g/kg: 21.33 ± 10.25 ng/mL; 360 μ g/kg: 692.67 ± 243.39 ng/ml).

Figure 9. Cmax was examined in relation to dose level - Study GC-F-627-01

<!-- image -->

<!-- image -->

AUC(0-inf) was used to investigate dose-dependencies. The % extrapolated AUC (from last measured time point to infinity) was low (8.00 ± 3.57%, 5.27 ± 3.16%, 0.86 ± 0.64%, 0.18 ± 0.13% and 0.23 ± 0.15% for 30, 60, 120, 240 and 360 μ g/kg, respectively). The relationship between dose level and AUC(0-inf) was nonlinear which was in support of the Cmax vs. Dose data discussed above.

Figure 10. AUC was examined in relation to dose level - Study GC-F-627-01

<!-- image -->

Thus, the PK of Ryzneuta is non-linear.

The time dependency was addressed in clinical pharmacology studies Study 2012-F-627-CH1, Study SP-CDR-

<!-- image -->

<div style=\"page-break-after: always\"></div>

1-1301, Study SP11502 and Study GC-627-05 and several PK parameters were analysed (Cmax, AUC0 t, and AUC0-inf, Tmax and t½). Systemic exposure assessment after (single and) multiple dose administration of the therapeutic dose and evaluation of time dependency was conducted, reveal decrease in Cmax, AUC and variable elimination in both healthy and cancer populations.

## Special populations

Clinical trials with Ryzneuta have not included patients with severe renal, severe hepatic impairments. No specific studies were conducted to evaluate the influence of gender, race, age, or weight on PK/PD.

No specific studies were conducted in the elderly. Limited data from Study GC-627-05 indicate that the pharmacokinetics of Ryzneuta in elderly subjects (&gt; 65 years) is similar to that in adults. The concentrations were slightly higher in Cycle 1 day 4 group in Age &gt; 65 years.

## Pharmacokinetic interaction studies

The Applicant did not conduct clinical (or nonclinical) studies of F-627 specifically designed to assess drugdrug interactions. The Applicant included number of provisions about the interaction mentioned in Neulasta SmPC. This is acceptable.

## 2.6.2.2. Pharmacodynamics

## Mechanism of action

Efbemalenograstim alfa is a sustained duration form of G-CSF due to decreased renal clearance. Efbemalenograstim alfa and other G-CSFs have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes. Neutrophils produced in response to G-CSF show normal or enhanced function as demonstrated by tests of chemotactic and phagocytic function. As with other haematopoietic growth factors, G-CSF has shown in vitro stimulating properties on human endothelial cells. G-CSF can promote growth of myeloid cells (including malignant cells) in vitro and similar effects may be seen on some non-myeloid cells in vitro .

There were 4 analyses performed based on the 3 different PD responses: breast cancer patients with average serum concentration data; breast cancer patients with any chemotherapy; patients who had TAC chemotherapy; and patients who had TC or EC chemotherapy. The depth of nadir was evaluated with Cave using all available PD models. With the comparison of Akaike information criterion (AIC), the best-fitted model was the simple Emax model. The duration of neutropenia and the time to ANC recovery were also evaluated with average PK serum concentration (Cave) using all available inhibitory effect models and the final model was the inhibitory effect Imax model, consistent with the pharmacological understanding of the PD response. The range for duration of neutropenia was (E0 - Imax, E0).

## Primary and secondary pharmacology

The PK/PD correlation analysis indicated that a 20 mg fixed-dose would provide a sufficient PD effect for depth of ANC nadir and time to ANC recovery regardless of the degree of chemotherapy-induced myelosuppression. The 20 mg dose was also predicted to provide a higher assurance of adequate PD effect for the duration of neutropenia compared to a 10 mg dose.

PK/ PD modelling was performed to support the selection of a fixed dose of F-627 for Phase III studies. A systematic review of the Phase I and II studies that collected F-627 PK and/or PD data was conducted. Based on the availability of PK and ANC data, a PK/PD modelling analysis was performed to characterize the F-627

<div style=\"page-break-after: always\"></div>

dose-response by modelling the PK/PD relationship, dose-response, and dose-response by chemotherapy type (i.e., moderately vs. highly myelosuppressive) for the duration of neutropenia, depth of ANC nadir, and time to ANC recovery endpoints.

The PK/PD was addressed in studies GC-F-627-01 (a single dose escalation trial), GC-F-627-03 (a single dose escalation trial), 2012-F-627-CH1, Study SP-CDR-1-1301, SP11502, GC-627-04, and GC-627-05. The ANC began to rise on Day 2 and reached the peak at 24 h after the administration of F-627. Higher dose leads to higher Cmax and AUC(0-inf). Increased neutrophile counts lead to reduction in Ryzneuta exposure. This was observed in both the liquid and lyophilized formulations. The median ANC profile was similar for the liquid and lyophilized F-627 formulations. Ryzneuta increases ANC levels. Dose-related, but nonlinear increases in PK parameters were observed across the three dose cohorts (80, 240, and 320 μ g/kg), as were dose-related changes in ANC profiles. When ANC gradually recovers from nadir, the serum drug concentration of F-627 decrease rapidly.

Figure 11 . PK/PD of F-627 in the 240 μ g/kg and 320 μ g/kg Cohorts in Cycle 1 - SP-CDR-1-1301

<!-- image -->

Note: From SP-CDR-1-1301 Figure 12.

Corresponding ANC values were always higher in Cycle 3 than Cycle 1, suggesting that neutrophils play an important role in the clearance of F-627 and serum clearance is related to the number of neutrophils. Selection of the dosing regimen of F-627 is based on reducing the duration of severe neutropenia. PK/PD correlation analysis indicated that a 20 mg fixed-dose would provide a sufficient PD effect for depth of ANC nadir and time to ANC recovery regardless of the degree of chemotherapy-induced myelosuppression. The 20 mg dose was also predicted to provide a higher assurance of adequate PD effect for the duration of neutropenia compared to a 10 mg dose.

Secondary pharmacology studies were not conducted, which is considered acceptable.

## Correlation Analysis of Pharmacokinetics and Pharmacodynamics

PK/ PD modelling work was performed to support the selection of a fixed dose of F-627 to take forward to Phase III studies. A systematic review of the Phase I and II studies that collected F-627 PK and/or PD data was conducted. Based on the availability of PK and ANC data, a PK/PD modelling analysis was performed to characterize the F-627 dose-response by modelling the PK/PD relationship, dose-response, and dose-

<div style=\"page-break-after: always\"></div>

response by chemotherapy type (i.e., moderately vs. highly myelosuppressive) for the duration of neutropenia, depth of ANC nadir, and time to ANC recovery endpoints. There were 4 analyses performed based on the 3 different PD responses: breast cancer patients with average serum concentration data; breast cancer patients with any chemotherapy; patients who had TAC chemotherapy; and patients who had TC or EC chemotherapy. For patients with TC/EC chemotherapy, IC50 for the duration of neutropenia was predicted to be 22.5 mg of F-627, whereas for TAC chemotherapy, IC50 was estimated to be 74.5 mg of F-627. Such a high predicted F-627 dose was likely due to the model construct to minimize the duration of neutropenia to approach zero, which is not attainable in clinical practice even with rhG-CSF administration.

PK/PD modelling supported the use of 20 mg dose in Phase III studies using data from previous Phase I (2012F-627-CH1, SP-CDR-1-1301 and GC-F-627-01) and Phase II (GC-627-02 and SP-CDR-1302) with emphasis on chemotherapy use (none, TC, TAC, EC).

As both fixed-dose of 10 mg and 20 mg as well as weight-based dose of 80 μ g/kg/dose 240 μ g/kg/dose and 320 μ g/kg/dose of F-627 were investigated in Phase II and Phase I studies (with an exception of GC-627-01 study), the dose of 20 mg was selected to be used in Phase III studies, as supported by the PK/PD modelling.

Regarding to immunogenicity, POP PK parameters (e.g., CL/F, V/F, KA) did not significantly change after exclusion of patients with antidrug antibodies. However, the inter-individual variability (IIV) estimates: the IIV for CL/F increased from 0.399 to 0.465 after exclusion; IIV for V/F decreased from 0.532 to 0.481 after exclusion; IIV for KA increased from 0.149 to 0.156 1/h after exclusion. The precision of IIV estimates also changed: 12.5% vs 13.4% after exclusion for CL/F; 17.0% vs 18.3% after exclusion for V/F; and 17.2% vs 17.2% after exclusion for KA. It seems that ADA antibodies introduce additional variability on clearance estimate. ADAs can form immune complexes and alter pharmacokinetics by increasing or decreasing clearance depending on the formed complex size.

## 2.6.3. Discussion on clinical pharmacology

The clinical pharmacology program included 6 studies: two studies conducted in healthy subjects provided information on a single dose administration of F-627 and four studies conducted in patients with breast cancer receiving myelosuppressive chemotherapy provided multiple-dose information. All studies utilized absolute neutrophil counts (ANC) as the primary PD measure. The population PK and the PK/PD correlation were also evaluated. There were no clinical (or nonclinical) studies of F-627 specifically designed to assess drug-drug interactions.

## Absorption

After subcutaneous injection of F-627, the peak serum concentration of F-627 occurs at 36 hours [min-max: 6 to 96 hours] after dosing and serum concentrations of F-627 are maintained during the period of neutropenia after myelosuppressive chemotherapy (SmPC section 5.2). The interval of 6 - 96 hours for Tmax was derived from the range (i.e., min-max) of Tmax in breast cancer patients after a single dose of 240 or 320 μ g/kg, considered clinically relevant doses.

Cmax and exposure (AUC0-t) of F-627 were not significantly different, with some variability in formulation liquid form prefilled syringe or in formulation lyophilized. The difference % of Mean AUC0-t from formulation liquid form prefilled syringe and lyophilized form was 31.4%. F-627 lyophilized form has lower bioavailability than the liquid form as evident from lower Cmax, AUC (0-t) and higher clearance and are unlikely to be interchangeable.

<div style=\"page-break-after: always\"></div>

## Distribution

In the final POP PK model, the apparent volume of distribution (V/F) was 20.3 (95% Bound: 16.6, 24.0). The final population V/F was: for liquid formulation, TVV = 7 and for lyophilized formulation, TVV = 20.3.

## Elimination

The half-life and clearance of F-627 do not change in a dose dependent manner. The applicant considered the elimination of F-627 to be non-linear with respect to dose; serum clearance of F-627 decreases with increasing dose. Since this was not a consistent observation throughout Phase I and II, the applicant added a saturable neutrophil-mediated clearance pathway to the updated population PK model to more accurately describe the PK data. No statistically significant relationships between F-627 exposure and duration of severe neutropenia (DSN), incidence of severe neutropenia, or time to ANC recovery were identified. No statistically significant E-R relationships were identified for any TEAE, grade ≥ 3 TEAE, alopecia, nausea, bone pain, asthenia, leukopenia, or thrombocytopenia.

Systemic exposure assessment after (single and) multiple dose administration of the therapeutic dose and evaluation of time dependency reveal decrease in Cmax, AUC and variable elimination in both healthy and cancer populations.

## Pharmacokinetics in special populations

Clinical trials with Ryzneuta have not included patients with severe renal impairment, severe hepatic impairment. The impact of gender, weight, or race on PK/PD was not assessed. Limited data indicate that the pharmacokinetics of Ryzneuta in elderly subjects (&gt; 65 years) is similar to that in adults. No specific studies were conducted in the elderly. Mean concentrations of Ryzneuta between the Age &lt; 65 years and Age &gt;65 cohorts were similar; the concentrations were slightly higher in Cycle 1 day 4 group in Age &gt; 65 years. This difference is unlikely to have clinically meaningful implications.

## Drug-drug interactions

The Applicant did not conduct clinical (or nonclinical) studies of F-627 to assess drug-drug interactions. However, in the SmPC section 4.5, it is noted that due to the potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy, efbemalenograstim alfa should be administered at least 24 hours after administration of cytotoxic chemotherapy, and at least 14 days before the next dose of chemotherapy and that concomitant use of Ryzneuta with chemotherapy (i.e. administration on the same day) has been shown to potentiate myelosuppression. It was considered acceptable to include this information as a class effect.

## Population PK

The Applicant conducted POP PK using standard methodology. Excluding 30 subjects whose immunogenicity test results were positive is understandable from modelling point of view, however this should be noted when assessing PK parameter variability, the true population variability is higher than the one shown in model because it is not possible to diagnose ADA antibodies. The exclusion of subjects with ADA positive results did not significantly change the final estimates and precision of PK parameters of base model or final model, suggesting that the immunogenicity has no effect on the PK of F-627.

The overall Visual predictive check is hard to interpret but it seems that the model predicts the concentrations better at earlier time points and overpredicts the concentrations at later time points time &gt;200 hours. The same is visible in other VPCs e.g.: Visual Predictive Checks 2012-F-627-CH1, SP-CDR-11301. The concentration data is highly variable.

<div style=\"page-break-after: always\"></div>

## PK/PD

The Applicant chose to evaluate the following PK/PD parameters: a) the depth of nadir evaluated with Cave using the Emax model; b) the duration of neutropenia and the time to ANC recovery were evaluated with Cave and the Imax model, consistent with the pharmacological understanding of the PD response, and the range for duration of neutropenia was (E0 - Imax, E0). This was considered acceptable and clinically relevant.

Higher dose leads to higher Cmax and AUC(0-inf) and the increased neutrophile counts lead to reduction in Ryzneuta exposure. This was observed in both the liquid and lyophilized formulations. The median ANC profile was similar for the liquid and lyophilized F-627 formulations. Ryzneuta increases ANC levels. Doserelated, but nonlinear increases in PK parameters were observed across the three dose cohorts (80, 240, and 320 μ g/kg), as were dose-related changes in ANC profiles. When ANC gradually recovers from nadir, the serum drug concentration of F-627 decrease rapidly.

When subjects with breast cancer were given F-627 at 320 μ g /kg dosed SC 24 hours after chemotherapy, F627 reached Cmax of 347.18 ng/mL at 41.14 h post-dose and AUC0-t value of 33972.14 h*ng/mL with Cl/F of 11.42 mL/h/kg. F-627 clearance in Cycle 3 increased compared to Cycle 1, as evidenced by F-627 serum concentrations in Cycle 3 always being lower than in Cycle 1. Corresponding ANC values were always higher in Cycle 3 than Cycle 1. The PK/PD correlation analysis indicated that a 20 mg fixed-dose would provide a sufficient PD effect for depth of ANC nadir and time to ANC recovery regardless of the degree of chemotherapy-induced myelosuppression. The 20 mg dose was also predicted to provide a higher assurance of adequate PD effect for the duration of neutropenia compared to a 10 mg dose.

## Immunogenicity

POP PK parameters (e.g. CL/F, V/F, KA) did not significantly change after exclusion of patients with antidrug antibodies. However, the inter-individual variability (IIV) estimates: the IIV for CL/F increased from 0.399 to 0.465 after exclusion; IIV for V/F decreased from 0.532 to 0.481 after exclusion; IIV for KA increased from 0.149 to 0.156 1/h after exclusion. The precision of IIV estimates also changed: 12.5% vs 13.4% after exclusion for CL/F; 17.0% vs 18.3% after exclusion for V/F; and 17.2% vs 17.2% after exclusion for KA.

Following a request, the applicant provided additional data showing no apparent differences in PK exposure due to binding ADA. Similarly, the absence of type II and III hypersensitivity AEs reported in GC-627-04 and GC-627-05 regardless of binding ADA status supports the conclusion that the development of ADA to F-627 did not impact patient safety.

## 2.6.4. Conclusions on clinical pharmacology

Clinical pharmacology was extensively investigated adequately characterising the PK and PD properties of Ryzneuta.

## 2.6.5. Clinical efficacy

## 2.6.5.1. Dose response studies

Two Phase II dose-ranging studies in breast cancer patients (SP-CDR-1-1302 [N = 138] and GC-627-02 [N = 232]) were conducted by the applicant.

<div style=\"page-break-after: always\"></div>

## Study SP-CDR-1-1302

Objectives: The main objective of this study was to compare the efficacy of recombinant human granulocyte colony stimulating factor-Fc fusion protein (F-627) versus recombinant human granulocyte colony stimulating factor (GRAN®) in the first cycle of prophylactic treatment in subjects with breast cancer receiving chemotherapy.

Design and Methods: This was a Phase II, multi-center, randomized, open-label, active-controlled, dosefinding study in females with breast cancer receiving up to 4 cycles of EC chemotherapy conducted in China. Subjects were randomized to SC administration of 10 mg or 20 mg F-627 (lyophilized formulation) on Day 3 of each chemotherapy cycle or daily SC injection of 5 μ g/kg/day filgrastim starting on Day 3 for a maximum of 2 weeks/cycle. This was the only study in the F-627 clinical program where the 10 mg fixed-dose was included.

The primary endpoint of the study was the duration of Grade 3 or 4 neutropenia in Cycle 1 (days with ANC &lt;1.0 × 10 9 /L). Secondary endpoints included the incidence of Grade 3 or 4 neutropenia in each cycle; the duration of Grade 3 or 4 neutropenia in Cycles 2-4; the incidence and duration of Grade 4 neutropenia in each cycle (ANC &lt;0.5 × 10 9 /L); the overall duration of Grade 3 and 4 neutropenia in all 4 cycles; the incidence of FN (defined as ANC &lt;1.0× 10 9 /L and a single measurement of body temperature &gt;38.3 ° C or a fever ≥ 38.0 ° C lasting for greater than 1 hour); and the duration of Grade 2 or greater neutropenia in each cycle (ANC &lt;1.5 × 10 9 /L).

Non-inferiority margin: The non-inferiority/ equivalence margin for F-627 and GRAN® is 1 day.

Results: A total of 138 subjects were enrolled and treated in the study; 39 received 10 mg F-627, 50 received 20 mg F-627, and 41 received 5 μ g/kg/day filgrastim (Table 11).

<div style=\"page-break-after: always\"></div>

Table 16. Primary and Key Secondary Efficacy Results in Study SP-CDR-1-1302

| Endpoint                                                                                                       | F-627 20 mg                                                        | F-627 10 mg                                                       | Filgrastim 5 μg/kg/day   |
|----------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------|-------------------------------------------------------------------|--------------------------|
| Analysis Set =Per Protocol Set                                                                                 |                                                                    |                                                                   |                          |
| PrimaryEfficacyResults                                                                                         |                                                                    |                                                                   |                          |
| Duration of Grade 3 or 4 neutropenia in Cycle 1; mean (SD) days, N Difference (95.02% CI) Difference (95% CI)2 | 0.6 (1.24) N=47 0.00 days (0.000, 0.000) 0.00 days (0.000, 0.000)  | 0.8 (1.23) N=37 0.00 days (0.000, 0.000) 0.00 days (0.000, 0.000) | 0.8 (1.23) N=39          |
| SecondaryEfficacyResults                                                                                       |                                                                    |                                                                   |                          |
| Incidence of Grade 3 or 4 neutropenia in Cycle 1; n/N (%)                                                      | 12/47 (25.5)                                                       | 13/37 (35.1)                                                      | 15/39 (38.5)             |
| Difference (95% CI)3 p-value?                                                                                  | -13% (-32.64, 6.78) 0.246                                          | -3.3 (-25.00, 18.35) 0.815                                        |                          |
| Duration of Grade 4 neutropenia in Cycle 1; mean (SD) days, N Difference (95% CI2                              | 0.2 (0.56) N=47 0.0 days (0.0, 0.0)                                | 0.2 (0.71) N=37 0.0 days (0.0, 0.0)                               | 0.4 (0.84) N=39          |
| Incidence of Grade 4 neutropenia in Cycle 1; n/N (%)                                                           | 5/47 (10.6)                                                        | 4/36 (10.8)                                                       | 7/39 (17.9)              |
| Difference (95% CI)3 p-value?                                                                                  | -7.3% (-22.24, 7.61) 0.365                                         | -7.1% (-22.80, 8.52) 0.518                                        |                          |
| Incidence rate of FN in Cycle 1; n (%)                                                                         | 0                                                                  | 0                                                                 | 0                        |
| Analysis Set =Intent-To-Treat Set (Sensitivity Analysis)                                                       | Analysis Set =Intent-To-Treat Set (Sensitivity Analysis)           |                                                                   |                          |
| PrimaryEfficacyResults                                                                                         |                                                                    |                                                                   |                          |
| Duration of Grade 3 or 4 neutropenia in Cycle 1; mean (SD) days, N Difference (95.02% CI) Difference (95% CI)2 | 0.7 (1.27) N= 50 0.00 days (0.000, 0.000) 0.00 days (0.000, 0.000) | 1.0 (1.91) N=39 0.00 days (0.000, 0.000) 0.00 days (0.000, 0.000) | 0.8 (1.20) N=41          |

Abbreviations:CI=confidenceinterval,FN=febrileneutropenia;SD=standard deviation

There was no imputation of data for primary endpoint analysis based on the Per Protocol Set; however, in the Intent-to-TreatSet-basedprimaryendpoint analysis,missingdatawasimputedbylastobservationcarried forward.

Hodges-Lehmann estimators of the differences in the duration of Grade 3 or 4 neutropenia in Cycle 1 for F-627 (10mg/dose and 20mg/dose)vs.filgrastim arepresentedwith95.02%CIsfornon-inferiority test.Noninferiority was established if the upper limit was ≤1.

Estimated differences in incidence rate of Grade 3 or 4 neutropenia for F-627 (10 mg/dose and 20 mg/dose) vs.

Hodges-Lehmann estimators of the differences in the duration of Grade 3 or 4 neutropenia in Cycle 1 for F-627 (10 mg/dose and 20 mg/dose) vs. filgrastim are presented with 95% CIs for superiority test. Superiority was established if the upper limit was &lt;0.

filgrastim with 95% CIs, and p-values for Fisher's test presented. Source: SP CDR 11302CSRTables1.3.1.1,1.3.1.2,1.3.2.2,1.3.3.2,1.3.4.2,and 1.3.5.2

## Study GC-627-02

Objectives: The purpose of this study was to assess the effectiveness of the once per chemotherapy cycle subcutaneous (SC) administration of 3 different doses of F-627 in aiding absolute neutrophil count (ANC) recovery post treatment as compared to Neulasta (Neulastim, pegfilgrastim).

Design and Methods: This was a Phase II, multi-center, randomized, open-label, active-controlled, dosefinding study in females with Stage I-IV invasive breast cancer, conducted in Russia, Ukraine, and the US. Subjects were randomized to receive SC administration of 80, 240, or 320 μ g/kg F-627 or 6 mg/kg SC pegfilgrastim on Day 2 of each 21-day chemotherapy cycle with TC chemotherapy for up to 4 cycles, or 240 or 320 μ g/kg F-627 or 6 mg/kg SC pegfilgrastim on Day 2 of each 21-day chemotherapy cycle with TAC[600] chemotherapy for up to 4 cycles.

The primary efficacy endpoint was the duration of Grade 3 and Grade 4 neutropenia during Cycle 1 (days with ANC &lt;1.0 × 10 9 /L). Secondary efficacy endpoints included the duration of Grade 3 and Grade 4

<div style=\"page-break-after: always\"></div>

neutropenia for all other chemotherapy cycles (Cycles 2 to 4); the duration of Grade 4 neutropenia in each chemotherapy cycle (days with ANC &lt;1.5 × 10 9 /L); the incidence of FN for each chemotherapy cycle (defined as ANC &lt;0.5 × 10 9 /L with oral temperature &gt;38.2°C); the duration of Grade 2, Grade 3, and Grade 4 neutropenia for each chemotherapy cycle (days with ANC &lt;1.5 × 10 9 /L); and the incidence rates for each of Grade 2, Grade 3, and Grade 4 neutropenia for all chemotherapy cycles. For the primary efficacy analysis, non-inferiority tests with a non-inferiority margin of 2 days were used to compare the duration of Grade 3 (moderate) neutropenia (this included by default Grade 4 or severe neutropenia) between 3 doses of F-627 vs. pegfilgrastim in Cycle 1 within 12 days of chemotherapy treatment.

Results: A total of 232 subjects were randomized (230 subjects were planned) in the study; 141 received TC chemotherapy and 91 received TAC chemotherapy. For those who received TC chemotherapy, 35 subjects were administered 80 μ g/kg F-627, 37 subjects were administered 240 μ g/kg F-627, 34 subjects were administered 320 μ g/kg F-627, and 35 subjects were 6 mg pegfilgrastim. For those who received TAC chemotherapy, 30 subjects were administered 240 μ g/kg F-627, 31 subjects were administered 320 μ g/kg F627, and 30 subjects were 6 mg pegfilgrastim. All doses of F-627 demonstrated non-inferiority to pegfilgrastim with respect to the duration of Grade 3-4 neutropenia (ANC ≤ 1.0 × 10 9 /L) in Cycle 1. Superiority of F-627 relative to pegfilgrastim was not observed. Duration of Grade 4 and Grades 2-4 neutropenia were similar to pegfilgrastim for all F-627 doses.

<div style=\"page-break-after: always\"></div>

Table 12. Primary and Key Secondary Efficacy Results in Study GC-627-02 (Per Protocol Population)

| TC Chemotherapy                                                                          | F-627 80 μg/kg                       | F-627 240 μg/kg                      | F-627 320 μg/kg                      | Pegfilgrastim 6 mg/dose   |
|------------------------------------------------------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|---------------------------|
| PrimaryEfficacyResults                                                                   |                                      |                                      |                                      |                           |
| Duration of Grade 3 or 4 neutropenia in Cycle 1; mean (SD) days, N Differencel (95% CI)1 | 0.6 (1.26) N=35 0.4 days (-0.1, 0.8) | 0.6 (1.01) N=37 0.3 days (-0.1, 0.7) | 0.4 (0.75) N=31 0.1 days (-0.4, 0.6) | 0.3 (0.56) N= 35          |
| SecondaryEfficacyResults                                                                 |                                      |                                      |                                      |                           |
| Incidence of Grade 3 or 4 neutropenia in Cycle 1; n/N (%)                                | 10/35 (28.6)                         | 10/37 (27.0)                         | 6/31 (19.4)                          | 7/35 (20.0)               |
| Difference' p-value?                                                                     | 8.6% 0.5781                          | 7.0% 0.5830                          | -0.6% 1.0000                         |                           |
| Duration of Grade 4 neutropenia in Cycle 1; mean (SD) days, N Difference' (95% CI)1      | 0.2 (0.73) N=35 0.1 days (-0.2, 0.4) | 0.4 (0.86) N=37 0.3 days (0.0, 0.6)  | 0.2 (0.48) N=31 0.1 days (-0.2, 0.4) | 0.1 (0.28) N=35           |
| Incidence of Grade 4 neutropenia in Cycle 1; n/N (%)                                     | 4/35 (11.4)                          | 7/37 (18.9)                          | 5/31 (16.1)                          | 3/35 (8.6)                |
| Differencel p-value2 Incidence rate of FN in Cycle 1; n/N (%)                            | 2.9% 1.0000 0                        | 10.3% 0.3092 0                       | 7.6% 0.4591 1/31 (3.2)               | 0                         |
| PrimaryEfficacy Results                                                                  |                                      |                                      |                                      |                           |
| Duration of Grade 3 or 4 neutropenia in Cycle 1; mean (SD) days, N Differencel           | 2.1 (1.58) N=30 0.3 days             | 2.1 (1.46)                           |                                      | 1.8 (1.28)                |
| (95% CI1 SecondaryEfficacyResults Incidence of Grade 3 or 4 neutropenia in               | (-0.4, 1.1) 23/30 (76.7)             | 0.3 days (-0.4, 1.1) 22/29 (75.9)    | N=29                                 | N=30                      |
| Cycle 1; n/N (%) Differencel p-value2                                                    | 0.0% 1.0000                          | -0.8% 1.0000 0.4 days                |                                      | 23/30 (76.7)              |
| Duration of Grade 4 neutropenia in Cycle 1; mean (SD) days, N                            | 1.5 (1.55) N=30                      |                                      | 1.4 (1.15) N=29                      | 1.1 (1.01) N=30           |
| Differencel (95% CI)1 Incidence of Grade 4 neutropenia in Cycle 1; n/N (%)               | 0.4 days (-0.2, 1.0) 20/30 (66.7)    | (-0.3, 1.0)                          | 21/29 (72.4) 9.1%                    | 19/30 (63.3)              |
| Difference' p-value? Incidence rate ofFN in Cycle 1; n/N (%)                             | 3.3% 1.0000 0                        | 0.5796                               | 1/29 (3.4)                           | 2/30 (6.7)                |

Abbreviations: CI= confidence interval, FN=febrile neutropenia; SD = standard deviation; TAC =TAC[600]; docetaxel 75 mg/m² + doxorubicin 50 mg/m² + cyclophosphamide 600 mg/m² chemotherapy; TC = docetaxel 75 mg/m2 + cyclophosphamide 600 mg/m² chemotherapy.

The p-valuie is for comparison of F-627 vs. pegfilgrastim using Fisher's Exact Test.

1Differences between F-627 dose compared to pegfilgrastim. For the primary endpoint, non-inferiority of F-627 to pegfilgrastim was achieved if the upper limit of the 2-sided 95% CI of the difference was &lt;2 days. Superiority ofF-627 to pegfilgrastim was achieved ifthe upper limit of the 2-sided 95%CI of the difference was &lt;0 days.

Source:GC-627-02Tables 4.1.1.1,4.2.1.1,4.4.1.1,and4.5.1.1;Listing6.2.14

The duration of severe Grade 3 or 4 neutropenia between F-627 20 mg, 10 mg, and Filgrastim 5 microg/kg groups was similar. This was reinforced with secondary endpoints. Similar results were observed with pegfilgrastim were all doses of F-627 (80 microg/kg, 240 microg/kg, 360 microg/kg demonstrated noninferiority to pegfilgrastim with respect to the duration of Grade 3-4 neutropenia. The non-inferiority/

<div style=\"page-break-after: always\"></div>

equivalence margin for F-627 and GRAN® was 1 day in study SP-CDR-1-1302 and 2 days in study Study GC627-02. Such flexible non-inferiority margin seems peculiar. Despite fluctuation in non-inferiority margin across the dose finding studies it seems that the tested doses of F-627 are indeed non-inferior to reference drugs. This is acceptable.

## 2.6.5.2. Main studies

There were 3 Phase III studies in which 402 subjects in total were randomised to 20 mg F-627 and 355 subjects to a comparator arm (either Placebo, 6 mg pegfilgrastim, or 5 μ g/kg/day filgrastim).

Study GC-627-04: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy

Study GC-627-05 : A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta ActiveControlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy

Study SP11631: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia

## Methods

## · Study Participants

## Study GC-627-04

Women were eligible for study entry if they met the following inclusion criteria: ≥ 18 and &lt; 75 years of age; diagnosis Stage II-IV breast cancer in the adjuvant or metastatic setting; Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2; WBC count ≥ 4.0 × 10 9 /L; hemoglobin ≥ 11.5 g/dL; platelet count ≥ 150 × 10 9 /L; adequate renal, hepatic and cardiac function; and scheduled for chemotherapy. Subjects were excluded from the study if their disease had progressed while receiving a taxane regimen, if they had undergone radiation therapy within 4 weeks of enrollment, or if they had undergone a bone marrow or stem cell transplantation. Subjects that had used or may have had to use a granulocyte-colony stimulating factor (GCSF) within 6 weeks of the screening period or a drug or substance that may potentiate the release of neutrophils were excluded (i.e., sargramostim or filgrastim). Subjects with a history of prior malignancy other than breast cancer may have entered the study if the malignancy was in remission and they were not receiving active treatment. This study is also referred to as study 004 throughout this report.

## Study GC-627-05

Eligible subjects included females ≥ 18 years of age with a diagnosis of Stage I-III invasive breast cancer that required neoadjuvant or adjuvant chemotherapy; Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2; white blood cell (WBC) count ≥ 4.0 × 10 9 /L; haemoglobin ≥ 11.5 g/dL; platelet count ≥ 150 × 10 9 /L; adequate renal, hepatic, and cardiac function; and scheduled for TC chemotherapy treatment. Subjects with a history of prior malignancy other than breast cancer may have entered the study if the malignancy was in remission. Subjects were excluded from the study if they had undergone radiation therapy within 4 weeks of enrolment, or chemotherapy within 180 days of screening, or if they had undergone a

<div style=\"page-break-after: always\"></div>

bone-marrow or stem-cell transplantation. Subjects that had used G-CSF, or any other drug that may potentiate release of neutrophils, within 6 weeks of the screening period were excluded. This study is also referred to as study 005 throughout this report.

## Study SP11631

Non-frail female patients who require adjuvant chemotherapy after radical mastectomy for breast cancer, and are planned to receive 4 cycles of EC chemotherapy (epirubicin [Pharmorubicin] 100 mg/m2 + cyclophosphamide 600 mg/m2) were included in this study. Patients with radiation therapy within 4 weeks prior to enrolment; patients with breast cancer who have received neoadjuvant chemotherapy before surgery and diagnosed with acute medical conditions (e.g. myocardial infarction, infection) were excluded from this study.

## · Treatments

Study GC-627-04 . Test Product: F-627: 20 mg dose in a PFS administered by subcutaneous (SC) injection. Placebo: saline in a PFS administered by SC injection.

Study GC-627-05 . Test Product: F-627: 20 mg dose in a PFS administered by subcutaneous (SC) injection. Reference Treatment: Neulasta (pegfilgrastim): 6 mg fixed dose administered by SC injection.

Study SP11631 . Investigational Drug: F-627, 20 mg/dose, s.c., 48 ± 4 hrs after starting chemotherapy (i.e., day 3 of each cycle), 20 mg/1 mL/vial; dosage form: prefilled syringe (PFS).

Reference treatment: GRAN (filgrastim): 5 μ g/kg/day, s.c., 48 ± 4 hrs after starting chemotherapy (i.e., day 3 of each cycle), once daily for 2 weeks or until ANC recovers to 5.0 × 10 9 /L, strength: 300 μ g/0.7mL/vial.

In all 3 studies patients received F-627 (PFS) 20 mg dose or pegfilgrastim (Neulasta) 6 mg or filgrastim (GRAN) 5 μ g/kg/day, s.c. Thus, it is acceptable as far as this corresponds to applied posology.

## · Objectives

## Study GC-627-04

The objective of the study was to evaluate the efficacy and safety of F-627 given as a single 20 mg fixed dose pre-filled syringe (PFS) in the subject's first chemotherapy cycle in comparison to Placebo.

## Study GC-627-05

The primary objective of this study was to evaluate the efficacy of F-627 given as a single fixed dose (20 mg) pre-filled syringe (PFS) as compared to Neulasta standard dosing (6 mg) in the first chemotherapy cycle.

## Study SP11631

The primary objective was to compare the efficacy of recombinant human granulocyte colony stimulating factor-Fc fusion protein (F-627) versus recombinant human granulocyte colony stimulating factor (GRAN) in cycle 1 of prophylactic treatment in subjects with breast cancer receiving EC chemotherapy.

## · Outcomes/endpoints

## Study GC-627-04

The primary efficacy endpoint was the duration of Grade 4 (severe) neutropenia (ANC &lt;0.5 × 10 9 /L) observed in chemotherapy cycle 1.

The secondary efficacy endpoints of this study were:

<div style=\"page-break-after: always\"></div>

- The duration in days of Grade 4 (severe) neutropenia (ANC &lt;0.5 × 10 9 /L) for chemotherapy cycles 2, 3, and 4, and over all cycles.
- The duration in days of Grade 2 (mild, ANC &lt;1.5 × 10 9 /L) and Grade 3 (moderate, ANC &lt;1.0 × 10 9 /L) neutropenia for each chemotherapy cycle and over all cycles.
- The incidence rates of febrile neutropenia (FN; defined as a single oral temperature of ≥38.3°C [10°F] or  a  temperature  of  &gt;38.0°C  [100.4°F]  sustained  for  &gt;1  hour  and  ANC  &lt;0.5  ×  10 9 /L)  for  each chemotherapy cycle.
- The incidence rates of Grade 2, Grade 3, and Grade 4 neutropenia for all chemotherapy cycles.
- The time in days to ANC recovery post nadir for each chemotherapy cycle and over all cycles; recovery was defined as an ANC ≥2.0 × 10 9 /L after the expected ANC nadir.
- The depth of the ANC nadir for each chemotherapy cycle and over all cycles.
- The incidence rates of infections for each chemotherapy cycle and over all cycles.
- The use of antibiotic and pain medications for each chemotherapy cycle and over all cycles.

## Study GC-627-05

The primary efficacy endpoint was the duration of Grade 4 (severe) neutropenia, defined as the number of days in which the subject had an ANC &lt;0.5 × 10 9 /L during cycle 1 of their chemotherapy treatment. The secondary efficacy endpoints of this study were as follows:

- The duration of use of intravenous (IV) antibiotics (total across all chemotherapy cycles).
- The duration of hospitalization for febrile neutropenia or any infection (total across all chemotherapy cycles).
- The incidence of febrile neutropenia; considering all chemotherapy cycles. Febrile neutropenia was defined as a single oral temperature of ≥38.3°C (101°F) or a temperature of &gt;38.0°C (100.4°F) sustained for &gt;1 hour and ANC &lt;0.5 × 10 9 /L) on the same day.
- The incidence of Grade 4 neutropenia for chemotherapy cycle 1.
- The incidence of use of IV antibiotics, considering all chemotherapy cycles.
- The incidence of hospitalization for febrile neutropenia or any infection, considering all chemotherapy cycles

## Study SP11631

The primary endpoint is the duration (days) of grade 3 or 4 (moderate and severe) neutropenia in cycle 1, that is, the number of days of ANC &lt; 1.0 × 10 9 /L in cycle 1.

The efficacy of recombinant human granulocyte colony stimulating factor-Fc fusion protein (F-627) will be further evaluated by the secondary efficacy endpoints below:

- The incidence rate of grade 3 or 4 neutropenia (Grade 3 defined as ANC &lt;1.0 × 10 9 /L and Grade 4 defined as ANC&lt;0.5 × 10 9 /L;) in each cycle;
- The durations (days) of grade 3 or 4 neutropenia (Grade3 defined as ANC &lt;1.0 × 10 9 /L and Grade 4 defined as ANC&lt;0.5 × 10 9 /L) in cycles 2-4;
- Grade 4 defined as ANC&lt;0.5 × 10 9 /L;
- Overall duration (days) of grade 3 or 4 neutropenia (ANC &lt; 1.0 × 10 9 /L and &lt; 0.5 × 10 9 /L, respectively) in all 4 cycles;
- Incidence rate and duration (days) of grade 2 or greater neutropenia (ANC &lt; 1.5 × 10 9 /L) in each cycle;
- The incidence rate of febrile neutropenia (FN) (defined as ANC &lt; 1.0 × 10 9 /L; with a single measurement of body temperature &gt; 38.3 °C or a temperature ≥ 38.0 °C sustained over 1 hr);
- ANC-time profile;

<div style=\"page-break-after: always\"></div>

- The ANC nadir from day 3 to day 13 of cycle 1;
- Time (days) of ANC nadir recovers to 2.0 × 10 9 /L in each cycle.

In the pivotal studies the primary efficacy endpoint was the duration of Grade 4 (severe) neutropenia (ANC &lt; 0.5 × 10 9 /L) observed in chemotherapy cycle 1 in Study GC-627-04 and Study GC-627-05, while the duration (days) of grade 3 or 4 (moderate and severe) neutropenia in cycle 1, that is, the number of days of ANC &lt; 1.0 × 10 9 /L in cycle 1 was chosen as the primary endpoint in study SP11631.

The incidence rates of infections for each chemotherapy cycle and over all cycles were analysed in Study GC627-04, while in study GC-627-05 the febrile neutropenia or any infection incidence was assessed as secondary endpoint, and only the incidence rate of febrile neutropenia was assessed in the SP11631 study.

## · Sample size

Study GC-627-04. This studied assumed an expected difference in the duration of severe neutropenia for F627 as compared to Placebo of 2.0 days. The dropout rate for the trial was assumed to be 10%. Under these assumptions, enrolment of 80 subjects for the F-627 arm and 40 subjects for the Placebo arm for Cycle 1 would be required to realize 90% power.

Study GC-627-05 For subjects dosed with TC chemotherapy, the difference in the duration of severe neutropenia for F-627 in this study as compared to Neulasta was 0.3 and 0.1 days, for the 240 and 320 μ g/kg arms respectively. Assuming a difference in the duration of severe neutropenia for F-627 as compared to Neulasta of up to 0.3 days and a common standard deviation of 0.86 days, with a non-inferiority margin of 0.6 days, a sample size of 174 per arm would be required to realize 90% power under these assumptions. Assuming a 10% drop-out rate, a total sample size of 386 should be randomized across both treatment arms.

Study SP11631 . The primary endpoint is the duration (days) of grade 3 or 4 neutropenia in cycle 1. The noninferiority margin for F-627 and GRAN® is defined to be 1 day. In the case of a one-sided α = 0.025 and a power of 95%, 94 subjects are required for each arm; and in consideration of a 15-20% drop-out rate, 120 subjects are required for each arm (a total of 240 subjects).

## · Randomisation and Blinding (masking)

Study GC-627-04 . Eligible subjects in this study will be randomized to either F-627 20 mg/dose or Placebo in a 2:1 ratio, respectively in Cycle 1. Treatment randomization will be stratified by country/region. This study is a double-blind study for the first cycle of chemotherapy.

Study GC-627-05 . Eligible subjects in this study will be randomized to receive F-627 20 mg/dose or 6 mg/dose Neulasta in a 1:1 ratio. Subjects will be randomized and stratified by country/region. Although the study is considered 'open-label' due to differences in study drug presentations, the primary endpoint is based on a laboratory measurement (ANC).

Study SP11631 . A randomized allocation table will be generated by block randomization through PLAN using SAS 9.4. Central randomization will be performed in this study using the Interactive Web-Response System (IWRS). This is a randomized and open-label trial.

## · Statistical methods

Study GC-627-04 . For the primary efficacy analysis, superiority of F-627 vs. Placebo in the first chemotherapy cycle was tested. This two-sided hypothesis test used an alpha of 0.05 for the comparison. Superiority is claimed if the lower bound of the 95% CI is &gt; 0.

<div style=\"page-break-after: always\"></div>

Study GC-627-05 . For the primary efficacy analysis, a non-inferiority test was used to explore the duration of grade 4 (severe) neutropenia between F-627 vs. Neulasta in cycle 1 within 12 days of chemotherapy treatment. Non-inferiority of F-627 to Neulasta is observed when the upper limit of the one-sided 97.5% confidence interval (CI) for the difference in mean duration of grade 4 neutropenia is &lt; 0.6 days.

Study SP11631 . The primary efficacy endpoint will test the non-inferiority of F-627 to GRAN in terms of the duration (days) of grade 3 neutropenia (including grade 4 or severe neutropenia) in cycle 1. The noninferiority margin is specified as 1 day and the test is one-sided with a significance level of α = 0.025.

The primary endpoints for all the studies seem reasonable. Multiplicity was not an issue since all the studies centred around single tests.

## Results

## · Participant flow

## Study GC-627-04

A total of 135 subjects were screened and 122 (90.4%) subjects were randomized to the study, including 83 subjects randomized to F-627 and 39 subjects randomized to Placebo as their treatment in chemotherapy cycle 1. All subjects received 20 mg F-627 during chemotherapy cycles 2, 3, and 4.

Table 13. Summary of Subject Disposition in Study GC-627-04

|                                              | Treatiment in Chemotherapy Cycle 1   | Treatiment in Chemotherapy Cycle 1   |                        |
|----------------------------------------------|--------------------------------------|--------------------------------------|------------------------|
|                                              | 20 mg F-627 (N=83)                   | Placebo (N =39)                      | All Subjects (N = 135) |
| Randomized                                   | 83 (100.0)                           | 39 (100.0)                           | 122 (90.4)             |
| Completed the Study                          | 81 (97.6)                            | 37 (94.9)                            | 118 (87.4)             |
| Completed Cycle 1                            | 83 (100.0)                           | 38 (97.4)                            | 121 (89.6)             |
| Number Withdrawn in Cycle 1                  | 0                                    | 1 (2.6)                              | 1 (0.7)                |
| Completed Cycle 2                            | 82 (98.8)                            | 37 (94.9)                            | 119 (88.1)             |
| Number Withdrawn in Cycle 2                  | 1(1.2)                               | 1 (2.6)                              | 2 (1.5)                |
| Completed Cycle 3                            | 82 (98.8)                            | 37 (94.9)                            | 119 (88.1)             |
| Number Withdrawn in Cycle 3                  | 0                                    | 0                                    | 0                      |
| Completed Cycle 4                            | 81 (97.6)                            | 37 (94.9)                            | 118 (87.4)             |
| Number Withdrawn in Cycle 4                  | 1(1.2)                               | 0                                    | 1 (0.7)                |
| Early Withdrawal                             | 2 (2.4)                              | 2 (5.1)                              | 4 (3.0)                |
| Reason for Discontinuation                   |                                      |                                      |                        |
| Adverse Event                                | 0                                    | 1 (2.6)                              | 1 (0.7)                |
| Failure to Comply with Protocol Requirements | 2 (2.4)                              | 0                                    | 2 (1.5)                |
| Sponsor Decision                             | 0                                    | 1 (2.6)                              | 1 (0.7)                |

All randomized subjects in both treatment arms received F-627 for cycles 2 to 4.

Data shown are n (%). N = number of allrandomized subjects for treatment groups and allsubjects. n = number of subjects within a specific category. Percentages were calculated as 100 × (n/N).

<div style=\"page-break-after: always\"></div>

## Study GC-627-05

A total of 416 subjects were screened and 393 were randomized to the study (197 randomized to F-627 and 196 randomized to Neulasta). Overall, 373 (94.9%) subjects completed the treatment program.

Table 14. Summary of Subject Disposition in Study GC-627-05

|                                            | 20mgF-627   | 6mg Neulasta   | AllSubjects   |
|--------------------------------------------|-------------|----------------|---------------|
| Screened!                                  |             |                | 416           |
| ScreenFailed                               |             |                | 23            |
| Randomized                                 | 197 (100.0) | 196 (100.0)    | 393 (100.0)   |
| Completed theTreatmentProgran?             | 186 (94.4)  | 187 (95.4)     | 373 (94.9)    |
| Conpleted Chemotberapy Cycle 1²            | 194 (98.5)  | 196 (100.0)    | 390 (99.2)    |
| Number Withdrawn im Chemotherapy Cycle 1²  | 3(1.5)      | 0              | 3 (0.8)       |
| Conpleted ChemotherapyCycle 22             | 193 (98.0)  | 191 (97.4)     | 384 (97.7)    |
| NumberWithdrawn in Chemotherapy Cycle 22   | 1(0.5)      | 5 (2.0)        | 6(1.5)        |
| Conpleted Chemotberapy Cycle 3             | 186 (94.4)  | 188 (95.9)     | 374 (95.2)    |
| Number Withdrawn im Chemotherapy Cycle 3   | 7(3.0)      | 3 (1.5)        | 10 (2.5)      |
| Conpleted Chemotberapy Cycle 42            | 186(94.4)   | 187 (95.4)     | 373 (94.9)    |
| NumberWithdrawn m Chemotherapy Cycle42     | 0           | 1 (0.5)        | 1 (0.3)       |
| Conpleted6monthFollowUp²                   | 181 (91.9)  | 182 (92.9)     | 363 (92.4)    |
| EarlyWithdrawaF                            | 11 (5.0)    | 9(4.0)         | 20 (5.1)      |
| Reason forDiscontinuation                  |             |                |               |
| AdverseEvents                              | 6 (3.0)     | 5 (2.0)        | 11 (2.8)      |
| Investigator Decision                      | 2 (1.0)     | 2 (1.0)        | 4(1.0)        |
| WithdrawalofConsent                        | 2(1.0)      | 1(0.5)         | 3 (0.8)       |
| Failure to ComplywithProtocol Requirements | 1(0.5)      | 1(0.5)         | 2(0.5)        |

Data shown aren(%)

%=100xnN,wheren=mumber of subjectswithin a specificcategoryand N= mmberofsubjects randomized.

PPD wasre-screened and rondouized umdera new subject mumbeg PPD This subject was counted oncein the totalnumber of subjectsscreened and notconsideredas screen failed

Percentage ofsubjectsinthiscategorywas based onadverse event. Sowrce:Table 1.1.1

## Study SP11631

266 subjects were screened, among whom 24 failed the screening and 242 were randomized. In the 242 subjects, 239 subjects (98.8%) received at least one dose of study drug and 214 subjects (88.4%) completed treatments of overall 4 cycles.

<div style=\"page-break-after: always\"></div>

Table 15. Overall disposition of subjects - all subject set in Study SP11631

|                                                  | F-627      | GRAN       | Overall    |
|--------------------------------------------------|------------|------------|------------|
| Screening                                        |            |            | 266        |
| Screening Failure                                |            |            | 24         |
| Randomization                                    | 122        | 120        | 242        |
| Withdrawal without treatment after randomization | 2 (1.6)    | 1 (0.8)    | 3 (1.2)    |
| Received at least one dose of study drug         | 120 (98.4) | 119 (99.2) | 239 (98.8) |

| Clinical Study Report Protocol No.: SP11631                                                                                        | Therapeutic Biological Products: Category 1 Completion Date of the Report: Apr. 13, 2020 (version: final 1.0)   | Therapeutic Biological Products: Category 1 Completion Date of the Report: Apr. 13, 2020 (version: final 1.0)   | Therapeutic Biological Products: Category 1 Completion Date of the Report: Apr. 13, 2020 (version: final 1.0)   |
|------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
| Completed cycle 1                                                                                                                  | 117 (95.9)                                                                                                      | 107 (89.2)                                                                                                      | 224 (92.6)                                                                                                      |
| Withdrawal during cycle 1                                                                                                          | 3 (2.5)                                                                                                         | 12 (10.0)                                                                                                       | 15 (6.2)                                                                                                        |
| Completed cycle 2                                                                                                                  | 115 (94.3)                                                                                                      | 103 (85.8)                                                                                                      | 218 (90.1)                                                                                                      |
| Withdrawal during cycle 2                                                                                                          | 2 (1.6)                                                                                                         | 4 (3.3)                                                                                                         | 6 (2.5)                                                                                                         |
| Completed cycle 3                                                                                                                  | 114 (93.4)                                                                                                      | 101 (84.2)                                                                                                      | 215 (88.8)                                                                                                      |
| Withdrawal during cycle 3                                                                                                          | 1 (0.8)                                                                                                         | 2 (1.7)                                                                                                         | 3 (1.2)                                                                                                         |
| Completed cycle 4                                                                                                                  | 113 (92.6)                                                                                                      | 101 (84.2)                                                                                                      | 214 (88.4)                                                                                                      |
| Withdrawal during cycle 4                                                                                                          | 1 (0.8)                                                                                                         | 0                                                                                                               | 1 (0.4)                                                                                                         |
| Completed study                                                                                                                    | 113 (92.6)                                                                                                      | 101 (84.2)                                                                                                      | 214 (88.4)                                                                                                      |
| Withdrawal from the study                                                                                                          | 9 (7.4)                                                                                                         | 19 (15.8)                                                                                                       | 28 (11.6)                                                                                                       |
| Reason for withdrawal                                                                                                              |                                                                                                                 |                                                                                                                 |                                                                                                                 |
| Subject withdrew voluntarily                                                                                                       | 5 (4.1)                                                                                                         | 14 (11.7)                                                                                                       | 19 (7.9)                                                                                                        |
| Occurrence of uncontrolled grade 3 or 4 AEs related to the study drug as judged by the investigator                                | 0                                                                                                               | 0                                                                                                               | 0                                                                                                               |
| Subject failed to comply with the study protocol                                                                                   | 4 (3.3)                                                                                                         | 1 (0.8)                                                                                                         | 5 (2.1)                                                                                                         |
| Termination by the investigator under safety considerationsorin thebestinterestof the subject when the subject's condition changed | 0                                                                                                               | 4 (3.3)                                                                                                         | 4 (1.7)                                                                                                         |

Note: The percentage was calculated based on the total number of subjects randomized to each treatment arm.

## · Recruitment

Study GC-627-04 . Study Initiation Date: 17 August 2016 (First subject's informed consent date);

Study Completion Date: 28 November 2017 (Last subject last visit/contact).

Study GC-627-05 . Study Initiation Date: 12 Apr 2018 (First subject's informed consent); Study Completion Date: 05 Mar 2020 (Last subject last visit/contact).

Study SP11631 . Study Initiation Date: Apr. 12, 2018 (when the first subject signed the informed consent form); Study Completion Date: Jun. 19, 2019 (when the last follow-up was completed for the last subject in F-627

group)

<div style=\"page-break-after: always\"></div>

## · Conduct of the study

There were no major protocol amendments in any of the 3 studies.

## Protocol Deviations

Study GC-627-04 : A total of 4 subjects were excluded from the PP Population for cycle 1 due to inappropriate use of rescue medication. A total of 1, 3, and 3 subjects were excluded from the PP Population for cycles 2, 3, and 4, respectively, due to early discontinuations in cycle 1 or 2.

Study GC-627-05 : There were 7 subjects (5 subjects randomized to F-627 and 2 subjects randomized to Neulasta enrolled into the study and treated that were later found to not meet eligibility requirements. A total of 4 subjects did not meet inclusion criterion 6 (WBC count ≥4.0 × 10 9 /L , hemoglobin ≥11.5 g/dL and a platelet count ≥150 × 10 9 /L), and 1 subject had a documented congestive heart failure, cardiomyopathy, or myocardial infarction , 1 subject had either an active infection or known to be infected with chronic active Hepatitis B with in the last 1 year, and 1 subject had a history of tuberculosis or had been previously exposed to tuberculosis.

Study SP11631 : For all 242 randomized subjects over the entire treatment period, a total of 10 subjects (4.1%) experienced major protocol deviations, and the incidence rates of major protocol deviations in the F627 and GRAN arms were similar, i.e., 4.9% and 3.3%, respectively. In cycle 1, major protocol deviations were observed in 3 subjects (1.2%) in total, among which 1 subject (0.8%) in the F-627 arm was classified into treatment compliance; and 2 subjects (1.7%) in the GRAN arm were classified into treatment compliance (1 subject (0.8%).

## · Baseline data

## Study GC-627-04.

Demographic and Baseline Disease Characteristics in study GC-627-04 are summarised in Table 16.

<div style=\"page-break-after: always\"></div>

Table 21 . Summary of Demographic and Baseline Disease Characteristics (Safety Population) in Study GC627-04

|                            | Treatment in Chemotherapy Cycle 1   | Treatment in Chemotherapy Cycle 1   |                       |
|----------------------------|-------------------------------------|-------------------------------------|-----------------------|
| Characteristic             | 20 mgF-627 (IN =83)                 | Placebo (N = 39)                    | All Subjects (N =122) |
| Age (years)                |                                     |                                     |                       |
| Mean (SD)                  | 50.8 (9.25)                         | 51.5 (9.00)                         | 51.0 (9.14)           |
| Median                     | 50.0                                | 51.0                                | 51.0                  |
| Range                      | 30, 69                              | 33,67                               | 30, 69                |
| Sex                        |                                     |                                     |                       |
| Female                     | 83 (100.0)                          | 39 (100.0)                          | 122 (100.0)           |
| Country/Region             |                                     |                                     |                       |
| Ukraine                    | 46 (55.4)                           | 22 (56.4)                           | 68 (55.7)             |
| Russia                     | 32 (38.6)                           | 16 (41.0)                           | 48 (39.3)             |
| Hungary                    | 4 (4.8)                             | 1 (2.6)                             | 5 (4.1)               |
| United States              | 1 (1.2)                             | 0                                   | 1 (0.8)               |
| Race                       |                                     |                                     |                       |
| White                      | 82 (98.8)                           | 39 (100.0)                          | 121 (99.2)            |
| BlackorAfricanAmerican     | 1 (1.2)                             | 0                                   | 1 (0.8)               |
| Ethnicity                  |                                     |                                     |                       |
| Not Hispanic or Latino     | 82 (98.8)                           | 38 (97.4)                           | 120 (98.4)            |
| Hispanic or Latino         | 1 (1.2)                             | 1 (2.6)                             | 2 (1.6)               |
| Reproductive Status        |                                     |                                     |                       |
| Childbearing potential     | 37 (44.6)                           | 15 (38.5)                           | 52 (42.6)             |
| Non-childbearing potential | 46 (55.4)                           | 24 (61.5)                           | 70 (57.4)             |
| Post-menopausal            | 42 (91.3)                           | 23 (95.8)                           | 65 (92.9)             |
| Surgically sterilel        | 4 (8.7)                             | 1 (4.2)                             | 5 (7.1)               |
| BMI (kg/m)                 |                                     |                                     |                       |
| Mean (SD)                  | 26.2 (5.36)                         | 27.4 (6.22)                         | 26.6 (5.65)           |
| Median                     | 26.1                                | 26.4                                | 26.1                  |
| Range                      | 16, 44                              | 17,44                               | 16,44                 |
| Baseline ECOG2             |                                     |                                     |                       |
| 0                          | 46 (55.4)                           | 27 (69.2)                           | 73 (59.8)             |
| 1                          | 37 (44.6)                           | 12 (30.8)                           | 49 (40.2)             |
| Cancer Stage at Screening  |                                     |                                     |                       |
| Stage II                   | 43 (51.8)                           | 21 (53.8)                           | 64 (52.5)             |
| Stage III                  | 22 (26.5)                           | 12 (30.8)                           | 34 (27.9)             |
| Stage IV                   | 18 (21.7)                           | 6 (15.4)                            | 24 (19.7)             |
| Days from Diagnosis²n      | 82                                  | 38                                  | 120                   |
| Mean (SD)                  | 224.5 (572.21)                      | 445.9 (1337.99)                     | 294.6 (888.93)        |
| Median                     | 45.5                                | 49.5                                | 48.0                  |
| Range                      | 12.4049                             | 6,7670                              | 6, 7670               |

Abbreviations: BM =body mass index; ECOG =Eastem Cooperative Oncology Group; SD = standard deviation. N = number of subjects in the Safety Population, n = number of subjects within a specific category. Percentages were calculated as 100 x (n/N).

2. ECOG Performance Status: 0 =Fully active, able to cairy on all pre-disease performance without restriction; 1 = Restricted in physicallystrenuous activitybut ambulatory and able to carry out workof a light or sedentary nature.

Percentage of subjects in this category was based on non-childbearing potential.

3 Days from diagnosis =Date of randomization - Date of diagnosis.

All subjects were administered the complete dose for all chemotherapy cycles they received. All subjects received myelotoxic chemotherapy during cycle 1, specifically 75 mg/m2 docetaxel and 60 mg/m2 doxorubicin; Table 22).

<div style=\"page-break-after: always\"></div>

Table 17 . Myelotoxic Chemotherapy Administration by Cycle and Treatment Group Safety Population in Study GC-627-04

|                                         | Placebo (N = 39) n (%)   | F-627 20 mg (N = 83) n (%)   | Total (N = 122) n (%)   |
|-----------------------------------------|--------------------------|------------------------------|-------------------------|
| MyelotoxicChemotherapyDoseLevel Cycle 1 |                          |                              |                         |
| Docetaxel, N1                           | 39                       | 83                           | 122                     |
| 75 mg/m2                                | 39 (100.0)               | 83 (100.0)                   | 122 (100.0)             |
| Other                                   | 0                        | 0                            | 0                       |
| Doxorubicin, N1                         | 39                       | 83                           | 122                     |
| 60 mg/m2                                | 39 (100.0)               | 83 (100.0)                   | 122 (100.0)             |
| Other                                   | 0                        | 0                            | 0                       |
| Cycle 2                                 |                          |                              |                         |
| Docetaxel, N1                           | 38                       | 83                           | 121                     |
| 75 mg/m2                                | 35 ( 92.1)               | 80 (96.4)                    | 115 ( 95.0)             |
| Other                                   | 3 7.9)                   | 3 (3.6)                      | 6 (5.0)                 |
| Doxorubicin, N1                         | 38                       | 83                           | 121                     |
| 60 mg/m²                                | 35( 92.1)                | 80 (96.4)                    | 115 ( 95.0)             |
| Other                                   | 3 (7.9)                  | 3 (3.6)                      | 6 (5.0)                 |

n = Number of subjects in dose level.Percentages are calculated as 1o0 x (n/Nl).

## Study GC-627-05 .

Demographic and Baseline Disease Characteristics in study GC-627-05 are summarised in Table 18 and Table 19, respectively.

<div style=\"page-break-after: always\"></div>

Table 23. Summary of Demographic Characteristics (Safety Population) of Study GC-627-05

| Characteristic            | 20 mgF-627 (N =197)   | 6 mg Neulasta? (N = 196)   | All Subjects (N =393)   |
|---------------------------|-----------------------|----------------------------|-------------------------|
| Age (years)               |                       |                            |                         |
| Mean (SD)                 | 51.4 (11.82)          | 53.4 (11.11)               | 52.4 (11.50)            |
| Median                    | 53.0                  | 55.0                       | 54.0                    |
| Minimum,Maximum           | 28,83                 | 26, 80                     | 26.83                   |
| Sex                       |                       |                            |                         |
| Female                    | 197 (100.0)           | 196 (100.0)                | 393 (100.0)             |
| Reproductive Status       |                       |                            |                         |
| Non-childbearingPotential | 111 (56.3)            | 126 (64.3)                 | 237 (60.3)              |
| Post-menopausall          | 100 (90.1)            | 116 (92.1)                 | 216 (91.1)              |
| Surgically Sterilel       | 11 (9.9)              | 10 (7.9)                   | 21 (8.9)                |
| Childbearing Potential    | 86 (43.7)             | 70 (35.7)                  | 156 (39.7)              |
| Country/Region            |                       |                            |                         |
| Ukraine                   | 82 (41.6)             | 84 (42.9)                  | 166 (42.2)              |
| Russia                    | 73 (37.1)             | 72 (36.7)                  | 145 (36.9)              |
| Hungary                   | 23 (11.7)             | 22 (11.2)                  | 45 (11.5)               |
| Bulgaria                  | 18 (9.1)              | 18 (9.2)                   | 36 (9.2)                |
| United States             | 1 (0.5)               | 0                          | 1 (0.3)                 |
| Race                      |                       |                            |                         |
| White                     | 197 (100.0)           | 196 (100.0)                | 393 (100.0)             |
| Ethnicity                 |                       |                            |                         |
| Not Hispanic or Latino    | 197 (100.0)           | 195 (99.5)                 | 392 (99.7)              |
| Hispanic or Latino        | 0                     | 1 (0.5)                    | 1 (0.3)                 |
| Weight (kg)               |                       |                            |                         |
| Mean (SD)                 | 75.84 (16.884)        | 74.93 (16.873)             | 75.39 (16.863)          |
| Median                    | 73.00                 | 72.00                      | 73.00                   |
| Minimum,Maximum           | 45.3, 137.0           | 46.0, 146.1                | 45.3, 146.1             |
| Height (cm)               |                       |                            |                         |
| Mean (SD)                 | 162.6 (6.27)          | 162.2 (6.67)               | 162.4 (6.47)            |
| Median                    | 163.0                 | 162.0                      | 162.0                   |
| Minimum, Maximum          | 144, 179              | 145, 191                   | 144, 191                |
| BMI (kg/m²)               |                       |                            |                         |
| Mean (SD)                 | 28.72 (6.358)         | 28.51 (6.197)              | 28.62 (6.271)           |
| Median                    | 27.64                 | 27.71                      | 27.66                   |
| Minimum,Maximum           | 18.3, 49.1            | 17.3, 56.4                 | 17.3, 56.4              |

Abbreviations:BvI=bodymassindex;SD=standarddeviation.

N=number of subjects in the Safety Population, n =number of subjects within a specific category.Percentages were calculated

1. Percentage of subjects in this category was based on non-childbearing potential.

as 100 x (n/N).

Table 24. Summary of Baseline Disease Characteristics (Safety Population) in Study GC-627-05

| Characteristic                 | 20 mg F-627 (N =197)   | 6 mg Neulasta? (N =196)   | All Subjects (N =393)   |
|--------------------------------|------------------------|---------------------------|-------------------------|
| BaselineECOGPerformanceStatusl |                        |                           |                         |
| 0                              | 153 (77.7)             | 146 (74.5)                | 299 (76.1)              |
| 1                              | 44 (22.3)              | 50 (25.5)                 | 94 (23.9)               |
| CancerStage atScreening        |                        |                           |                         |
| Stage I                        | 30 (15.2)              | 34 (17.3)                 | 64 (16.3)               |
| Stage II                       | 99 (50.3)              | 107 (54.6)                | 206 (52.4)              |
| Stage III                      | 68 (34.5)              | 55 (28.1)                 | 123 (31.1)              |
| Days from Diagnosis2           |                        |                           |                         |
| Mean (SD)                      | 67.8 (131.98)          | 69.2 (260.34)             | 68.5 (205.98)           |
| Median                         | 42.0                   | 40.0                      | 41.0                    |
| Minimum, Maximum               | 6,1374                 | 7,3600                    | 6,3600                  |

Abbreviations:ECOG=EasternCooperativeOncologyGroup;SD=standard deviation.

ECOG PerformanceStatus: 0=Fully active,able to carry on allpre-diseaseperformance without restriction;1 =Restricted in physicallystrenuousactivitybutambulatoryandabletocarryoutworkofalightorsedentarynature.

N=number of subjects in the Safety Population, n =number of subjects within a specific category.Percentages were calculated as 100 × (n/N).

Daysfromdiagnosis=Dateofrandomization-Dateofdiagnosis.

The majority of subjects (99.7%) received 75 mg/m2 docetaxel and 600 mg/m2 cyclophosphamide myelotoxic chemotherapy during chemotherapy cycle 1.

<div style=\"page-break-after: always\"></div>

## Study SP11631 .

Demographic and Baseline Disease Characteristics in Study SP11631 are summarised in Table 20 and Table 21, respectively.

Table 2522. Demographics and baseline data - FAS Study SP11631

| Parameters       | F-627 (N = 120)   | GRAN? (N = 119)   | Overall (= 239)   |
|------------------|-------------------|-------------------|-------------------|
| Age (years)      |                   |                   |                   |
| Mean (SD)        | 49.1 (9.32)       | 48.5 (9.14)       | 48.8 (9.21)       |
| Median           | 49.0              | 48.0              | 49.0              |
| Minimum,maximum  | 28, 71            | 28.67             | 28,71             |
| Sex, n (%)       |                   |                   |                   |
| Female           | 120 (100)         | 119 (100)         | 239 (100)         |
| Ethnicity, n (%) |                   |                   |                   |
| Han Chinese      | 116 (96.7)        | 115 (96.6)        | 231 (96.7)        |
| Other            | 4 (3.3)           | 4 (3.4)           | 8 (3.3)           |
| Height (cm)      |                   |                   |                   |
| Mean (SD)        | 157.97 (5.061)    | 157.87 (5.524)    | 157.92 (5.286)    |
| Median           | 158.00            | 158.00            | 158.00            |
| Minimum, maximum | 143.0, 170.0      | 143.0, 170.0      | 143.0, 170.0      |
| Weight (kg)      |                   |                   |                   |
| Mean (SD)        | 58.96 (8.945)     | 59.24 (8.487)     | 59.10 (8.703)     |
| Median           | 59.00             | 59.00             | 59.00             |
| Minimum, maximum | 40.0, 85.0        | 42.0, 88.0        | 40.0, 88.0        |
| BMII (kg/m²)     |                   |                   |                   |
| Mean (SD)        | 23.609 (3.278)    | 23.782 (3.336)    | 23.695 (3.301)    |
| Median           | 23.398            | 23.634            | 23.424            |
| Minimum,maximum  | 14.881,31.221     | 16.613,33.531     | 14.881,33.531     |
| BSA (m?)         |                   |                   |                   |
| Mean (SD)        | 1.591 (0.123)     | 1.594 (0.116)     | 1.593 (0.119)     |
| Median           | 1.590             | 1.596             | 1.591             |
| Minimum, maximum | 1.315, 1.946      | 1.324,1.926       | 1.315,1.946       |

Note: The percentages were calculated based on the number of subjects without missing data in each corresponding treatmentarmintheFAS

<div style=\"page-break-after: always\"></div>

Table 26. Disease baseline characteristics - FAS Study SP11631

|                                                                              | F-627        | GRAN?        | Overall      |
|------------------------------------------------------------------------------|--------------|--------------|--------------|
| Parameter's                                                                  | (N = 120)    | (N = 119)    | (N = 239)    |
| Diagnosedl with breast cancer,n (%)                                          |              |              |              |
| Yes                                                                          | 120 (100)    | 119 (100)    | 239 (100)    |
| Timefromdiagnosisofbreastcancerto signing ICF!]                              |              |              |              |
| Mean (SD)                                                                    | 24.5 (18.08) | 20.9 (13.51) | 22.7 (16.04) |
| Median                                                                       | 21.5         | 18.0         | 20.0         |
| Minimum, maximum                                                             | 3,107        | -2, 70       | -2, 107      |
| Histopathological iagnosis,n (%)                                             |              |              |              |
| Yes                                                                          | 120 (100)    | 119 (100)    | 239 (100)    |
| Receivedchemotherapywithinlyear before screening, n (%)                      |              |              |              |
| Yes                                                                          | 0            | 0            | 0            |
| Received radiation therapy withinl year before screening, n (%)              |              |              |              |
| Yes                                                                          |              |              |              |
| Received other treatments for breast cancerwithinlyearbeforescreening, n (%) |              |              |              |
| Yes                                                                          | 0            | 1 (0.8)      | 1 (0.4)      |
|                                                                              | F-627        | GRAN?        | Overall      |
| Clinical stagingll, n (%)                                                    |              |              |              |
| Ia                                                                           | 30 (25.0)    | 30 (25.2)    | 60 (25.1)    |
| ⅡIa                                                                          | 36 (30.0)    | 46 (38.7)    | 82 (34.3)    |
| Ib                                                                           | 22 (18.3)    | 20 (16.8)    | 42 (17.6)    |
| IIla                                                                         | 24 (20.0)    | 13 (10.9)    | 37 (15.5)    |
| IIIb                                                                         | 0            | 2 (1.7)      | 2 (0.8)      |
| IIIc                                                                         | 8 (6.7)      | 7 (5.9)      | 15 (6.3)     |
| IV                                                                           | 0            | 1 (0.8)      | 1 (0.4)      |
| ECOG performance status, n (%)                                               |              |              |              |
| 0                                                                            | 26 (21.7)    | 35 (29.4)    | 61 (25.5)    |
| 1                                                                            | 94 (78.3)    | 83 (69.7)    | 177 (74.1)   |
| 2                                                                            | 0            | 1 (0.8)      | 1 (0.4)      |

Note: The percentages were calculated based on the number of subjects without missing data in each corresponding treatment arm in the FAS set.

[1]Timefrom diagnosisofbreastcancer tosigningICF(days)=dateofsigningICF-dateofbreastcancer diagnosis+1.Ifthepathologicaldiagnosisofbreastcancerinvolvesmultipledates,thedateofdiagnosisisbasedon the date ofthelast diagnosis.

[2] The 7th edition of TNM staging for breast cancer was used for tumor staging and clinical staging.

## · Numbers analysed

Study GC-627-04 . The Intent-to-Treat Analysis Set (ITT) included all randomized subjects. The Safety Analysis Set included all enrolled subjects receiving any study treatment. The Safety Analysis Set was used for all safety analyses.

<div style=\"page-break-after: always\"></div>

Table 27. Data Sets Analysed in study GC-627-04

|                            | Treatment in Chemotherapy Cycle 1   | Treatment in Chemotherapy Cycle 1   |                       |
|----------------------------|-------------------------------------|-------------------------------------|-----------------------|
|                            | 20 mg F-627 (N =83)                 | Placebo (N =39)                     | All Subjects (N =135) |
| ITT Population'            | 83 (100.0)                          | 39 (100.0)                          | 122 (90.4)            |
| Safety Population2         | 83 (100.0)                          | 39 (100.0)                          | 122 (90.4)            |
| PP Population-Overall3     | 83 (100.0)                          | 39 (100.0)                          | 122 (90.4)            |
| Cycle 1                    | 81 (97.6)                           | 37 (94.9)                           | 118 (87.4)            |
| Cycle 2                    | 83 (100.0)                          | 38 (97.4)                           | 121 (89.6)            |
| Cycle 3                    | 82 (98.8)                           | 37 (94.9)                           | 119 (88.1)            |
| Cycle 4                    | 82 (98.8)                           | 37 (94.9)                           | 119 ($8.1)            |
| Immunogenicity Population* | 83 (100.0)                          | 38 (97.4)                           | 121 (89.6)            |

All randomized subjectsinboth treatment armsreceived F-627for cycles 2 to 4.

Data shown are n (%o). N = number of all randomized subjects for treatment groups and all subjects. n = number of subjects within a specific category. Percentages were calculated as 100 × (n/N).

Safety Population included all subjects who received any study treatment.

ITT (Intent-to-Treat) Population included all randomized subjects.

PP (Per-protocol) Population included all subjects who received study treatment and were without major protocol deviations during the first cycle.

ImmunogenicityPopulation included121subjectswhoreceived at least one dose of study treatment andhadat least one immunogenicity data point.

Study GC-627-05 . The Intent-to-Treat (ITT) Analysis Set (ITT Population) included all randomized subjects. The Safety Analysis Set was used for all safety analyses.

Table 23. Data Sets Analysed (All Subjects) in Study GC-627-05

|                            | 20mgF-627 (N =197)   | 6mgNeulasta (N=196)   | All Subjects (N=393)   |
|----------------------------|----------------------|-----------------------|------------------------|
| ITT Population'            | 197 (100.0)          | 196 (100.0)           | 393 (100.0)            |
| Safety Population?         | 197 (100.0)          | 196 (100.0)           | 393 (100.0)            |
| ppPopulation-Overall       | 197 (100.0)          | 196 (100.0)           | 393 (100.0)            |
| ImnminogenicityPopulation' | 197 (100.0)          | 195 (99.5)            | 392 (99.7)             |

Data shown aren(%e).N=mumberofall randomized subjects for treatment groups andall subjecis.n=mumberof subjects within a specificcategoryy.Percentageswerecalculated as100×(n/N)

SaferPopulationinchuded allsubjectswhoreceived F-627orNenlastatreatment PPD wio was randomized F-627treatmentgroupforallchemotherapycycies.

1.ITT(ntent-to-Treat) Population incuded all randomized subjecis.

PP(PerProtocol)Populationincluded allsubjeciswhorecelved studydrug treatmentand were withoutmajorprotocol violationsduringthefirstchemotherapycycle.

ImmnunogenicitlyPopulationinciudedall subjectswhoTeceived at leastonedoseofstudydrugandhad atleastone immunogenicirydatapoint.

Sowrce:Table1.1.landTable5.7.2

<div style=\"page-break-after: always\"></div>

## Study SP11631

Table 24. Distribution of analysis sets - randomized set in Study SP11631

|                               | F-627 N=122 n (%)   | GRAN? N=120 n (%)   | Overall N=242 n (%)   |
|-------------------------------|---------------------|---------------------|-----------------------|
| Ss!                           | 120 (98.4)          | 119 (99.2)          | 239 (98.8)            |
| FAS121                        | 120 (98.4)          | 119 (99.2)          | 239 (98.8)            |
| PP set Aβ]                    | 119 (97.5)          | 110 (91.7)          | 229 (94.6)            |
| PP set BI4                    | 110 (90.2)          | 99 (82.5)           | 209 (86.4)            |
| Immunogenicity analysis set5] | 120 (98.4)          | 0                   | 120 (49.6)            |

Note: N = the number of randomized subjects in each treatment arm, n = the number of randomized subjects in the corresponding treatment amm

[1] SS: all randomized subjects who received at least one dose of the study drug.

[2] FAS: allrandomized subjects who have received the study drug and undergone at least one post-baseline efficacy evaluation.

[3] PP set A: subjects in FAS and without major protocol deviations, serious medication noncompliance, loss to follow-up, or withdrawal during cycle 1.

[4] PP set B: subjects in FAS and without major protocol deviations, serious medication noncompliance, loss to follow-up, or withdrawal in any cycle.

[5] Immunogenicity analysis set: subjects with at least one result of serum anti-F-627 antibody assay after F-627 treatment.

The percentages were calculated based on the number of subjects in corresponding treatment arm.

Source:Table14.1.2

Data Sets Analysed in the Phase III studies were described appropriately and are acceptable.

## · Outcomes and estimation

## Study GC-627-04

## Primary endpoint

The mean difference (standard error [SE]) in the duration of Grade 4 (severe) neutropenia in chemotherapy cycle 1 between F-627 and Placebo, assessed using multiple imputation, was 2.9 (0.28) days (95% CI: 2.3, 3.4), which was significant with p &lt;0.0001 (Table 25).

<div style=\"page-break-after: always\"></div>

Table 30 . Duration of Grade 4 (Severe) Neutropenia in Cycle 1 by Treatment Group (ITT Population ) in Study GC-627-04

|                           | 20 mg F-627 (N = 83)   | Placebo (N = 39)   |
|---------------------------|------------------------|--------------------|
| Mean Duration (SD), days1 | 1.3 (1.19)             | 3.9 (1.44)         |
| Mean Difference (SE)2     | 2.9 (0.28)             |                    |
| 95% CI                    | 2.3, 3.4               |                    |
| p-value3                  | <0.0001                |                    |

Abbreviations: ANC = absolute neutrophil count; CI = confidence interval; SD = standard deviation; SE = standard error. N = number of subjects in the ITT Population of Cycle 1.

The duration of Grade 4 (severe) neutropenia was defined as the number of days in which the subject had an ANC &lt;0.5 x 109/L post nadir.

- Difference between the F-627 20 mg dose compared to Placebo (with multiple imputation). Superiority was achieved if the lower limit of the two-sided 95% CI of the difference of Placebo vs. F-627 &gt;0.

1. Mean duration of Grade 4 neutropenia calculated with no multiple imputation.

P-value was for the testing of mean (Placebo) = mean (F-627).

## Secondary endpoints

Table 26. The Incidence Rate of Febrile Neutropenia Over All Cycles by Treatment Group (ITT Population) in Study GC-627-04

| Subjects with FN               | 20 mg F-627 (N =83)   | Placebo (N =39)   | All Subjects (N = 122)   |
|--------------------------------|-----------------------|-------------------|--------------------------|
| Cycle 1                        |                       |                   |                          |
| Subjects with FN, n/N1 (%)     | 4/83 (4.8)            | 10/39 (25.6)      | 14/122 (11.5)            |
| Difference with F-627 (95% CI) | 20.8 (1.8, 38.8)      |                   |                          |
| P-value'                       | 0.0016                |                   |                          |
| Cycle 2                        |                       |                   |                          |
| Subjects with FN, n/N1 (%)     | 0/83 (0.0)            | 1/38 (2.6)        | 1/121 (0.8)              |
| Difference with F-627 (95% C1) | 2.6 (-16.5, 21.7)     |                   |                          |
| Cycle 3                        |                       |                   |                          |
| Subjects with FN, n/N1 (%)     | 0/82 (0.0)            | 0/37 (0.0)        | 0/119 (0.0)              |
| Cycle 4                        |                       |                   |                          |
| Subjects with FN, n/N1 (%)     | 0/82 (0.0)            | 0/37 (0.0)        | 0/119 (0.0)              |
| Over All Cycles                |                       |                   |                          |
| Subjects with FN, n/N1 (%)     | 4/83 (4.8)            | 11/39 (28.2)      | 15/122 (12.3)            |
| Difference with F-627 (95% C1) | 23.4 (4.5,41.2)       |                   |                          |

Abbreviations: CI = confidence interval, FN = febrile neutropenia.

N = number of subjects in the ITT population. N1 = number of cycle-specific subjects in the ITT Population. n = number of subjects with FN during the chemotherapy cycle.

I. 95% CI and p-value are for the proportion difference between Placebo and F-627 using Fisher's Exact Test.

<div style=\"page-break-after: always\"></div>

Table 27. The Duration in Days of Grade 4 (Severe) Neutropenia Over All Cycles by Treatment Group (ITT Population; No Multiple Imputation) in Study GC-627-04

| Duration of Grade 4 Neutropenia (days)   | 20 mg F-627 (N =83)   | Placebo (N =39)   | All Subjects (N = 122)   |
|------------------------------------------|-----------------------|-------------------|--------------------------|
| Cycle 1, n                               | 74                    | 27                | 101                      |
| Mean (SD)                                | 1.3 (1.19)            | 3.9 (1.44)        | 2.0 (1.70)               |
| Mean Difference (95% Cl)*                | 2.6 (2.0, 3.1)        |                   |                          |
| Cycle 2, n                               | 76                    | 36                | 112                      |
| Mean (SD)                                | 0.3 (0.76)            | 0.8 (1.24)        | 0.4 (0.97)               |
| Mean Difference (95% CI)                 | 0.5 (0.1, 0.9)        |                   |                          |
| Cycle 3, n                               | 71                    | 32                | 103                      |
| Mean (SD)                                | 0.3 (0.84)            | 0.5 (1.19)        | 0.4 (0.96)               |
| Mean Difference (95% CI)                 | 0.2 (-0.2, 0.6)       |                   |                          |
| Cycle 4, n                               | 73                    | 29                | 102                      |
| Mean (SD)                                | 0.2 (0.62)            | 0.7 (1.39)        | 0.3 (0.94)               |
| Mean Difference (95% CI)                 | 0.6 (0.2, 1.0)        |                   |                          |
| Over All Cycles, n                       | 83                    | 39                | 122                      |
| Mean (SD)                                | 0.5 (0.62)            | 1.4 (1.35)        | 0.8 (1.00)               |
| Mean Difference (95% Cl)                 | 0.9 (0.5, 1.2)        |                   |                          |

Abbreviations: ANC = absolute neutrophil count; CI = confidence interval, SD = standard deviation.

The duration of Grade 4 (severe) neutropenia is defined as the number of days in which the subject had an ANC &lt;0.5 × 109/L.

Differences between Placebo and F-627 20 mg.

<div style=\"page-break-after: always\"></div>

Table 28. The Incidence Rate of Use of Antibiotic Medications (WHO SDG Definition) Over All Cycles by Treatment Group (ITT Population) in Study GC-627-04

|                                             | Treatment in Chemotherapy Cycle 1   | Treatment in Chemotherapy Cycle 1   | All Subjects   |
|---------------------------------------------|-------------------------------------|-------------------------------------|----------------|
| Subjects Who Used IV Antibiotic Medications | 20 mg F-627 (N =83)                 | Placebo (N =39)                     | (N = 122)      |
| Cycle 1                                     |                                     |                                     |                |
| n/NI (%)                                    | 3/83 (3.6)                          | 7/39 (17.9)                         | 10/122 (8.2)   |
| Difference with F-627 (95% CI)              | 14.3 (-4.8, 32.8)                   |                                     |                |
| Cycle 2                                     |                                     |                                     |                |
| n/N1 (%)                                    | 0/83                                | 1/38 (2.6)                          | 1/121 (0.8)    |
| Difference with F-627 (95% CI)              | 2.6 (-16.5, 21.7)                   |                                     |                |
| Cycle 3                                     |                                     |                                     |                |
| n/N1 (%)                                    | 0                                   | 0                                   | 0              |
| Difference with F-627 (95% CI)              |                                     |                                     |                |
| Cycle 4                                     |                                     |                                     |                |
| n/N1 (%)                                    | 0                                   | 0                                   | 0              |
| Difference with F-627 (95% CI)              |                                     |                                     |                |
| Over All Cycles                             |                                     |                                     |                |
| n/NI (%)                                    | 3/83 (3.6)                          | 8/39 (20.5)                         | 11/122 (9.0)   |
| Difference with F-627 (95% CI)*             | 16.9 (-2.2, 35.2)                   |                                     |                |

Abbreviations: CI = confidence interval; WHO SDG = World Health Organization standardized drug grouping.

1. 95% CI and p-value are for the proportion difference between Placebo and F-627 using Fisher's Exact Test.

N = number of subjects in the ITT population. N1 = number of cycle-specific subjects in the ITT population. n = number of subjects who used antibiotic medications during the chemotherapy cycle.

<div style=\"page-break-after: always\"></div>

Table 29 . Summary of the Time to ANC Recovery Post Nadir Over All Cycles by Treatment Group (ITT Population) in Study GC-627-04

|                             | TreatmentinChemotherapyCyclel   | TreatmentinChemotherapyCyclel   |                       |
|-----------------------------|---------------------------------|---------------------------------|-----------------------|
| Time to ANC Recovery (days) | 20 mg F-627 (N=83)              | Placebo (N=39)                  | All Subjects (N =122) |
| Cycle1                      | 83                              | 38                              | 121                   |
| Mean (SD)                   | 2.1 (1.09)                      | 4.1 (2.06)                      | 2.8 (1.72)            |
| MeanDifference (95%6 CT)    | 2.0 (1.4,2.5)                   |                                 |                       |
| Cycle 2                     | 83                              | 38                              | 121                   |
| Mean (SD)                   | 1.6 (1.35)                      | 2.1(1.40)                       | 1.7 (1.39)            |
| MeanDifference (95% CT)     | 0.5 (0.0, 1.1)                  |                                 |                       |
| Cycle3                      | 82                              | 37                              | 119                   |
| Mean (SD)                   | 1.6 (1.39)                      | 1.6 (1.75)                      | 1.6 (1.50)            |
| Mean Difference (95% C1)    | 0.0 (-0.6,0.6)                  |                                 |                       |
| Cycle42                     | 82                              | 36                              | 118                   |
| Mean (SD)                   | 1.9 (1.39)                      | 1.5 (1.73)                      | 1.7 (1.50)            |
| MeanDifference (9596C1)     | -0.4 (-0.9,02)                  |                                 |                       |
| OverAll Cycles              | 83                              | 39                              | 122                   |
| Mean (SD)                   | 1.8 (0.95)                      | 2.4 (1.18)                      | 2.0 (1.06)            |
| Mean Difference (95% C1)    | 0.6 (0.2, 1.0)                  |                                 |                       |

AbbreviationsANC=absoluteneutrophilcount:CI=confidenceinterval

The time to ANCrecoverypost nadirwas defined as the time in days anANC=2.0×10/L after the expected ANCnndir. IfANC=2.0x10/L the entirecycle,thiswas 0.

ThetimetoANCrecoverypostnadiroverallcycleswascalculatedastheavengeofallcycles

DifferencebetweenPlacebotoF-627.

PPD wasevcludedfromtheanalysisinCycle4becausetherewasnotenoughdatatocalculatethetimetoANC recovery.

<div style=\"page-break-after: always\"></div>

Table 30. The Incidence Rate of Infection Over All Cycles by Treatment Group (ITT Population) in Study GC627-04

|                                 | Treatment in Chemotherapy Cycle 1   | Treatment in Chemotherapy Cycle 1   |                       |
|---------------------------------|-------------------------------------|-------------------------------------|-----------------------|
| Subjects with Infection         | 20 mg F-627 (N = 83)                | Placebo (N =39)                     | All Subjects (N =122) |
| Cycle 1                         |                                     |                                     |                       |
| n/N1 (%)                        | 2/83 (2.4)                          | 3/39 (7.7)                          | 5/122 (4.1)           |
| Difference with F-627 (95% CI)  | 5.3 (-13.8, 24.1)                   |                                     |                       |
| P-value'                        | 0.3258                              |                                     |                       |
| Cycle 2                         |                                     |                                     |                       |
| n/N1 (%)                        | 1/83 (1.2)                          | 2/38 (5.3)                          | 3/121 (2.5)           |
| Difference with F-627 (95% C1)  | 4.1 (-15.0, 23.1)                   |                                     |                       |
| Cycle 3                         |                                     |                                     |                       |
| n/N1 (%)                        | 5/82 (6.1)                          | 3/37 (8.1)                          | 8/119 (6.7)           |
| Difference with F-627 (95% CI)* | 2.0 (-17.3, 21.1)                   |                                     |                       |
| Cycle 4                         |                                     |                                     |                       |
| n/N1 (%)                        | 1/82 (1.2)                          | 0/37 (0.0)                          | 1/119 (0.8)           |
| Difference with F-627 (95% CI)* | -1.2 (-20.4, 18.0)                  |                                     |                       |
| Over All Cycles                 |                                     |                                     |                       |
| n/N1 (%)                        | 9/83 (10.8)                         | 8/39 (20.5)                         | 17/122 (13.9)         |
| Difference with F-627 (95% C1)  | 9.7 (-9.4, 28.2)                    |                                     |                       |

Abbreviations: CI = confidence interval.

N = number of subjects in the ITT population. N1 = number of cycle-specific subjects in the ITT population. n = number of subjects with infection during the chemotherapy cycle.

1. 95% CI and p-value are for the proportion difference between Placebo and F-627 using Fisher's Exact Test.

<div style=\"page-break-after: always\"></div>

## Study GC-627-05 .

Primary endpoint

Table 31. Duration of Grade 4 (Severe) Neutropenia in Cycle 1 by Treatment Group (ITT Population) in Study GC-627-05

|                          | 20 mgF-627 (N =197)   | 6 mg Neulasta? (N = 196)   |
|--------------------------|-----------------------|----------------------------|
| 1n1                      | 197                   | 196                        |
| Mean Duration (SD), days | 0.2 (0.51)            | 0.2 (0.45)                 |
| Mean Difference (SE)2    | 0.0 (0.05)            |                            |
| 95% CI                   | -0.1, 0.1             |                            |
| p-value3                 | 0.7074                |                            |

Abbreviations: ANC = absolute neutrophil count; CI = confidence interval; ITT = Intent-to-Treat; SD = standard deviation; SE = standard error.

N = number of subjects in the ITT Population of chemotherapy cycle 1.

Mean duration of Grade 4 neutropenia calculated with no multiple imputation, based on n = 188 for subjects randomized to F-627 and n = 184 for subjects randomized to Neulasta?.

The duration of Grade 4 (severe) neutropenia was defined as the number of days in which the subject had an ANC &lt;0.5 × 109/L post-nadir within the first 12 days of chemotherapy treatment.

Difference between the F-627 compared to Neulasta? (with multiple imputation). Non-inferiority of F-627 to Neulasta? was achieved if the upper limit of the one-sided 97.5% CI &lt;0.6 days. Superiority of F-627 to Neulasta? was achieved if the upper limit of the two sided 95% CI was less than 0 days.

p-value was for the testing of mean (F-627) = mean (Neulasta?).

## Secondary endpoints

Table 32 . The Incidence of Febrile Neutropenia Across All and Over Each Chemotherapy Cycle by Treatment Group (ITT Population) in Study GC-627-05

|                                              | 20 mg F-627 (N = 197)   | 6 mg Neulasta? (N =196)   | All Subjects (N = 393)   |
|----------------------------------------------|-------------------------|---------------------------|--------------------------|
| Total Across All Chemotherapy Cycles n (%)   | 6 (3.0)                 | 1 (0.5)                   | 7 (1.8)                  |
| Difference with Neulasta? (95% CI)1 p-value2 | 2.5 (-7.3, 12.4) 0.1217 |                           |                          |
| Chemotherapy Cycle 1 n/N1 (%)                | 5/197 (2.5)             | 0/196                     | 5/393 (1.3)              |
| Difference with Neulasta? (95% CI)1          | 2.5 (-7.3, 12.4)        |                           |                          |
| Chemotherapy Cycle 2 n/N1 (%)                | 0/194                   | 0/196                     | 0/390                    |
| Difference with Neulasta? (95% CI)1          | N/A                     |                           |                          |
| Chemotherapy Cycle 3 n/N1 (%)                | 1/193 (0.5)             | 1/191 (0.5)               | 2/384 (0.5)              |
| Difference with Neulasta? (95% CI)1          | -0.0 (-10.1, 10.1)      |                           |                          |
| Chemotherapy Cycle 4 n/N1 (%)                | 1/186 (0.5)             | 0/188                     | 1/374 (0.3)              |
| Difference with Neulasta? (95% CI)           | 0.5 (-9.7, 10.8)        |                           |                          |

Abbreviations: CI = confidence interval; ITT = Intent-to-Treat; N/A = not applicable

1.  95% CI was for the proportion difference between F-627 and Neulasta@ using Fisher's Exact Test.

N = number of subjects in the ITT Population. N1 = number of subjects in a chemotherapy cycle. n = number of subjects with febrile neutropenia during the chemotherapy cycle.

p-value was for the proportion difference between F-627and Neulasta? using Fisher's Exact Test.

<div style=\"page-break-after: always\"></div>

Table 33. Number of Days of Intravenous Antibiotic Use Across All and Over Each Chemotherapy Cycle by Treatment Group (ITT Population) in Study GC-627-05

|                                         | 20 mg F-627 (N = 197)   | 6 mg Neulasta? (N = 196)   | All Subjects (N = 393)   |
|-----------------------------------------|-------------------------|----------------------------|--------------------------|
| Total Across All Chemotherapy Cycles, n | 197                     | 196                        | 393                      |
| Mean (SD)                               | 0.3 (1.36)              | 0.1 (0.70)                 | 0.2 (1.09)               |
| Mean Difference (95% CI)1               | 0.2 (-0.01, 0.42)       |                            |                          |
| p-value2                                | 0.0538                  |                            |                          |
| Chemotherapy Cycle 1, n                 | 197                     | 196                        | 393                      |
| Mean (SD)                               | 0.1 (0.76)              | 0.0 (0.43)                 | 0.1 (0.62)               |
| Mean Difference (95% CI)1               | 0.1 (-0.04, 0.21)       |                            |                          |
| Chemotherapy Cycle 2, n                 | 194                     | 196                        | 390                      |
| Mean (SD)                               | 0.0 (0.29)              | 0.0 (0.29)                 | 0.0 (0.29)               |
| Mean Difference (95% CI)1               | 0.0 (-0.06, 0.06)       |                            |                          |
| Chemotherapy Cycle 3, n                 | 193                     | 191                        | 384                      |
| Mean (SD)                               | 0.1 (0.68)              | 0.0 (0.22)                 | 0.0 (0.51)               |
| Mean Difference (95% CI)1               | 0.0 (-0.06, 0.15)       |                            |                          |
| Chemotherapy Cycle 4, n                 | 186                     | 188                        | 374                      |
| Mean (SD)                               | 0.1 (0.79)              | 0.0 (0.00)                 | 0.0 (0.56)               |
| Mean Difference (95% C1)1               | 0.1 (-0.04, 0.19)       |                            |                          |

Abbreviations:CI=confidenceinterval;ITT=Intent-to-Treat;SD=standarddeviation.

N = number of subjects in the ITT Population.

The number of days of intravenous antibiotics used was defined as the cumulative number of days in which the subject had had intravenous antibiotics over all chemotherapy cycles.

n =number of subjects in a chemotherapy cycle.

1. Mean difference (F-627 - Neulasta?) and the CI were based on a two sample t-test.

2 p-valuewasbased on the two-sided exact test from aWilcoxonRank Sum test.

Table 34. Incidence of Use of Intravenous Antibiotics Across All and Over Each Chemotherapy Cycle by Treatment Group (ITT Population) in Study GC-627-05

|                                              | 20 mg F-627 (N = 197)   | 6 mg Neulasta? (N =196)   | AllSubjects (N = 393)   |
|----------------------------------------------|-------------------------|---------------------------|-------------------------|
| Total Across All Chemotherapy Cycles n (%)   | 9 (4.6)                 | 2 (1.0)                   | 11 (2.8)                |
| Difference with Neulasta? (95% CI)1 p-value2 | 3.5 (-6.3, 13.4) 0.0618 |                           |                         |
| Chemotherapy Cycle 1 n/N1 (%)                | 5/197 (2.5)             | 1/196 (0.5)               | 6/393 (1.5)             |
| Difference with Neulasta? (95% CI)1          | 2.0 (-7.8, 11.9)        |                           |                         |
| Chemotherapy Cycle 2 n/N1 (%)                | 1/194 (0.5)             | 1/196 (0.5)               | 2/390 (0.5)             |
| Difference with Neulasta? (95% CI)1          | 0.0 (-10.0, 10.1)       |                           |                         |
| Chemotherapy Cycle 3 n/N1 (%)                | 2/193 (1.0)             | 1/191 (0.5)               | 3/384 (0.8)             |
| Difference with Neulasta?(95% C1)1           | 0.5 (-9.6, 10.6)        |                           |                         |
| Chemotherapy Cycle 4 n/N1 (%)                | 2/186 (1.1)             | 0/188                     | 2/374 (0.5)             |
| Difference with Neulasta? (95% CI)1          | 1.1 (-9.2, 11.3)        |                           |                         |

Abbreviations:CI=confidence interval;ITT=Intent-to-Treat

N =number of subjects in the ITT Population. N1 = number of subjects in a chemotherapy cycle. n = number of subjects who used intravenous antibiotic medications during the chemotherapy cycle.

p-value was for the proportion difference between F-627 and Neulasta using Fisher's Exact Test.

95% CI was for the proportion difference between F-627 and Neulasta? using Fisher's Exact Test.

<div style=\"page-break-after: always\"></div>

Table 35. Median Absolute Neutrophil Counts (ANC) Over Time Over All Chemotherapy Cycles (ITT Population) in Study GC-627-05

<!-- image -->

Abbreviations: ANC = absolute neutrophil count; ITT = intent-to-treat; SD = standard deviation

Table 36. The Incidence of Infections Over All Chemotherapy Cycles by Treatment Group (ITT Population) in Study GC-627-05

|                                     | 20 mg F-627 (N = 197)   | 6 mg Neulasta? (N = 196)   | All Subjects (N = 393)   |
|-------------------------------------|-------------------------|----------------------------|--------------------------|
| Over All Chemotherapy Cycles        |                         |                            |                          |
| n/N1 (%)                            | 14/197 (7.1)            | 17/196 (8.7)               | 31/393 (7.9)             |
| Difference with Neulasta? (95% CI)1 | -1.6 (-11.4, 8.3)       |                            |                          |
| Chemotherapy Cycle 1                |                         |                            |                          |
| n/N1 (%)                            | 4/197 (2.0)             | 3/196 (1.5)                | 7/393 (1.8)              |
| Difference with Neulasta? (95% CI)1 | 0.5 (-9.4, 10.4)        |                            |                          |
| Chemotherapy Cycle 2                |                         |                            |                          |
| n/N1 (%)                            | 1/194 (0.5)             | 4/196 (2.0)                | 5/390 (1.3)              |
| Difference with Neulasta? (95% CI)1 | -1.5 (-11.6, 8.6)       |                            |                          |
| Chemotherapy Cycle 3                |                         |                            |                          |
| n/N1 (%)                            | 4/193 (2.1)             | 5/191 (2.6)                | 9/384 (2.3)              |
| Difference with Neulasta? (95% CI)1 | -0.5 (-10.7, 9.5)       |                            |                          |
| Chemotherapy Cycle 4                |                         |                            |                          |
| n/N1 (%)                            | 5/186 (2.7)             | 6/188 (3.2)                | 11/374 (2.9)             |
| Difference with Neulasta? (95% CI)1 | -0.5 (-10.7, 9.8)       |                            |                          |

Abbreviations: CI = confidence interval; ITT = Intent-to-Treat

1. CI for the differences between F-627 and Neulasta? used Fisher's Exact Test.

N = number of subjects in the ITT population. N1 = number of subjects in a chemotherapy cycle. n = number of subjects with infections during the chemotherapy cycle.

<div style=\"page-break-after: always\"></div>

Table 37 . Summary of the Depth of ANC Nadir in Each Cycle by Treatment Group (ITT Population) in Study GC-627-05

|                              | 20 mg F-627 (N = 197)   | 6 mg Neulasta? (N = 196)   | All Subjects (N = 393)   |
|------------------------------|-------------------------|----------------------------|--------------------------|
| Chemotherapy Cycle 1         | 197                     | 196                        | 393                      |
| Mean (SD)                    | 2.696 (2.3869)          | 2.652 (2.0796)             | 2.674 (2.2362)           |
| Ratio to Neulasta? (95% CI)1 | 0.97 (0.79, 1.19)       |                            |                          |
| Chemotherapy Cycle 2         | 194                     | 196                        | 390                      |
| Mean (SD)                    | 3.301 (2.2411)          | 3.529 (2.3238)             | 3.416 (2.2830)           |
| Ratio to Neulasta? (95% CI)1 | 0.95 (0.81, 1.12)       |                            |                          |
| Chemotherapy Cycle 3         | 193                     | 191                        | 384                      |
| Mean (SD)                    | 3.195 (2.4580)          | 3.103 (2.1227)             | 3.149 (2.2948)           |
| Ratio to Neulasta? (95% CI)1 | 1.04 (0.88, 1.22)       |                            |                          |
| Chemotherapy Cycle 4         | 186                     | 188                        | 374                      |
| Mean (SD)                    | 2.987 (2.0330)          | 3.197 (2.1456)             | 3.092 (2.0902)           |
| Ratio to Neulasta (95% CI)1  | 0.96 (0.82, 1.12)       |                            |                          |

Abbreviations: ANC = absolute neutrophil count; CI = confidence interval; ITT = Intent-to-Treat; SD = standard deviation. The depth of ANC nadir was the lowest ANC value within 12 days of chemotherapy treatment in the cycle.

Ratio to Neulasta? = ANC nadir value of F-627 group/ANC nadir value of Neulasta? group. The ratio was obtained using log-transformation of the data, then anti-log to get the relative effect and its 95% CI.

Table 38 . Summary of the Time to ANC Recovery Post Nadir in Each Cycle by Treatment Group (ITT Population)

|                           | 20 mg F-627 (N = 197)   | 6 mg Neulasta? (N = 196)   | All Subjects (N =393)   |
|---------------------------|-------------------------|----------------------------|-------------------------|
| Chemotherapy Cycle 1      | 194                     | 195                        | 389                     |
| Mean (SD)                 | 0.7 (0.83)              | 0.7 (0.81)                 | 0.7 (0.82)              |
| Mean Difference (95% CI)1 | 0.1 (-0.09, 0.23)       |                            |                         |
| Chemotherapy Cycle 2      | 190                     | 196                        | 386                     |
| Mean (SD)                 | 0.7 (1.07)              | 0.6 (0.96)                 | 0.6 (1.01)              |
| Mean Difference (95% CI)  | 0.1 (-0.08, 0.33)       |                            |                         |
| Chemotherapy Cycle 3      | 191                     | 190                        | 381                     |
| Mean (SD)                 | 0.7 (1.13)              | 0.6 (0.90)                 | 0.7 (1.02)              |
| Mean Difference (95% C1)  | 0.2 (-0.05, 0.36)       |                            |                         |
| Chemotherapy Cycle 42     | 185                     | 188                        | 373                     |
| Mean (SD)                 | 0.8 (1.19)              | 0.6 (1.00)                 | 0.7 (1.10)              |
| Mean Difference (95% CI)1 | 0.2 (-0.00, 0.44)       |                            |                         |

Abbreviations: ANC = absolute neutrophil count; CI = confidence interval; ITT = Intent-to-Treat; SD = standard deviation. The time to ANC recovery post nadir was defined as the time in days when the ANC ≥ 2.0 × 109/L after the expected ANC nadir.

1. Difference between F-627 and Neulasta?.

If ANC = 2.0 × 109/L for the entire cycle, this was 0.

<div style=\"page-break-after: always\"></div>

## Study SP11631

Table 39 . Duration (days) of grade 3 or 4 neutropenia in cycle 1 - FAS in Study SP11631

|                                                                              | F-627 (N = 120)     | GRAN? (N = 119)   |
|------------------------------------------------------------------------------|---------------------|-------------------|
| Mean (SD), day                                                               | 0.68 (1.100)        | 0.71 (0.951)      |
| Median                                                                       | 0.00                | 0.00              |
| Minimum,maximum                                                              | 0,4                 | 0,4               |
| (F-627 - GRAN) Hodges-Lehmann estimator (95% CI)                             | 0.00 (0.000, 0.000) |                   |
| (F-627 - GRAN) Hodges-Lehmann estimator (upper limit of one- sided 97.5% CI1 | 0.00 (0.000)        |                   |

Note: The missing ANC data of the first 13 days of each cycle were imputed using a method detailed in the SAP. The criteria for grade 3 or 4 neutropenia were ANC ≤ 1.0 x 10°/L and ANC &lt; 0.5 x 10°/L, respectively.

[1] Hodges-Lehmann estimator of the median of inter-arm difference (F-627-GRAN) in the duration of grade 3 or 4 neutropenia in cycle 1 was provided, along with the upper limit of one-sided 97.5% CI. Non-inferiority was established if the upper limit of CI was ≤ 1.

Table 40. Duration analysis on population with grade 3 or 4 neutropenia in cycle 1 - FAS in Study SP11631

|                                                                      | F-627 (N= 41)       | GRAN? (N = 51)   |
|----------------------------------------------------------------------|---------------------|------------------|
| Number                                                               | 41                  | 51               |
| Mean (SD), day                                                       | 2.00 (0.949)        | 1.65 (0.744)     |
| Median                                                               | 2.00                | 2.00             |
| Minimum,maximum                                                      | 1, 4                | 1, 4             |
| (F-627 - GRAN*) mean difference (95% CI)                             | 0.35 (0.003, 0.703) |                  |
| (F-627 - GRAN*) mean difference (upper limit of one-sided 97.5% CI)] | 0.35 (0.703)        |                  |

Note: The missing ANC data of the first 13 days of this cycle were imputed using a method detailed in the SAP. The criteria for grade 3 or 4 neutropenia were ANC &lt; 1.0 x 10%/L and ANC &lt; 0.5 x 10°/L, respectively.

[1] The mean duration (days) of the population with grade 3 or 4 neutropenia in the F-627 and GRAN arms in cycle 1 was provided, and the mean difference in the duration between the two arms and the corresponding CI were estimated by T-test.

<div style=\"page-break-after: always\"></div>

## Secondary endpoints

Table 41. Duration (days) of grade 4 neutropenia in cycle 1 in Study SP11631

|         |                                                   | F-627            | GRAN*      |
|---------|---------------------------------------------------|------------------|------------|
| FAS     | Number                                            | 120              | 119        |
|         | Mean (SD)                                         | 0.3 (0.69)       | 0.2 (0.58) |
|         | Median (range)                                    | 0.0[0, 3]        | 0.0[0, 2]  |
|         | (F-627 - GRAN°) Hodges-Lehmann estimator (95% C1) | 0.0 (0.00.0.00)  |            |
| PP SetA | Number                                            | 119              | 110        |
|         | Mean (SD)                                         | 0.2 (0.65)       | 0.2 (0.49) |
|         | Median (range)                                    | 0.0[0, 3]        | 0.0[0, 2]  |
|         | (F-627 - GRAN) Hodges-Lehmann estimalor (95% C1)  | 0.0 (0.00, 0.00) |            |

Note: The missing ANC data of the first 13 days of each cycle were imputed using a method detailed in the SAP.

Grade 4 neutropenia is defined as ANC ≤ 0.5 x 1o°/L.

Table 42 . Incidence rate of grade 3 or 4 neutropenia in cycle 1 in Study SP11631

|              |                                                 | F-627               | GRAN\"     |
|--------------|-------------------------------------------------|---------------------|-----------|
| FAS          | Number                                          | 120                 | 119       |
|              | n (%)                                           | 41 (34.2)           | 51 (42.9) |
|              | Incidenceratedifference(F-627-GRAN*) (95% C1)\"] | -8.7(-20.98，3.60)   |           |
|              | P valuel)                                       | 0.185               |           |
| PPSetANumber |                                                 | 119                 | 110       |
|              | n (%)                                           | 40 (33.6)           | 47 (42.7) |
|              | Incidenceratedifference(F-627-GRAN) (95% C1)\"]  | -9.1 (-21.66, 3.44) |           |
|              | Pvaluell)                                       | 0.174               |           |

Note:ThemissingANCdataofthefirst13daysofthiscyclewereimputedusingamethoddetailedintheSAP. The criteria for grade 3 or 4 neutropenia were ANC &lt; 1.0 × 10°/L or ANC &lt; 0.5 x 10°/L, respectively. ThepercentageswerecalculatedbasedonthenumberofevaluablesubjectsincorrespondingtreatmentarmintheFASor

[1]Theestimatevalue and95%CIofthedifferenceinincidencerateofgrade3or4neutropeniabetween theF-627and GRANarmswereprovided,alongwithPvalue bychi-squared/Fisher's test(when the expectedfrequency of agrid isless than 1).

PPsetA

<div style=\"page-break-after: always\"></div>

Table 43 . Incidence rate of FN in cycle 1 - FAS AND PP Set A in Study SP11631

|         |                                                                        | F-627                     | GRAN?   |
|---------|------------------------------------------------------------------------|---------------------------|---------|
| FAS     | Number                                                                 | 120                       | 119     |
|         | n (%) Incidence rate difference (F-627 - GRAN) (95% CI))               | 1 (0.8) -0.8 (-3.67，1.98) | 2 (1.7) |
|         | P valuell                                                              | 0.622                     |         |
| PP SetA | Number                                                                 | 119                       | 110     |
|         | n (%)                                                                  | 1 (0.8)                   | 2 (1.8) |
|         | Incidence rate difference (F-627 - GRAN®)-1.0 (-3.97, 2.01) (95% CI)[) |                           |         |
|         | P valuell]                                                             | 0.609                     |         |

Note: The missing ANC data of the first 13 days of this cycle were imputed using a method detailed in the SAP. Note: FN is defined as ANC &lt; 1.0 x 10°/L; a single measurement of body temperature &gt; 38.3 °C or body temperature≥38.0°℃formore than1 hr.

Note: The percentages were calculated based on the number of evaluable subjects in the corresponding cycle of the corresponding arm in the FAS or PP set A.

[1] The estimate value and 95% CI of the difference in the incidence rate of FN between F-627 and GRAN arms in cycle1wereprovided,alongwithPvalueby chi-squared/Fisher'stest(when the expectedfrequency of agridisless than 1).

Table 44 . ANC median-time profile in each arm in cycle 1 (log transformation) - FAS in Study SP11631

<!-- image -->

## · Ancillary analyses

<div style=\"page-break-after: always\"></div>

Table 45. The Duration in Days of Grade 4 (Severe) Neutropenia for Chemotherapy Cycle 1 by Treatment Group - Sensitivity Analyses in Study GC-627-04

| Analysis Method                                        | 20 mg F-627            | Placebo    | All Subjects   |
|--------------------------------------------------------|------------------------|------------|----------------|
| ITT Population                                         |                        |            |                |
| No Multiple Imputation, n                              | 74                     | 27         | 101            |
| Mean (SD)                                              | 1.3 (1.19)             | 3.9 (1.44) | 2.0 (1.70)     |
| Mean Difference (95% CI)                               | 2.6 (2.0, 3.1) <0.0001 |            |                |
| p-valuel Multiple Imputation and Bootstrap Sampling, n | 83                     | 39         |                |
| Mean Difference (95% CI)2.3                            | 2.9 (2.2,3.5)          |            |                |
| Imputation with FCS Method, n                          | 83                     | 39         |                |
| Mean Difference (95% C1)2                              | 2.9 (2.3, 3.5)         |            |                |
| p-valuel Imputation with Worst Case Scenario, n4       | <0.0001 83             | 39         | 122            |
| Mean (SD)                                              | 1.4 (1.18)             | 4.1 (1.85) | 2.3 (1.90)     |
| Mean Difference (95% CI)                               | 2.7 (2.1, 3.2) <0.0001 |            |                |
| p-valuel PPPopulation PP Population, n                 | 81                     | 37         |                |
| Mean Difference (95% C1)2                              | 2.9 (2.4, 3.5)         |            |                |
| p-valuel                                               | <0.0001                |            |                |

Abbreviations:ANC=absolute neutrophil count;CI=confidence interval, FCS=fully conditional specification; SD= standard deviation.

P-value was for the testing of mean (Placebo) = mean (F-627).

The duration of Grade 4(severe) neutropenia was defined as the number of days in which the subject had an ANC &lt;0.5 x 109/L post nadir.

2. Difference between the F-627 20 mg dose compared toPlacebo. Superiority was achieved if the lower limit ofthe twosided95%CIofthedifferenceofPlacebovs.F-627&gt;0.

5 CI was the empirical bootstrap confidence interval computed from the resampled imputed data using Multiple Imputation.

analysis were instead imputed using the following rule: missing values from F-627 arm were imputed as the worse (lower) valueofthetwoadjacentobservedANCvalues,missingvaluesfromPlaceboarmwereimputedasthebetter(higher)value of two adjacent observed ANC values.

<div style=\"page-break-after: always\"></div>

Table 46 . Duration in Days of Grade 4 (Severe) Neutropenia for Chemotherapy Cycle 1 by Treatment Group - Sensitivity Analyses in Study GC-627-05

| Analysis Method               | 20 mg F-627 (N = 197)   | 6 mg Neulasta? (N = 196)   | All Subjects (N = 393)   |
|-------------------------------|-------------------------|----------------------------|--------------------------|
| ITT Population                |                         |                            |                          |
| No Multiple Imputation, n     | 188                     | 184                        | 372                      |
| Mean (SD)                     | 0.2 (0.51)              | 0.2 (0.45)                 | 0.2 (0.48)               |
| Mean Difference (95% CI)      | 0.0 (-0.1, 0.1)         |                            |                          |
| p-valuel                      | 0.7189                  |                            |                          |
| Imputation with FCS Method, n | 197                     | 196                        |                          |
| Mean Difference (95% CI)2     | 0.0 (-0.08, 0.12)       |                            |                          |
| p-valuel                      | 0.6431                  |                            |                          |
| PP Population                 |                         |                            |                          |
| PP Population, n              | 197                     | 196                        |                          |
| Mean Difference (95% C1)2     | 0.0 (-0.1, 0.1)         |                            |                          |
| p-value1                      | 0.7074                  |                            |                          |

Table 47. Duration in Days of Grade 4 (Severe) Neutropenia for Chemotherapy Cycle 1 by Treatment Group - Sensitivity Analyses in Study GC-627-05

| Analysis Method                   | 20 mg F-627 (N = 197)   | 6 mg Neulasta? (N = 196)   | All Subjects (N = 393)   |
|-----------------------------------|-------------------------|----------------------------|--------------------------|
| Multiple Imputation and Bootstrap | 197                     | 196                        |                          |
| Mean Difference (95% CI)2         | 0.0 (-0.08, 0.12)       |                            |                          |

Abbreviations: ANC = absolute neutrophil count; CI = confidence interval, FCS = fully conditional specification; ITT =Intent-to-Treat; PP = Per Protocol; SD = standard deviation.

The duration of Grade 4 (severe) neutropenia was defined as the number of days in which the subject had an ANC &lt;0.5 x 109/L post-nadir within the first 12 days of chemotherapy treatment.

1. p-value was for the testing of mean (F-627) = mean (Neulasta?).

Difference between the F-627 compared to Neulasta?. Non-inferiority of F-627 to Neulasta was achieved if the upper limit of the one-sided 97.5% CI &lt;0.6 days. Superiority of F-627 to Neulasta was achieved if the upper limit of the two sided 95% CI was less than 0 days.

<div style=\"page-break-after: always\"></div>

Table 48 . Duration of Grade 3 or 4 Neutropenia during Cycle 1 - FAS (No Imputation for ANC missing data) in Study SP11631

<!-- image -->

| Statistics (Day)                                                                      | F-627 (N=120)     | GRAN? (N=119)   |
|---------------------------------------------------------------------------------------|-------------------|-----------------|
| n (missing)                                                                           | 120 (0)           | 119 (0)         |
| Mean (SD)                                                                             | 0.68 (1.100)      | 0.70(0.944)     |
| Median                                                                                | 0.00              | 0.00            |
| Min, Max                                                                              | 0，4               | 0,4             |
| (F-627-GRAN°) Hodges-Lehmann Estimation （95 CI)                                       | 0.00(0.000，0.000) |                 |
| (F-627-GRAN) Hodges-Lehmann Estimation (the upper 1imit of the one-sided97.5& CI) [1] | 0.00  (0.000)     |                 |

Table 49. Sensitivity Analysis for Duration of Grade 3 or 4 Neutropenia during Cycle 1 - Subjects with Grade 3 or 4 neutropenia during Cycle 1 in FAS in Study SP11631

<!-- image -->

| Statistics (Day)                                                                                                         | F-627 (N=41)                   | GRAN (N=51)   |
|--------------------------------------------------------------------------------------------------------------------------|--------------------------------|---------------|
| n                                                                                                                        | 41                             | 51            |
| Mean (SD) [1]                                                                                                            | 2.00 (0.949)                   | 1.65 (0.744)  |
| Median                                                                                                                   | 2.00                           | 2.00          |
| Min , Max                                                                                                                | 1, 4                           | 1,4           |
| (F-627 - GRAN) Difference in Mean (95% CI) (F-627 - GRAN°) Difference in Mean (the upper limit of the one-sided97.5% CI) | 0.35(0.003，0.703) 0.35 (0.703) |               |

## · Summary of main efficacy results

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 50. Summary of Efficacy for trial GC-627-04

| Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy   | Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy   | Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                       | Study GC-627-04                                                                                                                                                        | Study GC-627-04                                                                                                                                                        |
| Design                                                                                                                                                                 | Phase III, global, multi-center, randomized, double-blinded placebo- controlled clinical study .                                                                       | Phase III, global, multi-center, randomized, double-blinded placebo- controlled clinical study .                                                                       |
|                                                                                                                                                                        | Duration of main phase: Duration of screening phase: Duration of Extension phase:                                                                                      | 84 days 14-days not applicable                                                                                                                                         |
| Hypothesis                                                                                                                                                             | Superiority: To be claimed of F-627 over Placebo if the lower bound of the 95% confidence                                                                              | Superiority: To be claimed of F-627 over Placebo if the lower bound of the 95% confidence                                                                              |
| Treatments groups                                                                                                                                                      | interval (CI) was >0 F-627                                                                                                                                             | F-627: 20 mg dose in a PFS administered by subcutaneous (SC) injection, 84 days, ITT: N = 83.                                                                          |

<div style=\"page-break-after: always\"></div>

| Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy   | Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy   | Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy   | Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy                                                         |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                       | Study GC-627-04                                                                                                                                                        | Study GC-627-04                                                                                                                                                        | Study GC-627-04                                                                                                                                                                                                              |
|                                                                                                                                                                        | Placebo                                                                                                                                                                | Placebo                                                                                                                                                                | Placebo: saline in a PFS administered by SC injection, ITT: N = 39.                                                                                                                                                          |
| Endpoints and definitions                                                                                                                                              | Primary endpoint                                                                                                                                                       | Duration of Grade 4 neutropenia in cycle 1                                                                                                                             | The primary efficacy endpoint was the duration of Grade 4 (severe) neutropenia (ANC <0.5 × 10 9 /L) observed in chemotherapy cycle 1.                                                                                        |
| Endpoints and definitions                                                                                                                                              | Secondary                                                                                                                                                              | Duration in days of Grade 4 neutropenia in cycles 2, 3, and 4, and over all cycles.                                                                                    | The duration in days of Grade 4 (severe) neutropenia (ANC <0.5 × 10 9 /L) for chemotherapy cycles 2, 3, and 4, and over all cycles.                                                                                          |
| Endpoints and definitions                                                                                                                                              | Secondary                                                                                                                                                              | Duration in days of Grade 2 and Grade 3 neutropenia                                                                                                                    | The duration in days of Grade 2 (mild, ANC <1.5 × 10 9 /L) and Grade 3 (moderate, ANC <1.0 × 10 9 /L) neutropenia for each chemotherapy cycle and over all cycles                                                            |
|                                                                                                                                                                        | Secondary                                                                                                                                                              | Febrile neutropenia incidence                                                                                                                                          | The incidence rates of febrile neutropenia (FN; defined as a single oral temperature of ≥ 38.3 ° C [101 ° F] or a temperature of >38.0°C [100.4°F] sustained for >1 hour and ANC <0.5 × 10 9 /L) for each chemotherapy cycle |
|                                                                                                                                                                        | Secondary                                                                                                                                                              | Grade 2, Grade 3, and Grade 4 neutropenia incidence for all chemotherap y cycles                                                                                       | The incidence rates of Grade 2, Grade 3, and Grade 4 neutropenia for all chemotherapy cycles                                                                                                                                 |
|                                                                                                                                                                        | Secondary                                                                                                                                                              | Time in days to ANC recovery post nadir                                                                                                                                | The time in days to ANC recovery post nadir for each chemotherapy cycle and over all cycles; recovery was defined as an ANC ≥ 2.0 × 10 9 /L after the expected ANC nadir                                                     |
|                                                                                                                                                                        | Secondary                                                                                                                                                              | Depth of the ANC nadir                                                                                                                                                 | The depth of the ANC nadir for each chemotherapy cycle and over all cycles                                                                                                                                                   |
|                                                                                                                                                                        | Secondary                                                                                                                                                              | Incidence of infections                                                                                                                                                | The incidence rates of infections for each chemotherapy cycle and over all cycles                                                                                                                                            |
|                                                                                                                                                                        | Secondary                                                                                                                                                              | Antibiotic and pain medications use                                                                                                                                    | The use of antibiotic and pain medications for each chemotherapy cycle and over all cycles.                                                                                                                                  |
|                                                                                                                                                                        | Secondary                                                                                                                                                              | ECG endpoints                                                                                                                                                          | ECG endpoints: Change from baseline heart rate, PR, QRS and QTcF intervals. Categorical outliers and T-wave morphology changes on treatment.                                                                                 |
| Database lock Not identified properly                                                                                                                                  | Database lock Not identified properly                                                                                                                                  | Database lock Not identified properly                                                                                                                                  | Database lock Not identified properly                                                                                                                                                                                        |
| Results and Analysis                                                                                                                                                   | Results and Analysis                                                                                                                                                   | Results and Analysis                                                                                                                                                   | Results and Analysis                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy   | Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy                                                                                                                                                                                                                                                                                     | Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy                                                                                                                                                                                                                                                                                     | Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy                                                                                                                                                                                                                                                                                     | Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy                                                                                                                                                                                                                                                                                     |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                       | Study GC-627-04                                                                                                                                                                                                                                                                                                                                                                                                                                          | Study GC-627-04                                                                                                                                                                                                                                                                                                                                                                                                                                          | Study GC-627-04                                                                                                                                                                                                                                                                                                                                                                                                                                          | Study GC-627-04                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Analysis population and time point description                                                                                                                         | Intent to treat (ITT) set included all randomized subjects                                                                                                                                                                                                                                                                                                                                                                                               | Intent to treat (ITT) set included all randomized subjects                                                                                                                                                                                                                                                                                                                                                                                               | Intent to treat (ITT) set included all randomized subjects                                                                                                                                                                                                                                                                                                                                                                                               | Intent to treat (ITT) set included all randomized subjects                                                                                                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability                                                                                                                        | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                          | 20 mg F-627                                                                                                                                                                                                                                                                                                                                                                                                                                              | 20 mg F-627                                                                                                                                                                                                                                                                                                                                                                                                                                              | Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability                                                                                                                        | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                       | 83                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 83                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 39                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability                                                                                                                        | Mean Duration (SD), days                                                                                                                                                                                                                                                                                                                                                                                                                                 | 1.3 (1.19)                                                                                                                                                                                                                                                                                                                                                                                                                                               | 1.3 (1.19)                                                                                                                                                                                                                                                                                                                                                                                                                                               | 3.9 (1.44)                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability                                                                                                                        | Mean Difference (SE)                                                                                                                                                                                                                                                                                                                                                                                                                                     | 2.9 (0.28)                                                                                                                                                                                                                                                                                                                                                                                                                                               | 2.9 (0.28)                                                                                                                                                                                                                                                                                                                                                                                                                                               | 2.9 (0.28)                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability                                                                                                                        | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 2.3, 3.4                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 2.3, 3.4                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 2.3, 3.4                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability                                                                                                                        | p-value                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Notes                                                                                                                                                                  | <0.0001 The Applicant should identify the database lock date In the Placebo arm, fixed dose PFS was administered on Day 2 of the first chemotherapy cycle, and F-627, 20 mg fixed dose PFS was administered Day 2 of each of the following 3 chemotherapy cycles. Therefore, the main efficacy data of F-627 comes from the first cycle only. The data from the following cycles has mainly supportive evidence for safety, this approach is understood. | <0.0001 The Applicant should identify the database lock date In the Placebo arm, fixed dose PFS was administered on Day 2 of the first chemotherapy cycle, and F-627, 20 mg fixed dose PFS was administered Day 2 of each of the following 3 chemotherapy cycles. Therefore, the main efficacy data of F-627 comes from the first cycle only. The data from the following cycles has mainly supportive evidence for safety, this approach is understood. | <0.0001 The Applicant should identify the database lock date In the Placebo arm, fixed dose PFS was administered on Day 2 of the first chemotherapy cycle, and F-627, 20 mg fixed dose PFS was administered Day 2 of each of the following 3 chemotherapy cycles. Therefore, the main efficacy data of F-627 comes from the first cycle only. The data from the following cycles has mainly supportive evidence for safety, this approach is understood. | <0.0001 The Applicant should identify the database lock date In the Placebo arm, fixed dose PFS was administered on Day 2 of the first chemotherapy cycle, and F-627, 20 mg fixed dose PFS was administered Day 2 of each of the following 3 chemotherapy cycles. Therefore, the main efficacy data of F-627 comes from the first cycle only. The data from the following cycles has mainly supportive evidence for safety, this approach is understood. |
| Analysis descriptionSecondary analysis                                                                                                                                 | Analysis descriptionSecondary analysis                                                                                                                                                                                                                                                                                                                                                                                                                   | Analysis descriptionSecondary analysis                                                                                                                                                                                                                                                                                                                                                                                                                   | Analysis descriptionSecondary analysis                                                                                                                                                                                                                                                                                                                                                                                                                   | Analysis descriptionSecondary analysis                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                                                                                                                                                                        | Mean (SD) duration of Grade 4 (severe) neutropenia assessed without multiple imputation was 1.3 (1.19) days for subjects randomized to F-627 compared to 3.9 (1.44) days for Placebo, with a mean difference between treatments of 2.6 days (95% CI: 2.0, 3.1)                                                                                                                                                                                           | Mean (SD) duration of Grade 4 (severe) neutropenia assessed without multiple imputation was 1.3 (1.19) days for subjects randomized to F-627 compared to 3.9 (1.44) days for Placebo, with a mean difference between treatments of 2.6 days (95% CI: 2.0, 3.1)                                                                                                                                                                                           | Mean (SD) duration of Grade 4 (severe) neutropenia assessed without multiple imputation was 1.3 (1.19) days for subjects randomized to F-627 compared to 3.9 (1.44) days for Placebo, with a mean difference between treatments of 2.6 days (95% CI: 2.0, 3.1)                                                                                                                                                                                           | Mean (SD) duration of Grade 4 (severe) neutropenia assessed without multiple imputation was 1.3 (1.19) days for subjects randomized to F-627 compared to 3.9 (1.44) days for Placebo, with a mean difference between treatments of 2.6 days (95% CI: 2.0, 3.1)                                                                                                                                                                                           |
| Duration of Grade 4 neutropenia in cycle 1                                                                                                                             | Cycle 1                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 20 mg F-627 1.3 (1.19)                                                                                                                                                                                                                                                                                                                                                                                                                                   | Placebo 3.9 (1.44)                                                                                                                                                                                                                                                                                                                                                                                                                                       | Mean Difference (95% CI) 2.6 (2.0, 3.1)                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Duration of Grade 4 neutropenia in cycle 1                                                                                                                             | Cycle 2                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 0.3 (0.76)                                                                                                                                                                                                                                                                                                                                                                                                                                               | 0.8 (1.24)                                                                                                                                                                                                                                                                                                                                                                                                                                               | Mean Difference (95% CI) 0.5 (0.1, 0.9)                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Duration of Grade 4 neutropenia in cycle 1                                                                                                                             | Cycle 3                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 0.3 (0.84)                                                                                                                                                                                                                                                                                                                                                                                                                                               | 0.5 (1.19)                                                                                                                                                                                                                                                                                                                                                                                                                                               | Mean Difference (95% CI)1 0.2 (- 0.2, 0.6)                                                                                                                                                                                                                                                                                                                                                                                                               |
| Duration of Grade 4 neutropenia in cycle 1                                                                                                                             | Cycle 4                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 0.2 (0.62)                                                                                                                                                                                                                                                                                                                                                                                                                                               | 0.7 (1.39)                                                                                                                                                                                                                                                                                                                                                                                                                                               | Mean Difference (95% CI)1 0.6 (0.2, 1.0)                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Duration of Grade 4 neutropenia in cycle 1                                                                                                                             | Over All Cycles                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0.5 (0.62)                                                                                                                                                                                                                                                                                                                                                                                                                                               | 1.4 (1.35)                                                                                                                                                                                                                                                                                                                                                                                                                                               | Mean Difference (95% CI) 0.9 (0.5, 1.2).                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Duration in days of Grade 3 neutropenia, Mean (SD)                                                                                                                     | 20 mg F-627 Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                      | 20 mg F-627 Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                      | 20 mg F-627 Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                      | 20 mg F-627 Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Duration in days of Grade 3 neutropenia, Mean (SD)                                                                                                                     | Cycle 1                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 2.1 (1.51)                                                                                                                                                                                                                                                                                                                                                                                                                                               | 5.1 (1.90)                                                                                                                                                                                                                                                                                                                                                                                                                                               | 95% CI 2.2, 3.7, P-value <0.0001                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Duration in days of Grade 3 neutropenia, Mean (SD)                                                                                                                     | Cycle 2                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 1.0 (1.36)                                                                                                                                                                                                                                                                                                                                                                                                                                               | 1.2 (1.59)                                                                                                                                                                                                                                                                                                                                                                                                                                               | Mean Difference (95% CI) 0.2 (- 0.4, 0.8)                                                                                                                                                                                                                                                                                                                                                                                                                |
| Duration in days of Grade 3 neutropenia, Mean (SD)                                                                                                                     | Cycle 3                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 0.9 (1.56)                                                                                                                                                                                                                                                                                                                                                                                                                                               | 1.1 (1.45)                                                                                                                                                                                                                                                                                                                                                                                                                                               | Mean Difference (95% CI)1 0.2 (- 0.4, 0.9                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in   | Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in   | Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in   | Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in   | Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in   |
|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                            | Study GC-627-04                                                                                             | Study GC-627-04                                                                                             | Study GC-627-04                                                                                             | Study GC-627-04                                                                                             |
|                                                                                                             | Cycle 4                                                                                                     | 0.8 (1.27)                                                                                                  | 1.0 (1.41)                                                                                                  | Mean Difference (95% CI)1 0.2 (- 0.4, 0.8),                                                                 |
|                                                                                                             | Over All Cycles                                                                                             | 1.2 (1.09)                                                                                                  | 2.0 (1.51)                                                                                                  | Mean Difference (95% CI)1 0.7 (0.2, 1.2)                                                                    |
| Duration in days of                                                                                         |                                                                                                             | 20 mg F-627                                                                                                 | Placebo                                                                                                     |                                                                                                             |
| Grade 2 neutropenia                                                                                         | Cycle 1                                                                                                     | 2.6 (1.47)                                                                                                  | 6.8 (2.54)                                                                                                  | Mean Difference (SE)1 4.2 (0.40), P-value <0.0001                                                           |
| Duration in days of                                                                                         | Cycle 2                                                                                                     | 1.6 (1.60)                                                                                                  | 1.6 (1.63)                                                                                                  | Mean Difference (95% CI) 0.0 (- 0.6, 0.7)                                                                   |
| Duration in days of                                                                                         | Cycle 3                                                                                                     | 1.3 (1.68)                                                                                                  | 1.5 (1.65)                                                                                                  | Mean Difference (95% CI)1 0.2 (- 0.5, 0.9)                                                                  |
| Duration in days of                                                                                         | Cycle 4                                                                                                     | 1.4 (1.59)                                                                                                  | 1.6 (1.84)                                                                                                  | Mean Difference (95% CI) 0.1 (- 0.6, 0.8)                                                                   |
| Duration in days of                                                                                         | Over All Cycles                                                                                             | 1.8 (1.25)                                                                                                  | 2.7 (1.75)                                                                                                  | Mean Difference (95% CI)1 0.8 (0.3, 1.4)                                                                    |
| Febrile neutropenia incidence                                                                               |                                                                                                             | 20 mg F-627                                                                                                 | Placebo                                                                                                     |                                                                                                             |
| Febrile neutropenia incidence                                                                               | Cycle 1                                                                                                     | 4/83 (4.8)                                                                                                  | 10/39 (25.6)                                                                                                | (95% CI) 20.8 (1.8, 38.8), P- value 0.0016,                                                                 |
| Febrile neutropenia incidence                                                                               | Cycle 2                                                                                                     | 0/83 (0.0)                                                                                                  | 1/38 (2.6)                                                                                                  | Difference with F- 627 (95% CI) 2.6 (-16.5, 21.7)                                                           |
| Febrile neutropenia incidence                                                                               | Cycle 3                                                                                                     | 0/82 (0.0)                                                                                                  | 0/37 (0.0)                                                                                                  |                                                                                                             |
| Febrile neutropenia incidence                                                                               | Cycle 4                                                                                                     | 0/82 (0.0)                                                                                                  | 0/37 (0.0)                                                                                                  |                                                                                                             |
| Febrile neutropenia incidence                                                                               | Over All Cycles                                                                                             | 4/83 (4.8)                                                                                                  | 11/39 (28.2)                                                                                                | Difference with F- 627 (95% CI)1 23.4 (4.5, 41.2)                                                           |
| Grade 4 neutropenia                                                                                         |                                                                                                             | 20 mg F-627                                                                                                 | Placebo                                                                                                     |                                                                                                             |
| incidence for all chemotherapy cycles                                                                       | Cycle 1                                                                                                     | 58/83 (69.9)                                                                                                | 37/39 (94.9)                                                                                                | Difference with F-627 (95% CI) 25.0 (5.9, 42.9), p= 0.0019                                                  |
| incidence for all chemotherapy cycles                                                                       | Over All Cycles n/N1 (%)                                                                                    | 59/83 (71.1)                                                                                                | 37/39 (94.9)                                                                                                | Difference with F- 627 (95% CI) 23.8 (4.7, 41.8)                                                            |
| Grade 3 neutropenia                                                                                         |                                                                                                             | 20 mg F-627                                                                                                 | Placebo                                                                                                     |                                                                                                             |
| incidence for all                                                                                           | Cycle 1                                                                                                     | 70/83 (84.3)                                                                                                | 37/39 (94.9)                                                                                                |                                                                                                             |
| chemotherapy cycles                                                                                         | Over All Cycles n/N1 (%)                                                                                    | 71/83 (85.5)                                                                                                | 37/39 (94.9)                                                                                                | Difference with F- 627 (95% CI) 9.3 (-9.8, 28.0).                                                           |
| Grade 2 neutropenia                                                                                         |                                                                                                             | 20 mg F-627                                                                                                 | Placebo                                                                                                     |                                                                                                             |
| incidence for all chemotherapy cycles                                                                       | Cycle 1                                                                                                     | 76/83 (91.6)                                                                                                | 37/39 (94.9)                                                                                                | (95% CI) 3.3 (- 15.7, 22.2)                                                                                 |
| incidence for all chemotherapy cycles                                                                       | Over All Cycles n/N1 (%)                                                                                    | 77/83 (92.8)                                                                                                | 37/39 (94.9)                                                                                                | Difference with F- 627 (95% CI)1 2.1 (-16.9, 21.0).                                                         |
| incidence for all chemotherapy cycles                                                                       |                                                                                                             | 20 mg F-627                                                                                                 | Placebo                                                                                                     |                                                                                                             |

<div style=\"page-break-after: always\"></div>

| Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in   | Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in   | Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in   | Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in   | Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in   |
|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                            | Study GC-627-04                                                                                             | Study GC-627-04                                                                                             | Study GC-627-04                                                                                             | Study GC-627-04                                                                                             |
| Time in days to ANC recovery post nadir, Mean (SD)                                                          | Cycle 1                                                                                                     | 2.1 (1.09)                                                                                                  | 4.1 (2.06)                                                                                                  | Mean Difference (95% CI) 2.0 (1.4, 2.5)                                                                     |
| Time in days to ANC recovery post nadir, Mean (SD)                                                          | Over All Cycles n/N1 (%)                                                                                    | 1.8 (0.95)                                                                                                  | 2.4 (1.18)                                                                                                  | Mean Difference (95% CI)1 0.6 (0.2, 1.0)                                                                    |
| Depth of the ANC nadir, Mean (SD)                                                                           |                                                                                                             | 20 mg F-627                                                                                                 | Placebo                                                                                                     |                                                                                                             |
| Depth of the ANC nadir, Mean (SD)                                                                           | Cycle 1                                                                                                     | 0.7 (1.15)                                                                                                  | 0.2 (0.57)                                                                                                  | Ratio to Placebo (95% CI) 3.4 (2.0, 5.6)                                                                    |
| Depth of the ANC nadir, Mean (SD)                                                                           | Over All Cycles                                                                                             | 1.5 (1.21)                                                                                                  | 1.4 (1.23)                                                                                                  |                                                                                                             |
|                                                                                                             |                                                                                                             | 20 mg F-627                                                                                                 | Placebo                                                                                                     |                                                                                                             |
| Incidence of infections                                                                                     | Cycle 1                                                                                                     | 2/83 (2.4)                                                                                                  | 3/39 (7.7)                                                                                                  | Difference with F- 627 (95% CI) 5.3 (-13.8, 24.1), P- value 0.3258                                          |
| Incidence of infections                                                                                     | Over All Cycles                                                                                             | 9/83 (10.8)                                                                                                 | 8/39 (20.5)                                                                                                 | Difference with F- 627 (95% CI)1 9.7 (-9.4, 28.2)                                                           |
|                                                                                                             |                                                                                                             | 20 mg F-627                                                                                                 | Placebo                                                                                                     |                                                                                                             |
| Antibiotic use                                                                                              | Cycle 1                                                                                                     | 9/83 (10.8)                                                                                                 | 13/39 (33.3)                                                                                                | Difference with F- 627 (95% CI) 22.5 (3.4, 40.5), P-value 0.0047                                            |
| Antibiotic use                                                                                              | Over All Cycles                                                                                             | 13/83 (15.7)                                                                                                | 15/39 (38.5)                                                                                                | Difference with F- 627 (95% CI)1 22.8 (3.6, 40.8)                                                           |
|                                                                                                             |                                                                                                             | 20 mg F-627                                                                                                 | Placebo                                                                                                     |                                                                                                             |
| Antibiotic Medications use (WHO SDG Definition)                                                             | Cycle 1                                                                                                     | 7/83 (8.4)                                                                                                  | 11/39 (28.2)                                                                                                | Difference with F- 627 (95% CI)1 19.8 (0.8, 37.8)                                                           |
| Antibiotic Medications use (WHO SDG Definition)                                                             | Over All Cycles                                                                                             | 13/83 (15.7)                                                                                                | 14/39 (35.9)                                                                                                | Difference with F- 627 (95% CI) 20.2 (1.0, 38.4)                                                            |
|                                                                                                             |                                                                                                             | 20 mg F-627                                                                                                 | Placebo                                                                                                     |                                                                                                             |
| IV Antibiotic use (WHO SDG Definition)                                                                      | Cycle 1                                                                                                     | 3/83 (3.6)                                                                                                  | 7/39 (17.9)                                                                                                 | Difference with F- 627 (95% CI)1 14.3 (-4.8, 32.8)                                                          |
| IV Antibiotic use (WHO SDG Definition)                                                                      | Over All Cycles                                                                                             | 3/83 (3.6)                                                                                                  | 8/39 (20.5)                                                                                                 | Difference with F- 627 (95% CI) 16.9 (-2.2, 35.2)                                                           |
|                                                                                                             |                                                                                                             | 20 mg F-627                                                                                                 | Placebo                                                                                                     |                                                                                                             |
| Pain Medication use                                                                                         | Cycle 1                                                                                                     | 8/83 (9.6)                                                                                                  | 9/39 (23.1)                                                                                                 | Difference with F- 627 (95% CI)1 13.4 (-5.6, 31.8), P-value 0.0545                                          |
|                                                                                                             | Over All Cycles                                                                                             | 13/83 (15.7)                                                                                                | 13/39 (33.3)                                                                                                | Difference with F- 627 (95% CI)1 17.7 (-1.5, 36.0)                                                          |
| ECG endpoints                                                                                               | Presented in Clinical Safety section.                                                                       | Presented in Clinical Safety section.                                                                       | Presented in Clinical Safety section.                                                                       | Presented in Clinical Safety section.                                                                       |

<div style=\"page-break-after: always\"></div>

Table 51. Summary of efficacy for trial Study GC-627-05

| Title: A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled   | Title: A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Title: A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Title: A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                    | Study GC-627-05                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Study GC-627-05                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Study GC-627-05                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Design                                                                                              | Phase III, multi-centre, randomized, open-label, two-arm, active-controlled study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Phase III, multi-centre, randomized, open-label, two-arm, active-controlled study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Phase III, multi-centre, randomized, open-label, two-arm, active-controlled study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Design                                                                                              | Duration of main phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Duration of main phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 20 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Design                                                                                              | Duration of study:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Duration of study:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 9 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Hypothesis                                                                                          | One-sided non-inferiority test for the primary efficacy analysis and two-sided test for superiority of all secondary endpoints, with 'statistical significance' defined as a corresponding p-value <0.05. For the primary efficacy analysis, a non-inferiority test was used to explore the duration of Grade 4 (severe) neutropenia between F-627 vs. Neulasta® in chemotherapy cycle 1 within 12 days of chemotherapy treatment. Non-inferiority of F-627 to Neulasta® was observed when the upper limit of the one-sided 97.5% CI for the difference in mean duration of Grade 4 neutropenia | One-sided non-inferiority test for the primary efficacy analysis and two-sided test for superiority of all secondary endpoints, with 'statistical significance' defined as a corresponding p-value <0.05. For the primary efficacy analysis, a non-inferiority test was used to explore the duration of Grade 4 (severe) neutropenia between F-627 vs. Neulasta® in chemotherapy cycle 1 within 12 days of chemotherapy treatment. Non-inferiority of F-627 to Neulasta® was observed when the upper limit of the one-sided 97.5% CI for the difference in mean duration of Grade 4 neutropenia | One-sided non-inferiority test for the primary efficacy analysis and two-sided test for superiority of all secondary endpoints, with 'statistical significance' defined as a corresponding p-value <0.05. For the primary efficacy analysis, a non-inferiority test was used to explore the duration of Grade 4 (severe) neutropenia between F-627 vs. Neulasta® in chemotherapy cycle 1 within 12 days of chemotherapy treatment. Non-inferiority of F-627 to Neulasta® was observed when the upper limit of the one-sided 97.5% CI for the difference in mean duration of Grade 4 neutropenia |
| Treatments groups                                                                                   | was <0.6 days. F-627                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | was <0.6 days. F-627                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | F-627: 20 mg dose in a PFS administered by subcutaneous (SC) injection, 20 days, N = 197.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Treatments groups                                                                                   | Neulasta® (pegfilgrastim)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Neulasta® (pegfilgrastim)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Neulasta® (pegfilgrastim): 6 mg fixed dose administered by SC injection., 20 days, N = 196.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Endpoints and definitions                                                                           | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Duration of Grade 4 neutropeni a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | The primary efficacy endpoint was the duration of Grade 4 (severe) neutropenia, defined as the number of days in which the subject had an ANC <0.5 × 10 9 /L during cycle 1 of their chemotherapy treatment.                                                                                                                                                                                                                                                                                                                                                                                    |
| Endpoints and definitions                                                                           | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Duration of use of intravenous (IV) antibiotic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | The duration of use of intravenous (IV) antibiotics (total across all chemotherapy cycles).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Endpoints and definitions                                                                           | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Duration of hospitalizati on for febrile neutropenia or any infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | The duration of hospitalization for febrile neutropenia or any infection (total across all chemotherapy cycles).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Endpoints and definitions                                                                           | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Incidence of febrile neutropenia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | The incidence of febrile neutropenia; considering all chemotherapy cycles. Febrile neutropenia was defined as a single oral temperature of ≥ 38.3 ° C (101 ° F) or a temperature of >38.0 ° C (100.4 ° F) sustained for >1 hour and ANC <0.5 × 10 9 /L) on the same day.                                                                                                                                                                                                                                                                                                                        |
| Endpoints and definitions                                                                           | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Incidence of Grade 4 neutropenia (C1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | The incidence of Grade 4 neutropenia for chemotherapy cycle 1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| Clinical Trial of F-627 Study identifier                                       | Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Women with Breast Cancer Receiving Myelotoxic Chemotherapy                                                                                                    | Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Women with Breast Cancer Receiving Myelotoxic Chemotherapy                                                                                                    | Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Women with Breast Cancer Receiving Myelotoxic Chemotherapy                                                                                                    | Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Women with Breast Cancer Receiving Myelotoxic Chemotherapy                                                                                                    | Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Women with Breast Cancer Receiving Myelotoxic Chemotherapy                                                                                                    | Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Women with Breast Cancer Receiving Myelotoxic Chemotherapy                                                                                                    | Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Women with Breast Cancer Receiving Myelotoxic Chemotherapy                                                                                                    | Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Women with Breast Cancer Receiving Myelotoxic Chemotherapy                                                                                                    | Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Women with Breast Cancer Receiving Myelotoxic Chemotherapy                                                                                                    | Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Women with Breast Cancer Receiving Myelotoxic Chemotherapy                                                                                                    |
|--------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Clinical Trial of F-627 Study identifier                                       | Study GC-627-05 Secondary endpoint                                                                                                                                                                                                          | Incidence of use of IV antibiotics                                                                                                                                                                                                          | The incidence of use of IV antibiotics, considering all chemotherapy cycles.                                                                                                                                                                | The incidence of use of IV antibiotics, considering all chemotherapy cycles.                                                                                                                                                                | The incidence of use of IV antibiotics, considering all chemotherapy cycles.                                                                                                                                                                | The incidence of use of IV antibiotics, considering all chemotherapy cycles.                                                                                                                                                                | The incidence of use of IV antibiotics, considering all chemotherapy cycles.                                                                                                                                                                | The incidence of use of IV antibiotics, considering all chemotherapy cycles.                                                                                                                                                                | The incidence of use of IV antibiotics, considering all chemotherapy cycles.                                                                                                                                                                | The incidence of use of IV antibiotics, considering all chemotherapy cycles.                                                                                                                                                                |
|                                                                                | Secondary endpoint                                                                                                                                                                                                                          | Incidence of hospitalizati on for febrile neutropenia or any infection                                                                                                                                                                      | The incidence of hospitalization for febrile neutropenia or any infection, considering all chemotherapy cycles.                                                                                                                             | The incidence of hospitalization for febrile neutropenia or any infection, considering all chemotherapy cycles.                                                                                                                             | The incidence of hospitalization for febrile neutropenia or any infection, considering all chemotherapy cycles.                                                                                                                             | The incidence of hospitalization for febrile neutropenia or any infection, considering all chemotherapy cycles.                                                                                                                             | The incidence of hospitalization for febrile neutropenia or any infection, considering all chemotherapy cycles.                                                                                                                             | The incidence of hospitalization for febrile neutropenia or any infection, considering all chemotherapy cycles.                                                                                                                             | The incidence of hospitalization for febrile neutropenia or any infection, considering all chemotherapy cycles.                                                                                                                             | The incidence of hospitalization for febrile neutropenia or any infection, considering all chemotherapy cycles.                                                                                                                             |
| Database lock                                                                  | Not clearly stated                                                                                                                                                                                                                          | Not clearly stated                                                                                                                                                                                                                          | Not clearly stated                                                                                                                                                                                                                          | Not clearly stated                                                                                                                                                                                                                          | Not clearly stated                                                                                                                                                                                                                          | Not clearly stated                                                                                                                                                                                                                          | Not clearly stated                                                                                                                                                                                                                          | Not clearly stated                                                                                                                                                                                                                          | Not clearly stated                                                                                                                                                                                                                          | Not clearly stated                                                                                                                                                                                                                          |
| Results and Analysis                                                           | Results and Analysis                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                        |
| Analysis description                                                           | Primary Analysis                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                            |
| Analysis population and time point description                                 | The Intent-to-Treat (ITT) Analysis Set (all randomized subjects) was used as the primary analysis set for all efficacy analyses. A Per Protocol (PP) Analysis Set was used for sensitivity analyses of the primary and secondary endpoints. | The Intent-to-Treat (ITT) Analysis Set (all randomized subjects) was used as the primary analysis set for all efficacy analyses. A Per Protocol (PP) Analysis Set was used for sensitivity analyses of the primary and secondary endpoints. | The Intent-to-Treat (ITT) Analysis Set (all randomized subjects) was used as the primary analysis set for all efficacy analyses. A Per Protocol (PP) Analysis Set was used for sensitivity analyses of the primary and secondary endpoints. | The Intent-to-Treat (ITT) Analysis Set (all randomized subjects) was used as the primary analysis set for all efficacy analyses. A Per Protocol (PP) Analysis Set was used for sensitivity analyses of the primary and secondary endpoints. | The Intent-to-Treat (ITT) Analysis Set (all randomized subjects) was used as the primary analysis set for all efficacy analyses. A Per Protocol (PP) Analysis Set was used for sensitivity analyses of the primary and secondary endpoints. | The Intent-to-Treat (ITT) Analysis Set (all randomized subjects) was used as the primary analysis set for all efficacy analyses. A Per Protocol (PP) Analysis Set was used for sensitivity analyses of the primary and secondary endpoints. | The Intent-to-Treat (ITT) Analysis Set (all randomized subjects) was used as the primary analysis set for all efficacy analyses. A Per Protocol (PP) Analysis Set was used for sensitivity analyses of the primary and secondary endpoints. | The Intent-to-Treat (ITT) Analysis Set (all randomized subjects) was used as the primary analysis set for all efficacy analyses. A Per Protocol (PP) Analysis Set was used for sensitivity analyses of the primary and secondary endpoints. | The Intent-to-Treat (ITT) Analysis Set (all randomized subjects) was used as the primary analysis set for all efficacy analyses. A Per Protocol (PP) Analysis Set was used for sensitivity analyses of the primary and secondary endpoints. | The Intent-to-Treat (ITT) Analysis Set (all randomized subjects) was used as the primary analysis set for all efficacy analyses. A Per Protocol (PP) Analysis Set was used for sensitivity analyses of the primary and secondary endpoints. |
| Descriptive statistics and estimate variability                                | Treatment group 20 mg F-627                                                                                                                                                                                                                 | Treatment group 20 mg F-627                                                                                                                                                                                                                 | Treatment group 20 mg F-627                                                                                                                                                                                                                 | 6 mg Neulasta                                                                                                                                                                                                                               | 6 mg Neulasta                                                                                                                                                                                                                               | 6 mg Neulasta                                                                                                                                                                                                                               | 6 mg Neulasta                                                                                                                                                                                                                               | 6 mg Neulasta                                                                                                                                                                                                                               | 6 mg Neulasta                                                                                                                                                                                                                               | 6 mg Neulasta                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability                                | Number of 197                                                                                                                                                                                                                               | Number of 197                                                                                                                                                                                                                               | Number of 197                                                                                                                                                                                                                               | 196                                                                                                                                                                                                                                         | 196                                                                                                                                                                                                                                         | 196                                                                                                                                                                                                                                         | 196                                                                                                                                                                                                                                         | 196                                                                                                                                                                                                                                         | 196                                                                                                                                                                                                                                         | 196                                                                                                                                                                                                                                         |
| Descriptive statistics and estimate variability                                | subjects Duration of Grade 4 (Severe) Neutropenia in Chemotherapy Cycle 1 Mean Duration (SD), days 0.2 (0.51)                                                                                                                               | subjects Duration of Grade 4 (Severe) Neutropenia in Chemotherapy Cycle 1 Mean Duration (SD), days 0.2 (0.51)                                                                                                                               | subjects Duration of Grade 4 (Severe) Neutropenia in Chemotherapy Cycle 1 Mean Duration (SD), days 0.2 (0.51)                                                                                                                               | 0.2 (0.45)                                                                                                                                                                                                                                  | 0.2 (0.45)                                                                                                                                                                                                                                  | 0.2 (0.45)                                                                                                                                                                                                                                  | 0.2 (0.45)                                                                                                                                                                                                                                  | 0.2 (0.45)                                                                                                                                                                                                                                  | 0.2 (0.45)                                                                                                                                                                                                                                  | 0.2 (0.45)                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability                                | Mean Difference (SE) 0.0 (0.05)                                                                                                                                                                                                             | Mean Difference (SE) 0.0 (0.05)                                                                                                                                                                                                             | Mean Difference (SE) 0.0 (0.05)                                                                                                                                                                                                             | Mean Difference (SE) 0.0 (0.05)                                                                                                                                                                                                             | Mean Difference (SE) 0.0 (0.05)                                                                                                                                                                                                             | Mean Difference (SE) 0.0 (0.05)                                                                                                                                                                                                             | Mean Difference (SE) 0.0 (0.05)                                                                                                                                                                                                             | Mean Difference (SE) 0.0 (0.05)                                                                                                                                                                                                             | Mean Difference (SE) 0.0 (0.05)                                                                                                                                                                                                             | Mean Difference (SE) 0.0 (0.05)                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability                                | 95% CI -0.1, 0.1                                                                                                                                                                                                                            | 95% CI -0.1, 0.1                                                                                                                                                                                                                            | 95% CI -0.1, 0.1                                                                                                                                                                                                                            | 95% CI -0.1, 0.1                                                                                                                                                                                                                            | 95% CI -0.1, 0.1                                                                                                                                                                                                                            | 95% CI -0.1, 0.1                                                                                                                                                                                                                            | 95% CI -0.1, 0.1                                                                                                                                                                                                                            | 95% CI -0.1, 0.1                                                                                                                                                                                                                            | 95% CI -0.1, 0.1                                                                                                                                                                                                                            | 95% CI -0.1, 0.1                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability                                | p-value 0.7074                                                                                                                                                                                                                              | p-value 0.7074                                                                                                                                                                                                                              | p-value 0.7074                                                                                                                                                                                                                              | p-value 0.7074                                                                                                                                                                                                                              | p-value 0.7074                                                                                                                                                                                                                              | p-value 0.7074                                                                                                                                                                                                                              | p-value 0.7074                                                                                                                                                                                                                              | p-value 0.7074                                                                                                                                                                                                                              | p-value 0.7074                                                                                                                                                                                                                              | p-value 0.7074                                                                                                                                                                                                                              |
| Notes                                                                          |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |
| Analysis description Duration of use of intravenous (IV) antibiotic, Mean (SD) |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |
|                                                                                | 20 mg F-627 6 mg Neulasta®                                                                                                                                                                                                                  | 20 mg F-627 6 mg Neulasta®                                                                                                                                                                                                                  | 20 mg F-627 6 mg Neulasta®                                                                                                                                                                                                                  | 20 mg F-627 6 mg Neulasta®                                                                                                                                                                                                                  | 20 mg F-627 6 mg Neulasta®                                                                                                                                                                                                                  | 20 mg F-627 6 mg Neulasta®                                                                                                                                                                                                                  | 20 mg F-627 6 mg Neulasta®                                                                                                                                                                                                                  | 20 mg F-627 6 mg Neulasta®                                                                                                                                                                                                                  | 20 mg F-627 6 mg Neulasta®                                                                                                                                                                                                                  | 20 mg F-627 6 mg Neulasta®                                                                                                                                                                                                                  |
|                                                                                | Secondary analysis                                                                                                                                                                                                                          | Secondary analysis                                                                                                                                                                                                                          | Secondary analysis                                                                                                                                                                                                                          | Secondary analysis                                                                                                                                                                                                                          | Secondary analysis                                                                                                                                                                                                                          | Secondary analysis                                                                                                                                                                                                                          | Secondary analysis                                                                                                                                                                                                                          | Secondary analysis                                                                                                                                                                                                                          | Secondary analysis                                                                                                                                                                                                                          | Secondary analysis                                                                                                                                                                                                                          |
|                                                                                | Total Across All Chemotherapy Cycles                                                                                                                                                                                                        | (N = 197) (N = 196) 0.3 (1.36) 0.1 (0.70) Mean Difference (95% CI) 0.2 (-0.01, 0.42), p-value                                                                                                                                               | (N = 197) (N = 196) 0.3 (1.36) 0.1 (0.70) Mean Difference (95% CI) 0.2 (-0.01, 0.42), p-value                                                                                                                                               | (N = 197) (N = 196) 0.3 (1.36) 0.1 (0.70) Mean Difference (95% CI) 0.2 (-0.01, 0.42), p-value                                                                                                                                               | (N = 197) (N = 196) 0.3 (1.36) 0.1 (0.70) Mean Difference (95% CI) 0.2 (-0.01, 0.42), p-value                                                                                                                                               | (N = 197) (N = 196) 0.3 (1.36) 0.1 (0.70) Mean Difference (95% CI) 0.2 (-0.01, 0.42), p-value                                                                                                                                               | (N = 197) (N = 196) 0.3 (1.36) 0.1 (0.70) Mean Difference (95% CI) 0.2 (-0.01, 0.42), p-value                                                                                                                                               | (N = 197) (N = 196) 0.3 (1.36) 0.1 (0.70) Mean Difference (95% CI) 0.2 (-0.01, 0.42), p-value                                                                                                                                               | (N = 197) (N = 196) 0.3 (1.36) 0.1 (0.70) Mean Difference (95% CI) 0.2 (-0.01, 0.42), p-value                                                                                                                                               | (N = 197) (N = 196) 0.3 (1.36) 0.1 (0.70) Mean Difference (95% CI) 0.2 (-0.01, 0.42), p-value                                                                                                                                               |
|                                                                                |                                                                                                                                                                                                                                             | 0.0538 0.1 (0.76) 0.0 (0.43) Mean Difference                                                                                                                                                                                                | 0.0538 0.1 (0.76) 0.0 (0.43) Mean Difference                                                                                                                                                                                                | 0.0538 0.1 (0.76) 0.0 (0.43) Mean Difference                                                                                                                                                                                                | 0.0538 0.1 (0.76) 0.0 (0.43) Mean Difference                                                                                                                                                                                                | 0.0538 0.1 (0.76) 0.0 (0.43) Mean Difference                                                                                                                                                                                                | 0.0538 0.1 (0.76) 0.0 (0.43) Mean Difference                                                                                                                                                                                                | 0.0538 0.1 (0.76) 0.0 (0.43) Mean Difference                                                                                                                                                                                                | 0.0538 0.1 (0.76) 0.0 (0.43) Mean Difference                                                                                                                                                                                                | 0.0538 0.1 (0.76) 0.0 (0.43) Mean Difference                                                                                                                                                                                                |
|                                                                                | Cycle 1                                                                                                                                                                                                                                     | (95% CI)                                                                                                                                                                                                                                    | (95% CI)                                                                                                                                                                                                                                    | (95% CI)                                                                                                                                                                                                                                    | (95% CI)                                                                                                                                                                                                                                    | (95% CI)                                                                                                                                                                                                                                    | (95% CI)                                                                                                                                                                                                                                    | (95% CI)                                                                                                                                                                                                                                    | (95% CI)                                                                                                                                                                                                                                    | (95% CI)                                                                                                                                                                                                                                    |
|                                                                                | Cycle 2                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |
|                                                                                |                                                                                                                                                                                                                                             | 0.1 (-0.04, 0.21) 0.0 (0.29) 0.0 (0.29) Mean Difference                                                                                                                                                                                     | 0.1 (-0.04, 0.21) 0.0 (0.29) 0.0 (0.29) Mean Difference                                                                                                                                                                                     | 0.1 (-0.04, 0.21) 0.0 (0.29) 0.0 (0.29) Mean Difference                                                                                                                                                                                     | 0.1 (-0.04, 0.21) 0.0 (0.29) 0.0 (0.29) Mean Difference                                                                                                                                                                                     | 0.1 (-0.04, 0.21) 0.0 (0.29) 0.0 (0.29) Mean Difference                                                                                                                                                                                     | 0.1 (-0.04, 0.21) 0.0 (0.29) 0.0 (0.29) Mean Difference                                                                                                                                                                                     | 0.1 (-0.04, 0.21) 0.0 (0.29) 0.0 (0.29) Mean Difference                                                                                                                                                                                     | 0.1 (-0.04, 0.21) 0.0 (0.29) 0.0 (0.29) Mean Difference                                                                                                                                                                                     | 0.1 (-0.04, 0.21) 0.0 (0.29) 0.0 (0.29) Mean Difference                                                                                                                                                                                     |
|                                                                                | Cycle 3                                                                                                                                                                                                                                     | (95% CI)1 0.0 (-0.06, 0.06)                                                                                                                                                                                                                 | (95% CI)1 0.0 (-0.06, 0.06)                                                                                                                                                                                                                 | (95% CI)1 0.0 (-0.06, 0.06)                                                                                                                                                                                                                 | (95% CI)1 0.0 (-0.06, 0.06)                                                                                                                                                                                                                 | (95% CI)1 0.0 (-0.06, 0.06)                                                                                                                                                                                                                 | (95% CI)1 0.0 (-0.06, 0.06)                                                                                                                                                                                                                 | (95% CI)1 0.0 (-0.06, 0.06)                                                                                                                                                                                                                 | (95% CI)1 0.0 (-0.06, 0.06)                                                                                                                                                                                                                 | (95% CI)1 0.0 (-0.06, 0.06)                                                                                                                                                                                                                 |
|                                                                                |                                                                                                                                                                                                                                             | 0.1 (0.68) 0.0 (0.22) Mean Difference (95% CI)1                                                                                                                                                                                             | 0.1 (0.68) 0.0 (0.22) Mean Difference (95% CI)1                                                                                                                                                                                             | 0.1 (0.68) 0.0 (0.22) Mean Difference (95% CI)1                                                                                                                                                                                             | 0.1 (0.68) 0.0 (0.22) Mean Difference (95% CI)1                                                                                                                                                                                             | 0.1 (0.68) 0.0 (0.22) Mean Difference (95% CI)1                                                                                                                                                                                             | 0.1 (0.68) 0.0 (0.22) Mean Difference (95% CI)1                                                                                                                                                                                             | 0.1 (0.68) 0.0 (0.22) Mean Difference (95% CI)1                                                                                                                                                                                             | 0.1 (0.68) 0.0 (0.22) Mean Difference (95% CI)1                                                                                                                                                                                             | 0.1 (0.68) 0.0 (0.22) Mean Difference (95% CI)1                                                                                                                                                                                             |
|                                                                                |                                                                                                                                                                                                                                             | 0.0 (-0.06, 0.15)                                                                                                                                                                                                                           | 0.0 (-0.06, 0.15)                                                                                                                                                                                                                           | 0.0 (-0.06, 0.15)                                                                                                                                                                                                                           | 0.0 (-0.06, 0.15)                                                                                                                                                                                                                           | 0.0 (-0.06, 0.15)                                                                                                                                                                                                                           | 0.0 (-0.06, 0.15)                                                                                                                                                                                                                           | 0.0 (-0.06, 0.15)                                                                                                                                                                                                                           | 0.0 (-0.06, 0.15)                                                                                                                                                                                                                           | 0.0 (-0.06, 0.15)                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Title: A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy   | Title: A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy   | Title: A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy   | Title: A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy   | Title: A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                          | Study GC-627-05 Cycle 4                                                                                                                                                                   | 0.1 (0.79)                                                                                                                                                                                | 0.0 (0.00)                                                                                                                                                                                | Mean Difference (95% CI)1 0.1 (-0.04, 0.19)                                                                                                                                               |
| Duration of hospitalization for febrile neutropenia or any infection                                                                                                                      |                                                                                                                                                                                           | 20 mg F-627 (N = 197)                                                                                                                                                                     | 6 mg Neulasta® (N = 196)                                                                                                                                                                  |                                                                                                                                                                                           |
| Duration of hospitalization for febrile neutropenia or any infection                                                                                                                      | Total Across All Chemotherapy Cycles,                                                                                                                                                     | 0.1 (0.78)                                                                                                                                                                                | 0.0 (0.57)                                                                                                                                                                                | Mean Difference (95% CI)1 0.0 (- 0.12, 0.15), p- value 1.0000                                                                                                                             |
| Duration of hospitalization for febrile neutropenia or any infection                                                                                                                      | Cycle 1                                                                                                                                                                                   | 0.0 (0.00)                                                                                                                                                                                | 0.0 (0.57)                                                                                                                                                                                | Mean Difference (95% CI)1 -0.0 (- 0.12, 0.04)                                                                                                                                             |
| Duration of hospitalization for febrile neutropenia or any infection                                                                                                                      | Cycle 2                                                                                                                                                                                   | 0.0 (0.00)                                                                                                                                                                                | 0.0 (0.00)                                                                                                                                                                                | Mean Difference (95% CI)1 0.0 (0.00)                                                                                                                                                      |
| Duration of hospitalization for febrile neutropenia or any infection                                                                                                                      | Cycle 3                                                                                                                                                                                   | 0.0 (0.00)                                                                                                                                                                                | 0.0 (0.00)                                                                                                                                                                                | Mean Difference (95% CI)1 0.0 (0.00)                                                                                                                                                      |
| Duration of hospitalization for febrile neutropenia or any infection                                                                                                                      | Cycle 4                                                                                                                                                                                   | 0.1 (0.81)                                                                                                                                                                                | 0.0 (0.00)                                                                                                                                                                                | Mean Difference (95% CI)1 0.1 (- 0.06, 0.17)                                                                                                                                              |
| Incidence of febrile neutropenia                                                                                                                                                          |                                                                                                                                                                                           | 20 mg F-627 (N = 197)                                                                                                                                                                     | 6 mg Neulasta® (N = 196)                                                                                                                                                                  |                                                                                                                                                                                           |
| Incidence of febrile neutropenia                                                                                                                                                          | Total Across All Chemotherapy Cycles,                                                                                                                                                     | 6 (3.0)                                                                                                                                                                                   | 1 (0.5)                                                                                                                                                                                   | Difference with Neulasta® (95% CI) 2.5 (-7.3, 12.4) p-value 0.1217                                                                                                                        |
| Incidence of febrile neutropenia                                                                                                                                                          | Cycle 1                                                                                                                                                                                   | 5/197 (2.5)                                                                                                                                                                               | 0/196                                                                                                                                                                                     | Difference with Neulasta® (95% CI) 2.5 (-7.3, 12.4)                                                                                                                                       |
| Incidence of febrile neutropenia                                                                                                                                                          | Cycle 2                                                                                                                                                                                   | 0/194                                                                                                                                                                                     | 0/196                                                                                                                                                                                     |                                                                                                                                                                                           |
| Incidence of febrile neutropenia                                                                                                                                                          | Cycle 3                                                                                                                                                                                   | 1/193 (0.5)                                                                                                                                                                               | 1/191 (0.5)                                                                                                                                                                               | Difference with Neulasta® (95% CI) -0.0 (-10.1, 10.1)                                                                                                                                     |
| Incidence of febrile neutropenia                                                                                                                                                          | Cycle 4                                                                                                                                                                                   | 1/186 (0.5)                                                                                                                                                                               | 0/188                                                                                                                                                                                     | Difference with Neulasta® (95% CI) 0.5 (-9.7, 10.8)                                                                                                                                       |
| Incidence of Grade 4 neutropenia (C1)                                                                                                                                                     |                                                                                                                                                                                           | 20 mg F-627 (N = 197)                                                                                                                                                                     | 6 mg Neulasta® (N = 196)                                                                                                                                                                  |                                                                                                                                                                                           |
| Incidence of Grade 4 neutropenia (C1)                                                                                                                                                     |                                                                                                                                                                                           | 23 (11.7)                                                                                                                                                                                 | 23 (11.7)                                                                                                                                                                                 | Difference with Neulasta® (95% CI) -0.1 (-6.4, 6.3) p-value 0.9853                                                                                                                        |
| Incidence of use of IV antibiotics, n/N1 (%)                                                                                                                                              |                                                                                                                                                                                           | 20 mg F-627 (N = 197)                                                                                                                                                                     | 6 mg Neulasta® (N = 196)                                                                                                                                                                  |                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Title: A Clinical Study identifier                                    | Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy   | Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy   | Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy   | Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy   |
|-----------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Title: A Clinical Study identifier                                    | Study GC-627-05 Total Across All Chemotherapy Cycles, n (%)                    | 9 (4.6)                                                                        | 2 (1.0)                                                                        | Difference with Neulasta® (95% CI) 3.5 (-6.3, 13.4) p-value 0.0618             |
| Title: A Clinical Study identifier                                    | Cycle 1                                                                        | 5/197 (2.5)                                                                    | 1/196 (0.5)                                                                    | Difference with Neulasta® (95% CI)1 2.0 (-7.8, 11.9)                           |
| Title: A Clinical Study identifier                                    | Cycle 2                                                                        | 1/194 (0.5)                                                                    | 1/196 (0.5)                                                                    | Difference with Neulasta® (95% CI)1 0.0 (-10.0, 10.1)                          |
| Title: A Clinical Study identifier                                    | Cycle 3                                                                        | 2/193 (1.0)                                                                    | 1/191 (0.5)                                                                    | Difference with Neulasta® (95% CI)1 0.5 (-9.6, 10.6)                           |
| Title: A Clinical Study identifier                                    | Cycle 4                                                                        | 2/186 (1.1)                                                                    | 0/188                                                                          | Difference with Neulasta® (95% CI)1 1.1 (-9.2, 11.3)                           |
| Incidence of hospitalization for febrile neutropenia or any infection |                                                                                | 20 mg F-627 (N = 197)                                                          | 6 mg Neulasta® (N = 196)                                                       |                                                                                |
| Incidence of hospitalization for febrile neutropenia or any infection | Total Across All Chemotherapy Cycles, n (%)                                    | 1 (0.5)                                                                        | 1 (0.5)                                                                        | Difference with Neulasta® (95% CI) -0.0 (-9.9, 9.9) p-value 1.0000             |
| Incidence of hospitalization for febrile neutropenia or any infection | Cycle 1                                                                        | 0/197                                                                          | 1/196 (0.5)                                                                    | Difference with Neulasta® (95% CI)1 -0.5 (-10.4, 9.4)                          |
| Incidence of hospitalization for febrile neutropenia or any infection | Cycle 2                                                                        | 0/194                                                                          | 0/196                                                                          |                                                                                |
| Incidence of hospitalization for febrile neutropenia or any infection | Cycle 3                                                                        | 0/193                                                                          | 0/191                                                                          |                                                                                |
| Incidence of hospitalization for febrile neutropenia or any infection | Cycle 4                                                                        | 1/186 (0.5)                                                                    | 0/188                                                                          | Difference with Neulasta® (95% CI)1 0.5 (-9.7, 10.8)                           |

Table 52. Summary of efficacy for trial Study SP11631

| Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                                                    | SP11631                                                                                                                                                                                                                                                                                                                                             |
| Design                                                                                                                                                                                                                                                                                                                                              | Multi-center, randomized, open-label, active-controlled phase III clinical trial                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia         | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia         | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia         |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                                                    | SP11631                                                                                                                                                                                                                                                                                                                                                   | SP11631                                                                                                                                                                                                                                                                                                                                                   | SP11631                                                                                                                                                                                                                                                                                                                                                   |
|                                                                                                                                                                                                                                                                                                                                                     | Duration of main phase: Duration of treatment period: Duration of follow-up:                                                                                                                                                                                                                                                                              | Duration of main phase: Duration of treatment period: Duration of follow-up:                                                                                                                                                                                                                                                                              | 16 weeks 12 weeks 90 days                                                                                                                                                                                                                                                                                                                                 |
| Hypothesis                                                                                                                                                                                                                                                                                                                                          | Primary efficacy endpoint will test the non-inferiority using both PP set A and FAS. Priority is given to the FAS analysis results while PP set A is used for a sensitivity analysis. The hypotheses for non-inferiority between F-627 and GRAN® are as follows: H0: μ F-627 (20 mg/dose) - μ GRAN ® > 1 day; H1: μ F-627 (20 mg/dose) - μ GRAN ® ≤ 1 day | Primary efficacy endpoint will test the non-inferiority using both PP set A and FAS. Priority is given to the FAS analysis results while PP set A is used for a sensitivity analysis. The hypotheses for non-inferiority between F-627 and GRAN® are as follows: H0: μ F-627 (20 mg/dose) - μ GRAN ® > 1 day; H1: μ F-627 (20 mg/dose) - μ GRAN ® ≤ 1 day | Primary efficacy endpoint will test the non-inferiority using both PP set A and FAS. Priority is given to the FAS analysis results while PP set A is used for a sensitivity analysis. The hypotheses for non-inferiority between F-627 and GRAN® are as follows: H0: μ F-627 (20 mg/dose) - μ GRAN ® > 1 day; H1: μ F-627 (20 mg/dose) - μ GRAN ® ≤ 1 day |
| Treatments groups                                                                                                                                                                                                                                                                                                                                   | F-627                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                                     | F-627: 20 mg/dose, s.c., 48 ± 4 hrs after starting chemotherapy (i.e., day 3 of each cycle), 12 weeks, N = 120.                                                                                                                                                                                                                                           |
| Treatments groups                                                                                                                                                                                                                                                                                                                                   | GRAN®                                                                                                                                                                                                                                                                                                                                                     | GRAN®                                                                                                                                                                                                                                                                                                                                                     | GRAN®: 5 μg/kg/day, s.c., 48 ± 4 hrs after starting chemotherapy (i.e., day 3 of each cycle), once daily for 2 weeks or until ANC recovers to 5.0 × 10 9 /L, 12 weeks, N = 119.                                                                                                                                                                           |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                           | Primary endpoint                                                                                                                                                                                                                                                                                                                                          | Duration (days) of grade 3 or 4 neutropenia in cycle 1                                                                                                                                                                                                                                                                                                    | The primary endpoint is the duration (days) of grade 3 or 4 (moderate and severe) neutropenia in cycle 1, that is, the number of days of ANC < 1.0 × 10 9 /L in cycle 1.                                                                                                                                                                                  |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                           | Secondary endpoint                                                                                                                                                                                                                                                                                                                                        | Incidence rate of grade 3 or 4 neutropenia                                                                                                                                                                                                                                                                                                                | The incidence rate of grade 3 or 4 neutropenia (Grade 3 defined as ANC <1.0 × 10 9 /L and Grade 4 defined as ANC<0.5 × 10 9 /L) in each cycle;                                                                                                                                                                                                            |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                           | Secondary endpoint                                                                                                                                                                                                                                                                                                                                        | Durations (days) of grade 3 or 4 neutropenia                                                                                                                                                                                                                                                                                                              | The durations (days) of grade 3 or 4 neutropenia (Grade3 defined as ANC <1.0 × 10 9 /L and Grade4 defined as ANC<0.5 × 10 9 /L) in cycles 2-4;                                                                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                     | Secondary endpoint                                                                                                                                                                                                                                                                                                                                        | Grade 4 defined as ANC                                                                                                                                                                                                                                                                                                                                    | Grade 4 defined as ANC<0.5 × 10 9 /L                                                                                                                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                                                                                                     | Secondary endpoint                                                                                                                                                                                                                                                                                                                                        | Overall duration (days) of grade 3 or 4 neutropenia                                                                                                                                                                                                                                                                                                       | Overall duration (days) of grade 3 or 4 neutropenia (ANC < 1.0 × 10 9 /L and < 0.5 × 10 9 /L, respectively) in all 4 cycles                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                                                                                                                                     | Secondary endpoint                                                                                                                                                                                                                                                                                                                                        | Incidence rate and duration (days) of grade 2 or greater neutropenia                                                                                                                                                                                                                                                                                      | Incidence rate and duration (days) of grade 2 or greater neutropenia (ANC < 1.5 × 10 9 /L) in each cycle                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia                                                                                                                                                                                                                                                                            | Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia                                                                                                                                                                                                                                                                            | Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia                                                                                                                                                                                                                                                                            | Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia                                                                                                                                                                                                                                                                            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                   | SP11631                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | SP11631                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | SP11631                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | SP11631                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                    | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Incidence rate of febrile neutropenia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | The incidence rate of febrile neutropenia (FN) (defined as ANC < 1.0 × 10 9 /L; with a single measurement of body temperature > 38.3 ° C or a temperature ≥ 38.0 ° C sustained over 1 hr);                                                                                                                                                                                                                                                                                                                                  | The incidence rate of febrile neutropenia (FN) (defined as ANC < 1.0 × 10 9 /L; with a single measurement of body temperature > 38.3 ° C or a temperature ≥ 38.0 ° C sustained over 1 hr);                                                                                                                                                                                                                                                                                                                                  |
|                                                                                                                                                                                                                                                    | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | ANC-time profile                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | ANC-time profile                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | ANC-time profile                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                                                    | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | The ANC nadir                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | The ANC nadir from day 3 to day 13 of cycle 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | The ANC nadir from day 3 to day 13 of cycle 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                                    | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Time (days) of ANC nadir recovery                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Time (days) of ANC nadir recovers to 2.0 × 10 9 /L in each cycle                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Time (days) of ANC nadir recovers to 2.0 × 10 9 /L in each cycle                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Database lock                                                                                                                                                                                                                                      | Not clearly identified                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Not clearly identified                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Not clearly identified                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Not clearly identified                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Results and Analysis                                                                                                                                                                                                                               | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Analysis description Primary Analysis                                                                                                                                                                                                              | Analysis description Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Analysis description Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Analysis description Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Analysis description Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Analysis population and time point description                                                                                                                                                                                                     | Efficacy analysis is performed based on full analysis set (FAS) and per-protocol (PP) set. FAS: all randomized subjects who have received the study drug and undergone at least one postbaseline efficacy evaluation. PP set A: subjects in FAS and without major protocol deviations, serious medication noncompliance, loss to follow-up, or withdrawal during cycle 1. PP set B: subjects in FAS and without major protocol deviations, serious medication noncompliance, loss to follow-up, or withdrawal in any cycle. | Efficacy analysis is performed based on full analysis set (FAS) and per-protocol (PP) set. FAS: all randomized subjects who have received the study drug and undergone at least one postbaseline efficacy evaluation. PP set A: subjects in FAS and without major protocol deviations, serious medication noncompliance, loss to follow-up, or withdrawal during cycle 1. PP set B: subjects in FAS and without major protocol deviations, serious medication noncompliance, loss to follow-up, or withdrawal in any cycle. | Efficacy analysis is performed based on full analysis set (FAS) and per-protocol (PP) set. FAS: all randomized subjects who have received the study drug and undergone at least one postbaseline efficacy evaluation. PP set A: subjects in FAS and without major protocol deviations, serious medication noncompliance, loss to follow-up, or withdrawal during cycle 1. PP set B: subjects in FAS and without major protocol deviations, serious medication noncompliance, loss to follow-up, or withdrawal in any cycle. | Efficacy analysis is performed based on full analysis set (FAS) and per-protocol (PP) set. FAS: all randomized subjects who have received the study drug and undergone at least one postbaseline efficacy evaluation. PP set A: subjects in FAS and without major protocol deviations, serious medication noncompliance, loss to follow-up, or withdrawal during cycle 1. PP set B: subjects in FAS and without major protocol deviations, serious medication noncompliance, loss to follow-up, or withdrawal in any cycle. |
| Descriptive statistics and estimate variability                                                                                                                                                                                                    | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | F-627 20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | F-627 20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | GRAN®: 5 μg/kg/day, FAS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability                                                                                                                                                                                                    | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | mg/dose, FAS N = 120                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | mg/dose, FAS N = 120                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | N = 119                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability                                                                                                                                                                                                    | Duration (days) of grade 3 or 4 neutropenia in cycle 1, Mean (SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 0.68 (1.100)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 0.68 (1.100)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 0.71 (0.951)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability                                                                                                                                                                                                    | Median                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Effect estimate per comparison                                                                                                                                                                                                                     | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | (F- 627 - GRAN®) Hodges-Lehmann estimator of the median of inter-arm                                                                                                                                                                                                                                                                                                                                                                                                                                                        | (F- 627 - GRAN®) Hodges-Lehmann estimator of the median of inter-arm                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.00 (0.000, 0.000)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Effect estimate per comparison                                                                                                                                                                                                                     | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | difference (95% CI) (F- 627 - GRAN®) Hodges-Lehmann estimator (upper limit of one-sided 97.5% CI)                                                                                                                                                                                                                                                                                                                                                                                                                           | difference (95% CI) (F- 627 - GRAN®) Hodges-Lehmann estimator (upper limit of one-sided 97.5% CI)                                                                                                                                                                                                                                                                                                                                                                                                                           | 0.00 (0.000)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                   | SP11631                                                                                                                                                                                                                                            | SP11631                                                                                                                                                                                                                                            | SP11631                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability                                                                                                                                                                                                    | Co- Primary endpoint: Duration analysis on population with grade 3 or 4 neutropenia in cycle 1                                                                                                                                                     | F-627 20 mg/dose, FAS                                                                                                                                                                                                                              | GRAN®: 5 μg/kg/day, FAS                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability                                                                                                                                                                                                    | Number                                                                                                                                                                                                                                             | 41                                                                                                                                                                                                                                                 | 51                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability                                                                                                                                                                                                    | Mean (days)                                                                                                                                                                                                                                        | 2.00 (0.949)                                                                                                                                                                                                                                       | 1.65                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability                                                                                                                                                                                                    | Standard deviation                                                                                                                                                                                                                                 | 0.949                                                                                                                                                                                                                                              | 0.744                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability                                                                                                                                                                                                    | Co- Primary endpoint                                                                                                                                                                                                                               | (F- 627 - GRAN®) mean difference (95% CI)                                                                                                                                                                                                          | 0.35 (0.003, 0.703)                                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability                                                                                                                                                                                                    | Co- Primary endpoint                                                                                                                                                                                                                               | (F- 627 - GRAN®) mean difference (upper limit of one-sided 97.5% CI)                                                                                                                                                                               | 0.35 (0.703)                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability                                                                                                                                                                                                    | Duration (days) of grade 3 or 4 neutropenia in cycle 1 - PP set A                                                                                                                                                                                  | F-627 20 mg/dose, FAS, N=119.                                                                                                                                                                                                                      | GRAN®: 5 μg/kg/day, FAS, N = 110.                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability                                                                                                                                                                                                    | Mean, day                                                                                                                                                                                                                                          | 0.66                                                                                                                                                                                                                                               | 0.68                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability                                                                                                                                                                                                    | Standard deviation                                                                                                                                                                                                                                 | 1.061                                                                                                                                                                                                                                              | 0.928                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability                                                                                                                                                                                                    | Standard deviation                                                                                                                                                                                                                                 | (F- 627 - GRAN®) Hodges-Lehmann estimator (95% CI)                                                                                                                                                                                                 | 0.00 (0.000, 0.000)                                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability                                                                                                                                                                                                    | Standard deviation                                                                                                                                                                                                                                 | (F- 627 - GRAN®) Hodges-Lehmann estimator (upper limit of onesided 97.5% CI)                                                                                                                                                                       | 0.00 (0.000)                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability                                                                                                                                                                                                    | Co- Primary endpoint: Duration (days) of grade 3 or 4 neutropenia in cycle 1 - FAS (without imputation of missing ANC data)                                                                                                                        | F-627 (N = 120)                                                                                                                                                                                                                                    | GRAN® (N = 119)                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability                                                                                                                                                                                                    | Mean                                                                                                                                                                                                                                               | 0.68                                                                                                                                                                                                                                               | 0.70                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability                                                                                                                                                                                                    | Standard deviation                                                                                                                                                                                                                                 | 1.100                                                                                                                                                                                                                                              | 0.944                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability                                                                                                                                                                                                    | Standard deviation                                                                                                                                                                                                                                 | F- 627 - GRAN®) Hodges - Lehmann estimator (95% CI)                                                                                                                                                                                                | 0.00 (0.000, 0.000)                                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability                                                                                                                                                                                                    | Standard deviation                                                                                                                                                                                                                                 | (F- 627 - GRAN®) Hodges-Lehmann estimator (upper limit of one-sided 97.5% CI)                                                                                                                                                                      | 0.00 (0.000)                                                                                                                                                                                                                                       |
| Notes                                                                                                                                                                                                                                              | The Applicant should clearly specify the date of database lock.                                                                                                                                                                                    | The Applicant should clearly specify the date of database lock.                                                                                                                                                                                    | The Applicant should clearly specify the date of database lock.                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                                                    | SP11631                                                                                                                                                                                                                                                                                                                                             | SP11631                                                                                                                                                                                                                                                                                                                                             | SP11631                                                                                                                                                                                                                                                                                                                                             | SP11631                                                                                                                                                                                                                                                                                                                                             |
| Analysis description                                                                                                                                                                                                                                                                                                                                | Secondary analysis                                                                                                                                                                                                                                                                                                                                  | Secondary analysis                                                                                                                                                                                                                                                                                                                                  | Secondary analysis                                                                                                                                                                                                                                                                                                                                  | Secondary analysis                                                                                                                                                                                                                                                                                                                                  |
| Incidence rate of grade 3 or 4 neutropenia in cycle 1, FAS                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                                                                                                     | n                                                                                                                                                                                                                                                                                                                                                   | 120                                                                                                                                                                                                                                                                                                                                                 | 119                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                                                                                                     | n (%)                                                                                                                                                                                                                                                                                                                                               | 41 (34.2)                                                                                                                                                                                                                                                                                                                                           | 51 (42.9)                                                                                                                                                                                                                                                                                                                                           | Incidence rate difference (F-627 - GRAN®) (95% CI) -8.7 (-20.98 ， 3.60), P value 0.185                                                                                                                                                                                                                                                              |
| Incidence rate of grade 3 or 4 neutropenia in cycle 1, PP Set A                                                                                                                                                                                                                                                                                     | n                                                                                                                                                                                                                                                                                                                                                   | 119                                                                                                                                                                                                                                                                                                                                                 | 110                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| Incidence rate of grade 3 or 4 neutropenia in cycle 1, PP Set A                                                                                                                                                                                                                                                                                     | n (%)                                                                                                                                                                                                                                                                                                                                               | 40 (33.6)                                                                                                                                                                                                                                                                                                                                           | 47 (42.7)                                                                                                                                                                                                                                                                                                                                           | Incidence rate difference (F-627 - GRAN®) (95% CI) -9.1 (- 21.66, 3.44), P value 0.174                                                                                                                                                                                                                                                              |
|                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
| Incidence rates of grade 3 or 4 neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                      | Cycle 2, n                                                                                                                                                                                                                                                                                                                                          | 117                                                                                                                                                                                                                                                                                                                                                 | 107                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| Incidence rates of grade 3 or 4 neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                      | Cycle 2, n (%)                                                                                                                                                                                                                                                                                                                                      | 7 (6.0)                                                                                                                                                                                                                                                                                                                                             | 7 (6.5)                                                                                                                                                                                                                                                                                                                                             | Incidence rate difference (F-627 - GRAN®) 95% CI -0.6 (- 6.92, 5.80), P value >0.999                                                                                                                                                                                                                                                                |
| Incidence rates of grade 3 or 4 neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                      | Cycle 3, n                                                                                                                                                                                                                                                                                                                                          | 115                                                                                                                                                                                                                                                                                                                                                 | 103                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| Incidence rates of grade 3 or 4 neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                      | Cycle 3, n (%)                                                                                                                                                                                                                                                                                                                                      | 4 (3.5)                                                                                                                                                                                                                                                                                                                                             | 18 (17.5)                                                                                                                                                                                                                                                                                                                                           | Incidence rate difference (F-627 - GRAN®) 95% CI -14.0 (- 22.06, -5.94), P value <0.001                                                                                                                                                                                                                                                             |
| Incidence rates of grade 3 or 4 neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                      | Cycle 4, n                                                                                                                                                                                                                                                                                                                                          | 114                                                                                                                                                                                                                                                                                                                                                 | 101                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| Incidence rates of grade 3 or 4 neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                      | Cycle 4, n (%)                                                                                                                                                                                                                                                                                                                                      | 10 (8.8)                                                                                                                                                                                                                                                                                                                                            | 10 (9.9)                                                                                                                                                                                                                                                                                                                                            | Incidence rate difference (F-627 - GRAN®) 95% CI -1.1 (- 8.93, 6.67), P value 0.817                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
| Incidence rates of                                                                                                                                                                                                                                                                                                                                  | Cycle 2, n                                                                                                                                                                                                                                                                                                                                          | 110                                                                                                                                                                                                                                                                                                                                                 | 99                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                                                    | SP11631                                                                                                                                                                                                                                                                                                                                             | SP11631                                                                                                                                                                                                                                                                                                                                             | SP11631                                                                                                                                                                                                                                                                                                                                             | SP11631                                                                                                                                                                                                                                                                                                                                             |
| grade 3 or 4 neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                                    | Cycle 2, n (%)                                                                                                                                                                                                                                                                                                                                      | 6 (5.5)                                                                                                                                                                                                                                                                                                                                             | 6 (6.1)                                                                                                                                                                                                                                                                                                                                             | Incidence rate difference (F-627 - GRAN®) 95% CI -0.6 (- 6.94, 5.73), P value >0.999                                                                                                                                                                                                                                                                |
| grade 3 or 4 neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                                    | Cycle 3, n                                                                                                                                                                                                                                                                                                                                          | 110                                                                                                                                                                                                                                                                                                                                                 | 99                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                     |
| grade 3 or 4 neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                                    | Cycle 3, n (%)                                                                                                                                                                                                                                                                                                                                      | 4 (3.6)                                                                                                                                                                                                                                                                                                                                             | 16 (16.2)                                                                                                                                                                                                                                                                                                                                           | Incidence rate difference (F-627 - GRAN®) 95% CI -12.5 (- 20.58, -4.47), p 0.004.                                                                                                                                                                                                                                                                   |
| grade 3 or 4 neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                                    | Cycle 4, n                                                                                                                                                                                                                                                                                                                                          | 110                                                                                                                                                                                                                                                                                                                                                 | 99                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                     |
| grade 3 or 4 neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                                    | Cycle 4, n (%)                                                                                                                                                                                                                                                                                                                                      | 7 (6.4)                                                                                                                                                                                                                                                                                                                                             | 10 (10.1)                                                                                                                                                                                                                                                                                                                                           | Incidence rate difference (F-627 - GRAN®) 95% CI -3.7 (- 11.22, 3.75), p 0.448                                                                                                                                                                                                                                                                      |
| Mean durations of grade 3 or 4 neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
| Mean durations of grade 3 or 4 neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                       | Cycle 2, n                                                                                                                                                                                                                                                                                                                                          | 117                                                                                                                                                                                                                                                                                                                                                 | 107                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| Mean durations of grade 3 or 4 neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                       | Cycle 2, Mean (SD)                                                                                                                                                                                                                                                                                                                                  | 0.1 (0.35)                                                                                                                                                                                                                                                                                                                                          | 0.1 (0.25)                                                                                                                                                                                                                                                                                                                                          | Hodges-Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                  |
| Mean durations of grade 3 or 4 neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                       | Cycle 3, n                                                                                                                                                                                                                                                                                                                                          | 115                                                                                                                                                                                                                                                                                                                                                 | 103                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| Mean durations of grade 3 or 4 neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                       | Cycle 3, Mean (SD)                                                                                                                                                                                                                                                                                                                                  | 0.0 (0.18)                                                                                                                                                                                                                                                                                                                                          | 0.2 (0.54)                                                                                                                                                                                                                                                                                                                                          | Hodges-Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                  |
| Mean durations of grade 3 or 4 neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                       | Cycle 4, n                                                                                                                                                                                                                                                                                                                                          | 114                                                                                                                                                                                                                                                                                                                                                 | 101                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| Mean durations of grade 3 or 4 neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                       | Cycle 4, Mean (SD)                                                                                                                                                                                                                                                                                                                                  | 0.1 (0.38)                                                                                                                                                                                                                                                                                                                                          | 0.1 (0.41)                                                                                                                                                                                                                                                                                                                                          | Hodges-Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                  |
| Mean durations of grade 3 or 4 neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
| Mean durations of grade 3 or 4 neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                  | Cycle 2, n Cycle 2, Mean (SD)                                                                                                                                                                                                                                                                                                                       | 110 0.1 (0.23)                                                                                                                                                                                                                                                                                                                                      | 99 0.1 (0.24)                                                                                                                                                                                                                                                                                                                                       | Hodges-Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                  |
| Mean durations of grade 3 or 4 neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                  | Cycle 3, n                                                                                                                                                                                                                                                                                                                                          | 110                                                                                                                                                                                                                                                                                                                                                 | 99                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                     |
| Mean durations of grade 3 or 4 neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                  | Cycle 3, Mean (SD)                                                                                                                                                                                                                                                                                                                                  | 0.0 (0.19)                                                                                                                                                                                                                                                                                                                                          | 0.2 (0.46)                                                                                                                                                                                                                                                                                                                                          | Hodges-Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                  |
| Mean durations of grade 3 or 4 neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                  | Cycle 4, n                                                                                                                                                                                                                                                                                                                                          | 110                                                                                                                                                                                                                                                                                                                                                 | 99                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                                                    | SP11631                                                                                                                                                                                                                                                                                                                                             | SP11631                                                                                                                                                                                                                                                                                                                                             | SP11631                                                                                                                                                                                                                                                                                                                                             | SP11631                                                                                                                                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                                                                                                     | Cycle 4, Mean (SD)                                                                                                                                                                                                                                                                                                                                  | 0.1 (0.25)                                                                                                                                                                                                                                                                                                                                          | 0.1 (0.41)                                                                                                                                                                                                                                                                                                                                          | Hodges-Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                  |
| Duration (days) of grade 4 neutropenia                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
| Duration (days) of grade 4 neutropenia                                                                                                                                                                                                                                                                                                              | Number                                                                                                                                                                                                                                                                                                                                              | 120                                                                                                                                                                                                                                                                                                                                                 | 119                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| in cycle 1, FAS                                                                                                                                                                                                                                                                                                                                     | Mean (SD)                                                                                                                                                                                                                                                                                                                                           | 0.3 (0.69)                                                                                                                                                                                                                                                                                                                                          | 0.2 (0.58)                                                                                                                                                                                                                                                                                                                                          | F- 627 - GRAN®) Hodges-Lehmann estimator (95% CI) 0.0 (0.00 ， 0.00)                                                                                                                                                                                                                                                                                 |
| Duration (days) of grade 4 neutropenia in cycle 1, PP Set A                                                                                                                                                                                                                                                                                         | Number                                                                                                                                                                                                                                                                                                                                              | 119                                                                                                                                                                                                                                                                                                                                                 | 110                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                                                                                                     | Mean (SD)                                                                                                                                                                                                                                                                                                                                           | 0.2 (0.65)                                                                                                                                                                                                                                                                                                                                          | 0.2 (0.49)                                                                                                                                                                                                                                                                                                                                          | (F- 627 - GRAN®) Hodges-Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                 |
| Incidence rate of                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
| grade 4 neutropenia                                                                                                                                                                                                                                                                                                                                 | Number                                                                                                                                                                                                                                                                                                                                              | 120                                                                                                                                                                                                                                                                                                                                                 | 119                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| in cycle 1, FAS                                                                                                                                                                                                                                                                                                                                     | n (%)                                                                                                                                                                                                                                                                                                                                               | 17 (14.2)                                                                                                                                                                                                                                                                                                                                           | 19 (16.0)                                                                                                                                                                                                                                                                                                                                           | Incidence rate difference (F-627 - GRAN®) (95% CI) -1.8 (-10.87, 7.27), P value 0.721                                                                                                                                                                                                                                                               |
| Incidence rate of                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
| grade 4 neutropenia                                                                                                                                                                                                                                                                                                                                 | Number                                                                                                                                                                                                                                                                                                                                              | 119                                                                                                                                                                                                                                                                                                                                                 | 110                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| in cycle 1, PP Set A                                                                                                                                                                                                                                                                                                                                | n (%)                                                                                                                                                                                                                                                                                                                                               | 16 (13.4)                                                                                                                                                                                                                                                                                                                                           | 15 (13.6)                                                                                                                                                                                                                                                                                                                                           | Incidence rate difference (F-627 - GRAN®) (95% CI) -0.2 (-9.06, 8.68), P value >0.999                                                                                                                                                                                                                                                               |
| Durations (days) of grade 4 neutropenia                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                                                                                                     | Cycle 2, n                                                                                                                                                                                                                                                                                                                                          | 117                                                                                                                                                                                                                                                                                                                                                 | 107                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| in cycles 2-4, FAS                                                                                                                                                                                                                                                                                                                                  | Cycle 2, Mean (SD)                                                                                                                                                                                                                                                                                                                                  | 0.0 (0.13)                                                                                                                                                                                                                                                                                                                                          | 0.0 (0.10)                                                                                                                                                                                                                                                                                                                                          | Hodges- Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                                                                                                     | Cycle 3, n                                                                                                                                                                                                                                                                                                                                          | 115                                                                                                                                                                                                                                                                                                                                                 | 103                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                                                                                                     | Cycle 3, Mean (SD)                                                                                                                                                                                                                                                                                                                                  | 0.0 (0.00)                                                                                                                                                                                                                                                                                                                                          | 0.1 (0.34)                                                                                                                                                                                                                                                                                                                                          | Hodges- Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                                                                                                     | Cycle 4, n                                                                                                                                                                                                                                                                                                                                          | 114                                                                                                                                                                                                                                                                                                                                                 | 101                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                                                    | SP11631                                                                                                                                                                                                                                                                                                                                             | SP11631                                                                                                                                                                                                                                                                                                                                             | SP11631                                                                                                                                                                                                                                                                                                                                             | SP11631                                                                                                                                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                                                                                                     | Cycle 4, Mean (SD)                                                                                                                                                                                                                                                                                                                                  | 0.0 (0.13)                                                                                                                                                                                                                                                                                                                                          | 0.0 (0.20)                                                                                                                                                                                                                                                                                                                                          | Hodges- Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
| Durations (days) of grade 4 neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                     | Cycle 2, n                                                                                                                                                                                                                                                                                                                                          | 110                                                                                                                                                                                                                                                                                                                                                 | 99                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                     |
| Durations (days) of grade 4 neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                     | Cycle 2, Mean (SD)                                                                                                                                                                                                                                                                                                                                  | 0.0 (0.10)                                                                                                                                                                                                                                                                                                                                          | 0.0 (0.10)                                                                                                                                                                                                                                                                                                                                          | Hodges- Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                 |
| Durations (days) of grade 4 neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                     | Cycle 3, n                                                                                                                                                                                                                                                                                                                                          | 115                                                                                                                                                                                                                                                                                                                                                 | 103                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| Durations (days) of grade 4 neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                     | Cycle 3, Mean (SD)                                                                                                                                                                                                                                                                                                                                  | 0.0 (0.00)                                                                                                                                                                                                                                                                                                                                          | 0.0 (0.17)                                                                                                                                                                                                                                                                                                                                          | Hodges- Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                 |
| Durations (days) of grade 4 neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                     | Cycle 4, n                                                                                                                                                                                                                                                                                                                                          | 114                                                                                                                                                                                                                                                                                                                                                 | 101                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| Durations (days) of grade 4 neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                     | Cycle 4, Mean (SD)                                                                                                                                                                                                                                                                                                                                  | 0.0 (0.00)                                                                                                                                                                                                                                                                                                                                          | 0.0 (0.20)                                                                                                                                                                                                                                                                                                                                          | Hodges- Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                 |
| Incidence rates of grade 4 neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
| Incidence rates of grade 4 neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                           | Cycle 2, n                                                                                                                                                                                                                                                                                                                                          | 117                                                                                                                                                                                                                                                                                                                                                 | 107                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| Incidence rates of grade 4 neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                           | Cycle 2, n (%)                                                                                                                                                                                                                                                                                                                                      | 2 (1.7)                                                                                                                                                                                                                                                                                                                                             | 1 (0.9)                                                                                                                                                                                                                                                                                                                                             | 95% CI 0.8 (- 2.20, 3.75) p >0.999                                                                                                                                                                                                                                                                                                                  |
| Incidence rates of grade 4 neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                           | Cycle 3, n                                                                                                                                                                                                                                                                                                                                          | 115                                                                                                                                                                                                                                                                                                                                                 | 103                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| Incidence rates of grade 4 neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                           | Cycle 3, n (%)                                                                                                                                                                                                                                                                                                                                      | 0                                                                                                                                                                                                                                                                                                                                                   | 4 (3.9)                                                                                                                                                                                                                                                                                                                                             | 95% CI -3.9 (- 7.61, -0.15) p 0.048                                                                                                                                                                                                                                                                                                                 |
| Incidence rates of grade 4 neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                           | Cycle 4, n                                                                                                                                                                                                                                                                                                                                          | 114                                                                                                                                                                                                                                                                                                                                                 | 101                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| Incidence rates of grade 4 neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                           | Cycle 4, n (%)                                                                                                                                                                                                                                                                                                                                      | 2 (1.8)                                                                                                                                                                                                                                                                                                                                             | 4 (4.0)                                                                                                                                                                                                                                                                                                                                             | 95% CI -2.2 (- 6.71, 2.30) p 0.423                                                                                                                                                                                                                                                                                                                  |
| Incidence rates of grade 4 neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
| Incidence rates of grade 4 neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                      | Cycle 2, n                                                                                                                                                                                                                                                                                                                                          | 110                                                                                                                                                                                                                                                                                                                                                 | 99                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                     |
| Incidence rates of grade 4 neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                      | Cycle 2, n (%)                                                                                                                                                                                                                                                                                                                                      | 1 (0.9)                                                                                                                                                                                                                                                                                                                                             | 1 (1.0)                                                                                                                                                                                                                                                                                                                                             | 95% CI -0.1 (- 2.75, 2.55) p >0.999                                                                                                                                                                                                                                                                                                                 |
| Incidence rates of grade 4 neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                      | Cycle 3, n                                                                                                                                                                                                                                                                                                                                          | 110                                                                                                                                                                                                                                                                                                                                                 | 99                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                     |
| Incidence rates of grade 4 neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                      | Cycle 3, n (%)                                                                                                                                                                                                                                                                                                                                      | 0                                                                                                                                                                                                                                                                                                                                                   | 3 (3.0)                                                                                                                                                                                                                                                                                                                                             | 95% CI -3.0 (- 6.41, 0.35) p 0.105                                                                                                                                                                                                                                                                                                                  |
| Incidence rates of grade 4 neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                      | Cycle 4, n                                                                                                                                                                                                                                                                                                                                          | 110                                                                                                                                                                                                                                                                                                                                                 | 99                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                                                    | SP11631                                                                                                                                                                                                                                                                                                                                             | SP11631                                                                                                                                                                                                                                                                                                                                             | SP11631                                                                                                                                                                                                                                                                                                                                             | SP11631                                                                                                                                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                                                                                                     | Cycle 4, n (%)                                                                                                                                                                                                                                                                                                                                      | 0                                                                                                                                                                                                                                                                                                                                                   | 4 (4.0)                                                                                                                                                                                                                                                                                                                                             | 95% CI -4.0 (- 7.92, -0.16) p 0.049                                                                                                                                                                                                                                                                                                                 |
| Overall duration (days) of grade 3 or 4 neutropenia in                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                                                                                                     | Number                                                                                                                                                                                                                                                                                                                                              | 120                                                                                                                                                                                                                                                                                                                                                 | 119                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| overall 4 cycles, FAS                                                                                                                                                                                                                                                                                                                               | Mean (SD)                                                                                                                                                                                                                                                                                                                                           | 0.9 (1.44)                                                                                                                                                                                                                                                                                                                                          | 1.1 (1.43)                                                                                                                                                                                                                                                                                                                                          | Hodges-Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                  |
|                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
| Overall duration (days) of grade 3 or 4 neutropenia in overall 4 cycles, PP Set B                                                                                                                                                                                                                                                                   | Number                                                                                                                                                                                                                                                                                                                                              | 110                                                                                                                                                                                                                                                                                                                                                 | 99                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                     |
| Overall duration (days) of grade 3 or 4 neutropenia in overall 4 cycles, PP Set B                                                                                                                                                                                                                                                                   | Mean (SD)                                                                                                                                                                                                                                                                                                                                           | 0.8 (1.28)                                                                                                                                                                                                                                                                                                                                          | 1.0 (1.47)                                                                                                                                                                                                                                                                                                                                          | Hodges-Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                  |
| Duration (days) of                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
| grade 2 or greater                                                                                                                                                                                                                                                                                                                                  | Number                                                                                                                                                                                                                                                                                                                                              | 120                                                                                                                                                                                                                                                                                                                                                 | 119                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| neutropenia in cycle 1, FAS                                                                                                                                                                                                                                                                                                                         | Mean (SD)                                                                                                                                                                                                                                                                                                                                           | 1.1 (1.30)                                                                                                                                                                                                                                                                                                                                          | 1.0 (1.10)                                                                                                                                                                                                                                                                                                                                          | Hodges-Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                  |
| Duration (days) of                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
| grade 2 or greater                                                                                                                                                                                                                                                                                                                                  | Number                                                                                                                                                                                                                                                                                                                                              | 119                                                                                                                                                                                                                                                                                                                                                 | 110                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| neutropenia in cycle 1, PP Set A                                                                                                                                                                                                                                                                                                                    | Mean (SD)                                                                                                                                                                                                                                                                                                                                           | 1.1 (1.28)                                                                                                                                                                                                                                                                                                                                          | 1.0 (1.03)                                                                                                                                                                                                                                                                                                                                          | Hodges-Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                  |
| Incidence rate of                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
| grade 2 or greater                                                                                                                                                                                                                                                                                                                                  | Number                                                                                                                                                                                                                                                                                                                                              | 120                                                                                                                                                                                                                                                                                                                                                 | 119                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| neutropenia in cycle 1, FAS                                                                                                                                                                                                                                                                                                                         | n (%)                                                                                                                                                                                                                                                                                                                                               | 58 (48.3)                                                                                                                                                                                                                                                                                                                                           | 67 (56.3)                                                                                                                                                                                                                                                                                                                                           | (95% CI) -8.0 (- 20.59, 4.65), p 0.245                                                                                                                                                                                                                                                                                                              |
| Incidence rate of                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
| grade 2 or greater                                                                                                                                                                                                                                                                                                                                  | Number                                                                                                                                                                                                                                                                                                                                              | 119                                                                                                                                                                                                                                                                                                                                                 | 110                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| neutropenia in cycle 1, PP Set A                                                                                                                                                                                                                                                                                                                    | n (%)                                                                                                                                                                                                                                                                                                                                               | 57 (47.9)                                                                                                                                                                                                                                                                                                                                           | 63 (57.3)                                                                                                                                                                                                                                                                                                                                           | (95% CI) -9.4 (- 22.26, 3.51), p 0.186                                                                                                                                                                                                                                                                                                              |
| Durations (days) of                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
| grade 2 or greater                                                                                                                                                                                                                                                                                                                                  | Cycle 2, n                                                                                                                                                                                                                                                                                                                                          | 117                                                                                                                                                                                                                                                                                                                                                 | 107                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                                                      | Cycle 2, Mean (SD)                                                                                                                                                                                                                                                                                                                                  | 0.2 (0.50)                                                                                                                                                                                                                                                                                                                                          | 0.2 (0.50)                                                                                                                                                                                                                                                                                                                                          | Hodges- Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                 |
| grade 2 or greater                                                                                                                                                                                                                                                                                                                                  | Cycle 3, n                                                                                                                                                                                                                                                                                                                                          | 115                                                                                                                                                                                                                                                                                                                                                 | 103                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                                                    | SP11631                                                                                                                                                                                                                                                                                                                                             | SP11631                                                                                                                                                                                                                                                                                                                                             | SP11631                                                                                                                                                                                                                                                                                                                                             | SP11631                                                                                                                                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                                                                                                     | Cycle 3, Mean (SD)                                                                                                                                                                                                                                                                                                                                  | 0.1 (0.42)                                                                                                                                                                                                                                                                                                                                          | 0.4 (0.67)                                                                                                                                                                                                                                                                                                                                          | Hodges- Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                                                                                                     | Cycle 4, n                                                                                                                                                                                                                                                                                                                                          | 114                                                                                                                                                                                                                                                                                                                                                 | 101                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                                                                                                     | Cycle 4, Mean (SD)                                                                                                                                                                                                                                                                                                                                  | 0.3 (0.68)                                                                                                                                                                                                                                                                                                                                          | 0.3 (0.63)                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                     |
| Durations (days) of                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
| grade 2 or greater neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                              | Cycle 2,                                                                                                                                                                                                                                                                                                                                            | 110                                                                                                                                                                                                                                                                                                                                                 | 99                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                     |
| grade 2 or greater neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                              | n Cycle 2, Mean (SD)                                                                                                                                                                                                                                                                                                                                | 0.1 (0.42)                                                                                                                                                                                                                                                                                                                                          | 0.2 (0.52)                                                                                                                                                                                                                                                                                                                                          | Hodges- Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                 |
| grade 2 or greater neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                              | Cycle 3, n                                                                                                                                                                                                                                                                                                                                          | 110                                                                                                                                                                                                                                                                                                                                                 | 99                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                     |
| grade 2 or greater neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                              | Cycle 3, Mean (SD)                                                                                                                                                                                                                                                                                                                                  | 0.1 (0.41)                                                                                                                                                                                                                                                                                                                                          | 0.3 (0.63)                                                                                                                                                                                                                                                                                                                                          | Hodges- Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                 |
| grade 2 or greater neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                              | Cycle 4, n                                                                                                                                                                                                                                                                                                                                          | 110                                                                                                                                                                                                                                                                                                                                                 | 99                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                     |
| grade 2 or greater neutropenia in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                                              | Cycle 4, Mean (SD)                                                                                                                                                                                                                                                                                                                                  | 0.2 (0.52)                                                                                                                                                                                                                                                                                                                                          | 0.3 (0.64)                                                                                                                                                                                                                                                                                                                                          | Hodges- Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                 |
| Incidence rates of grade 2 or greater neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
| Incidence rates of grade 2 or greater neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                | Cycle 2, n                                                                                                                                                                                                                                                                                                                                          | 117                                                                                                                                                                                                                                                                                                                                                 | 107                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| Incidence rates of grade 2 or greater neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                | Cycle 2, n (%)                                                                                                                                                                                                                                                                                                                                      | 16 (13.7)                                                                                                                                                                                                                                                                                                                                           | 14 (13.1)                                                                                                                                                                                                                                                                                                                                           | 95% CI 0.6 (- 8.33, 9.51), p>0.999                                                                                                                                                                                                                                                                                                                  |
| Incidence rates of grade 2 or greater neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                | Cycle 3, n                                                                                                                                                                                                                                                                                                                                          | 115                                                                                                                                                                                                                                                                                                                                                 | 103                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| Incidence rates of grade 2 or greater neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                | Cycle 3, n (%)                                                                                                                                                                                                                                                                                                                                      | 14 (12.2)                                                                                                                                                                                                                                                                                                                                           | 30 (29.1)                                                                                                                                                                                                                                                                                                                                           | 95% CI -17.0 (- 27.57, -6.34), p 0.002                                                                                                                                                                                                                                                                                                              |
| Incidence rates of grade 2 or greater neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                | Cycle 4, n                                                                                                                                                                                                                                                                                                                                          | 114                                                                                                                                                                                                                                                                                                                                                 | 101                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| Incidence rates of grade 2 or greater neutropenia in cycles 2-4, FAS                                                                                                                                                                                                                                                                                | Cycle 4, n (%)                                                                                                                                                                                                                                                                                                                                      | 20 (17.5)                                                                                                                                                                                                                                                                                                                                           | 26 (25.7)                                                                                                                                                                                                                                                                                                                                           | 95% CI -8.2 (- 19.22, 2.82), p 0.182                                                                                                                                                                                                                                                                                                                |
| Incidence rates of grade 2 or greater neutropenia in cycles 2-4, PP Set B,                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
| Incidence rates of grade 2 or greater neutropenia in cycles 2-4, PP Set B,                                                                                                                                                                                                                                                                          | Cycle 2, n                                                                                                                                                                                                                                                                                                                                          | 110                                                                                                                                                                                                                                                                                                                                                 | 99                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                     |
| Incidence rates of grade 2 or greater neutropenia in cycles 2-4, PP Set B,                                                                                                                                                                                                                                                                          | Cycle 2, n (%)                                                                                                                                                                                                                                                                                                                                      | 13 (11.8)                                                                                                                                                                                                                                                                                                                                           | 13 (13.1)                                                                                                                                                                                                                                                                                                                                           | 95% CI -1.3 (- 10.29, 7.67), p 0.835                                                                                                                                                                                                                                                                                                                |
| Incidence rates of grade 2 or greater neutropenia in cycles 2-4, PP Set B,                                                                                                                                                                                                                                                                          | Cycle 3, n                                                                                                                                                                                                                                                                                                                                          | 110                                                                                                                                                                                                                                                                                                                                                 | 99                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                     |
| Incidence rates of grade 2 or greater neutropenia in cycles 2-4, PP Set B,                                                                                                                                                                                                                                                                          | Cycle 3, n (%)                                                                                                                                                                                                                                                                                                                                      | 12 (10.9)                                                                                                                                                                                                                                                                                                                                           | 28 (28.3)                                                                                                                                                                                                                                                                                                                                           | 95% CI -17.4 (- 27.99, -6.76), p 0.002                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                                                    | SP11631                                                                                                                                                                                                                                                                                                                                             | SP11631                                                                                                                                                                                                                                                                                                                                             | SP11631                                                                                                                                                                                                                                                                                                                                             | SP11631                                                                                                                                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                                                                                                     | Cycle 4, n                                                                                                                                                                                                                                                                                                                                          | 110                                                                                                                                                                                                                                                                                                                                                 | 99                                                                                                                                                                                                                                                                                                                                                  | 99                                                                                                                                                                                                                                                                                                                                                  |
|                                                                                                                                                                                                                                                                                                                                                     | Cycle 4, n (%)                                                                                                                                                                                                                                                                                                                                      | 17 (15.5)                                                                                                                                                                                                                                                                                                                                           | 26 (26.3)                                                                                                                                                                                                                                                                                                                                           | 95% CI -10.8 (- 21.80, 0.18), p 0.061                                                                                                                                                                                                                                                                                                               |
| Incidence rate of FN in cycle 1, FAS                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
| Incidence rate of FN in cycle 1, FAS                                                                                                                                                                                                                                                                                                                | Number                                                                                                                                                                                                                                                                                                                                              | 120                                                                                                                                                                                                                                                                                                                                                 | 119                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| Incidence rate of FN in cycle 1, FAS                                                                                                                                                                                                                                                                                                                | n (%)                                                                                                                                                                                                                                                                                                                                               | 1 (0.8)                                                                                                                                                                                                                                                                                                                                             | 2 (1.7)                                                                                                                                                                                                                                                                                                                                             | 95% CI) -0.8 (- 3.67 ， 1.98), p 0.622                                                                                                                                                                                                                                                                                                               |
| Incidence rate of FN                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
| in cycle 1, PP Set A                                                                                                                                                                                                                                                                                                                                | Number                                                                                                                                                                                                                                                                                                                                              | 119                                                                                                                                                                                                                                                                                                                                                 | 110                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| Incidence rate of FN                                                                                                                                                                                                                                                                                                                                | n (%)                                                                                                                                                                                                                                                                                                                                               | 1 (0.8)                                                                                                                                                                                                                                                                                                                                             | 2 (1.8)                                                                                                                                                                                                                                                                                                                                             | 95% CI) -1.0 (- 3.97, 2.01), p 0.609                                                                                                                                                                                                                                                                                                                |
| The ANC nadir from day 3 to day 13 of cycle 1, FAS                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
| The ANC nadir from day 3 to day 13 of cycle 1, FAS                                                                                                                                                                                                                                                                                                  | Number                                                                                                                                                                                                                                                                                                                                              | 120                                                                                                                                                                                                                                                                                                                                                 | 119                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| The ANC nadir from day 3 to day 13 of cycle 1, FAS                                                                                                                                                                                                                                                                                                  | Mean (SD)                                                                                                                                                                                                                                                                                                                                           | 2.059 (1.502)                                                                                                                                                                                                                                                                                                                                       | 1.603 (1.206)                                                                                                                                                                                                                                                                                                                                       | Hodges-Lehmann estimator (95% CI) 0.3 (0.04, 0.65)                                                                                                                                                                                                                                                                                                  |
| The ANC nadir from day 3 to day 13 of cycle 1, PP Set A                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
| The ANC nadir from day 3 to day 13 of cycle 1, PP Set A                                                                                                                                                                                                                                                                                             | Number                                                                                                                                                                                                                                                                                                                                              | 119                                                                                                                                                                                                                                                                                                                                                 | 110                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| The ANC nadir from day 3 to day 13 of cycle 1, PP Set A                                                                                                                                                                                                                                                                                             | Mean (SD)                                                                                                                                                                                                                                                                                                                                           | 2.075 (1.499)                                                                                                                                                                                                                                                                                                                                       | 1.578 (1.158)                                                                                                                                                                                                                                                                                                                                       | Hodges-Lehmann estimator (95% CI) 0.3 (0.05, 0.68)                                                                                                                                                                                                                                                                                                  |
| The time (days) of ANC recovered to 2 × 10 9 /L from nadir in cycle 1, FAS                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                                                                                                     | Number                                                                                                                                                                                                                                                                                                                                              | 120                                                                                                                                                                                                                                                                                                                                                 | 119                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                                                                                                     | Mean (SD)                                                                                                                                                                                                                                                                                                                                           | 0.9 (1.01)                                                                                                                                                                                                                                                                                                                                          | 1.0 (0.84)                                                                                                                                                                                                                                                                                                                                          | Hodges-Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                  |
| The time (days) of ANC recovered to 2 × 10 9 /L from nadir in cycle 1, PP Set A                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                                                                                                     | Number                                                                                                                                                                                                                                                                                                                                              | 119                                                                                                                                                                                                                                                                                                                                                 | 110                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                                                                                                     | Mean (SD)                                                                                                                                                                                                                                                                                                                                           | 0.8 (0.97)                                                                                                                                                                                                                                                                                                                                          | 1.0 (0.82)                                                                                                                                                                                                                                                                                                                                          | Hodges-Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                  |
|                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
| The time of ANC recovered to 2.0 × 10 9 /L from nadir in cycles 2-4, FAS                                                                                                                                                                                                                                                                            | Cycle 2, n                                                                                                                                                                                                                                                                                                                                          | 117                                                                                                                                                                                                                                                                                                                                                 | 107                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
| The time of ANC recovered to 2.0 × 10 9 /L from nadir in cycles 2-4, FAS                                                                                                                                                                                                                                                                            | Cycle 2, Mean (SD)                                                                                                                                                                                                                                                                                                                                  | 0.5 (1.10)                                                                                                                                                                                                                                                                                                                                          | 0.7 (0.99)                                                                                                                                                                                                                                                                                                                                          | Hodges- Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                 |
| The time of ANC recovered to 2.0 × 10 9 /L from nadir in cycles 2-4, FAS                                                                                                                                                                                                                                                                            | Cycle 3, n                                                                                                                                                                                                                                                                                                                                          | 115                                                                                                                                                                                                                                                                                                                                                 | 103                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   | Title: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F- 627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                                                    | SP11631                                                                                                                                                                                                                                                                                                                                             | SP11631                                                                                                                                                                                                                                                                                                                                             | SP11631                                                                                                                                                                                                                                                                                                                                             | SP11631                                                                                                                                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                                                                                                     | Cycle 3, Mean (SD)                                                                                                                                                                                                                                                                                                                                  | 0.4 (0.87)                                                                                                                                                                                                                                                                                                                                          | 0.9 (1.50)                                                                                                                                                                                                                                                                                                                                          | Hodges- Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                                                                                                     | Cycle 4, n                                                                                                                                                                                                                                                                                                                                          | 114                                                                                                                                                                                                                                                                                                                                                 | 101                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                                                                                                     | Cycle 4, Mean (SD)                                                                                                                                                                                                                                                                                                                                  | 0.7 (1.14)                                                                                                                                                                                                                                                                                                                                          | 1.2 (1.73)                                                                                                                                                                                                                                                                                                                                          | Hodges- Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                 |
| The time of ANC recovered to 2.0 × 10 9 /L from nadir in cycles 2-4, PP Set B                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                     | F-627                                                                                                                                                                                                                                                                                                                                               | GRAN®                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                                                                                                     | Cycle 2, n                                                                                                                                                                                                                                                                                                                                          | 110                                                                                                                                                                                                                                                                                                                                                 | 99                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                                                                                                     | Cycle 2, Mean (SD)                                                                                                                                                                                                                                                                                                                                  | 0.5 (1.06)                                                                                                                                                                                                                                                                                                                                          | 0.7 (1.00)                                                                                                                                                                                                                                                                                                                                          | Hodges- Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                                                                                                     | Cycle 3, n                                                                                                                                                                                                                                                                                                                                          | 110                                                                                                                                                                                                                                                                                                                                                 | 99                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                                                                                                     | Cycle 3, Mean (SD)                                                                                                                                                                                                                                                                                                                                  | 0.4 (0.85)                                                                                                                                                                                                                                                                                                                                          | 0.9 (1.52)                                                                                                                                                                                                                                                                                                                                          | Hodges- Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                                                                                                     | Cycle 4, n                                                                                                                                                                                                                                                                                                                                          | 110                                                                                                                                                                                                                                                                                                                                                 | 99                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                                                                                                     | Cycle 4, Mean (SD)                                                                                                                                                                                                                                                                                                                                  | 0.7 (1.06)                                                                                                                                                                                                                                                                                                                                          | 1.1 (1.60)                                                                                                                                                                                                                                                                                                                                          | Hodges- Lehmann estimator (95% CI) 0.0 (0.00, 0.00)                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

## 2.6.5.3. Clinical studies in special populations

<!-- image -->

|                          | Age 65-74 (Number of elderly subjects /total number)                                                                                                                                                                  | Age 75-84 (Number of elderly subjects /total number)                                           | Age 85+ (Number of elderly subjects /total number)   |
|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------|
| Controlled Trials        | N=95 / 1160 (8.2%)                                                                                                                                                                                                    | N=4 / 1160 (0.3%)                                                                              | N=0/ 1160                                            |
| GC-627-04 (Phase III)    | F-627 20 mg （N=7) DSN: 1.9 (1.07) ISN: 6/7 (85.7%) Placebo (N=3): DSN: 4.3 (1.15) ISN: 3/3 (100%)                                                                                                                     | N/A                                                                                            | N/A                                                  |
| GC-627-05 (Phase III)    | F-627 20 mg (N=23) DSN: 0.3 (0.70) ISN: 5/23 (21.7%) Pegfilgrastim (N=34) DSN: 0.4 (0.69) ISN: 8/34 (23.5%)                                                                                                           | F-627 20 mg (N=3) DSN: 0.7 (1.15) ISN: 1/3 (33.3%) Pegfilgrastim (N=1) DSN: 0.0 (N/A) ISN: 0/1 | N/A                                                  |
| SPii631 (Phase II1)      | F-627 20 mg (N=6) DSN: 1.0 (1.26) ISN: 3/6 (50.0%) Filgrastim (N=5) DSN: 0.2 (0.45) ISN: 1/5 (20.0%)                                                                                                                  | N/A                                                                                            | N/A                                                  |
| SP-CDR-1-1302 (Phase 11) | F-627 10 mg (N=0) F-627 20 mg (N=3): DSN: 0.3 (0.58) ISN: 1/3 (33.3%) Filgrastim (N=1) DSN: 0.0 (N/A) ISN: 0/1                                                                                                        | N/A                                                                                            | N/A                                                  |
| GC-627-02 (Phase II)     | TC Chemotherapy: F-627 80 μg/kg (N=2) DSN: 0.0 (0.00) ISN: 0/2 F-627 240 μg/kg (N=2) DSN: 0.5 (0.71) ISN: 1/2 F-627 320 μg/kg (N=4) DSN: 0.3 (0.50) ISN: 1/4 (25%) Pegfilgrastim (N=1) DSN: 1.0 (N/A) ISN: 1/1 (100%) | N/A                                                                                            | N/A                                                  |

## 2.6.5.4. In vitro biomarker test for patient selection for efficacy

## NA

<div style=\"page-break-after: always\"></div>

## 2.6.5.5. Analysis performed across trials (pooled analyses and meta-analysis)

NA

## 2.6.5.6. Supportive studies

Two Phase II dose-ranging studies in breast cancer patients (SP-CDR-1-1302 [N = 138] and GC-627-02 [N = 232]) were conducted by the applicant.

## Study SP-CDR-1-1302

Objectives: The main objective of this study was to compare the efficacy of recombinant human granulocyte colony stimulating factor-Fc fusion protein (F-627) versus recombinant human granulocyte colony stimulating factor (GRAN®) in the first cycle of prophylactic treatment in subjects with breast cancer receiving chemotherapy.

Design and Methods: This was a Phase II, multi-center, randomized, open-label, active-controlled, dosefinding study in females with breast cancer receiving up to 4 cycles of EC chemotherapy conducted in China. Subjects were randomized to SC administration of 10 mg or 20 mg F-627 (lyophilized formulation) on Day 3 of each chemotherapy cycle or daily SC injection of 5 μ g/kg/day filgrastim starting on Day 3 for a maximum of 2 weeks/cycle. This was the only study in the F-627 clinical program where the 10 mg fixed-dose was included.

The primary endpoint of the study was the duration of Grade 3 or 4 neutropenia in Cycle 1 (days with ANC &lt;1.0 × 10 9 /L). Secondary endpoints included the incidence of Grade 3 or 4 neutropenia in each cycle; the duration of Grade 3 or 4 neutropenia in Cycles 2-4; the incidence and duration of Grade 4 neutropenia in each cycle (ANC &lt;0.5 × 10 9 /L); the overall duration of Grade 3 and 4 neutropenia in all 4 cycles; the incidence of FN (defined as ANC &lt;1.0 × 10 9 /L and a single measurement of body temperature &gt;38.3 ° C or a fever ≥ 38.0 ° C lasting for greater than 1 hour); and the duration of Grade 2 or greater neutropenia in each cycle (ANC &lt;1.5 × 10 9 /L).

Non-inferiority margin: The non-inferiority/ equivalence margin for F-627 and GRAN® is 1 day.

Results: A total of 138 subjects were enrolled and treated in the study; 39 received 10 mg F-627, 50 received 20 mg F-627, and 41 received 5 μ g/kg/day filgrastim (Table 53).

<div style=\"page-break-after: always\"></div>

Table 58. Primary and Key Secondary Efficacy Results in Study SP-CDR-1-1302

| Endpoint                                                                                                        | F-627 20 mg                                                        | F-627 10 mg                                                       | Filgrastim 5 μg/kg/day   |
|-----------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------|-------------------------------------------------------------------|--------------------------|
| AnalysisSet=PerProtocol Set                                                                                     |                                                                    |                                                                   |                          |
| PrimaryEfficacyResults                                                                                          |                                                                    |                                                                   |                          |
| Duration of Grade3or 4 neutropenia in Cycle 1;mean (SD) days,N Difference (95.02% CI) Difference (95% CI)2      | 0.6 (1.24) N=47 0.00 days (0.000, 0.000) 0.00 days (0.000, 0.000)  | 0.8 (1.23) N=37 0.00 days (0.000, 0.000) 0.00 days (0.000, 0.000) | 0.8 (1.23) N=39          |
| SecondaryEfficacyResults                                                                                        |                                                                    |                                                                   |                          |
| Incidence of Grade3or 4 neutropenia in Cycle 1; n/N (%) Difference (95% CI)3                                    | 12/47 (25.5) -13% (-32.64, 6.78) 0.246                             | 13/37 (35.1) -3.3 (-25.00, 18.35) 0.815                           | 15/39 (38.5)             |
| Cycle 1; mean (SD) days, N Difference (95% CI)²                                                                 | 0.2 (0.56) N=47 0.0 days (0.0, 0.0)                                | 0.2 (0.71) N=37                                                   |                          |
| Durationof Grade4neutropeniain                                                                                  |                                                                    | 0.0 days (0.0, 0.0)                                               | 0.4 (0.84) N=39          |
| Incidence of Grade 4 neutropenia in Cycle 1; n/N (%)                                                            | 5/47 (10.6)                                                        | 4/36 (10.8)                                                       | 7/39 (17.9)              |
| Difference (95% CI)3 p-value?                                                                                   | -7.3% (-22.24, 7.61) 0.365                                         | -7.1% (-22.80, 8.52) 0.518                                        |                          |
| Incidence rate ofFN in Cycle 1; n (%)                                                                           | 0                                                                  | 0                                                                 |                          |
| Analysis Set =Intent-To-Treat Set (Sensitivity Analysis)                                                        | Analysis Set =Intent-To-Treat Set (Sensitivity Analysis)           |                                                                   |                          |
| PrimaryEfficacyResults                                                                                          |                                                                    |                                                                   |                          |
| Duration of Grade 3 or 4 neutropenia in Cycle 1; mean (SD) days, N Difference (95.02% CI)1 Difference (95% CI)2 | 0.7 (1.27) N= 50 0.00 days (0.000, 0.000) 0.00 days (0.000, 0.000) | 1.0 (1.91) N=39 0.00 days (0.000, 0.000) 0.00 days (0.000, 0.000) | 0.8 (1.20) N=41          |

Abbreviations: CI= confidence interval, FN =febrile neutropenia; SD = standard deviation

Therewasnoimputation of dataforprimaryendpoint analysisbasedon thePerProtocol Set;however,inthe Intent-to-Treat Set-based primary endpoint analysis, missing data was imputed by last observation carried forward.

Hodges-Lehmannestimators of thedifferencesinthe durationof Grade 3or 4 neutropenia in Cycle1forF-627 (10 mg/dose and 20 mg/dose)vs. filgrastim are presented with 95.02% CIs for non-inferiority test. Noninferiority was established if the upper limit was ≤1.

Estimated differences in incidence rate of Grade 3 or 4 neutropenia for F-627 (10 mg/dose and 20 mg/dose) vs. filgrastim with 95% CIs, and p-values for Fisher's test presented.

Hodges-Lehmannestimators of the differencesinthe duration of Grade 3or 4 neutropenia in Cycle1for F-627 (10 mg/dose and 20 mg/dose)vs. filgrastim are presented with 95% CIs for superiority test. Superiority was established if the upper limit was &lt;0.

## Study GC-627-02

Objectives: The purpose of this study was to assess the effectiveness of the once per chemotherapy cycle subcutaneous (SC) administration of 3 different doses of F-627 in aiding absolute neutrophil count (ANC) recovery post treatment as compared to Neulasta (Neulastim, pegfilgrastim).

Design and Methods: This was a Phase II, multi-center, randomized, open-label, active-controlled, dosefinding study in females with Stage I-IV invasive breast cancer, conducted in Russia, Ukraine, and the US. Subjects were randomized to receive SC administration of 80, 240, or 320 μ g/kg F-627 or 6 mg/kg SC pegfilgrastim on Day 2 of each 21-day chemotherapy cycle with TC chemotherapy for up to 4 cycles, or 240 or 320 μ g/kg F-627 or 6 mg/kg SC pegfilgrastim on Day 2 of each 21-day chemotherapy cycle with TAC[600] chemotherapy for up to 4 cycles.

The primary efficacy endpoint was the duration of Grade 3 and Grade 4 neutropenia during Cycle 1 (days with ANC &lt;1.0 × 10 9 /L). Secondary efficacy endpoints included the duration of Grade 3 and Grade 4

<div style=\"page-break-after: always\"></div>

neutropenia for all other chemotherapy cycles (Cycles 2 to 4); the duration of Grade 4 neutropenia in each chemotherapy cycle (days with ANC &lt;0.5 × 10 9 /L); the incidence of FN for each chemotherapy cycle (defined as ANC &lt;0.5 × 10 9 /L with oral temperature &gt;38.2°C); the duration of Grade 2, Grade 3, and Grade 4 neutropenia for each chemotherapy cycle (days with ANC &lt;1.5 × 10 9 /L); and the incidence rates for each of Grade 2, Grade 3, and Grade 4 neutropenia for all chemotherapy cycles. For the primary efficacy analysis, non-inferiority tests with a non-inferiority margin of 2 days were used to compare the duration of Grade 3 (moderate) neutropenia (this included by default Grade 4 or severe neutropenia) between 3 doses of F-627 vs. pegfilgrastim in Cycle 1 within 12 days of chemotherapy treatment.

Results: A total of 232 subjects were randomized (230 subjects were planned) in the study; 141 received TC chemotherapy and 91 received TAC chemotherapy. For those who received TC chemotherapy, 35 subjects were administered 80 μ g/kg F-627, 37 subjects were administered 240 μ g/kg F-627, 34 subjects were administered 320 μ g/kg F-627, and 35 subjects were 6 mg pegfilgrastim. For those who received TAC chemotherapy, 30 subjects were administered 240 μ g/kg F-627, 31 subjects were administered 320 μ g/kg F627, and 30 subjects were 6 mg pegfilgrastim. All doses of F-627 demonstrated non-inferiority to pegfilgrastim with respect to the duration of Grade 3-4 neutropenia (ANC ≤ 1.0 × 10 9 /L) in Cycle 1. Superiority of F-627 relative to pegfilgrastim was not observed. Duration of Grade 4 and Grades 2-4 neutropenia were similar to pegfilgrastim for all F-627 doses.

<div style=\"page-break-after: always\"></div>

Table 54. Primary and Key Secondary Efficacy Results in Study GC-627-02 (Per Protocol Population)

| TC Chemotherapy                                                                          | F-627 80 μg/kg                       | F-627 240 μg/kg                      | F-627 320 μg/kg                      | Pegfilgrastim 6 mg/dose   |
|------------------------------------------------------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|---------------------------|
| PrimaryEfficacyResults                                                                   |                                      |                                      |                                      |                           |
| Duration of Grade 3 or 4 neutropenia in Cycle 1; mean (SD) days, N Differencel (95% CI)1 | 0.6 (1.26) N=35 0.4 days (-0.1, 0.8) | 0.6 (1.01) N=37 0.3 days (-0.1, 0.7) | 0.4 (0.75) N=31 0.1 days (-0.4, 0.6) | 0.3 (0.56) N=35           |
| SecondaryEfficacyResults                                                                 |                                      |                                      |                                      |                           |
| Incidence of Grade3or 4neutropenia in Cycle 1; n/N (%)                                   | 10/35 (28.6)                         | 10/37 (27.0)                         | 6/31 (19.4)                          | 7/35 (20.0)               |
| Difference' p-value?                                                                     | 8.6% 0.5781                          | 7.0% 0.5830                          | -0.6% 1.0000                         |                           |
| Duration of Grade 4 neutropenia in Cycle 1; mean (SD) days, N Difference' (95% CI1       | 0.2 (0.73) N=35 0.1 days (-0.2,0.4)  | 0.4 (0.86) N=37 0.3 days (0.0, 0.6)  | 0.2 (0.48) N=31 0.1 days (-0.2,0.4)  | 0.1 (0.28) N=35           |
| Incidence of Grade 4 neutropenia in Cycle 1; n/N (%)                                     | 4/35 (11.4)                          | 7/37 (18.9)                          | 5/31 (16.1)                          | 3/35 (8.6)                |
| Differencel p-value2                                                                     | 2.9% 1.0000                          | 10.3% 0.3092                         | 7.6% 0.4591                          |                           |
| Incidence rate of FN in Cycle 1; n/N (%)                                                 | 0                                    | 0                                    | 1/31 (3.2)                           | 0                         |
| PrimaryEfficacy Results                                                                  |                                      |                                      |                                      |                           |
| Duration of Grade 3 or 4 neutropenia in Cycle 1; mean (SD) days, N Differencel           | 2.1 (1.58) N=30 0.3 days             | 2.1 (1.46) N= 29 0.3 days            |                                      | 1.8 (1.28) N= 30          |
| (95% CI)1 SecondaryEfficacyResults Incidence of Grade 3or 4neutropenia in                | (-0.4, 1.1) 23/30 (76.7)             | 22/29 (75.9)                         | (-0.4, 1.1)                          | 23/30 (76.7)              |
| Cycle 1; n/N (%) Differencel p-value?                                                    | 0.0% 1.0000                          |                                      | -0.8% 1.0000                         |                           |
| Duration of Grade 4 neutropenia in Cycle 1; mean (SD) days, N                            | 1.5 (1.55) N=30                      |                                      | 1.4 (1.15) N= 29                     | 1.1 (1.01) N= 30          |
| Differencel                                                                              | 0.4 days                             |                                      | 0.4 days (-0.3, 1.0)                 |                           |
|                                                                                          | (-0.2, 1.0)                          |                                      |                                      |                           |
| (95% CI)1                                                                                |                                      |                                      |                                      |                           |
| 1; n/N (%)                                                                               | 20/30 (66.7)                         |                                      |                                      |                           |
| Incidence of Grade 4 neutropenia in Cycle                                                | 3.3%                                 | 21/29 (72.4)                         | 9.1%                                 | 19/30 (63.3)              |
| Difference' p-value?                                                                     | 1.0000                               |                                      | 0.5796                               |                           |
|                                                                                          | 0                                    |                                      |                                      |                           |
|                                                                                          |                                      |                                      | 1/29 (3.4)                           | 2/30 (6.7)                |
| Incidence rate ofFN in Cycle 1; n/N (%)                                                  |                                      |                                      |                                      |                           |

Abbreviations: CI = confidence interval, FN = febrile neutropenia; SD = standard deviation; TAC = TAC[60o]; docetaxel 75 mg/m² + doxorubicin 50 mg/m² + cyclophosphamide 600 mg/m² chemotherapy; TC = docetaxel 75 mg/m² + cyclophosphamide 600 mg/m² chemotherapy.

The p-valuie is for comparison of F-627vs. pegfilgrastim usingFisher's Exact Test.

1Differences between F-627 dose compared to pegflgrastim. For the primary endpoint, non-inferiority of F-627 to pegfilgrastim was achieved if the upper limit of the 2-sided 95% CI of the difference was &lt;2 days. Superiority ofF-627 topegfilgrastim was achieved ifthe upperlimit of the 2-sided 95%CI of the difference was &lt;0 days.

<div style=\"page-break-after: always\"></div>

## 2.6.6. Discussion on clinical efficacy

The claimed therapeutic indication for the product is reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes.

Main efficacy data relevant to the claimed indication are from 3 Phase III studies in breast cancer female patients (GC-627-04 (N = 122), GC-627-05 (N = 393), and SP11631 (N = 242)). Supportive data are provided form 2 Phase II dose-ranging studies in breast cancer patients (SP-CDR-1-1302 (N = 138) and GC627-02 (N = 232)), and 3 Phase I studies in breast cancer patients (SP-CDR-1-1301 (N = 15), 2012-F-627CH1 (N = 18), and SP11502 (N = 7)).

## Design and conduct of clinical studies

The 3 Phase III studies randomized 402 subjects to 20 mg F-627 and 355 subjects to a comparator arm (either Placebo, 6 mg pegfilgrastim, or 5 μ g/kg/day filgrastim).

The Phase III study population included non-frail female breast cancer patients who require chemotherapy.

Patients received F-627 (PFS) 20 mg dose or pegfilgrastim 6 mg or filgrastim (GRAN) 5 μ g/kg/day, s.c. The main objective of the Phase III studies was to evaluate the efficacy of F-627 given as a single 20 mg fixed dose pre-filled syringe (PFS).

The primary efficacy endpoint was either the duration of Grade 4 (severe) neutropenia (ANC &lt;0.5 × 10 9 /L) observed in chemotherapy cycle 1 with the non-inferiority (NI) margin for the primary endpoint of 0 days and a two-sided hypothesis test with an α of 0.05 for the comparison, superiority was to be claimed if the lower bound of the 95% CI was &gt;0. vs. placebo (Study GC-627-04), while the NI vs. Neulasta was 0.6 days and the two-sided 95% CI was assessed to determine superiority (study GC-627-05): superiority was claimed if the upper and lower bound of the 95% CI was &lt;0. The number of days of ANC &lt; 1.0 × 10 9 /L (Grade 3 or 4) in cycle 1 was chosen as the primary endpoint in study SP11631 when comparing Ryzneuta versus GRAN with the non-inferiority margin specified as 1 day with test that was one-sided with a significance level of α = 0.025. The non-inferiority margins were different across studies, but this is unlikely to have significant clinical implications. This is acceptable.

The incidence of infection and febrile neutropenia should be regarded as the key secondary efficacy variables.

The incidence rates of infections for each chemotherapy cycle and over all cycles were analysed in Study GC627-04, while in study GC-627-05 the febrile neutropenia or any infection incidence was assessed as a secondary endpoint, and only the incidence rate of febrile neutropenia was assessed in the SP11631 study and not the incidence of infection.

The chosen endpoints reflect clinical practice and are endorsed. Data Sets Analysed in the Phase III studies were described appropriately and are acceptable. The participant flow and recruitment procedures were described appropriately and are acceptable. There were no major protocol amendments that could impact the overall study results.

There was a triggered GCP inspections for Studies GC-627-04 and GC-627-05 to verify the validity of the data, ethical conduct of the studies as well as compliance with good clinical practice (GCP) and applicable regulations. Despite inspection findings for both studies the recommendation from the inspection report was that the efficacy data presented in both studies could be used in the evaluation of efficacy of Ryzneuta.

<div style=\"page-break-after: always\"></div>

The Phase III clinical development program rests heavily on the female population, but this is acceptable in the  context  of  a  bridging  development  programme  aiming  at  establishing  non-inferiority  to  established treatments.    Other  demographic  characteristics  do  not  indicate  major  imbalances  in  characteristics  across treatment arms.

## Efficacy data and additional analyses

## Pivotal studies

Results from GC-627-04 showed that F-627 is superior to placebo in decreasing the mean duration of Grade 4 neutropenia in Cycle 1. The mean duration of Grade 4 neutropenia (calculated without MI of missing ANC data) was 1.3 days for F-627 and 3.9 days for placebo, and the mean difference, calculated with MI, was 2.9 days (95% CI: 2.3, 3.4; p &lt;0.0001). Sensitivity analyses using alternate methods of imputing missing ANC data, including worst case scenario imputation, and results for the Per Protocol [PP] Population demonstrated the robustness of the primary analysis, with mean differences ranging between 2.6 and 2.9 days (GC-627-04 CSR) use of F-627 significantly reduced the incidence of FN in Cycle 1 compared to placebo (4.8% vs. 25.6%, respectively; p = 0.0016). The differences in the incidence of infection, antibiotic uses were numerically favouring the investigational arm although not statistically significant.

Efficacy results from GC-627-05 demonstrated that F-627 is non-inferior to pegfilgrastim in decreasing the duration of Grade 4 neutropenia in chemotherapy Cycle 1. The mean duration of Grade 4 neutropenia, without MI of missing ANC data, was 0.2 days for both treatment groups. The mean difference, calculated using MI, was 0.0 days (95% CI: -0.1, 0.1; p = 0.7074). Based on the non-inferiority margin of 0.6 days, F627 was concluded to be non-inferior to pegfilgrastim. The efficacy of F-627 was comparable to that for pegfilgrastim, with no statistically significant differences noted between treatments for endpoints related to FN, IV antibiotic use, and hospitalization for FN or infection between the F-627 and pegfilgrastim groups.

Results from study SP11631 demonstrated that F-627 was non-inferior to filgrastim in decreasing the duration of Grade 3 neutropenia in chemotherapy Cycle 1. The mean duration of Grade 3 neutropenia was 0.68 days for F-627 and 0.71 days for filgrastim. The Hodges-Lehmann estimate of the difference in duration was 0 days (95% CI: 0.00, 0.00).  Based on the non-inferiority margin of 1 day, F-627 was concluded to be non-inferior to filgrastim. Incidence of FN and the incidences of Grade 3 and Grade 4 neutropenia were consistent with the duration of neutropenia endpoints in showing no significant differences between the F-627 and filgrastim groups.

These results are not entirely consistent to pivotal studies 004 and 005. However, clinically relevant endpoints such as incidence rates of infections, use of antibiotics and incidence of hospitalization were not recorded in this study. For this reason, the study has only limited and value to support the efficacy of the test product as the results regarding febrile neutropenia and duration of grade 3 or 4 neutropenia should be always interpreted in context of parameters such as incidence rates of infections, use of antibiotics and incidence of hospitalization, which is not possible in this study.

In Study GC-627-04, 18.1% of F-627 subjects and 28.2% of placebo subjects had missing data points Regardless of whether or not multiple imputation was applied, F-627 was superior to Placebo in decreasing the duration of severe neutropenia. In Study GC-627-05, 6.1% of F-627 subjects and 11.7% of pegfilgrastim subjects, respectively, had missing data points. This appeared to have minimal impact on the results as the LS-mean of duration of severe neutropenia was 0.2 days for both treatment groups regardless of the multiple imputation rules applied. In Study SP11631, the proportion of subjects with missing data imputed with

<div style=\"page-break-after: always\"></div>

multiple imputation was very low; 0.8% of F-627 subjects and 2.5% of filgrastim subjects. This had minimal impact on the results as the LS-mean duration of severe neutropenia was similar for both treatment groups. Overall handling of missing data does not seem to impact on the overall conclusions regarding the efficacy of the product.

The Phase III clinical development program rests heavily on the female population. This is acceptable considering bridging nature of the clinical development. Study 005 seems recruiting somewhat less severe patients as compared to study 004 (due to higher proportion of patients with baseline ECOG 0 [77 vs 55%] and shorter duration from diagnosis [mean 68 days vs 224 days]. Chemotherapy cycles were different among all three pivotal studies and thus potential for ANC nadir cannot be compared directly. The compliance level of applying EC chemotherapy in Studies 004 and 005 seems sufficient and thus, acceptable. Other demographic and disease characteristics do not indicate major asymmetry in characteristics across treatment arms. In general, the demographic characteristics are balanced between treatment arms. Nevertheless, it should be noted that studies GC-627-04 and GC-627-05 were conducted mostly on white population, while the study SP11631 was conducted only on Asian population.

## Supportive studies

In the 2 Phase II dose-ranging studies in breast cancer patients (SP-CDR-1-1302 (N = 138) and GC-627-02 (N = 232)) the duration of severe Grade 3 or 4 neutropenia between F-627 20 mg, 10 mg, and Filgrastim 5 microg/kg groups was similar. This was reinforced with secondary endpoints. Similar results were observed with pegfilgrastim where all doses of F-627 (80 microg/kg, 240 microg/kg, 360 microg/kg) demonstrated non-inferiority to pegfilgrastim with respect to the duration of Grade 3-4 neutropenia. The non-inferiority/ equivalence margin for F-627 and GRAN was 1 day in study SP-CDR-1-1302 and 2 days in Study GC-627-02. This variation in the non-inferiority margin is difficult to justify, however, given the supportive nature of these studies and the overall reported results, it does not seem to be of particular significance.

## 2.6.7. Conclusions on the clinical efficacy

Clinical efficacy of Ryzneuta is established for the applied indication as results demonstrate that it is superior to placebo and non-inferior to pegfilgrastim and filgrastim for the treatment of neutropenia.

## 2.6.8. Clinical safety

## 2.6.8.1. Patient exposure

The primary clinical safety information on F-627 is derived from the 3 Phase III studies in patients with breast cancer, i.e., the placebo-controlled study GC-627-04 and two active-controlled studies GC-627-05 and SP11631. Due to the differences in study design, data from the 3 studies were analysed and presented separately.

Supportive safety information is available from the 7 clinical pharmacology studies, of which 2 were performed in healthy subjects. Pooled analyses were performed from Cancer population (from 7 of the 8 studies with breast cancer patients; to be noted, that phase I study SP11502 with 7 cancer subjects was excluded from integrated analysis due to different F-627 dosing regimen (dosed on same day as chemotherapy)) and Healthy population from 2 studies. In addition, safety information on the reference

<div style=\"page-break-after: always\"></div>

medicinal products pegfilgrastim and filgrastim, available in the SmPC, public databases, and published literature, contributes to the evaluation of the safety of F-627.

Exposure data and demographics by treatment groups in the pivotal safety populations from the phase III studies are summarised in Table 60 and Table 61 respectively.

Table 55. Extent of exposure by treatment group in the Phase III studies

|                                       | GC-627-04                             | GC-627-04                             | GC-627-05                             | GC-627-05                             | SP11631                               | SP11631                               |
|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
|                                       | F-627 N = 83                          | Placebo N = 39                        | F-627 N = 197                         | Pegfilgrasti m N = 196                | F-627 N = 120                         | Filgrastim N = 119                    |
| Number of treatments                  | Number of treatments                  | Number of treatments                  | Number of treatments                  | Number of treatments                  | Number of treatments                  | Number of treatments                  |
| Mean (SD)                             | 4.0 (0.22)                            | 3.9(0.57)                             | 3.9 (0.43)                            | 3.9 (0.34)                            | 3.9 (0.54)                            | 27.6 (8.44)                           |
| Median (min, max)                     | 4.0 (2, 4)                            | 4.0 (1, 4)                            | 4.0 (1, 4)                            | 4.0 (2, 4)                            | 4.0 (1, 4)                            | 31.0 (1, 38)                          |
| Treatment duration (weeks) 1          | Treatment duration (weeks) 1          | Treatment duration (weeks) 1          | Treatment duration (weeks) 1          | Treatment duration (weeks) 1          | Treatment duration (weeks) 1          | Treatment duration (weeks) 1          |
| Mean (SD) Median (min, max)           | 9.33 (0.855) 9.14 (3.1, 12.0)         | 9.13 (1.929) 9.14 (0.1,12.3)          | 9.14 (1.435) 9.14 (0.1, 12.7)         | 9.13 (1.134) 9.14 (3.1, 12.4)         |                                       |                                       |
| Total dose received, all treatments 2 | Total dose received, all treatments 2 | Total dose received, all treatments 2 | Total dose received, all treatments 2 | Total dose received, all treatments 2 | Total dose received, all treatments 2 | Total dose received, all treatments 2 |
| Mean (SD)                             | 79.5 (4.39)                           | 57.4(11.41) 60.0                      | 78.1 (8.66) 80.0 80)                  | 23.6 (2.06) 24.0                      | 77.67 (10.748) 80.00                  | 8151.29 (2785.183) 8825.0             |
| Median (min, max)                     | 80.0 (40, 80)                         | (0, 60)                               | (20,                                  | (12, 24)                              | (20.0, 80.0)                          | (280.0, 13960.0)                      |

1  Treatment duration (weeks) = (Date of last study drug dose - date of first study drug dose + 1)/7.

2  Total dose summed over all cycles in mg for studies GC-627-04 and GC-627-05, in µg for study SP11631. For study GC627- 04, this was the total dose of F-627 taken over all cycles in the randomized group; subjects randomized to placebo were intended to receive 3 cycles of treatment with 20 mg F-627. Cells shaded in grey did not have data reported in the study CSR.

Table 56. Demographics in the Phase III Studies

|                                                          | GC-627-04 1               | GC-627-04 1               | GC-627-05                 | GC-627-05                  | SP11631                                                 | SP11631                                                            |
|----------------------------------------------------------|---------------------------|---------------------------|---------------------------|----------------------------|---------------------------------------------------------|--------------------------------------------------------------------|
|                                                          | F-627 N = 83              | Placebo N = 39            | F-627 N = 197             | Pegfilgrastim N = 196      | F-627 N = 120                                           | Filgrastim N = 119                                                 |
| Age (years) Mean (SD) Median (min, max)                  | 50.8 (9.25) 51.0 (33, 67) | 51.5 (9.00) 51.0 (33, 67) | 51.4(11.82) 53.0 (28, 83) | 53.4 (11.11) 55.0 (26, 80) | 49.1 (9.32) 49.0 (28, 71)                               | 48.5 (9.14) 48.0 (28, 67)                                          |
| Sex, n (%) Female                                        | 83 (100.0)                | 39 (100.0)                | 197 (100.0)               | 196 (100.0)                | 120 (100)                                               | 119 (100)                                                          |
| Race, n (%) White Black or African- American Asian Other | 82 (98.8) 1 (1.2) 0 0     | 39 (100.0) 0 N            | 197 (100.0)               | 196 (100.0)                | Not collected Not collected Not collected Not collected | 115 (96.6) Not collected Not collected Not collected Not collected |
| Ethnicity, n (%) Hispanic or Latino Not Hispanic         | 1 (1.2) 82 (98.8)         | 1 (1.2) 82 (98. 8)        | 0 197 (100.0)             | 10.5) 1 (0.5) . 195 (99.5) | 116 (96.7) 4 (3.3) Not collected                        | 115 (96.6) 4 (3.4)                                                 |
|                                                          | 1 (1.2)                   | 1 (2.6)                   | 0                         | 1 (0.5)                    | Not collected Not collected Not collected               | Not collected Not collected Not collected Not collected            |
| or Latino                                                | 82 (98.8)                 | 38 (97.4)                 | 197 (100.0)               | 195 (99.5)                 | Not collected                                           | Not collected                                                      |

<div style=\"page-break-after: always\"></div>

| Weight (kg) Mean (SD) Median (min, max)   | 70.4 (13.74) 68.0 (45, 112)   | 73.5 (15.60) 70.0 (46, 108)   | 75.84(16.88) 73.00 (45.3, 137.0)   | 74.93 (16.87) 72.00 (46.0, 146.1)   | 58.96 (8.95) 59.00 (40.0, 85.0)     | 59.24 (8.49) 59.00 (42.0, 88.0)     |
|-------------------------------------------|-------------------------------|-------------------------------|------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| Height (cm) Mean (SD) Median (min, max)   | 164.2 (6.55) 164.0 (150, 186) | 163.9 (6.55) 163.0 (152, 178) | 162.6 (6.27) 163.0 (144, 179)      | 162.2 (6.67) 162.0 (145, 191)       | 157.97 (5.06) 158.00 (143.0, 170.0) | 157.87 (5.52) 158.00 (143.0, 170.0) |
| BMI(kg/m 2 ) Mean (SD) Median (min, max)  | 26.2 (5.36) 26.1 (16, 44)     | 27.4 (6.22) 26.4 (17, 44)     | 28.72 (6.36) 27.64 (18.3, 49.1)    | 28.51 (6.20) 27.71 (17.3, 56.4)     | 23.609 (3.28) 23.40 (14.88, 31.22)  | 23.782 (3.34) 23.63 (16.61, 33.53)  |

Placebo patients were all from Study GC-627-04 and were treated with placebo in Cycle 1, followed by F-627 in Cycles 2-4.

Of all 689 cancer patients treated with F-627, 450 subjects received a 20 mg dose. All 54 subjects in the Healthy Population received F-627, from which 24 received a 20 mg dose. Study SP11631 comprised 7 subjects who received a unique F-627 dosing strategy (dosing the same day as chemotherapy), with a mean total actual F-627 dose of 77.7 mg.

The most commonly reported medical history categories, such as prior cancer systemic therapy and prior radiation therapy, as well as prior and concomitant medication use, were in general similar across treatment groups in each phase III study (See clinical efficacy section).

Most of cancer subjects overall had a baseline ECOG status of 0 (59.8%), cancer stage of II (52.0%) and median time since cancer diagnosis was 34.0 days. Only 3.0% of the overall Cancer Population had metastatic (Stage IV) disease. Although these characteristics were generally similar across treatment groups, most filgrastim subjects had a baseline ECOG of 1, and a higher proportion of placebo subjects had Stage IV disease. Pivotal Study 005 seems to have recruited less severe patients as compared to study 004 (due to higher proportion of patients with baseline ECOG 0 [77 vs 55%] and shorter duration from diagnosis [mean 68 days vs 224 days]). Chemotherapy cycles were different among all three pivotal studies and thus potential for ANC nadir cannot be compared directly.

## 2.6.8.2. Adverse events

The most commonly reported TEAEs in the Phase III trials included events associated with chemotherapy, including alopecia, neutropenia, nausea, asthenia, and anaemia.

Table 57 . Overview of TEAEs in the Phase III Trials over All Cycles

| Group            | GC-627-04    | GC-627-04      | GC-627-05     | GC-627-05             | SP11631       | SP11631            |
|------------------|--------------|----------------|---------------|-----------------------|---------------|--------------------|
|                  | F-627 N = 83 | Placebo N = 39 | F-627 N = 197 | Pegfilgrastim N = 196 | F-627 N = 120 | Filgrastim N = 119 |
| At Least 1 TEAE  | 82 (98.8)    | 39 (100.0)     | 178 (90.4)    | 169 (86.2)            | 119 (99.2)    | 119 (100)          |
| [                | [881]        | [396]          | [1628]        | [1394]                | [2040]        | [2157]             |
| Related TEAEs 26 | (31.3)       | 9 (23.1)       | 88 (44.7)     | 67 (34.2)             | 57 (47.5)     | 66 (55.5)          |
|                  | [118]        | [45]           | [303]         | [251]                 | [108]         | [138]              |
| Death            | 0            | 0              | 1             | 2                     | 0             | 0                  |

<div style=\"page-break-after: always\"></div>

| At least 1 SAE                  |   4 (4.8) [4] | 11 (28.2) [13]   | 12 (6.1) [12]   | 3 (1.5) [5]   |   6 (5.0) [9] | 8 (6.7) [9]   |
|---------------------------------|---------------|------------------|-----------------|---------------|---------------|---------------|
| TEAE leading to discontinuation |             0 | 1 (2.6)          | 6 (3.0)         | 5 (2.6)       |             0 | 2 (1.7) [3]   |

Data presented as n (%) [events].

Table 58. Overview of Treatment-emergent Adverse Events over All Cycles (Cancer Population)

| Group                                  | F-627             | F-627             | Pegfilgrastim N = 261   | Filgrastim N = 160   | Placebo 1 N = 39   | Total N = 1149      |
|----------------------------------------|-------------------|-------------------|-------------------------|----------------------|--------------------|---------------------|
| Group                                  | 20 mg N = 488     | All doses N = 727 | Pegfilgrastim N = 261   | Filgrastim N = 160   | Placebo 1 N = 39   | Total N = 1149      |
| At Least 1 TEAE                        | 461 (94.5) [5772] | 689 (94.8) [9159] | 228 (87.4) [1805]       | 159 (99.4) [3191]    | 36 (92.3) [167]    | 1081 (94.1) [14322] |
| Related TEAEs                          | 175 (35.9) [527]  | 254 (34.9) [815]  | 82 (31.4) [287]         | 79 (49.4) [181]      | 4 (10.3) [15]      | 417 (36.3) [1298]   |
| Subjects with TEAEs ≥Grade 3 1         | 209 (42.8) [605]  | 307 (42.2) [1016] | 64 (24.5) [185]         | 100 (62.5) [290]     | 31 (79.5) [51]     | 484 (42.1) [1542]   |
| Subjects with related TEAEs ≥Grade 3 1 | 9 (1.8) [9]       | 29 (4.0) [64]     | 9 (3.4) [25]            | 0                    | 1 (2.6) [1]        | 39 (3.4) [90]       |
| Deaths                                 | 1 (0.2)           | 1 (0.1)           | 2 (0.8)                 | 0                    | 0                  | 1 (0.1)             |
| At least 1 SAE                         | 25 (5.1) [29]     | 34 (4.7) [39]     | 7 (2.7) [12]            | 12 (7.5) [16]        | 10 (25.6)[11]      | 63 (5.5) [78]       |
| Related SAEs                           | 2 (0.4) [2]       | 3 (0.4) [3]       | 1 (0.4) [1]             | 1 (0.6) [1]          | 0                  | 5 (0.4) [5]         |
| TEAE leading to discontinuation        | 7 (1.4)           | 11 (1.5)          | 8 (3.1)                 | 3 (1.9)              | 0                  | 22 (1.9)            |

Data presented as n (%) [events].  1  Grading based on NCI-CTCAE criteria (v4.03). NCI-CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events

## Common adverse events

Table 59. Most Common Treatmentemergent Adverse Events in ≥5% of Subjects in Any Treatment Group in the Phase III Studies by System Organ Class and Preferred Term

|                                        | GC-627-04 (Cycle 1 only)   | GC-627-04 (Cycle 1 only)   | GC-627-05 (All Cycles)   | GC-627-05 (All Cycles)   | SP11631 (All Cycles)   | SP11631 (All Cycles)   |
|----------------------------------------|----------------------------|----------------------------|--------------------------|--------------------------|------------------------|------------------------|
| System Organ Class Preferred Term      | F-627 N = 83               | Placebo N = 39             | F-627 N = 197            | Pegfilgrastim N = 196    | F-627 N =120           | Filgrastim N = 119     |
| At least 1 TEAE                        | 74 (89.2)                  | 36 (92.3)                  | 178 (90.4)               | 169 (86.2)               | 119 (99.2)             | 119 (100)              |
| Skin and subcutaneous tissue disorders | 33 (39.8)                  | 16 (41.0)                  | 125 (63.5)               | 112 (57.1)               | 93 (77.5)              | 83 (69.7)              |
| Alopecia                               | 33 (39.8)                  | 14 (35.9)                  | 103 (52.3)               | 100 (51.0)               | 93 (77.5)              | 83 (69.7)              |
| Erythema                               | 5 (6.0)                    | 2 (5.1)                    | 17 (8.6)                 | 17 (8.7)                 |                        |                        |
| Gastrointestinal disorders             | 46 (55.4)                  | 26 (66.7)                  | 97 (49.2)                | 82 (41.8)                | 110 (91.7)             | 115 (96.6)             |
| Nausea                                 | 42 (50.6)                  | 15 (38.5)                  | 71 (36.0)                | 58 (29.6)                | 104 (86.7)             | 102 (85.7)             |
| Vomiting                               | 10 (12.0)                  | 8 (20.5)                   | 12 (6.1)                 | 7 (3.6)                  | 76 (63.3)              | 89 (74.8)              |

<div style=\"page-break-after: always\"></div>

| Diarrhoea                                            | 17 (20.5)           | 10 (25.6)          | 32 (16.2)           | 27 (13.8)           | 10 (8.3)            | 9 (7.6)             |
|------------------------------------------------------|---------------------|--------------------|---------------------|---------------------|---------------------|---------------------|
| Constipation                                         | 2 (2.4)             | 1 (2.6)            | 2 (1.0)             | 2 (1.0)             | 17 (14.2)           | 17 (14.3)           |
| Stomatitis                                           | 7 (8.4)             | 5 (12.8)           | 13 (6.6)            | 12 (6.1)            | 4 (3.3)             | 6 (5.0)             |
| Abdominal pain upper                                 | 1 (1.2)             | 0                  | 7 (3.6)             | 4 (2.0)             | 7 (5.8)             | 12 (10.1)           |
| Dry mouth                                            |                     |                    | 3 (1.5)             | 2 (1.0)             | 7 (5.8)             | 8 (6.7)             |
| Abdominal distension                                 |                     |                    | 1 (0.5)             | 0                   | 14                  |                     |
|                                                      |                     |                    |                     |                     | (11.7)              | 8 (6.7)             |
| Gastritis                                            | 0                   | 2 (5.1)            | 2 (1.0)             | 1 (0.5)             |                     |                     |
| Blood and lymphatic system disorders                 | 60 (72.3)           | 31 (79.5)          | 79 (40.1)           | 84 (42.9)           | 81 (67.5) 81 (67.5) | 79 (66.4) 79 (66.4) |
| Anaemia Neutropenia                                  | 12 (14.5) 54 (65.1) | 4 (10.3) 25 (64.1) | 47 (23.9) 40 (20.3) | 38 (19.4) 50 (25.5) |                     |                     |
| Leukopenia                                           | 38 (45.8)           | 15 (38.5)          | 39 (19.8)           | 44 (22.4)           |                     |                     |
|                                                      | 10 (12.0)           | 1 (2.6)            | 20 (10.2)           | 20                  |                     |                     |
| Thrombocytopenia                                     |                     | 10 (25.6)          |                     | (10.2)              |                     |                     |
| Febrile neutropenia                                  | 4 (4.8)             |                    | 6 (3.0)             | 1 (0.5)             | 2 (1.7)             | 4 (3.4)             |
| Leukocytosis                                         | 1 (1.2)             | 0                  | 14 (7.1)            | 10 (5.1)            |                     |                     |
| General disorders and administration site conditions | 26 (31.3)           | 18 (46.2)          | 87 (44.2)           | 73 (37.2)           | 46 (38.3)           | 40 (33.6)           |
| Asthenia                                             | 10 (12.0)           | 8 (20.5)           | 58 (29.4)           | 46 (23.5)           | 42 (35.0)           | 35 (29.4)           |
| Fatigue                                              | 13 (15.7)           | 9 (23.1)           | 24 (12.2)           | 17 (8.7)            | 4 (3.3)             | 4 (3.4)             |
| Pyrexia                                              | 1 (1.2)             | 1 (2.6)            | 18 (9.1)            | 9 (4.6)             | 5 (4.2)             | 5 (4.2)             |
| Chest discomfort                                     |                     |                    | 1 (0.5)             | 0                   | 8 (6.7)             | 7 (5.9)             |
| Musculoskeletal and connective                       |                     |                    | 90 (45.7)           | 74 (37.8)           | 48 (40.0)           | 61 (51.3)           |
| tissue disorders                                     | 16 (19.3)           | 7 (17.9)           |                     |                     |                     |                     |
| Bone pain                                            | 6 (7.2)             | 4 (10.3)           | 41 (20.8)           | 34 (17.3)           | 30 (25.0)           | 40 (33.6)           |
| Arthralgia                                           | 7 (8.4)             | 2 (5.1)            | 30 (15.2)           | 22 (11.2)           | 5 (4.2)             | 5 (4.2)             |
| Back pain                                            | 1 (1.2)             | 0                  | 7 (3.6)             | 5 (2.6)             | 19 (15.8)           | 28 (23.5)           |
| Myalgia                                              | 2 (2.4)             | 1 (2.6)            | 21 (10.7)           | 18 (9.2)            | 5 (4.2)             | 8 (6.7)             |
| Pain in                                              |                     |                    |                     |                     |                     |                     |
| extremity                                            |                     |                    | 1 (0.5)             | 1 (0.5)             | 6 (5.0)             | 5 (4.2)             |
| Investigations                                       | 1 (1.2)             | 1 (2.6)            | 47 (23.9)           | 27 (13.8)           | 101 (84.2)          | 108 (90.8)          |
| Neutrophil count decreased                           |                     |                    | 15 (7.6)            | 6 (3.1)             | 71 (59.2)           | 99 (83.2)           |
| White blood cell count decreased                     |                     |                    | 5 (2.5)             | 2 (1.0)             | 79 (65.8)           | 99 (83.2)           |
| Platelet count decreased                             |                     |                    | 6 (3.0)             | 6 (3.1)             | 56 (46.7)           | 40 (33.6)           |
| Alanine aminotransferase increased                   | 1 (1.2)             | 1 (2.6)            | 19 (9.6)            | 13 (6.6)            | 36 (30.0)           | 19 (16.0)           |
| Aspartate aminotransferase increased                 | 0                   | 1 (2.6)            | 11 (5.6)            | 10 (5.1)            | 30 (25.0)           | 14 (11.8)           |
| Weight                                               |                     |                    |                     |                     | 6 (5.0)             | 7 (5.9)             |
| decreased Weight increased                           |                     |                    |                     | 0                   | 9 (7.5)             | 4 (3.4)             |
| Metabolism and nutrition                             |                     |                    | 1 (0.5)             |                     |                     |                     |
| disorders                                            | 4 (4.8)             | 3 (7.7)            | 20 (10.2)           | 13 (6.6)            | 29 (24.2)           | 30 (25.2)           |
| Decreased appetite                                   | 3 (3.6)             | 2 (5.1)            | 11 (5.6)            | 7 (3.6)             | 29 (24.2)           | 30 (25.2)           |
| Nervous system disorders                             | 4 (4.8)             | 4 (10.3)           | 34 (17.3)           | 27 (13.8)           | 21 (17.5)           | 29 (24.4)           |
| Headache                                             | 2 (2.4)             | 2 (5.1)            | 18 (9.1)            | 10 (5.1)            | 7 (5.8)             | 15 (12.6)           |
| Dizziness                                            |                     |                    | 4 (2.0)             | 3 (1.5)             | 8 (6.7)             | 14 (11.8)           |
| Dysgeusia                                            | 1 (1.2)             | 3 (7.7)            | 8 (4.1)             | 4 (2.0)             |                     |                     |
| Poor quality sleep                                   |                     |                    |                     |                     | 1 (0.8)             | 7 (5.9)             |
| Infections and infestations                          | 2 (2.4)             | 3 (7.7)            | 14 (7.1)            | 17 (8.7)            | 14 (11.7)           | 16 (13.4)           |
| Upper respiratory tract infection                    | 1 (1.2)             | 0                  | 2 (1.0)             | 1 (0.5)             | 14 (11.7)           | 16 (13.4)           |
| Pharyngitis                                          | 1 (1.2)             | 3 (7.7)            | 1 (0.5)             | 2 (1.0)             |                     |                     |
| Respiratory, thoracic and mediastinal disorders      | 1 (1.2)             | 1 (2.6)            | 12 (6.1)            | 11 (5.6)            | 10 (8.3)            | 7 (5.9)             |
| Cough                                                |                     |                    | 0                   | 2 (1.0)             |                     |                     |
| Oropharyngeal pain                                   | 1 (1.2)             | 0                  | 0                   | 2 (1.0)             | 10 (8.3) 4 (3.3)    | 7 (5.9) 1 (0.8)     |
| Psychiatric disorders                                | 1 (1.2)             | 0                  | 6 (3.0)             | 7 (3.6)             | 14 (11.7)           | 16 (13.4)           |
| Insomnia                                             | 1 (1.2)             | 0                  | 4 (2.0)             | 6 (3.1)             | 14 (11.7)           | 16 (13.4)           |
| Ear and labyrinth disorders                          | 1 (1.2)             | 1 (2.6)            | 1 (0.5)             | 1 (0.5)             | 27 (22.5)           | 21 (17.6)           |
| Vertigo Cardiac disorders                            | 1 (1.2)             | 1 (2.6)            | 16 (8.1)            | 15 (7.7)            | 27 (22.5) 7 (5.8)   | 21 (17.6) 1 (0.8)   |
| Palpitations                                         |                     |                    | 3 (1.5)             | 1 (0.5)             | 7 (5.8)             | 1 (0.8)             |

<div style=\"page-break-after: always\"></div>

Table 60. Most Common Related Treatmentemergent Adverse Events in ≥5% of Subjects in Any Treatment Group in the Phase III Studies by System Organ Class and Preferred Term

0                         0

0                         0

0                          0

| System Organ Class Preferred Term                                                                                                                           | GC-627-04 (Cycle 1 only)   | GC-627-04 (Cycle 1 only)   | GC-627-05 (All Cycles)                        | GC-627-05 (All Cycles)         | SP11631 (All Cycles)                  | SP11631 (All Cycles)   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|----------------------------|-----------------------------------------------|--------------------------------|---------------------------------------|------------------------|
|                                                                                                                                                             | F-627                      | Placebo                    | F-627                                         | Pegfilgrastim                  | F-627                                 | Filgrastim             |
|                                                                                                                                                             | N = 83                     | N = 39                     | N = 197                                       | N = 196                        | N = 120                               | N = 119                |
| At least 1 TEAE                                                                                                                                             | 17 (20.5)                  | 5 (12.8)                   | 88 (44.7)                                     | 67 (34.2)                      | 57 (47.5)                             | 66 (55.5)              |
| Gastrointestinal disorders Nausea Diarrhoea                                                                                                                 | 7 (8.4) 6 (7.2) 4 (4.8)    | 4 (10.3) 1 (2.6) 1 (2.6)   | 9 (4.6) 7 (3.6) 3 (1.5)                       | 7 (3.6) 6 (3.1) 0              | 2 (1.7) 0 0                           | 4 (3.4) 0 0            |
| Musculoskeletal and connective tissue Bone pain                                                                                                             |                            |                            | 0                                             | 23 6                           |                                       |                        |
| Stomatitis                                                                                                                                                  | 3 (3.6)                    | 2 (5.1)                    |                                               | 0                              | 0                                     | 0                      |
| disorders                                                                                                                                                   | 7 (8.4) 4 (4.8) 1 (1.2)    | 1 (2.6) 0 1 (2.6)          | 54 (27.4) 31 (15.7) 12 (6.1) 4 (2.0) 19 (9.6) | 36 (18.4) (11.7) (3.1) 3 (1.5) | 46 (38.3) 30 (25.0) 3 (2.5) 14 (11.7) | 58 (48.7) 39 (32.8)    |
| Arthralgia Back pain Blood and lymphatic system disorders Leukocytosis General disorders and administration site conditions Fatigue Asthenia Investigations | 1 (1.2)                    |                            | 24 (12.2) 6 (3.0) 13 (6.6) 8 (4.1) 2 (1.0)    |                                |                                       |                        |
|                                                                                                                                                             | 1 (1.2)                    |                            |                                               |                                |                                       | 2 (1.7) 24 (20.2)      |
|                                                                                                                                                             |                            | 0                          |                                               |                                |                                       |                        |
|                                                                                                                                                             | 1 (1.2)                    | 1 (2.6) 0                  | 14 (7.1)                                      | 15 (7.7) 10 (5.1)              | 3 (2.5) 0                             | 0 0                    |
|                                                                                                                                                             | 4 (4.8)                    | 2 (5.1)                    |                                               | 21 (10.7)                      |                                       | (5.0)                  |
|                                                                                                                                                             | 3 (3.6) 1 (1.2)            | 2 (5.1)                    |                                               | 5 (2.6)                        | 6 (5.0) 0                             | 0                      |
| Nervous system disorders                                                                                                                                    | 0                          | 0 0                        |                                               | 12 (6.1)                       | 4 (3.3)                               | 6 2 (1.7)              |
| Alanine aminotransferase increased                                                                                                                          | 1 (1.2)                    |                            |                                               | 1                              | 8 (6.7) 8 (6.7)                       | 7                      |
|                                                                                                                                                             | 1 (1.2)                    | 0                          |                                               | 10 (5.1)                       |                                       | (5.9)                  |
| Aspartate                                                                                                                                                   |                            |                            |                                               | (0.5)                          |                                       | 6 (5.0)                |
| aminotransferase increased                                                                                                                                  |                            | 0                          | 0                                             | 1 (0.5)                        | 6 (5.0)                               | 2 (1.7)                |
|                                                                                                                                                             | 2 (2.4)                    |                            | 10                                            | 8 (4.1)                        | 3 (2.5)                               | 7 (5.9)                |
| Headache                                                                                                                                                    | 1 (1.2)                    | 1 (2.6) 1 (2.6)            | (5.1) 6 (3.0)                                 | 5 (2.6)                        | 2 (1.7)                               | 7                      |
|                                                                                                                                                             |                            |                            |                                               |                                |                                       | (5.9)                  |

Table 61. Summary of the Most Common Related Treatmentemergent Adverse Events in ≥2% of Subjects in Any Treatment Group in Any Population (Integrated Analysis; Cancer Subjects, All Cycles)

| System Organ Class             | F-627         | F-627             | Pegfilgrastim N = 261   | Filgrastim N = 160   | Placebo N = 39   |
|--------------------------------|---------------|-------------------|-------------------------|----------------------|------------------|
| Preferred Term                 | 20 mg N = 488 | All doses N = 727 |                         |                      |                  |
| At least 1 TEAE                | 175 (35.9)    | 254 (34.9)        | 82 (31.4)               | 79 (49.4)            | 4 (10.3)         |
| Musculoskeletal and connective | 114 (23.4)    | 157 (21.6)        | 44 (16.9)               | 68 (42.5)            | 1 (2.6)          |
| tissue disorders               |               |                   |                         |                      |                  |
| Bone pain                      | 69 (14.1)     | 81 (11.1)         | 27 (10.3)               | 44 (27.5)            | 0                |
| Back pain                      | 20 (4.1)      | 36 (5.0)          | 5 (1.9)                 | 28 (17.5)            | 0                |
| Arthralgia                     | 19 (3.9)      | 28 (3.9)          | 7 (2.7)                 | 3 (1.9)              | 1 (2.6)          |
| Pain in extremity              | 6 (1.2)       | 14 (1.9)          | 1 (0.4)                 | 5 (3.1)              | 0                |
| Myalgia                        | 4 (0.8)       | 10 (1.4)          | 3 (1.1)                 | 5 (3.1)              | 1 (2.6)          |

<div style=\"page-break-after: always\"></div>

| Spinal pain                        | 6 (1.2)   | 7 (1.0)   | 6 (2.3)   | 1 (0.6)   | 0       |
|------------------------------------|-----------|-----------|-----------|-----------|---------|
| General disorders and              | 34 (7.0)  | 54 (7.4)  | 21 (8.0)  | 9 (5.6)   | 2 (5.1) |
| administration site conditions     |           |           |           |           |         |
| Asthenia                           | 14 (2.9)  | 23 (3.2)  | 11 (4.2)  | 2 (1.3)   | 0       |
| Fatigue                            | 11 (2.3)  | 13 (1.8)  | 4 (1.5)   | 0         | 2 (5.1) |
| Pyrexia                            | 6 (1.2)   | 8 (1.1)   | 2 (0.8)   | 4 (2.5)   | 0       |
| Skin and subcutaneous tissue       | 21 (4.3)  | 46 (6.3)  | 19 (7.3)  | 0         | 1 (2.6) |
| disorders                          |           |           |           |           |         |
| Alopecia                           | 4 (0.8)   | 24 (3.3)  | 7 (2.7)   | 0         | 1 (2.6) |
| Rash                               | 2 (0.4)   | 6 (0.8)   | 6 (2.3)   | 0         | 0       |
| Blood and lymphatic system         | 26 (5.3)  | 43 (5.9)  | 22 (8.4)  | 0         | 0       |
| disorders                          |           |           |           |           |         |
| Leukocytosis                       | 15 (3.1)  | 15 (2.1)  | 10 (3.8)  | 0         | 0       |
| Neutropenia                        | 3 (0.6)   | 17 (2.3)  | 8 (3.1)   | 0         | 0       |
| Leukopenia                         | 3 (0.6)   | 11 (1.5)  | 7 (2.7)   | 0         | 0       |
| Nervous system disorders           | 17 (3.5)  | 30 (4.1)  | 8 (3.1)   | 8 (5.0)   | 1 (2.6) |
| Headache                           | 7 (1.4)   | 18 (2.5)  | 5 (1.9)   | 8 (5.0)   | 1 (2.6) |
| Dysgeusia                          | 3 (0.6)   | 3 (0.4)   | 0         | 0         | 1 (2.6) |
| Investigations                     | 15 (3.1)  | 19 (2.6)  | 9 (3.4)   | 8 (5.0)   | 0       |
| Alanine aminotransferase increased | 9 (1.8)   | 11 (1.5)  | 0         | 6 (3.8)   | 0       |
| Neutrophil count increased         | 3 (0.6)   | 4 (0.6)   | 6 (2.3)   | 1 (0.6)   | 0       |
| Gastrointestinal disorders         | 20 (4.1)  | 24 (3.3)  | 5 (1.9)   | 4 (2.5)   | 2 (5.1) |
| Nausea                             | 15 (3.1)  | 16 (2.2)  | 3 (1.1)   | 0         | 1 (2.6) |
| Vomiting                           | 5 (1.0)   | 5 (0.7)   | 0         | 1 (0.6)   | 1 (2.6) |
| Stomatitis                         | 4 (0.8)   | 4 (0.6)   | 0         | 0         | 2 (5.1) |
| Dyspepsia                          | 2 (0.4)   | 2 (0.3)   | 0         | 0         | 1 (2.6) |
| Constipation                       | 0         | 0         | 1 (0.4)   | 0         | 1 (2.6) |
| Respiratory, thoracic and          | 7 (1.4)   | 8 (1.1)   | 2 (0.8)   | 0         | 1 (2.6) |
| mediastinal disorders              |           |           |           |           |         |
| Rhinorrhoea                        | 0         | 0         | 0         | 0         | 1 (2.6) |
| Ear and labyrinth disorders        | 5 (1.0)   | 6 (0.8)   | 0         | 3 (1.9)   | 1 (2.6) |
| Vertigo                            | 5 (1.0)   | 6 (0.8)   | 0         | 3 (1.9)   | 1 (2.6) |

## 2.6.8.3. Serious adverse event/deaths/other significant events

## Study GC-627-04

Overall, 17 SAEs were reported in 15 (12.3%) subjects. All of them were assessed as unrelated or unlikely related to study drug. 15 of 17 SAEs occurred during chemotherapy Cycle 1. All SAEs were resolved by EOS.

## Study GC-627-05

12 SAEs were reported in 12 (6.1%) F-627 subjects and 5 SAEs in 3 (1.5%) pegfilgrastim subjects. The most common SAE was pneumonia. 2 SAEs were assessed as possibly related to the study drug, including angioedema and urticaria (in 1 F-627 subject each). In general SAEs resolved by EOS.

## Study SP11631

<div style=\"page-break-after: always\"></div>

SAEs were reported in 6 (5.0%) F-627 subjects and in 8 (6.7%) filgrastim. All of them were assessed as unrelated to the study drug. The most common SAEs were neutrophil count decreased, platelet count decreased, and febrile neutropenia. All SAEs were resolved or stable by the EOS. No deaths occurred in this study.

Table 62. Treatment-emergent Serious Adverse Events in Any Treatment Group in Any Cycle in the Phase III Studies, by System Organ Class and Preferred Term

| System Organ Class Preferred Term                            | GC-627-04 (Cycle 1 only)   | GC-627-04 (Cycle 1 only)   | GC-627-05 (All Cycles)   | GC-627-05 (All Cycles)   | SP11631 (All Cycles)   | SP11631 (All Cycles)   |
|--------------------------------------------------------------|----------------------------|----------------------------|--------------------------|--------------------------|------------------------|------------------------|
|                                                              | F-627 N = 83               | Placebo N = 39             | F-627 N = 197            | Pegfilgrastim N = 196    | F-627 N = 120          | Filgrastim N =119      |
| At least 1 SAE                                               | 4 (4.8)                    | 11 (28.2)                  | 12 (6.1)                 | 3 (1.5)                  | 6 (5.0)                | 8 (6.7)                |
| Blood and lymphatic system disorders                         | 3 (3.6)                    | 11 (28.2)                  | 2 (1.0)                  | 2 (1.0)                  | 1 (0.8)                | 2 (1.7)                |
| Febrile neutropenia                                          | 3 (3.6)                    | 11 (28.2)                  | 2 (1.0)                  | 0                        | 1 (0.8)                | 2 (1.7)                |
| Anaemia                                                      |                            |                            | 0                        | 1 (0.5)                  |                        |                        |
| Neutropenia                                                  |                            |                            | 0                        | 1 (0.5)                  |                        |                        |
| Investigations                                               |                            |                            |                          |                          | 4 (3.3)                | 4 (3.4)                |
| Neutrophil count decreased                                   |                            |                            |                          |                          | 3 (2.5)                | 3 (2.5)                |
| Platelet count decreased                                     |                            |                            |                          |                          | 3 (2.5)                | 2 (1.7)                |
| White blood cell count decreased                             |                            |                            |                          |                          | 1 (0.8)                | 0                      |
| Skin and subcutaneous tissue                                 |                            |                            | 2 (1.0)                  | 0                        |                        |                        |
| disorders                                                    |                            |                            |                          |                          |                        |                        |
| Angioedema                                                   |                            |                            | 1 (0.5)                  | 0                        |                        |                        |
| Urticaria                                                    |                            |                            |                          |                          |                        |                        |
| Gastrointestinal disorders                                   |                            |                            | 1 (0.5)                  | 0                        |                        |                        |
|                                                              | 0                          | 1 (2.6)                    |                          |                          |                        |                        |
| Diarrhoea                                                    | 0                          | 1 (2.6)                    |                          |                          |                        |                        |
| Infections and infestations                                  | 0                          | 1 (2.6)                    | 2 (1.0)                  | 1 (0.5)                  |                        |                        |
| Pneumonia                                                    | 0                          | 1 (2.6)                    | 2 (1.0)                  | 1 (0.5)                  |                        |                        |
| Hepatobiliary disorders                                      |                            |                            | 0                        | 1 (0.5)                  |                        |                        |
| Hepatitis toxic                                              |                            |                            | 0                        | 1 (0.5)                  |                        |                        |
| Drug-induced liver injury                                    |                            |                            |                          |                          | 0                      | 1 (0.8)                |
| Neoplasms benign, malignant and                              |                            |                            |                          |                          | 0                      | 1 (0.8)                |
| unspecified (incl cysts and                                  | 1 (1.2)                    | 0                          |                          |                          |                        |                        |
| Lung adenocarcinoma                                          |                            |                            |                          |                          | 0                      | 1 (0.8)                |
| Tumour haemorrhage                                           | 1 (1.2)                    | 0                          |                          |                          |                        |                        |
| Vascular disorders                                           |                            |                            | 1 (0.5)                  | 0                        | 1 (0.8)                | 0                      |
| Jugular vein thrombosis                                      |                            |                            | 1 (0.5)                  |                          | 1 (0.8)                | 0                      |
| Hypertension                                                 |                            |                            |                          | 0                        |                        |                        |
| Cardiac disorders                                            |                            |                            | 0                        | 1 (0.5)                  |                        |                        |
| Myocardial infarction                                        |                            |                            | 0                        | 1 (0.5)                  |                        |                        |
| General disorders and administration site conditions Fatigue |                            |                            | 1 (0.5) 1 (0.5)          | 0 0                      |                        |                        |
| Metabolism and nutrition                                     |                            |                            | 1 (0.5)                  | 0                        |                        |                        |

<div style=\"page-break-after: always\"></div>

| disorders                                        |         |    |
|--------------------------------------------------|---------|----|
| Diabetic ketoacidosis                            | 1 (0.5) |  0 |
| Nervous system disorders                         | 1 (0.5) |  0 |
| Syncope                                          | 1 (0.5) |  0 |
| Renal and urinary disorders                      | 1 (0.5) |  0 |
| Acute kidney injury                              | 1 (0.5) |  0 |
| Respiratory, thoracic, and mediastinal disorders | 1 (0.5) |  0 |
| Pulmonary embolism                               | 1 (0.5) |  0 |

## Deaths

Over F-627 clinical programme, 3 deaths were reported, all in study GC-627-05. One event occurred in patients receiving 20 mg F-627 and was considered unrelated to study drug.  The other two in patients receiving pegfilgrastim.

## Adverse Events of Special Interest (AESI)

## Leukocytosis

Only one subject in the F-627 clinical program experienced an AESI of leukocytosis (WBC &gt; 100 × 109 /L), a subject treated with pegfilgrastim in Study GC-627-02. No subjects experienced leukocytosis in any other treatment group or in Cycle 1. The highest WBC value observed in any subject in the Cancer Population treated with any F-627 dose was a subject in study GC-627-02 who received 320 µg/kg F-627 with a leukocyte value of 90.3 × 10 9 /L on Cycle 1 Day 11 and had no associated TEAEs. In the Healthy Population, no subjects experienced leukocytosis.

## Splenic Involvement

Over all cycles, 6 (0.5%) subjects in the Cancer Population experienced 6 AESIs with splenic involvement; 3 (0.6%) subjects in the 20 mg F-627 group, 2 (0.8%) pegfilgrastim subjects, 0 filgrastim subjects, and no placebo subjects; all were AESIs of splenomegaly. There were no AESIs of splenic rupture in any cycle. No AESIs of splenic involvement were reported in Cycle 1.

## Musculoskeletal pain

Over all cycles, 28.7% of Cancer Population subjects experienced AESIs of musculoskeletal pain, including 26.4% of subjects in the 20 mg F-627 group, 22.6% of pegfilgrastim subjects, 45.0% of filgrastim subjects, and 15.4% of placebo subjects. The most frequently reported PT contributing to these AESIs was bone pain (17.0% 20 mg F-627; 16.9% pegfilgrastim, 28.1% filgrastim, and 10.3% placebo). Up to 8.7% of F-627 subjects reported headache (7.6% at 20 mg F-627) compared to 5.4%, 11.9%, and 5.1% of pegfilgrastim, filgrastim, and placebo subjects; 7.2% of F-627 subjects at any dose had back pain compared to 2.7% of pegfilgrastim and 20.6% of filgrastim subjects. None of the musculoskeletal TEAEs were serious; most were mild or moderate in severity and assessed as related to study drug.

There were 2 subjects with TEAEs of bone pain that were considered severe in study GC-627-05. One subject receiving 20 mg F-627 experienced bone pain on Cycle 1 Day 4 that was assessed as unrelated to study drug and resolved within 10 days. Another subject also receiving 20 mg F-627 experienced bone pain on Cycle 1 Day 6 that was assessed as possibly related to study drug and resolved 3 days later.

In Cycle 1, approximately 22% of F-627 subjects had AESIs of musculoskeletal pain compared to 15.7% of pegfilgrastim subjects, 35.6% of filgrastim subjects and 15.4% of placebo subjects. Similar to all cycles, the

<div style=\"page-break-after: always\"></div>

most frequently reported term was bone pain in 14.9% of 20 mg F-627 subjects, 13.5% at any F-627 dose, 13.0% of pegfilgrastim subjects, 20.0% of filgrastim subjects, and 10.3% of placebo subjects.

## Allergic reactions

Over all cycles, there were 7.6% of 20 mg F-627 subjects with AESIs of allergic reactions; 7.4% subjects at any F-627 dose, 7.3% of pegfilgrastim subjects, 3.8% of filgrastim subjects, and 2.6% of placebo subjects. Most of the identified TEAEs were reactions at the injection site, including rash, urticaria, and oedema/swelling. There were 3 subjects with serious allergic reactions, which were the only reported serious AESIs; 2 (0.4%) were in F-627 20 mg subjects and 1 (0.4%) was in a pegfilgrastim subject.

One subject received 20 mg F-627 in study GC-627-05 and experienced angioedema on Cycle 3 Day 12 resulting in study drug discontinuation. Another subject, also administered 20 mg F-627 in study GC-627-05, experienced an SAE of urticaria on Cycle 3 Day 8 resulting in study drug discontinuation. Both events were allergic reactions considered possibly related to study drug and all occurred in Cycle 3.

In Cycle 1, 27 (2.3%) subjects had allergic reactions including 2.0% of 20 mg F-627 subjects, 2.6% of subjects at any F-627 dose, 3.1% of pegfilgrastim subjects, 0 filgrastim subjects, and 2.6% of placebo subjects; none were serious.

## Tumour growth, progression of disease

A single subject in the Cancer Population (0.1%) experienced an AESI of tumour growth, progression of disease. This subject from study GC-627-05 received 20 mg F-627 and had an event of breast cancer recurrent with the onset on Cycle 3 Day 38 that was ongoing at the end of the study; the event was assessed as possibly related to study drug and led to discontinuation. No other AESIs of tumour growth, progression of disease were reported, and none were serious.

## Injection site reactions

Overall, in the cancer population, there were 5 (0.4%) subjects with AESIs of ISRs for a total of 10 events; none occurred in the 20 mg F-627 group and 2 (0.3%) subjects had ISRs in the All-Doses F-627 group; none occurred in Cycle 1. There was 1 (0.4%) pegfilgrastim subject with an injection site AESI and 2 (1.3%) subjects in the filgrastim group. The most commonly reported term for F-627 was injection site erythema (0.3%). One subject (240 µg/kg/dose) in study GC-627-02 experienced 2 events of injection site erythema on Cycle 3 Day 2 and Cycle 4 Day 2. Another subject, (320 µg/kg/dose) in study GC-627-02 experienced 3 events of injection site erythema on Cycle 2 Day 2 and Cycle 3 Day 2, and Cycle 4 Day 2. All were assessed as definitely related to the study drug, were either mild or moderate in intensity, and resolved within the same day without treatment.

Injection site pain was reported for 1 subject each in the pegfilgrastim and filgrastim groups and 1 filgrastim subject also reported an AESI of injection site vesicles. None of the AESIs were serious.

## 2.6.8.4. Laboratory findings

Haematology and biochemistry parameters fluctuated during F-627 trials, as expected with the administration of rhG-CSF in parallel with chemotherapy. These parameters returned to baseline or near baseline values by the end of the cycle and/or study.

Study GC-627-04 . In the first 12 days of cycle 1, mean ANC levels in subjects randomized to F-627 were increased from baseline levels at Day 3 of the cycle, decreased compared to baseline at Day 8, approached

<div style=\"page-break-after: always\"></div>

baseline around Day 10, and were increased compared to baseline at Day 12. In subjects randomized to Placebo, mean ANC levels decreased from baseline until Day 10 before increasing, with levels still below baseline at Day 12.

Study GC-627-05 . Baseline ANC (Day 1) was similar between treatments. Median ANC values in both treatment groups increased between Day 2 and Day 3, and then decreased, with nadir reached by Day 7; ANC levels then increased to peak levels (at or above Day 3 levels) by Day 9 to Day 10.

Overall, the ANC levels were higher in F-627 group than in placebo and similar to those in Neulasta or GRAN (pegfilgrastim). Other biochemistry, and haematology parameters were similar between the F-627 group and comparator groups.

## 2.6.8.5. In vitro biomarker test for patient selection for safety

NA

## 2.6.8.6. Safety in special populations

Safety analysis in different elderly groups was performed and did not reveal any deviations . Nevertheless, experience with elderly patients is limited due to low number of patients of ≥65 years (53 patients in 65 -74 year group, and 3 patients in 75-84 year group).

There were no reports of pregnancy or treatment of nursing mothers in any of the F-627 clinical studies.

## 2.6.8.7. Immunological events

In study GC-627-04, one (1.2%) subject had treatment-emergent anti-F-627 binding antibodies in Cycle 1. No ADA cross-reactivity to G-CSF or neutralizing antibodies to F-627 or G-CSF were found in Cycle 1. In Cycles 2-4, two (5.3%) subjects had treatment-emergent anti-F-627 binding antibodies. No anti-G-CSF binding antibodies were detected et EOS.

In study GC-627-05, 17 (8.6%) subjects had treatment-emergent anti-F-627 antibodies. Treatmentemergent anti-G-CSF binding antibodies were detected in 15 (7.6%) subjects. No neutralizing antibodies to F-627 or G-CSF were detected in any subject treated with F-627 at any time point. To be pointed out, that there was nearly 3-fold increase of treatment-emergent anti-F-627 antibodies in F-627 arm comparing with pegfilgrastim arm.

In study SP11631, neither treatment-emergent anti-F-627 binding antibodies nor anti-G-CSF binding antibodies were detected. It is not possible to compare results for two groups as immunogenicity was assessed for the F-627 arm only.

Of the subjects positive for binding antibodies, &gt;80% in any treatment group had at least 1 TEAE (summarised in Table 68) and approximately one-third of those were considered at least possibly related to study treatment; none were SAEs. There was no evidence of allergic reactions in any of the subjects that tested positive in any arm of any study.

Table 63 . Summary of treatmentemergent adverse events in ≥10% of Phase III subjects with treatment -emergent anti-F-627 or anti-G-CSF antibodies by SOC, PT and treatment group (Cancer Population)

<div style=\"page-break-after: always\"></div>

|                                                | Group   | F-627 20mg Pegfilgrastim N=35 N=18   | Total N=53   |
|------------------------------------------------|---------|--------------------------------------|--------------|
| AnyTEAE                                        |         | 33 (94.3) 15 (83.3)                  | 48 (90.6)    |
| Skin and subcutaneous tissue disorders         |         | 9 (50.0)                             | 34(64.2)     |
| Alopccia                                       |         | 24 (68.6) 20 (57.1) 8 (44.4)         | 29 (54.7)    |
| Erythema                                       |         | 6(17.1) 1 (5.6)                      | 7(13.2)      |
| MIusculoskeletalandconnective tissue disorders |         | 16 (45.7) 7 (38.9) 3(16.7)           | 23 (43.4)    |
| Bone pain                                      |         | 9(25.7)                              | 12 (22.6)    |
| Myalgia                                        |         | 5 (14.3) 3(16.7)                     | 8(15.1)      |
| Arthralgia                                     |         | 5(14.3) 0                            | 5 (9.4)      |
| Spinal pain                                    |         | 2 (5.7) 2 (11.1)                     | 4 (7.5)      |
| Blood and Iymphatic system disorders           |         | 14 (40.0) 8 (44.4) 10(28.6)          | 22 (41.5)    |
| Anaemia                                        |         | 5(27.8)                              | 15 (28.3)    |
| Neutropenia                                    |         | 7(20.0) 5 (27.8)                     | 12 (22.6)    |
| Leukopenia                                     |         | 8 (22.9) 4(22.2)                     | 12 (22.6)    |
| Gastrointestinal disorders                     |         | 17 (48.6) 5(27.8)                    | 22 (41.5)    |
| Nausea                                         |         | 12(34.3) 4(22.2)                     | 16 (30.2)    |
| Diarrhoea                                      |         | 9(25.7) 2(11.1)                      | 11 (20.8)    |
| Stomatitis                                     |         | 4 (11.4) 0                           | 4 (7.5)      |
| Vomiting                                       |         | 2 (5.7) 0                            | 2 (3.8)      |
| Generaldisordersandadministrationsite          |         |                                      |              |
| conditions                                     |         | 14 (40.0) 5 (27.8)                   | 20 (37.7)    |
| Asthenia                                       |         | 7(20.0) 5 (27.8)                     | 12 (22.6)    |
| Fatigue                                        |         | 5(14.3) 0                            | 6(11.3)      |
| Pyrexia                                        |         | 4(11.4) 0                            | 4 (7.5)      |
| Investigations                                 |         | 12 (34.3) 3 (16.7)                   | 15 (28.3)    |
| Neutrophil count decreased                     |         | 5 (14.3) 2(11.1)                     | 7(13.2)      |
| Alanine aminotransferaseincreased              |         | 4(11.4) 1 (5.6)                      | 5(9.4)       |
| Platelet count decreased                       |         | 0 2 (11.1)                           | 2(3.8)       |
| Nervoussystem disorder's                       |         | 4 (11.4) 1(2.9)                      | 8(15.1)      |
| Dysgeusia                                      |         | 3 (16.7) 0                           | 2(3.8)       |

Abbreviations:ADA-anti-drugantibody,G-CSF-granulocyte colony stimlating factor;NA-not applicable;

Values are n (%).Nisthe number ofsubjectswith a treatment-emergent ADA.

PT-preferred term;SOC-system organ class.

## 2.6.8.8. Safety related to drug-drug interactions and other interactions

No clinical drug interaction studies have been conducted with F-627.

## 2.6.8.9. Discontinuation due to adverse events

Overall, in the F-627 clinical studies, the rate of subjects with TEAEs leading to discontinuation was low (&lt;2%) and similar across treatment groups. The most frequent events were related to neutropenia or febrile neutropenia.

In the Cancer Population, there were 22 (1.9%) subjects with TEAEs leading to discontinuation over all cycles, spread across several SOCs and PTs - the only PTs that were reported for more than a single subject were related to neutropenia and febrile neutropenia. There were 7 (1.4%) 20 mg F-627 subjects with TEAEs leading to discontinuation and 11 (1.5%) subjects at any dose of F-627 in the ISS analysis. In the comparator arms, there were 8 (3.1%) pegfilgrastim subjects, 3 (1.9%) filgrastim subjects, and no placebo subjects with TEAEs leading to discontinuation.

One additional subject in the SP11502 study (outside the integrated cancer population) experienced several TEAEs leading to discontinuation. All of the reported AEs were in Cycle 1 with onset between Day 6 and Day 11 and most resolved prior to the EOS; 10 of the 25 events were assessed as possibly related to the study drug.

All but one of the events in the 20 mg F-627 arm occurred in study GC-627-05 and included events of angioedema, dermatitis allergic, pulmonary embolism, breast cancer recurrent, urticaria, and alanine

<div style=\"page-break-after: always\"></div>

aminotransferase increased. The remaining event (in study GC-627-04) was pneumonia that led to discontinuation during Cycle 2, in a subject who had been randomized to treatment with placebo in Cycle 1 and was switched to 20 mg F-627 for Cycle 2. All events in the 20 mg F-627 group occurred in Cycles 2 or Cycle 3, and most were Grade 3 in severity. Four (4) of these TEAEs were SAEs (angioedema, pneumonia, pulmonary embolism, and urticaria), one of which was a death resulting from pulmonary embolism. In addition, 3 of the events were assessed by the investigator as possibly related to the study drug (angioedema, breast cancer recurrent, and urticaria). Of the remaining subjects that received any F-627 dose (i.e., those not in the 20 mg F-627 group), 2 TEAEs leading to discontinuation were SAEs, both of which were Grade 3 febrile neutropenia unrelated to the study drug. An event of type I hypersensitivity led to discontinuation of one subject from study GC-627-02 and was the result of a hypersensitivity to docetaxel) and not the study drug. One event of Grade 2 uveitis led to discontinuation of one subject in study GC-62702 and was assessed as possibly related to the study drug.

## 2.6.8.10. Post marketing experience

NA

## 2.6.9. Discussion on clinical safety

The primary clinical safety of F-627 was assessed in Phase III studies involving patients with breast cancer.

A GCP inspection suggested that for study GC-627-05 trial that information bias could not be ruled out as in at least some of the sites some of the investigators may have been unblinded to treatment allocation. The results in this study, however, did not appear to favour F-627. In addition, the study included two treatments that could be expected to be similar and thus the investigators who would have been experienced in the close monitoring and management of patients in the oncology area reduces the likelihood of the effect of the information bias.

In study GC-627-04, 98.8% of subjects had at least 1 TEAE. In the F-627 arm, 31.3% of subjects had treatment related TEAEs over all Cycles, and 20.5% had ADRs in Cycle 1. Both in Cycle 1 and over all Cycles, the most commonly reported TEAEs of SOCs were blood and lymphatic system disorders, gastrointestinal disorders and skin and subcutaneous tissue disorders. In Cycle 1, the most common PTs were neutropenia, nausea and leukopenia. Over all Cycles, the most common PTs were alopecia, neutropenia, and nausea. In Cycle 1, the most common ADRs were nausea, diarrhoea, stomatitis, vomiting, fatigue, and bone pain. Over all Cycles, the most common ADRs were the same except for vomiting. Anaemia and Thrombocytopenia were more common in F-627 20 mg group, while febrile neutropenia (FN) was more common in the Placebo arm in Cycle 1 and Over All Chemotherapy Cycles. Overall, chemotherapy cycles Gastrointestinal disorders were more common in the F-627 arm. There was a higher proportion of treatment related TEAEs and subjects with treatment related TEAEs (especially bone pain) reported in those randomized to F-627 compared to Placebo.

In study GC-627-05, 90.4% of all subjects had at least 1 TEAE and 44.7% had a study drug-related TEAE in F-627 arm. The most commonly reported TEAEs of SOCs were skin and subcutaneous tissue disorders, gastrointestinal disorders, musculoskeletal and connective tissue disorders, and blood and lymphatic system disorders. The most common PTs were alopecia, nausea, asthenia, neutropenia, anaemia, leukopenia, and bone pain. The most common ADRs were bone pain, asthenia, leukocytosis and arthralgia. GI disorders, Bone pain and pyrexia occurred more often in the F-627 arm. The most commonly reported TEAEs by subject incidence (F-627 vs. Neulasta) were alopecia (52.3% vs. 51.0%), nausea (36.0% vs. 29.6%), asthenia

<div style=\"page-break-after: always\"></div>

(29.4% vs. 23.5%), neutropenia (20.3% vs. 25.5%), anaemia (23.9% vs. 19.4%), leukopenia (19.8% vs. 22.4%), and bone pain (20.8% vs. 17.3%). Incidence of blood and lymphatic system disorders were similar between the groups. Overall, the most commonly reported Grade 4 events were the ones related to the expected haematologic effects of chemotherapy. Of them, neutropenia (2.0% F-627 subjects vs. 8.7% pegfilgrastim), neutrophil count decreased (2.5% F-627 subjects vs. 0.5% pegfilgrastim), and leukopenia (0 F-627 vs. 2.0% pegfilgrastim) were noted. The most frequent Grade 3 events also included the expected effects of chemotherapy (the ones similar to Grade 4 and additionally febrile neutropenia, alopecia, diarrhoea, and asthenia). Grade 4 and Grade 5 AE incidence profile was somewhat different between groups.

In study SP11631 all subjects had at least 1 TEAE and 47.5% of them had study drug-related TEAEs in F-627 arm. The most commonly reported TEAEs of SOCs were gastrointestinal disorders, investigations, skin and subcutaneous tissue disorders, blood and lymphatic system disorders, and musculoskeletal and connective tissue disorders. The most common PTs were nausea, white blood cell count decreased, alopecia, neutrophil count decreased, vomiting and anaemia. The most common ADRs were bone pain and back pain.

Some ADRs (i.e. headache and nausea) presented in the SmPC have lower frequency compared to pegfilgrastim and  filgrastim.  Across  treatment  groups,  SAEs  were  recorded  in  5.1%  F-627  20  mg  subjects.  In  Cancer population, febrile neutropenia was the most common SAE in the 20 mg F-627 group. No SAEs occurred in Healthy subjects. In study GC-627-04, 17 SAEs were reported; all were assessed as unrelated or unlikely related to study drug. In study GC-627-05, 12 SAEs were reported in 12 (6.1%) F-627 subjects, 2 of them (angioedema and urticaria) assessed as possibly related to the study drug. In study SP11631 all SAEs were assessed as unrelated to the study drug. All SAEs in Phase III trials were resolved or stable by the EOS.

The incidences of ADRs and SAEs were found to be higher with Ryzneuta than with Neulasta (~45% vs ~34% and 6.1% vs 1.5%, respectively). There are several possible explanations for this occurrence. Firstly, the differences could be true; however, these differences were not seen in the other two Phase III trials. Study GC-627-04 reported more treatment related TEAEs in the F-627 group compared to placebo in Cycle 1 (20.5% vs. 12.8% respectively) but fewer SAEs (4.8% vs. 25.6%). In Study SP11631, there were both fewer treatment related TEAEs in the F-627 group compared to filgrastim (47.5% vs. 55.5% respectively) as well as SAEs (5% vs. 6.7%). Secondly, the difference could be due to chance, and despite randomisation the subjects who received F-627 were more likely to develop and/or report a broad range of ADRs. In evaluating the treatment related TEAEs in Study GC-627-05, there was no single SOC or PT which justify the difference between arms. Instead, there were small differences in PTs which cumulatively add up to the observed overall difference for F-627 vs. Neulasta (44.7% vs.34.2% respectively). In aggregate 'any study drugrelated TEAE' reported in the cancer population in the ISS showed comparable results for F-627 vs. pegfilgrastim (34.9% vs. 31.4%, respectively). Finally, it is possible that knowledge of treatment allocation led to some degree of reporting bias across a broad range of ADRs. Sites were instructed to have the study drug administered by qualified personnel other than the investigator such that study assessments could be conducted without knowledge of treatment assignment. While sites attempted to blind assessors, the applicant stated the possibility that investigators were aware of treatment allocation, which may have influenced ADR reporting. Regarding the observed difference of 6.1% vs. 1.5% in SAEs between F-627 and Neulasta in Study GC-627-05, most of the SAEs were consistent with the population of women undergoing cytotoxic chemotherapy for breast cancer and were assessed as unrelated to study drug. There were 3 events (angioedema, urticarial, hypertension) deemed as related to study drug in 3 subjects randomized to F-627.

Asymptomatic cases of splenomegaly have been reported after administration of efbemalenograstim alfa. In addition, cases of splenic rupture, including some fatal cases, have been reported following administration of

<div style=\"page-break-after: always\"></div>

G-CSF. Therefore, spleen size should be carefully monitored (e.g. clinical examination, ultrasound). A diagnosis of splenic rupture should be considered in patients reporting left upper abdominal pain or shoulder tip pain.

The applicant identified a number of AESI, based on the mechanism of action of other G-CSF containing products. Even if those events were not observed in the clinical development programme for F-627, it is reasonable to assume that these risks associated with the use of G-CSF can also apply to the use if this product.

G-CSF can promote growth of myeloid cells in vitro and similar effects may be seen on some non-myeloid cells in vitro and this information has been reflected in the product information.

Pulmonary adverse reactions, in particular interstitial pneumonia, have been reported after G-CSF administration. Patients with a recent history of pulmonary infiltrates or pneumonia may be at higher risk. The onset of pulmonary signs such as cough, fever, and dyspnoea in association with radiological signs of pulmonary infiltrates, and deterioration in pulmonary function along with increased neutrophil count may be preliminary signs of acute respiratory distress syndrome (ARDS). In such circumstances, efbemalenograstim alfa should be discontinued at the discretion of the physician and the appropriate treatment should be administered.

Glomerulonephritis has been reported in patients receiving G-CSF (e.g. filgrastim and pegfilgrastim). Generally, events of glomerulonephritis resolved after dose reduction or withdrawal of G-CSF. Urinalysis monitoring is recommended.

Capillary leak syndrome has been reported after G-CSF administration and is characterised by hypotension, hypoalbuminaemia, oedema and haemoconcentration. Patients who develop symptoms of capillary leak syndrome should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care.

Sickle cell crises have been associated with the use of G-CSF in patients with sickle cell trait or sickle cell disease. Therefore, physicians should use caution when prescribing efbemalenograstim alfa in patients with sickle cell trait or sickle cell disease, clinical parameters and laboratory status should be monitored appropriately and attentively by the physician for the possible association of this medicinal product with splenic enlargement and vaso-occlusive crisis.

White blood cell (WBC) counts of 100 × 10 9 /L or greater have been observed in patients receiving G-CSF. No adverse events directly attributable to this degree of leukocytosis have been reported. Such elevation in white blood cells is transient, being typically seen 24 to 48 hours after administration and is consistent with the pharmacodynamic effects of this medicinal product. Consistent with the clinical effects and the potential for leukocytosis, a WBC count should be performed at regular intervals during therapy. If leukocyte counts exceed 50 × 10 9 /L after the expected nadir, this medicinal product should be discontinued immediately.

Stevens-Johnson syndrome (SJS), which can be life-threatening or fatal, has been reported rarely in association with G-CSF treatment. If the patient has developed SJS with the use of efbemalenograstim alfa, treatment with efbemalenograstim alfa must not be restarted in this patient at any time.

Aortitis has been reported after G-CSF administration in healthy subjects and in cancer patients. The symptoms experienced included fever, abdominal pain, malaise, back pain and increased inflammatory markers (e.g. c-reactive protein and white blood cell count). In most cases aortitis was diagnosed by computed tomography (CT) scan and generally resolved after withdrawal of G-CSF.

<div style=\"page-break-after: always\"></div>

Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been observed following the use of some G-CSF (e.g. pegfilgrastim) in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer. Patients with breast and lung cancer should be monitored for signs and symptoms of MDS/AML.

As treatment with efbemalenograstim alfa alone does not preclude thrombocytopenia and anaemia because full dose myelosuppressive chemotherapy is maintained on the prescribed schedule. Regular monitoring of platelet count and haematocrit is recommended. Special care should be taken when administering single or combination chemotherapeutic agents which are known to cause severe thrombocytopenia.

The safety and efficacy of efbemalenograstim alfa has not been investigated in patients with myelodysplastic syndrome, chronic myelogenous leukaemia, or acute myeloid leukaemia. Therefore, it should not be used in such patients. Furthermore, as efbemalenograstim alfa has also not been investigated in patients receiving high dose chemotherapy it should not be used to increase the dose of cytotoxic chemotherapy beyond established dosage regimens.

Due to the potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy, efbemalenograstim alfa should be administered at least 24 hours after administration of cytotoxic chemotherapy, and at least 14 days before the next dose of chemotherapy. Concomitant use of Ryzneuta with chemotherapy (i.e. administration on the same day) has been shown to potentiate myelosuppression.

Possible interactions with other haematopoietic growth factors and cytokines have not been specifically investigated in clinical trials. The potential for interaction with lithium, which also promotes the release of neutrophils, has not been specifically investigated. There is no evidence that such an interaction would be harmful.

Over the F-627 clinical programme, 3 deaths were reported, all in study GC-627-05. It occurred in one 20 mg F-627 patient and in two pegfilgrastim patients. None was considered related to study drug.

In Study GC-627-05, the treatment-emergent ADA positive rate was 8.6% for the F-627 arm vs. 3.1% for the Neulasta arm. This discrepancy could possibly be explained by the fact that in the ADA screen assay the capture and detection agent was F-627. Therefore, the assay may not have been able to capture ADA elicited by administration of Neulasta, leading to a possible under-estimation of the true ADA rate in the Neulasta group. The human Fc moiety in F-627 is not expected to be immunogenic in humans, therefore the G-CSF ADA assay using G-CSF as the capture and detection agent may be more valid with respect to assessing immunogenicity of F-627 vs. Neulasta and also potentially more relevant to product efficacy and safety. Results from this assay showed that the anti-G-CSF ADA rate is 7.6% in the F-627 arm vs. 6.7% from the Neulasta arm. The data demonstrate that, from the perspective of induction of ADA to the G-CSF moiety, there is no meaningful difference between subjects administered F-627 compared to Neulasta.

As cross-reactivity and hypersensitivity to other rhG-CSFs in the setting of hypersensitivity to efbemalenograstim alfa has not been formally assessed, the product information contains a warning that hhypersensitivity, including serious allergic reactions, occurring on initial or subsequent treatment have been reported in patients treated with G-CSF. Efbemalenograstim alfa should be permanently discontinued in patients with clinically significant hypersensitivity. Efbemalenograstim alfa should not be administered to patients with a history of hypersensitivity to efbemalenograstim alfa. Caution should also be exercised if using efbemalenograstim alfa in patients with a history of serious allergic reactions to other G-CSF products as the risk of cross-reactivity cannot be excluded. In such circumstances, efbemalenograstim alfa should be administered at the discretion of the physician with the appropriate assessment of risks and benefits. If a

<div style=\"page-break-after: always\"></div>

serious allergic reaction occurs, appropriate therapy should be administered, with close patient follow-up over several days.

There are no data from the use of efbemalenograstim alfa in pregnant women. Although studies in animals have not shown reproductive toxicity (see Non-clinical section of this report), efbemalenograstim is not recommended during pregnancy and in women of childbearing potential not using contraception. There is insufficient information on the excretion of efbemalenograstim alfa in human milk; a risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from efbemalenograstim therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

## 2.6.10. Conclusions on the clinical safety

The clinical safety of efbemalenograstim alfa was primarily assessed in Phase III studies involving patients with breast cancer. Supportive safety information from 7 clinical pharmacology studies, 2 of which performed in healthy subjects, was also considered. The total number of subjects studied enables an adequate characterisation of the overall safety profile especially as safety information from other G-CSF and variants is also available and applicable to this product.

The safety profile of efbemalenograstim alfa seems to be in line with what is expected from a G-CSF derivative. Warnings and recommendations in the product information are in line with other G-CSFs and expected to minimise the risks associated with its use.

## 2.7. Risk Management Plan

## 2.7.1. Safety concerns

| Summary of safety concerns   | Summary of safety concerns   |
|------------------------------|------------------------------|
| Important identified risks   | None                         |
| Important potential risks    | Immunogenicity               |
| Missing information          | None                         |

## 2.7.2. Pharmacovigilance plan

No additional pharmacovigilance activities.

## 2.7.3. Risk minimisation measures

| Safety concern            | Safety concern   | Risk minimisation measures                           |
|---------------------------|------------------|------------------------------------------------------|
| Important potential risks | Immunogenicity   | Routine risk minimisation measures: SmPC section 4.4 |

<div style=\"page-break-after: always\"></div>

| Safety concern   | Risk minimisation measures             |
|------------------|----------------------------------------|
|                  | PL Section 2, Warnings and precautions |

## 2.7.4. Conclusion

The CHMP considers that the risk management plan version 0.3 is acceptable.

## 2.8. Pharmacovigilance

## 2.8.1. Pharmacovigilance system

The  CHMP  considered  that  the  pharmacovigilance  system  summary  submitted  by  the  applicant  fulfils  the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.8.2. Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion. The applicant did request alignment of the PSUR cycle with the international birth date (IBD). The IBD is 06.05.2023. The new EURD list entry will therefore use the IBD to determine the forthcoming Data Lock Points.

## 2.9. Product information

## 2.9.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 2.9.2. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Ryzneuta (efbemalenograstim alfa) is included in the additional monitoring list as it contains a new active substance which, on 1 January 2011, was not contained in any medicinal product authorised in the EU.

Therefore, the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The target indication applied for by the applicant is for management of neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy.

## 3.1.2. Available therapies and unmet medical need

Treatment options for neutropenia management include prophylactic antibacterial, antifungal, and antiviral agents that have been administered to prevent the development of infection as a complication of neutropenia. Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) are used to reduce the duration and degree of neutropenia. G-CSF increases the proliferation and differentiation of neutrophils from progenitor cells, induces maturation and enhances the survival and function of mature neutrophils.

Recombinant hG-CSF (filgrastim) has been introduced in clinical use since 1991 under the trade name Neupogen. Recombinant hG-CSF is produced in E. coli and its amino acid sequence is identical to human GCSF, except for the addition of an N-terminal methionine necessary for the expression in E. coli . The PEGylated formulation of G-CSF (trade name Neulasta), a recombinant N-methionyl form of human G-CSF, covalently bound to a single 20 kDa PEG molecule, is produced in E. coli and is also modified with the addition of the N-terminal methionine. Lipegfilgrastim (trade name Lonquex) is a conjugate of recombinant N-methionyl human granulocyte-colony stimulating factor (r met-Hu-G-CSF, Filgrastim) and a single polyethylene glycol (PEG) molecule. To generate Lipegfilgrastim, a PEG molecule is covalently attached, via a carbohydrate linker, to filgrastim at Threonine134. This site-specific glycoPEGylation is achieved through sequential action of two recombinant glycosyltransferase enzymes, with activated sugar nucleotide donor substrates.

The long-acting G-CSFs have prolonged half-life, permitting the administration of a single dose after each (generally weekly) chemotherapy cycle rather than daily administration.

## 3.1.3. Main clinical studies

The main evidence of efficacy submitted derived from three clinical Phase III studies in patients after chemotherapy for malignancy: 402 subjects were randomized to 20 mg F-627 and 355 subjects to a comparator arm (either Placebo [PBO], 6 mg pegfilgrastim [PEG], or 5 μ g/kg/day filgrastim [GRN]).

## 3.2. Favourable effects

In one of main pivotal phase III studies (PEG controlled Study 005), the Duration of Grade 4 (severe) Neutropenia in Cycle 1 (primary endpoint, measured as Mean duration (SD) of ANC &lt; 0.5 x 10(9)) in days in Ryzneuta vs PEG arms were 0.2 (0.51) vs 0.2 (0.45) days with difference [95%CI] of 0.0 [-0,1, 0.1] that is meeting the predefined statistical NI margin of 0,6 days. The Incidences of FN across all Cycles (1 to 4), measured as N (%) in Ryzneuta vs PEG arms were 6/197 (3) vs 1/196 (0.5) with mean difference [95%CI]

<div style=\"page-break-after: always\"></div>

of 2.5 [-7.3, 12.4]. The Incidences of Infections across all Cycles (1 to 4), measured as N (%) in Ryzneuta vs PEG arms were 14/197 (7.1) vs 17/196 (8.7) with mean difference [95%CI] of 1.6 [-11.4, 8.3].

In the second pivotal study (PBO controlled Study 004), the Duration of Grade 4 (severe) Neutropenia in Cycle 1 (primary endpoint, measured similarly to Study 005) in days in Ryzneuta vs PBO arm were 1.3 (1.19) vs 3.9 (1.44) days with difference [95%CI] of 2.6 [2.0, 3.1] that is meeting the statistically proven superiority. The Incidences of FN across all Cycles (1 to 4), measured as N (%) in Ryzneuta vs PBO arms were 4/83 (4.8) vs 10/39 (25.6) with mean difference [95%CI] of 2.6 [2.0, 3.1]. The Incidences of Infections across all Cycles (1 to 4), measured as N (%) in Ryzneuta vs PBO arms were 9/83 (10.8) vs 8/39 (20.5) with mean difference [95%CI] of 9.7 [-9.4, 28.2].

In the third pivotal study (GRN controlled Study 11631), the Duration of Grade 3 or 4 Neutropenia in Cycle 1 (primary endpoint) measured as Mean duration (SD) of ANC&lt;1x10(9) in days in Ryzneuta vs GRN arms were 0.68 (1.1) vs 0.71 (0.951) days with median difference [95%CI] of 0.0 [0.000, 0.000] that is meeting the predefined statistical NI margin of 1 day.

The incidences of FN across all Cycles (1 to 4), measured as N (%) in Ryzneuta vs GRN arms were 6/197 1/120 (0.8) vs 2/119 (1.7) with mean difference [95%CI] of -0.8 [-3.67, 1.98].

## 3.3. Uncertainties and limitations about favourable effects

The phase III studies enrolled only female subjects. However, due to the known effects of G-CSF, it is expected that reported results can be extrapolated to male patients.

In Study SP11631, incidence rates of infections, use of antibiotics and incidence of hospitalization were not recorded. As these types of events are important in determining the clinical benefit of treatment, the results of this study are difficult to interpret however demonstration of efficacy is further supported by the reported results on febrile neutropenia and reduced use of antibiotics and infection rates compared to placebo and/or pegfilgrastim from the two other studies.

Efbemalenograstim alfa has not been investigated in patients receiving high dose chemotherapy. A warning has been included to that effect in Section 4.4. of the SmPC.

## 3.4. Unfavourable effects

In general, at least one TEAE/ADRs were observed in 90.4 to 99.8%/ 31 to 44.7% in Ryzneuta arms vs in 86.2 to 100% /34.2 to 55% in active arms (PEG or GRN) and in 100%/23.1% in PBO arm. At least one SAEs were observed in 5 to 6% in Ryzneuta arms vs in 1.5 to ~7% in active arms (PEG or GRN) and in 28% in PBO arm.

The most often reported unfavourable effects were musculoskeletal related such as bone and back pain, arthralgia and pain in extremity which were reported commonly. However, musculoskeletal pain was generally of mild to moderate severity, transient and could be controlled in most patients with standard analgesics. Immunogenicity appears to be the most important risk associated with Efbemalenograstim alfa use and was reported in 15.2% and 9.6% of patients treated with efbemalenograstim alfa in studies 005 and 004 respectively.

Serious adverse events were not frequently reported and did not raise any concerns outside what is known from other G-SCF containing products.

<div style=\"page-break-after: always\"></div>

## 3.5. Uncertainties and limitations about unfavourable effects

G-CSF and other derivatives have been in use for a long period to time and their safety profile is well established. Several known effects of these types of products were not observed in the clinical studies conducted with efbemalenograstim alfa, possibly due to the short duration of treatment and the relatively low numbers of patients treated.

With regards to study GC-627-05 trial and following a GCP inspection, it was considered that information bias could not be ruled out as in at least some of the sites some of the investigators may have been unblinded to treatment allocation. The CHMP noted however, that the results in this study, did not favour the investigational product. In addition, the close monitoring and management of patients in the oncology area by treating physicians which are accustomed with the treatments used in that study, reduces the likelihood of impact of any information bias.

## 3.6. Effects Table

Table 64 . Effects Table for Ryzneuta for the management of neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy. (data cut-off: 5 March 2020).

| Effect                                      | Short Description                    | Unit                 | 20 mg F- 627 (n=197)   | 6 mg PEG (n=196)     | Uncertainties/ Strength of evidence                       | Reference s          |
|---------------------------------------------|--------------------------------------|----------------------|------------------------|----------------------|-----------------------------------------------------------|----------------------|
| Favourable Effects                          | Favourable Effects                   | Favourable Effects   | Favourable Effects     | Favourable Effects   | Favourable Effects                                        | Favourable Effects   |
| Duration of Grade 4 Neutropenia in Cycle 1  | Mean duration of ANC<0.5x10(9)       | Days (SD)            | 0.2 (0.51)             | 0.2 (0.45)           | Primary endpoint within non-inferiority margin            | Study 005            |
| Incidence of use of IV AB across all Cycles |                                      | N(%)                 | 9 (4.6)                | 2 (1)                | Similar results obtained in placebo-controlled study 004. | Study 005            |
| Incidence of Infections across all Cycles   |                                      | N(%)                 | 14 (7.1)               | 17 (8.7)             |                                                           | Study 005            |
| Unfavourable Effects                        | Unfavourable Effects                 | Unfavourable Effects | Unfavourable Effects   | Unfavourable Effects | Unfavourable Effects                                      | Unfavourable Effects |
| SAE                                         | Patients experiencing at least 1 SAE | N(%)                 | 12 (6.1) 4 (4.8)       | 3 (1.5) 11 (28)      | Bias in reporting for study 005 cannot be ruled out       | Study 005 Study 004  |
| Immunogeni city                             |                                      | N(%)                 | 30 (15.2) 8 (9.6)      | 15 (7.7) 3 (7.9)     |                                                           | Study 005 Study 004  |

Abbreviations: AB : antibiotics; ANC : absolute neutrophil count; IV : intravenous; F-627 : Efbemalenograstim alfa; PEG - Pegfilgrastim; SAE : serious AE.

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Treatment with efbemalenograstim alfa clearly results in a reduction of the incidence of severe neutropenia compared to placebo treatment and to a similar extent to pegfilgrastim treatment. The clinical importance of this effect is further supported by the reported results on febrile neutropenia, use of antibiotics and infection rates which were reduced compared to placebo and/or pegfilgrastim. The totality of evidence supports the use of efbemalenograstim alfa in the claimed indication.

The safety profile of efbemalenograstim alfa did not reveal any new safety concerns compared to what is known from the experience from G-SF and derivatives use in clinical practice. Appropriate warnings in the product information provide sufficient information to health-care professionals to manage these risks.

## 3.7.2. Balance of benefits and risks

Available efficacy data suggest that efbemalenograstim alfa represents an additional treatment option for the management of neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy.

## 3.8. Conclusions

The overall benefit/risk balance of Ryzneuta is positive, subject to the conditions stated in section 'Recommendations'.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Ryzneuta is favourable in the following indication(s):

Ryzneuta is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

## · Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in

<div style=\"page-break-after: always\"></div>

the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

- Risk Management Plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

Not applicable.

## New Active Substance Status

Based on the CHMP review of the available data, the CHMP considers that efbemalenograstim alfa is to be qualified as a new active substance in itself as it is not a constituent of a medicinal product previously authorised within the European Union.